Delaware (State or Other Jurisdiction of Incorporation or Organization) | 7372 (Primary Standard Industrial Classification Code Number) | 82-3060021 (I. R. S. Employer Identification Number) | ||||
Michael Gilson, Esq. Michael Kaplan, Esq. Tierney O’Rourke, Esq. Hillary A. Coleman, Esq. Davis Polk & Wardwell LLP 900 Middlefield Road, Suite 200 Redwood City, California 94063 (650) 752-2000 | Kristen McVeety General Counsel Nisha Antony Deputy General Counsel CoreWeave, Inc. 290 W Mt. Pleasant Ave., Suite 4100 Livingston, NJ 07039 (973) 270-9737 | David A. Katz, Esq. Karessa L. Cain, Esq. Wachtell, Lipton, Rosen & Katz 51 West 52nd Street New York, New York 10019 (212) 403-1000 | ||||
Large accelerated filer | ☐ | Accelerated filer | ☐ | ||||||
Non-accelerated filer | ☒ | Smaller reporting company | ☐ | ||||||
Emerging growth company | ☐ | ||||||||


a. | to vote on a proposal to adopt the Agreement and Plan of Merger, dated July 7, 2025, as it may be amended from time to time, by and among CoreWeave, Inc., a Delaware corporation (“CoreWeave”), Miami Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of CoreWeave (“Merger Sub”), and Core Scientific (the “Merger Agreement”), which provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, at the effective time, Merger Sub will merge with and into Core Scientific, with Core Scientific surviving as a wholly owned subsidiary of CoreWeave (the “Merger”), which is further described in the section titled “The Merger Agreement” beginning on page 218, and a copy of which is attached as Annex A to the proxy statement/prospectus of which this notice forms a part (the “Merger Agreement Proposal”); and |
b. | to hold a non-binding advisory vote to approve the compensation that may be paid or become payable to Core Scientific’s named executive officers that is based on or otherwise related to the Merger (the “Advisory Compensation Proposal”). |
• | “closing” refers to the closing of the Merger; |
• | “closing date” refers to the date on which the closing occurs; |
• | “Core Scientific 2029 Convertible Notes” refers to Core Scientific’s 3.00% Convertible Senior Notes due 2029 issued under the Core Scientific 2029 Notes Indenture; |
• | “Core Scientific 2029 Notes Indenture” refers to the Indenture, dated August 19, 2024, between Core Scientific and U.S. Bank Trust Company, National Association, as Trustee, as amended, restated, supplemented or otherwise modified from time to time, governing the terms of the Core Scientific 2029 Convertible Notes; |
• | “Core Scientific 2031 Convertible Notes” refers to Core Scientific’s 0.00% Convertible Senior Notes due 2031 issued under the Core Scientific 2031 Notes Indenture; |
• | “Core Scientific 2031 Notes Indenture” refers to the Indenture, dated December 5, 2024, between Core Scientific and U.S. Bank Trust Company, National Association, as Trustee, as amended, restated, supplemented or otherwise modified from time to time, governing the terms of the Core Scientific 2031 Convertible Notes; |
• | “Core Scientific” refers to Core Scientific, Inc., a Delaware corporation; |
• | “Core Scientific board” refers to the board of directors of Core Scientific; |
• | “Core Scientific bylaws” refers to the Third Amended and Restated Bylaws of Core Scientific; |
• | “Core Scientific certificate of incorporation” refers to the Fourth Amended and Restated Certificate of Incorporation of Core Scientific; |
• | “Core Scientific common stock” refers to the common stock, par value $0.00001 par value per share, of Core Scientific; |
• | “Core Scientific Convertible Notes” refers to the Core Scientific 2029 Convertible Notes and the Core Scientific 2031 Convertible Notes; |
• | “Core Scientific CVR Agreement” refers to the Contingent Value Rights Agreement, dated as of January 23, 2024, by and between Core Scientific and Computershare Inc. and its affiliate, Computershare Trust Company, N.A.; |
• | “Core Scientific warrant holders” refers to the holders of Tranche 1 Warrants and Tranche 2 Warrants of Core Scientific, in each case as of immediately prior to the effective time; |
• | “Core Scientific Warrant Agreement” or “Warrant Agreement” refers to the Warrant Agreement, dated as of January 23, 2024, by and between Core Scientific and Computershare Inc. and its affiliate, Computershare Trust Company, N.A.; |
• | “Core Scientific warrants” refers to the Tranche 1 Warrants and the Tranche 2 Warrants; |
• | “CoreWeave” refers to CoreWeave, Inc., a Delaware corporation; |
• | “CoreWeave board” refers to the board of directors of CoreWeave; |
• | “CoreWeave bylaws” or “amended and restated bylaws” refers to the Amended and Restated Bylaws of CoreWeave; |
• | “CoreWeave certificate of incorporation” or “amended and restated certificate of incorporation” refers to the Amended and Restated Certificate of Incorporation of CoreWeave; |
• | “CoreWeave common stock” or “Class A common stock” refers to the Class A common stock, par value $0.000005 par value per share, of CoreWeave; |
• | “CoreWeave Class B common stock” or “Class B common stock” refers to the Class B common stock, par value $0.000005 par value per share, of CoreWeave; |
• | “CoreWeave Class C common stock” or “Class C common stock” refers to the Class C common stock, par value $0.000005 par value per share, of CoreWeave; |
• | “CoreWeave warrants” refers to the warrants to purchase CoreWeave common stock registered pursuant to this registration statement on Form S-4; |
• | “CVRs” refers to the CVRs as set forth in the Core Scientific CVR Agreement; |
• | “DGCL” refers to the Delaware General Corporation Law; |
• | “effective time” refers to the effective time of the Merger; |
• | “Merger” refers to the merger of Merger Sub with and into Core Scientific, with Core Scientific surviving as a wholly owned subsidiary of CoreWeave; |
• | “Merger Agreement” refers to the Agreement and Plan of Merger, dated as of July 7, 2025, by and among CoreWeave, Merger Sub and Core Scientific (as it may be amended from time to time); |
• | “Merger Sub” refers to Miami Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of CoreWeave; |
• | “New Tranche 1 Warrants” refers to the New Tranche 1 Warrants as set forth in the Core Scientific Warrant Agreement; |
• | “New Tranche 2 Warrants” refers to the New Tranche 2 Warrants as set forth in the Core Scientific Warrant Agreement; |
• | “SEC” refers to the U.S. Securities and Exchange Commission; |
• | “Surviving Corporation” refers to Core Scientific after Merger Sub merges with and into Core Scientific, with Core Scientific surviving the Merger as a wholly owned subsidiary of CoreWeave and as the surviving entity of the Merger; |
• | “Tranche 1 Warrants” refers to the Tranche 1 Warrants as set forth in the Core Scientific Warrant Agreement; |
• | “Tranche 2 Warrants” refers to the Tranche 2 Warrants as set forth in the Core Scientific Warrant Agreement; and |
• | “transactions” refers to each of the transactions contemplated by the Merger Agreement, including the Merger. |
Q: | Why am I receiving this document? |
A: | CoreWeave, Merger Sub and Core Scientific have entered into the Merger Agreement, providing for the merger of Merger Sub with and into Core Scientific, with Core Scientific surviving the Merger as a wholly owned subsidiary of CoreWeave. In order to complete the Merger, Core Scientific stockholders must approve Merger Agreement Proposal and all other conditions to the Merger must be satisfied or (to the extent permitted by applicable law) waived. |
Q: | What is the purpose of the Special Meeting? |
A: | At the Special Meeting, holders of Core Scientific common stock as of the Core Scientific record date will act upon all the matters outlined in the Notice of Special Meeting of Stockholders. These include: |
1. | a proposal to adopt the Merger Agreement (the “Merger Agreement Proposal”); and |
2. | a proposal to approve, on a non-binding advisory basis, the compensation that may be paid or become payable to Core Scientific’s named executive officers that is based on or otherwise related to the Merger (the “Advisory Compensation Proposal”). |
Q: | What is a proxy and how does it work? |
A: | The Core Scientific board is asking for your proxy. A “proxy” is your legal designation of another person to vote the stock you own in the manner you direct. If you designate someone as your proxy in a written document, that document is also called a proxy or a proxy card. By giving your proxy to the persons named as proxy holders in the proxy card accompanying this proxy statement/prospectus, you authorize them to vote your shares of Core Scientific common stock at the Special Meeting in the manner you direct. You may cast votes “FOR,” “AGAINST” or “ABSTAIN” with respect to both, either or neither of the matters the Core Scientific board is submitting to a vote of holders of Core Scientific common stock at the Special Meeting. |
Q: | Who is soliciting my vote? |
A: | The Core Scientific board is soliciting your proxy. Core Scientific will pay for the proxy solicitation costs related to the Special Meeting. In addition to sending and making available these materials, some of Core Scientific’s directors, officers and other employees may solicit proxies by contacting Core Scientific stockholders by telephone, by mail, by e-mail or online. Core Scientific stockholders may also be solicited by, among others, news releases issued by Core Scientific and/or CoreWeave, postings on Core Scientific’s or CoreWeave’s websites and social media accounts and advertisements in periodicals. None of Core Scientific’s directors, officers or employees will receive any extra compensation for their solicitation services. Core Scientific has also retained MacKenzie Partners, Inc. as its proxy solicitor to assist in the solicitation of proxies. For these proxy solicitation services, MacKenzie Partners, Inc. will receive a fee not to exceed $175,000, plus reasonable out-of-pocket expenses and fees for any additional services. Core Scientific may also reimburse banks, brokers, and other nominees for their expenses in sending proxy solicitation materials to the beneficial owners of shares of Core Scientific common stock and obtaining their proxies. |
Q: | What will Core Scientific stockholders receive for their shares of Core Scientific common stock in the Merger? |
A: | At the effective time, by virtue of the Merger, each share of Core Scientific common stock (other than each share of Core Scientific common stock held in treasury or held or owned by Core Scientific, CoreWeave or Merger Sub immediately prior to the effective time) outstanding immediately prior to the effective time will be cancelled and converted into the right to receive 0.1235 fully paid and non-assessable shares of CoreWeave common stock. No fractional shares of CoreWeave common stock will be delivered to any holder of shares of Core Scientific common stock upon completion of the Merger. Instead, all fractional shares of CoreWeave common stock that a holder of shares of Core Scientific common stock would otherwise be entitled to receive as a result of the Merger will be aggregated and, if a fractional share results from such aggregation, such holder will be entitled to receive the cash proceeds from the sale of such fractional share by the exchange agent for the account of such holder, without interest and subject to any applicable withholding taxes, in accordance with the Merger Agreement. |
Q: | How will the Merger affect Core Scientific equity awards? |
A: | At or immediately prior to the effective time: |
• | each award of restricted stock units of Core Scientific (each a “Core Scientific RSU Award”) that is outstanding as of immediately prior to the effective time and held by certain specified individuals, including Adam Sullivan, Jim Nygaard and Todd M. DuChene (each, a “Specified Individual”) or a non-employee member of the Core Scientific board will fully vest and be cancelled and converted automatically into the right to receive (without interest and less applicable tax withholding) a number of fully paid and non-assessable shares of CoreWeave common stock equal to the product (rounded up to the nearest whole number of shares) of (x) the total number of shares of Core Scientific common stock underlying such Core Scientific RSU Award as of immediately prior to the effective time, multiplied by (y) the exchange ratio; |
• | all other Core Scientific RSU Awards (other than Core Scientific PSU Awards) that are outstanding immediately prior to the effective time (each, an “Unvested Core Scientific RSU Award”) will each be canceled and converted into a restricted stock unit award with respect to a number of shares of CoreWeave |
• | each Core Scientific RSU Award that vests or is earned subject to the achievement of performance conditions and that is outstanding immediately prior to the effective time (each a “Core Scientific PSU Award”) and held by a Specified Individual will fully vest and be cancelled and converted automatically into the right to receive (without interest and less applicable tax withholding) a number of fully paid and non-assessable shares of CoreWeave common stock equal to the product (rounded up to the nearest whole number of shares) of (x) the total number of shares of Core Scientific common stock underlying such Core Scientific PSU Award as of immediately prior to the effective time (which number will be determined by deeming the applicable performance level to equal 300%), multiplied by (y) the exchange ratio; |
• | all other Core Scientific PSU Awards that are outstanding immediately prior to the effective time will each be cancelled and converted into a time-based restricted stock unit award with respect to a number of shares of CoreWeave common stock equal to the product (rounded up to the nearest whole number of shares) of (x) the total number of shares of Core Scientific common stock underlying a Core Scientific PSU Award as of immediately prior to the effective time assuming a performance level of 300% multiplied by (y) the exchange ratio (each a “CoreWeave Rollover PSU Award”), and each such CoreWeave Rollover PSU Award will otherwise continue to be subject to the same terms and conditions (including service-based vesting and forfeiture conditions) as were applicable to the corresponding Core Scientific PSU Award immediately prior to the effective time (other than the applicable performance conditions); |
• | each option to purchase shares of Core Scientific common stock (each a “Core Scientific Option”) that is outstanding and unexercised as of immediately prior to the effective time that has a per share exercise price that is less than (x) the exchange ratio multiplied by (y) the average of the volume weighted average trading prices of CoreWeave common stock on each of the five consecutive trading days ending on (and including) the last trading day prior to the date of the effective time (the “Per Core Scientific Share Price”) (each an “In the Money Option”) will be cancelled and converted into the right to receive (without interest and less applicable tax withholding) a number of fully paid and non-assessable shares of CoreWeave common stock equal to (x) the quotient obtained by dividing (a) the product obtained by multiplying (A) the excess, if any, of the Per Core Scientific Share Price over the exercise price per share of Core Scientific common stock subject to such Core Scientific Option immediately prior to the effective time by (B) the number of shares of Core Scientific common stock subject to such Core Scientific Option immediately prior to the effective time by (b) the Per Core Scientific Share Price multiplied by (y) the exchange ratio; and |
• | each Core Scientific Option that is not an In the Money Option and that is outstanding and unexercised as of immediately prior to the effective time will be cancelled at the effective time with no consideration payable in respect of such Core Scientific Option. |
Q: | What will Core Scientific warrant holders receive for their Tranche 1 Warrants and Tranche 2 Warrants in the Merger? |
A: | At the effective time, each (i) Tranche 1 Warrant will be automatically redeemed in exchange for the right to receive a New Tranche 1 Warrant exercisable for a number of shares of CoreWeave common stock (subject to cashless exercise as described below) equal to (a) the number of Warrant Shares (as defined in the Core Scientific Warrant Agreement) underlying such Tranche 1 Warrant, multiplied by (b) the exchange ratio, with such New Tranche 1 Warrant having an exercise price equal to (x) the Tranche 1 Exercise Price (as defined in the Core Scientific Warrant Agreement) in effect immediately prior to the effective time divided by (y) the exchange ratio, and otherwise having terms substantially the same as the terms of the Tranche 1 Warrants and (ii) Tranche 2 Warrant will be converted into a non-penny Converted Tranche 2 Warrant (as defined in the Core Scientific Warrant Agreement) with an exercise price of $7.50 per Warrant Share (subject to adjustment on the terms set forth in the Core Scientific Warrant Agreement), which Converted Tranche 2 Warrant will be automatically redeemed in exchange for the right to receive a New Tranche 2 Warrant exercisable for a number |
Q: | How will the Merger affect the Core Scientific 2029 Convertible Notes and 2031 Convertible Notes? |
A: | Holders of the Core Scientific 2029 Convertible Notes and Core Scientific 2031 Convertible Notes may convert their Core Scientific 2029 Convertible Notes and Core Scientific 2031 Convertible Notes, as applicable, only under the following circumstances: (i) during the calendar quarter commencing after any quarter in which the last reported sale price of Core Scientific common stock for at least 20 of the last 30 consecutive trading days of such quarter exceeds 130% of the conversion price; (ii) during the five consecutive business days following any 10 consecutive trading day period when the trading price of the relevant notes is less than 98% of the product of the last reported sales price of Core Scientific common stock and the conversion rate on each such trading day; (iii) upon the occurrence of specified corporate events, including in connection with most mergers or changes of control (including the Merger) or significant distributions made on Core Scientific common stock; (iv) upon notice of redemption by Core Scientific; and (v) on or after June 1, 2029 or March 17, 2031, respectively, until the close of business of the scheduled trading day immediately before the applicable maturity date. Whether or not the Core Scientific 2029 Convertible Notes and Core Scientific 2031 Convertible Notes are otherwise then convertible, the consummation of the Merger will permit holders to convert their convertible notes as described in clause (iii) of the preceding sentence for a period of time set forth in the Core Scientific 2029 Notes Indenture and the Core Scientific 2031 Notes Indenture, as applicable. |
Q: | If I am a holder of Core Scientific common stock, how will I receive the Merger Consideration to which I am entitled? |
A: | The conversion of Core Scientific common stock into the right to receive the Merger Consideration will occur automatically upon the completion of the Merger. Promptly following the effective time, the exchange agent will mail to the record holders of any certificate formerly representing any share of Core Scientific common stock: (i) a letter of transmittal in customary form containing such provisions as CoreWeave and Core Scientific may reasonably specify (including a provision that delivery of certificates will be effected, and risk of loss and title to shares of Core Scientific common stock will pass, only upon delivery of such certificates to the exchange agent) and (ii) instructions for use in effecting the surrender of certificates in exchange for the Merger Consideration. Upon surrender of a certificate to the exchange agent for exchange, together with a duly executed letter of transmittal and such other documents as may be reasonably required by the exchange agent or CoreWeave, the holder of such certificate will be entitled to receive (A) a certificate or evidence of shares in book-entry form representing the number of whole shares of CoreWeave common stock that such holder has the right to receive pursuant to the Merger Agreement and (B) cash in lieu of any fractional shares of CoreWeave common stock pursuant to the Merger Agreement. Any such certificate so surrendered will immediately be cancelled. |
Q: | Who will own CoreWeave common stock immediately following the transactions? |
A: | CoreWeave and Core Scientific estimate that, as of immediately following completion of the Merger, holders of CoreWeave common stock as of immediately prior to the Merger will hold approximately [ ]% and holders of Core Scientific common stock as of immediately prior to the Merger will hold approximately [ ]% of the outstanding shares of CoreWeave common stock (or, on a fully diluted basis, holders of CoreWeave common stock as of immediately prior to the Merger will hold approximately [ ]% and holders of Core Scientific common stock as of immediately prior to the Merger will hold approximately [ ]% of the shares of CoreWeave common stock). |
Q: | How important is my vote? |
A: | Your vote “FOR” each proposal presented at the Special Meeting is very important regardless of the number of shares of Core Scientific common stock that you own, and you are encouraged to submit a proxy or proxies as soon as possible. |
Q: | What vote is required to approve each proposal at the Special Meeting? |
A: | Approval of the Merger Agreement Proposal requires the affirmative vote of holders of a majority of the issued and outstanding shares of Core Scientific common stock as of the Core Scientific record date and entitled to vote thereon. The required vote on the Merger Agreement Proposal is based on the number of outstanding shares—not the number of shares actually voted. The failure of any Core Scientific stockholder to submit a vote (i.e., by not submitting a proxy and not voting at the Special Meeting) and any abstention from voting by a Core Scientific stockholder will have the same effect as a vote “AGAINST” the Merger Agreement Proposal. |
Q: | How does the Core Scientific board recommend that I vote? |
A: | At a meeting held on July 7, 2025, the Core Scientific board unanimously (i) determined that the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Merger, on the terms and conditions set forth in the Merger Agreement, were fair to and in the best interests of Core Scientific and its stockholders, (ii) approved and deemed advisable the execution and delivery of the Merger Agreement, the performance by Core Scientific of its covenants and agreements contained in the Merger Agreement and the consummation of the transactions contemplated by the Merger Agreement, including the Merger and (iii) directed that the adoption of the Merger Agreement be submitted to a vote of Core Scientific stockholders and resolved to recommend that Core Scientific stockholders approve the Merger and adopt the Merger Agreement. |
Q: | Why am I being asked to consider and vote on the Advisory Compensation Proposal? |
A: | Under SEC rules, Core Scientific is required to seek a non-binding, advisory vote with respect to the compensation that may be paid or become payable to Core Scientific’s named executive officers that is based on or otherwise related to the Merger. See the section titled “Interests of Core Scientific’s Directors and Executive Officers in the Merger” beginning on page 252 of this proxy statement/prospectus. |
Q: | Are there any Core Scientific stockholders who have already committed to voting in favor of the Merger Agreement Proposal at the Special Meeting? |
A: | At the close of business on [ ] Core Scientific’s directors and executive officers had the right to vote approximately [ ] shares of the then-outstanding Core Scientific common stock, collectively representing approximately [ ]% of the Core Scientific common stock outstanding and entitled to vote on that date. |
Q: | Will the CoreWeave common stock, New Tranche 1 Warrants and New Tranche 2 Warrants issued at the time of completion of the Merger be traded on an exchange? |
A: | It is a condition to the consummation of the Merger that the shares of CoreWeave common stock to be issued to Core Scientific stockholders in connection with the Merger be approved for listing on the Nasdaq, subject to official notice of issuance. CoreWeave will use its reasonable best efforts to cause the New Tranche 1 Warrants and New Tranche 2 Warrants to be issued to Core Scientific warrant holders in connection with the Merger to be listed on the Nasdaq, subject to official notice of issuance, as promptly as practicable after the date of the Merger Agreement, and in any event prior to the effective time. |
Q: | How will CoreWeave stockholders be affected by the Merger? |
A: | Upon completion of the Merger, each CoreWeave stockholder will hold the same number of shares of CoreWeave stock that such stockholder held immediately prior to completion of the Merger. As a result of the Merger, CoreWeave stockholders will own shares in a larger consolidated company with more assets. However, |
Q: | What are the material U.S. federal income tax consequences of the Merger to U.S. holders of shares of Core Scientific common stock? |
A: | Core Scientific and CoreWeave intend for the Merger to qualify as a “reorganization” within the meaning of Section 368(a) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) for U.S. federal income tax purposes. Assuming the Merger so qualifies, U.S. holders (as defined in the section titled “Material U.S. Federal Income Tax Consequences of the Merger”) of shares of Core Scientific common stock generally will not recognize any gain or loss for U.S. federal income tax purposes upon receipt of CoreWeave common stock in exchange for Core Scientific common stock in the Merger, other than gain or loss, if any, with respect to any cash received in lieu of a fractional share of CoreWeave common stock. |
Q: | When do CoreWeave and Core Scientific expect to complete the Merger? |
A: | CoreWeave and Core Scientific currently expect to complete the Merger in the fourth quarter of 2025, subject to timing of satisfaction of closing conditions to the Merger. However, neither CoreWeave nor Core Scientific can predict the actual date on which the Merger will be completed, nor can the parties provide any assurance that the Merger will be completed. See the section titled “Risk Factors,” “The Merger—Regulatory Approvals Required for the Merger” and “The Merger Agreement—Conditions to the Consummation of the Merger” beginning on pages 28, 212 and 223, respectively, of this proxy statement/prospectus. |
Q: | Is the completion of the Merger subject to any conditions? |
A: | Yes. CoreWeave, Merger Sub and Core Scientific are not required to complete the Merger unless certain conditions are satisfied or waived (to the extent permitted by applicable law). These conditions include, among others, the affirmative vote of the holders of a majority of the issued and outstanding shares of Core Scientific common stock entitled to vote at the Special Meeting adopting the Merger Agreement and the expiration or termination of any applicable waiting period (or any extension thereof, including any commitment to, or agreement with, any governmental body to delay the consummation of, or not to consummate before a certain date, the Merger) applicable to the Merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) (see the section titled “The Merger Agreement—Regulatory Approvals” beginning on page 239 of this proxy statement/prospectus). For a more complete summary of the conditions that must be |
Q: | What happens if the Merger is not completed? |
A: | In the event that the Merger Agreement is not adopted by Core Scientific’s stockholders at the Special Meeting or the Merger is not completed for any other reason, Core Scientific’s stockholders will not receive any consideration for shares of Core Scientific common stock they own. Instead, Core Scientific will remain an independent public company, Core Scientific common stock, Tranche 1 Warrants and Tranche 2 Warrants will each continue to be listed and traded on Nasdaq and registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Core Scientific will continue to file periodic reports with the Securities and Exchange Commission (the “SEC”) on account of Core Scientific common stock. If the Merger is not completed for any reason, including as a result of Core Scientific stockholders failing to approve the Merger Agreement Proposal, the ongoing businesses of Core Scientific may be adversely affected, and the anticipated benefits of having completed the Merger will not be realized. See the section titled “Risk Factors—Failure to complete the Merger could negatively impact the stock price and the future business and financial results of Core Scientific and CoreWeave” beginning on page 35 of this proxy statement/prospectus. |
Q: | When and where is the Special Meeting? |
A: | The Special Meeting will be a virtual only meeting conducted exclusively via live webcast at www.virtualshareholdermeeting.com/CORZ2025SM starting at [ ], Eastern Time (with log-in beginning at [ ], Eastern Time) on [ ]. You will be able to attend the Special Meeting and vote your shares electronically during the meeting by going to www.virtualshareholdermeeting.com/CORZ2025SM and entering the 16-digit control number included on the proxy card or voting instruction form that you received. Because the Special Meeting is completely virtual and being conducted via live webcast, stockholders will not be able to attend the meeting in person. |
Q: | Who can vote at, and what is the record date of, the Special Meeting? |
A: | All Core Scientific stockholders who hold shares of Core Scientific common stock of record at the close of business on [ ], 2025, the record date for the Special Meeting (the “Core Scientific record date”), are entitled to receive notice of, and to vote, at the Special Meeting or any adjournments or postponements thereof. |
Q: | How many votes may I cast? |
A: | Each issued and outstanding share of Core Scientific common stock entitles its holder of record to one vote on each matter to be considered at the Special Meeting. The Core Scientific stockholders of record on the Core Scientific record date are the only Core Scientific stockholders that are entitled to receive notice of, and to vote at, the Special Meeting or any adjournments or postponements thereof. |
Q: | What constitutes a quorum at the Special Meeting? |
A: | In order for business to be conducted at the Special Meeting, a quorum must be present. A quorum at the Special Meeting requires the presence of the holders of a majority of the voting power of the outstanding shares of Core Scientific common stock entitled to vote, present in person, by remote communication or by proxy at the Special Meeting. |
Q: | What do I need to do now? |
A: | After you have carefully read and considered the information contained in or incorporated by reference into this proxy statement/prospectus, please submit your proxy via the internet or by telephone in accordance with the instructions set forth on the enclosed proxy card or voting instruction form you received, or complete, sign, date and return the enclosed proxy card or voting instruction form in the self-addressed, stamped envelope provided as soon as possible so that your shares will be represented and voted at the Special Meeting. |
Q: | How will my proxy be voted? |
A: | If you submit your proxy via the internet, by telephone or by completing, signing, dating and returning the enclosed proxy card or voting instruction form, your proxy will be voted in accordance with your instructions. If you sign your proxy card and return it without indicating how you would like to vote your shares, your proxy card will be voted in accordance with the recommendation of the Core Scientific board. |
Q: | Who will count the votes? |
A: | The votes at the Special Meeting will be counted by an individual designated by the Core Scientific board to serve as inspector of election. |
Q: | How do I vote my shares if I am a stockholder of record? |
A: | Core Scientific stockholders of record at the close of business on [ ] may vote in one of the following ways: |
• | Internet: Core Scientific stockholders of record may submit their proxy over the internet at www.proxyvote.com. Internet voting is available 24 hours a day and will be accessible until 11:59 p.m., Eastern Time, on [ ]. Stockholders will be given an opportunity to confirm that their voting instructions have been properly recorded. Core Scientific stockholders who submit a proxy this way need not send in their proxy card by mail. |
• | Telephone: Core Scientific stockholders of record may submit their proxy by calling 1-800-690-6903. Telephone voting is available 24 hours a day and will be accessible until 11:59 p.m., Eastern Time, on [ ]. Easy-to-follow voice prompts will guide stockholders through the voting and allow them to confirm that their instructions have been properly recorded. Core Scientific stockholders who submit a proxy this way need not send in their proxy card by mail. |
• | Mail: Core Scientific stockholders of record may submit their proxy by properly completing, signing, dating and mailing their proxy card or voting instruction form in the self-addressed, stamped envelope (if mailed in the United States) included with this proxy statement/prospectus. Core Scientific stockholders who vote this way should mail the proxy card early enough so that it is received prior to the closing of the polls at the Special Meeting. |
• | Online During the Virtual Meeting: Core Scientific stockholders of record may attend the virtual Special Meeting by entering his, her or its unique 16-digit control number and vote online; attendance at the virtual Special Meeting will not, however, in and of itself constitute a vote or a revocation of a prior proxy. |
Q: | How can I vote during the Special Meeting? |
A: | All stockholders of record may vote online during the Special Meeting. Street name holders may vote online during the Special Meeting if they have a voting instruction form with a 16-digit control number, as described below. You may cast your vote electronically during the Special Meeting using the 16-digit control number |
Q: | Who do I contact if I am encountering difficulties attending the Special Meeting online? |
A: | If you encounter any difficulties while accessing the virtual meeting during the check-in or meeting time, a technical assistance phone number will be made available on the virtual meeting registration page 15 minutes prior to the start of the meeting. Please give yourself sufficient time to log-in and ensure you can hear the streaming audio before the meeting starts. |
Q: | What should I do if I receive more than one set of voting materials for the Special Meeting? |
A: | You may receive more than one set of voting materials for the Special Meeting, including multiple copies of this proxy statement/prospectus and multiple proxy cards or voting instruction forms. For example, if you hold your shares of Core Scientific common stock in more than one brokerage account, you will receive a separate voting instruction form for each brokerage account in which you hold shares. If you are a holder of record of Core Scientific common stock and your shares are registered in more than one name, you will receive more than one proxy card. Please submit each separate proxy or voting instruction form that you receive by following the instructions set forth in each separate proxy or voting instruction form. If you fail to submit each separate proxy or voting instruction form that you receive, not all of your shares will be voted. |
Q: | What’s the difference between holding shares as a stockholder of record and holding shares as a beneficial owner? |
A: | If your shares of Core Scientific common stock are registered directly in your name with Core Scientific’s transfer agent, Computershare Trust Company, N.A., you are considered, with respect to those shares, to be the stockholder of record. If you are a stockholder of record, then this proxy statement/prospectus and your proxy card have been sent directly to you by Core Scientific. |
Q: | If my shares are held in “street name” by my broker, bank or other nominee, will my broker, bank or other nominee automatically vote my shares for me? |
A: | No. If your shares are held in the name of a broker, bank or other nominee, you will receive separate instructions from your broker, bank or other nominee describing how to vote your shares. The availability of the Internet or telephonic voting will depend on your broker’s, bank’s or other nominee’s voting process. Please check with your broker, bank or other nominee and follow the voting procedures provided by your broker, bank or other nominee on your voting instruction form. |
• | your broker, bank or other nominee may not vote your shares on the Merger Agreement Proposal, which will have the same effect as a vote “AGAINST” such proposal; and |
• | your broker, bank or other nominee will not be permitted to vote your shares on the Advisory Compensation Proposal, which will have no effect on the vote count for such proposal. |
Q: | I am a Core Scientific stockholder and I received a proxy card from someone other than Core Scientific. Should I sign and mail it? |
A: | It is recommended that you disregard any proxy card sent to you by or on behalf of any other person other than Core Scientific, including any gold proxy card and solicitation materials that may be sent to you by or on behalf of Two Seas, which is soliciting proxies to vote against the Merger Agreement Proposal and the Advisory Compensation Proposal. If you have submitted such a proxy card (including a gold proxy card), it is recommended that you subsequently recast your vote as instructed on the WHITE proxy card mailed to you by Core Scientific, which will revoke any earlier dated proxy card that you submitted. Only the last validly executed proxy that you submit will be counted and such proxy will be counted only if it has been received 11:59 p.m., Eastern Time on [ ]. If you have any questions or need assistance, please contact MacKenzie Partners, Inc. toll free at (800) 322-2885 or by e-mail at proxy@mackenziepartners.com. |
Q: | What do I do if I am a Core Scientific stockholder and I want to revoke my proxy? |
A: | Core Scientific stockholders of record may revoke their proxies at any time before their shares of Core Scientific common stock are voted at the Special Meeting in any of the following ways: |
• | delivering written notice of revocation of the proxy to Core Scientific’s corporate secretary at Core Scientific’s principal executive offices at 838 Walker Road, Suite 21-2105, Dover, Delaware 19904, by no later than 11:59 p.m., Eastern Time on [ ]; |
• | delivering another proxy with a later date to Core Scientific’s corporate secretary at Core Scientific’s principal executive offices at 838 Walker Road, Suite 21-2105, Dover, Delaware 19904, by no later than 11:59 p.m., Eastern Time on [ ] (in which case only the later-dated proxy is counted and the earlier proxy is revoked); |
• | submitting another proxy again via the internet or by telephone at a later date, by no later than 11:59 p.m., Eastern Time on [ ] (in which case only the later-dated proxy is counted and the earlier proxy is revoked); or |
• | attending the Special Meeting virtually, using his, her or its unique 16-digit control number and voting their shares online during the meeting; attendance at the virtual Special Meeting will not, in and of itself, revoke a valid proxy that was previously delivered unless you give written notice of revocation to the Core Scientific corporate secretary before the proxy is exercised or unless you vote your shares online during the Special Meeting. |
Q: | What happens if I sell or otherwise transfer my shares of Core Scientific common stock before the Special Meeting? |
A: | The Core Scientific record date is prior to the date of the Special Meeting. If you sell or otherwise transfer your shares of Core Scientific common stock after the Core Scientific record date but before the Special Meeting, unless special arrangements (such as provision of a proxy) are made between you and the person to whom you transfer your shares of Core Scientific common stock, you will retain your right to vote such shares at the Special Meeting but will otherwise transfer ownership of and the economic interest in your shares of Core Scientific common stock. |
Q: | What happens if I sell or otherwise transfer my shares of Core Scientific common stock before the completion of the Merger? |
A: | Only holders of shares of Core Scientific common stock at the effective time will become entitled to receive the Merger Consideration. If you sell your shares of Core Scientific common stock prior to the completion of the Merger, you will not be entitled to receive the Merger Consideration by virtue of the Merger. |
Q: | Do any of the officers or directors of Core Scientific have interests in the Merger that may differ from or be in addition to my interests as a Core Scientific stockholder? |
A: | In considering the recommendation of the Core Scientific board that Core Scientific stockholders vote to approve the Merger Agreement Proposal and to approve the Advisory Compensation Proposal, Core Scientific stockholders should be aware that certain of Core Scientific’s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Core Scientific stockholders generally. These interests may include, among others: |
• | the treatment of outstanding equity awards described in the section entitled “The Merger Agreement—Treatment of Core Scientific Equity Awards” beginning on page 220 of this proxy statement/prospectus; |
• | severance payments and benefits to certain Core Scientific executive officers under their individual letter agreements; |
• | agreements with certain Core Scientific executive officers providing for excise tax reimbursements; |
• | payment of annual cash incentive bonuses for fiscal year 2025 if such bonuses have not been paid prior to the effective time; and |
• | continued indemnification and directors’ and officers’ liability insurance. |
Q: | Where can I find voting results of the Special Meeting? |
A: | Core Scientific intends to publish the final results in a Current Report on Form 8-K that will be filed with the SEC following the Special Meeting. All reports that Core Scientific and CoreWeave file with the SEC are publicly available when filed. See the section titled “Where You Can Find More Information” beginning on page 317 of this proxy statement/prospectus. |
Q: | Do Core Scientific stockholders have dissenters’ or appraisal rights? |
A: | Core Scientific stockholders are not entitled to dissenters’ or appraisal rights in connection with the Merger. See the section titled “The Merger—No Dissenters’ or Appraisal Rights” beginning on page 214 of this proxy statement/prospectus. |
Q: | How can I find more information about CoreWeave and Core Scientific? |
A: | You can find more information about CoreWeave and Core Scientific from various sources described in the section titled “Where You Can Find More Information” beginning on page 317 of this proxy statement/prospectus. |
Q: | Who can answer any questions I may have about the Special Meeting, the Merger or the transactions contemplated by the Merger Agreement? |
A: | If you have any questions about the Special Meeting, the Merger or the other transactions contemplated by the Merger Agreement or how to submit your proxy, or if you need additional copies of this proxy statement/prospectus or documents incorporated by reference herein, the enclosed proxy card or voting instructions, you should contact Core Scientific or Core Scientific’s proxy solicitor: |
• | Proposal 1—the Merger Agreement Proposal: to adopt the Merger Agreement, a copy of which is attached as Annex A to this proxy statement/prospectus and the material provisions of which are summarized in the section titled “The Merger Agreement” beginning on page 218 of this proxy statement/prospectus, pursuant to which, among other things, Merger Sub will merge with and into Core Scientific and each outstanding share of Core Scientific common stock will be converted into the right to receive 0.1235 shares of CoreWeave common stock. |
• | Proposal 2—the Advisory Compensation Proposal: to approve, on a non-binding advisory basis, the compensation that may be paid or become payable to Core Scientific’s named executive officers that is based on or otherwise related to the Merger, the estimated value of which is disclosed in the table in the section titled “Interests of Core Scientific’s Directors and Executive Officers in the Merger—Quantification of Potential Payments and Benefits to Core Scientific’s Named Executive Officers” beginning on page 254 of this proxy statement/prospectus. |
• | Proposal 1—the Merger Agreement Proposal. The affirmative vote of holders of a majority of the issued and outstanding shares of Core Scientific common stock on the Core Scientific record date and entitled to vote thereon is required to approve the Merger Agreement Proposal. The required vote on Proposal 1 is based on the number of outstanding shares—not the number of shares actually voted. The failure of any Core Scientific stockholder to submit a vote (i.e., by not submitting a proxy and not voting at the Special Meeting) and any abstention from voting by a Core Scientific stockholder will have the same effect as a vote “AGAINST” the Merger Agreement Proposal. Because the Merger Agreement Proposal is non-routine, brokers, banks and other nominees do not have discretionary authority to vote on the Merger Agreement Proposal, and will not be able to vote on the Merger Agreement Proposal absent instructions from the beneficial owner of any Core Scientific shares held of record by them. As a result, a broker non-vote will have the same effect as a vote “AGAINST” the Merger Agreement Proposal. |
• | Proposal 2—the Advisory Compensation Proposal. The affirmative vote of the holders of a majority of the votes cast on such matter, voting affirmatively or negatively (excluding abstentions and broker non-votes), where a quorum is present, is required to approve the Advisory Compensation Proposal. The required vote on the Advisory Compensation Proposal is based on the number of shares actually voted—not the number |
• | receipt of the affirmative vote of the holders of a majority of the issued and outstanding shares of Core Scientific common stock entitled to vote thereon in favor of the adoption of this Merger Agreement, in accordance with applicable law and Core Scientific’s certificate of incorporation and bylaws (the “Core Scientific Stockholder Approval”); |
• | this registration statement on Form S-4 becoming effective under the Securities Act, no SEC stop order suspending the effectiveness of this registration statement having been issued by the SEC and remaining in effect and no proceedings for such purpose pending before the SEC; |
• | the expiration or termination of the waiting period (and any extension thereof, including any commitment to, or agreement with, any governmental body to delay the consummation of, or not to consummate before a certain date, the transactions contemplated by the Merger Agreement) applicable to the transactions contemplated by the Merger Agreement under the HSR Act; |
• | the absence of any order enacted, promulgated, issued or entered by any governmental body enjoining, restraining, preventing or prohibiting the consummation of the Merger and the absence of any law in effect or enacted or promulgated prohibiting or making illegal the consummation of the Merger; and |
• | the approval for listing on Nasdaq, subject to official notice of issuance, of the CoreWeave common stock issuable to the Core Scientific stockholders in the Merger. |
• | accuracy of the representations and warranties made in the Merger Agreement by, in the case of Core Weave and Merger Sub’s obligations to complete the Merger, Core Scientific and, in the case of Core Scientific’s obligation to complete the Merger, CoreWeave and Merger Sub, in each case, as of the date of completion of the Merger, subject to certain materiality thresholds; |
• | performance in all material respects by, in the case of CoreWeave and Merger Sub’s obligations to complete the Merger, Core Scientific and, in the case of Core Scientific’s obligation to complete the Merger, CoreWeave and Merger Sub, of the obligations required to be performed by it or them at or prior to the effective time of the Merger; |
• | the absence since the date of the Merger Agreement of a material adverse effect on, in the case of CoreWeave and Merger Sub’s obligations to complete the Merger, Core Scientific and, in the case of Core Scientific’s obligation to complete the Merger, CoreWeave (see the section titled “The Merger Agreement—Definition of ‘Material Adverse Effect’” beginning on page 226 of this proxy statement/prospectus for the definition of material adverse effect); and |
• | receipt of a certificate signed by a duly authorized officer of, in the case of CoreWeave and Merger Sub’s obligations to complete the Merger, Core Scientific and, in the case of Core Scientific’s obligation to complete the Merger, CoreWeave, as to the satisfaction of the conditions described in the preceding three bullets. |
• | initiate, seek or solicit, or knowingly encourage or facilitate (including by way of furnishing non-public information) or knowingly cooperate with or take any other action that would reasonably be expected to promote, directly or indirectly, any inquiries or the making or submission of any proposal by a third party that constitutes, or would reasonably be expected to lead to, an Acquisition Proposal (as defined under the section titled “The Merger Agreement—No Solicitation” beginning on page 238 of this proxy statement/prospectus); |
• | participate, engage in or continue discussions (except to notify a person that makes an inquiry or offer with respect to an Acquisition Proposal of the existence of the provisions of the Merger Agreement described by this paragraph or to clarify whether any such inquiry, offer or proposal constitutes an Acquisition Proposal) or negotiations with, or disclose any non-public information or data relating to, Core Scientific or any of its subsidiaries or afford access to the properties, books or records of Core Scientific, or any of its subsidiaries to, or otherwise knowingly assist, facilitate or encourage any effort by, any third party, in each case, that has made or could reasonably be expected to make an Acquisition Proposal; |
• | enter into any agreement, including any letter of intent, term sheet, memorandum of understanding, agreement in principle, merger agreement, acquisition agreement or other similar agreement (other than certain confidentiality agreements permitted under the Merger Agreement), with respect to an Acquisition Proposal; or |
• | otherwise resolve or agree to do any of the items in the three bullet points above. |
• | at any time prior to the effective time, by the mutual written consent of CoreWeave and Core Scientific; |
• | by CoreWeave: |
○ | at any time prior to the effective time, if any of Core Scientific’s covenants, representations or warranties contained in the Merger Agreement are or have become untrue, such that any of the closing conditions for CoreWeave relating to the accuracy of Core Scientific’s representations and warranties or compliance by Core Scientific with its covenants and agreements would not be satisfied, and such breach (A) is incapable of being cured by Core Scientific by or before the End Date or (B) is not cured within 30 days of receipt by Core Scientific of written notice from CoreWeave of such breach; provided, however, that CoreWeave will not have the right to terminate the Merger Agreement as described in this bullet point if any of CoreWeave or Merger Sub is then in breach of any representation, warranty, covenant or obligation under the Merger Agreement that would result in the failure to be satisfied of any of the closing conditions for Core Scientific relating to the accuracy of CoreWeave’s or Merger Sub’s representations and warranties or compliance by CoreWeave or Merger Sub with their covenants and agreements under the Merger Agreement; or |
○ | at any time prior to obtaining the Core Scientific Stockholder Approval, if the Core Scientific board or any committee thereof makes an Adverse Recommendation Change. |
• | by Core Scientific: |
○ | at any time prior to the effective time, if any of CoreWeave’s or Merger Sub’s covenants, representations or warranties contained in the Merger Agreement are or have become untrue, such that any of the closing conditions for Core Scientific relating to the accuracy of CoreWeave’s or Merger Sub’s representations and warranties or compliance by CoreWeave or Merger Sub with its covenants and agreements would not be satisfied, and such breach (A) is incapable of being cured by CoreWeave or Merger Sub, as the case may be, by or before the End Date (as defined below), or (B) is not cured within 30 days of receipt by CoreWeave of written notice from Core Scientific of such breach; provided, however, that Core Scientific will not have the right to terminate the Merger Agreement as described in this bullet point if Core Scientific is then in breach of any representation, warranty, covenant or obligation under the Merger Agreement that would result in the failure to be satisfied of any of the closing conditions for CoreWeave relating to the accuracy of Core Scientific’s representations and warranties or compliance by Core Scientific with its covenants and agreements under the Merger Agreement; or |
○ | at any time prior to obtaining the Core Scientific Stockholder Approval (and subject to Core Scientific’s obligation to pay CoreWeave the Termination Fee (as defined under the section titled “The Merger Agreement—Termination Fee” beginning on page 246 of this proxy statement/prospectus)), upon written notice to CoreWeave, in order to enter into a definitive agreement with a third party providing for a Superior Proposal, if in connection with such Superior Proposal, Core Scientific has complied in all material respects with its requirements as described in the sections titled “Merger Agreement—Obligation to Recommend the Adoption of the Merger Agreement” and “Merger Agreement—No Solicitation” beginning on pages 236 and 238 respectively, of this proxy statement/prospectus. |
• | by either CoreWeave or Core Scientific at any time prior to the effective time, if: |
○ | (A) any order has become final and non-appealable, or (B) there is a law, in each case of (A) and (B) having the effect of permanently enjoining or restricting the consummation of the Merger or making the Merger illegal or otherwise prohibited; provided, however, that the right to terminate the Merger Agreement as described in this bullet point will not be available to any party material failure to comply with any provision of the Merger Agreement has been the primary cause of such order or law; |
○ | the closing has not been consummated by 5:00 p.m., New York time on April 7, 2026 (the “End Date”); provided, that the right to terminate the Merger Agreement as described in this bullet point will not be available to any party whose material failure to comply with any provision of the Merger Agreement has been the primary cause of the failure of the Merger to occur on or before the End Date; or |
○ | the Core Scientific Stockholder Approval has not been obtained at the Special Meeting, including any adjournment or postponement thereof; provided, that the right to terminate the Merger Agreement as described in this bullet point will not be available to Core Scientific if its material failure to comply with any provision of the Merger Agreement has been the primary cause of the failure to obtain the Core Scientific Stockholder Approval on or before such date. |
• | Because the consideration to be received by Core Scientific stockholders in connection with the Merger will include a fixed number of shares of CoreWeave common stock, and the market price of such shares has fluctuated and will continue to fluctuate, Core Scientific stockholders cannot be sure of the value of the consideration they will receive in the Merger. Furthermore, under Delaware law, Core Scientific stockholders are not entitled to an appraisal of the fair value of their shares in connection with the Merger. |
• | CoreWeave’s and Core Scientific’s business relationships may be subject to disruption due to uncertainty associated with the Merger. |
• | Third parties may terminate or alter existing contracts or relationships with Core Scientific or CoreWeave. |
• | While the Merger Agreement is in effect, Core Scientific and CoreWeave are subject to restrictions on their respective business activities, including, among other things, restrictions on their respective ability to issue equity securities and engage in certain kinds of transactions, which could prevent each of Core Scientific and CoreWeave from pursuing strategic business opportunities, taking actions with respect to their respective businesses that they may consider advantageous and responding effectively and/or timely to competitive pressures and industry developments, and may as a result materially adversely affect each of their businesses, results of operations and financial conditions. |
• | The Merger Agreement limits Core Scientific’s ability to pursue alternatives to the Merger and may discourage other companies from trying to acquire Core Scientific for greater consideration than what CoreWeave has agreed to pay pursuant to the Merger Agreement. |
• | Completion of the Merger is subject to certain conditions and if these conditions are not satisfied, waived or fulfilled in a timely manner, the Merger may be delayed or not completed within the anticipated timeframe or at all. |
• | After completion of the Merger, CoreWeave may fail to realize the anticipated benefits of the Merger. |
• | The historical financials of CoreWeave as provided in this proxy statement/prospectus may not be an indication of the future financial condition or results of operations of CoreWeave following the consummation of the Merger. |
• | The unaudited pro forma condensed combined financial information included in this proxy statement/prospectus is preliminary and the actual financial condition and results of operations of the combined company after the Merger may differ materially. |
• | The financial forecasts are based on various assumptions that may not be realized. |
• | The opinions of Core Scientific’s financial advisors will not reflect changes in circumstances between the signing of the Merger Agreement and the completion of the Merger. |
• | Certain of Core Scientific’s executive officers and directors have interests in the Merger that may be different from, or in addition to, your interests as a stockholder of Core Scientific or as a stockholder of CoreWeave. |
• | Failure to complete the Merger could negatively impact the stock price and the future business and financial results of Core Scientific and CoreWeave. |
• | After the Merger, Core Scientific stockholders, as a group, will have a significantly lower ownership and voting interest in CoreWeave than they currently have in Core Scientific and will exercise less influence over management, in particular because the class of high-vote common stock of CoreWeave has the effect of concentrating voting power with CoreWeave’s co-founders. |
• | Potential litigation against CoreWeave and Core Scientific could result in substantial costs, an injunction preventing the completion of the Merger and/or a judgment resulting in the payment of damages. |
• | The expected dilution caused by the issuance of shares of CoreWeave common stock in connection with the Merger may adversely affect the market price of CoreWeave common stock. |
• | CoreWeave’s recent growth may not be indicative of its future growth, and if it does not effectively manage its future growth, CoreWeave’s business, operating results, financial condition, and prospects may be adversely affected. |
• | CoreWeave has a limited number of suppliers for significant components of the equipment it uses to build and operate its platform and provide its solutions and services. Any disruption in the availability of these components could delay CoreWeave’s ability to expand or increase the capacity of its infrastructure or replace defective equipment. |
• | CoreWeave’s business would be harmed if it were not able to access sufficient power or by increased costs to procure power, prolonged power outages, shortages, or capacity constraints. |
• | If CoreWeave’s data center providers fail to meet the requirements of its business, or if the data center facilities experience damage, interruption, or a security breach, CoreWeave’s ability to provide access to its infrastructure and maintain the performance of its network could be negatively impacted. |
• | A substantial portion of CoreWeave’s revenue is driven by a limited number of its customers, and the loss of, or a significant reduction in, spend from one or a few of its top customers would adversely affect CoreWeave’s business, operating results, financial condition, and prospects. |
• | If CoreWeave fails to efficiently enhance its platform and develop and sell new solutions and services and respond effectively to rapidly changing technology, evolving industry standards, changing regulations, and changing customer needs, requirements, or preferences, CoreWeave’s platform may become less competitive. |
• | The broader adoption, use, and commercialization of artificial intelligence (“AI”) technology, and the continued rapid pace of developments in the AI field, are inherently uncertain. Failure by CoreWeave’s customers to continue to use its CoreWeave Cloud Platform to support AI use cases in their systems, or CoreWeave’s ability to keep up with evolving AI technology requirements and regulatory frameworks, could have a material adverse effect on CoreWeave’s business, operating results, financial condition, and prospects. |
• | CoreWeave’s operations require substantial capital expenditures, and it will require additional capital to fund its business and support its growth, and any inability to generate or obtain such capital on acceptable terms, if at all, or to lower our total cost of capital, may adversely affect CoreWeave’s business, operating results, financial condition, and prospects. |
• | CoreWeave’s substantial indebtedness could materially adversely affect its financial condition, its ability to raise additional capital to fund its operations, its ability to operate its business, its ability to react to changes in the economy or its industry, its ability to meet its obligations under its outstanding indebtedness and could divert its cash flow from operations for debt payments, and it may still incur substantially more indebtedness in the future. |
• | The multi-class structure of CoreWeave’s common stock has the effect of concentrating voting power with its Co-Founders (as defined below), which will limit your ability to influence the outcome of important transactions, including a change in control. |
• | See the section titled “Where You Can Find More Information” beginning on page 317 of this proxy statement/prospectus for a listing of documents incorporated by reference into this proxy |
• | integrating the companies’ physical assets, facilities and technologies; |
• | integrating and achieving anticipated synergies of the combined business; |
• | succeeding in applying CoreWeave’s technologies to Core Scientific’s assets; |
• | harmonizing the companies’ operating practices, employee development and compensation programs, internal controls and other policies, procedures and processes; |
• | maintaining existing agreements with commercial counterparties and avoiding delays in entering into new agreements with prospective commercial counterparties; |
• | identifying and eliminating redundant and underperforming assets; |
• | combining certain of the companies’ operations, financial, reporting and corporate functions; |
• | addressing possible differences in business backgrounds, corporate cultures and management philosophies; |
• | consolidating the companies’ administrative and information technology infrastructure; |
• | managing the movement of certain businesses and positions to different locations; |
• | coordinating geographically dispersed organizations; and |
• | effecting potential actions that may be required in connection with obtaining regulatory approvals. |
• | Core Scientific and CoreWeave may experience negative reactions from the financial markets, including negative impacts on their respective stock prices; |
• | Core Scientific and CoreWeave may experience negative reactions from their respective customers, vendors, joint venture and other business partners, regulators and employees; |
• | Core Scientific and CoreWeave will be required to pay certain costs relating to the Merger, such as legal, accounting, financial advisor and printing fees, whether or not the Merger is completed; |
• | the Merger Agreement places certain restrictions on the conduct of Core Scientific’s and CoreWeave’s businesses prior to completion of the Merger, and such restrictions, the waiver of which is subject to the written consent of the other party (such consent not to be unreasonably withheld, conditioned or delayed), and subject to certain exceptions and qualifications, may prevent Core Scientific and CoreWeave from taking certain other specified actions or otherwise pursuing business opportunities during the pendency of the Merger that Core Scientific or CoreWeave would have made, taken or pursued if these restrictions were not in place (see the section titled “The Merger Agreement—Conduct of Business Pending the Merger” beginning on page 229 of this proxy statement/prospectus for a description of the restrictive covenants applicable to Core Scientific and CoreWeave); |
• | matters relating to the Merger (including integration planning) will require substantial commitments of time and resources by Core Scientific and CoreWeave management, which would otherwise have been devoted to day-to-day operations and other opportunities that may have been beneficial to Core Scientific or CoreWeave as an independent company; |
• | in the event of a termination of the Merger Agreement under certain circumstances specified in the Merger Agreement, Core Scientific may be required to pay a termination fee of $270 million to CoreWeave; to the extent that a termination fee is not promptly paid by Core Scientific when due, Core Scientific will be required to pay CoreWeave interest on such fee at the annual rate equal to the prime rate, as published in The Wall Street Journal in effect on the date such payment was required to be made, through the date such payment was actually received; and |
• | Core Scientific and CoreWeave may face litigation related to any failure to complete the Merger or related to any enforcement proceeding commenced against Core Scientific or CoreWeave preventing the performance of their respective obligations pursuant to the Merger Agreement. |
• | operate its cloud infrastructure, including due to supply chain limitations and data center or power availability; |
• | compete with other companies in its industry, including those with greater financial, technical, marketing, sales, and other resources; |
• | continue to develop new solutions and services and new functionality for its platform and successfully further optimize its existing infrastructure, solutions, and services; |
• | retain existing customers and increase sales to existing customers, as well as attract new customers and grow its customer base; |
• | successfully expand its business domestically and internationally; |
• | generate sufficient cash flow from operations and raise additional capital, including through indebtedness, to support continued investments in its platform to maintain its technological leadership and the security of its platform; |
• | strategically expand its direct sales force and leverage its existing sales capacity; |
• | introduce and sell its solutions and services to new markets and verticals; |
• | recruit, hire, train, and manage additional qualified personnel for its research and development activities; |
• | maintain its existing, and enter into new, more cost-efficient, financing structures; and |
• | successfully identify and acquire or invest in businesses, products, or technologies that it believes could complement or expand its platform. |
• | asymmetry between component availability and contractual performance obligations, including where specified components are required; |
• | shifts in market-leading technologies away from those offered by its current suppliers that could impact its ability to offer its customers the solutions and services that they are seeking; |
• | reduced control over production costs and constraints based on the then current availability, terms, and pricing of these components, including any delays in its supply chain (such as the recent delays associated with NVIDIA’s Blackwell GPUs); |
• | limited ability to control aspects of the quality, performance, quantity, and cost of its infrastructure or of its components; |
• | the potential for binding price or purchase commitments with its suppliers at higher than market rates; |
• | reliance on its suppliers to keep up with technological advancements at the same pace as its business and customer demands, including their ability to continue to deliver next generation components that are substantially better than the prior generation; |
• | consolidation among suppliers in its industry, which may harm its ability to negotiate and obtain favorable terms from its suppliers and the third-party suppliers that its suppliers rely on; |
• | labor and political unrest at facilities it does not operate or own; |
• | geopolitical disputes disrupting its or any of its suppliers’ supply chains; |
• | business, legal compliance, litigation, and financial concerns affecting its suppliers or their ability to manufacture and ship components in the quantities, quality, and manner CoreWeave requires; |
• | impacts on its supply chain from adverse public health developments, including outbreaks of contagious diseases or pandemics; and |
• | disruptions due to floods, earthquakes, storms, and other natural disasters, particularly in countries with limited infrastructure and disaster recovery resources, or regional conflicts. |
• | the development, maintenance, and functioning of the infrastructure of the internet as a whole; |
• | the performance and availability of third-party telecommunications services with the necessary speed, data capacity, and security for providing reliable internet access and services; |
• | the success or failure of its redundancy systems; |
• | the success or failure of its disaster recovery and business continuity plans; |
• | decisions by the owners and operators of the data center facilities where its infrastructure is installed or by global telecommunications service provider partners who provide it with network bandwidth to terminate its contracts, discontinue services to it, shut down operations or facilities, increase prices, change service levels, limit bandwidth, declare bankruptcy, breach their contracts with it, or prioritize the traffic of other parties; |
• | its ability to enter into data center agreements and leases according to its business needs and on terms and with counterparties acceptable to it; and |
• | changing sentiment by government regulators relating to data center development, including in response to public concerns regarding environmental impact and development, which may result in restrictive government regulation or otherwise impact the future construction of additional data centers. |
• | customers may develop their own infrastructure that may compete with its services; |
• | some of its customers may redesign their systems to require fewer of its services with limited notice to it and may choose not to renew or increase their purchases of its platform, solutions, and services; and |
• | its customers may have pre-existing or concurrent relationships with, or may be, current or potential competitors that may affect such customers’ decisions to purchase its platform, solutions, and services. |
• | the amount and timing of operating costs and capital expenditures related to the expansion of its business; |
• | any power outages, shortages, supply chain issues, capacity constraints, or significant increases in the cost of securing power; |
• | general global macroeconomic and political conditions, both domestically and in its foreign markets that could impact some or all regions where it operates, including global economic slowdowns, domestic and foreign regulatory uncertainty, changes in trade policies, including the imposition of tariffs, trade controls and other trade barriers, actual or perceived global banking and finance related issues, increased risk of inflation, potential uncertainty with respect to the federal debt ceiling and budget and potential government shutdowns related thereto, interest rate volatility, supply chain disruptions, labor shortages, increases in energy costs and potential global recession; |
• | the impact of natural or man-made global events on its business, including wars and other armed conflict, such as the conflicts in the Middle East and Ukraine and tensions between China and Taiwan; |
• | changes in its legal or regulatory environment, including developments in regulations relating to AI and machine learning; |
• | its ability to attract new and retain existing customers, increase sales of its platform, or sell additional solutions and services to existing customers; |
• | the budgeting cycles, seasonal buying patterns, and purchasing practices of customers; |
• | the timing and length of its sales cycles; |
• | changes in customer requirements or market needs; |
• | changes in the growth rate of the cloud infrastructure market generally; |
• | the timing and success of new solution and service introductions by it or its competitors or any other competitive developments, including consolidation among its customers or competitors; |
• | any disruption in its strategic relationships; |
• | its ability to successfully expand its business domestically and internationally; |
• | equity or debt financings and the capital markets environment, including interest rate changes; |
• | its ability to reduce its cost of capital over time; |
• | decisions by organizations to purchase specialized AI cloud infrastructure from larger, more established vendors; |
• | its ability to successfully and timely deliver its solutions and services to customers under its committed contracts, including due to data center lead times; |
• | its ability to successfully and timely deploy launches of additional data centers; |
• | the timing and success of the integration of new infrastructure, including new GPU generations, into its platform; |
• | changes in its pricing policies or those of its competitors; |
• | insolvency or credit difficulties confronting its customers, including bankruptcy or liquidation, due to individual, macroeconomic, and regulatory factors, including those specifically impacting early-stage AI ventures, affecting their ability to purchase or pay for its platform; |
• | significant security breaches of, technical difficulties with, or interruptions to, the use of its platform or other cybersecurity incidents; |
• | extraordinary expenses such as litigation or other dispute-related settlement payments or outcomes, taxes, regulatory fines or penalties; |
• | the timing of revenue recognition and revenue deferrals; |
• | future accounting pronouncements or changes in its accounting policies or practices; |
• | negative media coverage or publicity; and |
• | increases or decreases in its expenses caused by fluctuations in foreign currency exchange rates. |
• | changes in customer or market needs, requirements, and preferences and its ability to fulfill those needs, requirements, and preferences; |
• | its ability to expand and augment its platform, including through infrastructure and new technologies, or increase sales of its platform; |
• | any power outages, shortages, supply chain issues, capacity constraints, or significant increases in the cost of securing power; |
• | its ability to attract, train, retain, and motivate talented employees; |
• | its ability to retain existing customers and increase sales to existing customers, as well as attract and retain new customers; |
• | the budgeting cycles, seasonal buying patterns, and purchasing practices of its customers, including any slowdown in technology spending due to U.S. and general global macroeconomic conditions; |
• | price competition; |
• | stagnation in the adoption rate or changes in the growth rate of AI and AI cloud infrastructure sectors, including due to emerging AI technologies, which may lead to further compute efficiencies; |
• | the timing and success of new solution and service introductions by it or its competitors, including new competing technologies that may displace cloud infrastructure, or any other change in the competitive landscape of its industry, including consolidation among its competitors or customers and strategic partnerships entered into by and between its competitors; |
• | changes in its mix of solution and services sold, including changes in the average contracted usage of its platform; |
• | its ability to successfully and continuously expand its business domestically and internationally; |
• | its ability to secure necessary funding; |
• | deferral of orders from customers in anticipation of new or enhanced solutions and services announced by it or its competitors; |
• | significant security breaches or, technical difficulties with, or interruptions to the use of its platform, including data security; |
• | the timing and costs related to the development or acquisition of technologies or businesses or entry into strategic partnerships; |
• | its ability to execute, complete, or efficiently integrate any acquisitions that it may undertake; |
• | increased expenses, unforeseen liabilities, or write-downs and any impact on its operating results from any acquisitions it consummates; |
• | its ability to increase the size and productivity of its sales teams; |
• | decisions by potential customers to purchase cloud infrastructure and associated services from larger, more established technology companies; insolvency or credit difficulties confronting its customers, which could increase due to U.S. and global macroeconomic issues and which would adversely affect its customers’ ability to purchase or pay for its platform in a timely manner or at all; |
• | the cost and potential outcomes of litigation, regulatory investigations or actions, or other proceedings, which could have a material adverse effect on its business; |
• | future accounting pronouncements or changes in its accounting policies; |
• | increases or decreases in its expenses caused by fluctuations in foreign currency exchange rates; |
• | its ability to comply with applicable domestic and international regulations and laws and to obtain the necessary licenses to conduct its business; |
• | general global macroeconomic and political conditions, both domestically and in its foreign markets that could impact some or all regions where it operates, including global economic slowdowns, domestic and foreign regulatory uncertainty, changes in trade policies, including the imposition of tariffs. trade controls |
• | the impact of natural or man-made global events on its business, including outbreaks of contagious diseases or pandemics and wars and other armed conflicts, such as the conflicts in the Middle East and Ukraine and the tensions between China and Taiwan. |
• | potential customers’ commitments to existing solutions or services or greater familiarity or comfort with other solutions or services; |
• | its ability to secure sufficient power for its platform and solutions; |
• | decreased spending on specialized AI cloud infrastructure or AI or machine learning development generally; |
• | deteriorating general economic and geopolitical conditions; |
• | future governmental regulation, which could adversely impact growth of the AI sector; |
• | negative media, industry, or financial analyst commentary regarding its platform, AI, and the identities and activities of some of its customers; |
• | its ability to expand, retain, and motivate its sales, customer success, cloud operations, and marketing personnel; |
• | its ability to obtain or maintain industry security certifications for its platform; |
• | the perceived risk, commencement, or outcome of litigation; and |
• | increased expenses associated with being a public company. |
• | slower than anticipated demand for AI and machine learning solutions offered by existing and potential customers outside the United States and slower than anticipated adoption of specialized AI cloud-based infrastructures by international businesses; |
• | fluctuations in foreign currency exchange rates, which could add volatility to its operating results; |
• | limitations within its debt agreements that may restrict its ability to make investments in its foreign subsidiaries; |
• | new, or changes in, regulatory requirements, including with respect to AI; |
• | tariffs, export and import restrictions, restrictions on foreign investments, sanctions, and other trade barriers or protection measures; |
• | exposure to numerous, increasing, stringent (particularly in the European Union), and potentially inconsistent laws and regulations relating to privacy, data protection, and information security; |
• | costs of localizing its platform; |
• | lack of acceptance of localized solutions and services; |
• | the need to make significant investments in people, solutions, and infrastructure, typically well in advance of revenue generation; |
• | challenges inherent in efficiently managing an increased number of employees over large geographic distances, including the need to implement appropriate systems, policies, benefits, and compliance programs; |
• | difficulties in maintaining its corporate culture with a dispersed and distant workforce; |
• | treatment of revenue from international sources, evolving domestic and international tax environments, and other potential tax issues, including with respect to its corporate operating structure and intercompany arrangements; |
• | different or weaker protection of its intellectual property, including increased risk of theft of its proprietary technology and other intellectual property; |
• | economic weakness or currency-related disparities or crises; |
• | compliance with multiple, conflicting, ambiguous or evolving governmental laws and regulations, including employment, tax, data privacy, anti-corruption, import/export, antitrust, data transfer, storage and protection, and industry-specific laws and regulations, including regulations related to AI; |
• | generally longer payment cycles and greater difficulty in collecting accounts receivable; |
• | its ability to adapt to sales practices and customer requirements in different cultures; |
• | the lack of reference customers and other marketing assets in regional markets that are new or developing for it, as well as other adaptations in its market generation efforts that it may be slow to identify and implement; |
• | dependence on certain third parties, including third-party data center facility providers; |
• | natural disasters, acts of war, terrorism, or pandemics, including the armed conflicts in the Middle East and Ukraine and tensions between China and Taiwan; |
• | actual or perceived instability in the global banking system; |
• | cybersecurity incidents; |
• | corporate espionage; and |
• | political instability and security risks in the countries where it is doing business and changes in the public perception of governments in the countries where it operates or plans to operate. |
• | diversion of management’s time and focus from operating its business to addressing acquisition integration challenges; |
• | the inability to coordinate research and development and sales and marketing functions; |
• | the inability to integrate solution and service offerings; |
• | retention of key employees from the acquired company; |
• | changes in relationships with strategic partners or the loss of any key customers or partners as a result of acquisitions or strategic positioning resulting from the acquisition; |
• | cultural challenges associated with integrating employees from the acquired company into its organization; |
• | integration of the acquired company’s accounting, customer relationship management, management information, human resources, and other administrative systems; |
• | the need to implement or improve controls, procedures, and policies at a business that prior to the acquisition may have lacked sufficiently effective controls, procedures, and policies; |
• | unexpected security risks or higher than expected costs to improve the security posture of the acquired company; |
• | higher than expected costs to bring the acquired company’s IT infrastructure up to its standards; |
• | additional legal, regulatory, or compliance requirements; |
• | financial reporting, revenue recognition, or other financial or control deficiencies of the acquired company that it does not adequately address and that cause its reported results to be incorrect; |
• | liability for activities of the acquired company before the acquisition, including intellectual property infringement claims, violations of laws, commercial disputes, tax liabilities, and other known and unknown liabilities; |
• | failing to achieve the expected benefits of the acquisition or investment; and |
• | litigation or other claims in connection with the acquired company, including claims from or against terminated employees, customers, current and former stockholders, or other third parties. |
• | it may not have the right to exercise sole decision-making authority regarding the properties, partnership, joint venture, or other entity; |
• | if its partners become bankrupt or fail to fund their share of required capital contributions, it may choose to or be required to contribute such capital; |
• | its partners may have economic, tax, or other business interests or goals which are inconsistent with its business interests or goals, and may be in a position to take actions contrary to its interests or objectives; |
• | its joint venture partners may take actions that are not within its control, which could require it to dispose of the joint venture asset or purchase the partner’s interests or assets at an above-market price; |
• | its joint venture partners may take actions unrelated to its business agreement but which reflect poorly on it because of its joint venture relationship; |
• | disputes between it and its partners may result in litigation or arbitration that would increase its expenses and prevent its management from focusing their time and effort on its day-to-day business; |
• | it may in certain circumstances be liable for the actions of its third-party partners or guarantee all or a portion of the joint venture’s liabilities, which may require it to pay an amount greater than its investment in the joint venture; |
• | it may need to change the structure of an established joint venture or create new complex structures to meet its business needs or the needs of its partners which could prove challenging; and |
• | a joint venture partner’s decision to exit the joint venture may not be at an opportune time for it or in its business interests. |
• | changes in governmental laws and regulations, including the Americans with Disabilities Act and zoning ordinances, and the related costs of compliance; |
• | increased upfront costs of purchasing real property; |
• | the ongoing need for repair, maintenance and capital improvements; |
• | natural disasters, including earthquakes and floods, and acts of war or terrorism; |
• | general liability, property and casualty losses, some of which may be uninsured; |
• | liabilities for clean-up of undisclosed environmental contamination; and |
• | liabilities incurred in the ordinary course of business. |
• | its intellectual property rights will not lapse or be invalidated, circumvented, challenged, or, in the case of third-party intellectual property rights licensed to it, be licensed to others; |
• | its intellectual property rights will provide competitive advantages to it; |
• | rights previously granted by third parties to intellectual property licensed or assigned to it, including portfolio cross-licenses, will not hamper its ability to assert its intellectual property rights or hinder the settlement of currently pending or future disputes; |
• | any of its pending or future trademark or patent applications will be issued or have the coverage originally sought; |
• | it will be able to enforce its intellectual property rights in certain jurisdictions where competition is intense or where legal protection may be weak; or |
• | it has sufficient intellectual property rights to protect its solutions and services or its business. |
• | consulted with experts on technical accounting matters, internal controls, and in the preparation of its financial statements; |
• | performed a risk assessment over the organization and IT systems used as part of financial reporting and business processes, including the various layers of technology; and |
• | hired additional accounting, finance, and operations resources, including critical leadership roles with public company and internal control experience responsible for designing, implementing, and monitoring its internal controls, including the Chief Accounting Officer, Chief Operating Officer, and Chief Information Officer. |
• | designing, developing, and deploying an enhanced IT General Controls (“ITGC”) framework, including the implementation of a number of systems, processes and tools to enable the effectiveness and consistent execution of these controls; |
• | continuing to implement ITGCs to manage access and program changes within its IT environment and to support the evaluation, monitoring, and ongoing effectiveness of key applications and key reports; |
• | continuing to implement processes and controls to better manage and monitor its segregation of duties risks, including enhancing the usage of technology and tools for segregation of duties within CoreWeave’s systems, applications and tools; and |
• | continuing to expand its resources with the appropriate level of expertise within its accounting, finance, and operations functions; to implement, monitor, and maintain business processes and ITGCs. |
• | it may be difficult for CoreWeave to satisfy its obligations, including debt service requirements under its outstanding debt; |
• | CoreWeave’s ability to obtain additional financing for working capital, capital expenditures, debt service requirements, acquisitions, or other general corporate purposes may be impaired; |
• | a substantial portion of cash flow from operations are required to be dedicated to the payment of principal and interest on CoreWeave’s indebtedness, therefore reducing its ability to use its cash flow to fund its operations, capital expenditures, future business opportunities, and other purposes; |
• | CoreWeave could be more vulnerable to economic downturns and adverse industry conditions and its flexibility to plan for, or react to, changes in its business or industry is more limited; |
• | CoreWeave’s ability to capitalize on business opportunities and to react to competitive pressures, as compared to its competitors, may be compromised due to its high level of debt and the restrictive covenants in the credit agreements that govern its Credit Facilities and the indentures that govern the Notes; |
• | CoreWeave’s ability to borrow additional funds or to refinance debt may be limited; and |
• | it may cause potential or existing customers to not contract with CoreWeave due to concerns over its ability to meet its financial obligations under such contracts. |
• | incur or guarantee additional debt or issue disqualified stock or preferred stock; |
• | pay dividends and make other distributions on, or redeem or repurchase, capital stock; |
• | make certain investments or acquisitions; |
• | incur certain liens; |
• | enter into transactions with its affiliates; |
• | merge or consolidate; |
• | enter into agreements that restrict the ability of restricted subsidiaries to make dividends or other payments to the lenders; |
• | prepay, redeem or repurchase any subordinated indebtedness or enter into amendments to certain subordinated indebtedness in a manner materially adverse to the lenders; |
• | designate restricted subsidiaries as unrestricted subsidiaries; and |
• | transfer or sell certain assets. |
• | actual or anticipated changes or fluctuations in CoreWeave’s operating results; |
• | CoreWeave’s incurrence of any additional indebtedness or any fluctuations in interest rates impacting its existing indebtedness; |
• | the exercise by the former holders of CoreWeave’s Series C convertible preferred stock of the Put Right; |
• | CoreWeave’s ability to produce timely and accurate financial statements; |
• | the financial projections CoreWeave may provide to the public, any changes in these projections, or its failure to meet these projections; |
• | announcements by CoreWeave or its competitors of new offerings or new or terminated significant contracts, commercial relationships, acquisitions, or capital commitments; |
• | industry or financial analyst or investor reaction to CoreWeave’s press releases, other public announcements and filings with the SEC; |
• | rumors and market speculation involving CoreWeave or other companies in its industry; |
• | price and volume fluctuations in the overall stock market from time to time; |
• | the overall performance of the stock market or technology companies; |
• | the expiration of market standoff or contractual lock up agreements and sales of shares of CoreWeave’s Class A common stock by it or its stockholders; |
• | failure of industry or financial analysts to maintain coverage of CoreWeave, changes in financial estimates by any analysts who follow its company, or its failure to meet these estimates or the expectations of investors; |
• | actual or anticipated developments in CoreWeave business or its competitors’ businesses or the competitive landscape generally; |
• | litigation or other proceedings involving CoreWeave, its industry or both, or investigations by regulators into its operations or those of its competitors; |
• | developments or disputes concerning CoreWeave’s intellectual property rights or its solutions, or third-party proprietary rights; |
• | new laws or regulations or new interpretations of existing laws or regulations applicable to CoreWeave’s business; |
• | any major changes in CoreWeave’s management or its board of directors; |
• | the global political, economic, and macroeconomic climate, including but not limited to, actual or perceived instability in the banking industry, potential uncertainty with respect to the federal debt ceiling and budget |
• | other events or factors, including those resulting from war, armed conflict, including the conflicts in the Middle East and Ukraine and tensions between China and Taiwan, incidents of terrorism, or responses to these events; and |
• | cybersecurity incidents. |
• | provide that CoreWeave’s board of directors is classified into three classes of directors with staggered three-year terms; |
• | permit CoreWeave’s board of directors to establish the number of directors and fill any vacancies and newly created directorships; |
• | require supermajority voting to amend some provisions in CoreWeave’s amended and restated certificate of incorporation and amended and restated bylaws; |
• | authorize the issuance of “blank check” preferred stock that CoreWeave’s board of directors could use to implement a stockholder rights plan; |
• | provide that only the chairman of CoreWeave’s board of directors, its chief executive officer, its lead independent director or a majority of its board of directors will be authorized to call a special meeting of stockholders; |
• | eliminate the ability of CoreWeave’s stockholders to call special meetings of stockholders; |
• | do not provide for cumulative voting; |
• | provide that directors may only be removed “for cause” and only with the approval of two-thirds of CoreWeave’s stockholders; |
• | provide for a multi-class common stock structure in which holders of CoreWeave’s Class B common stock may have the ability to control the outcome of matters requiring stockholder approval, even if they own significantly less than a majority of the outstanding shares of its common stock, including the election of directors and other significant corporate transactions, such as a merger or other sale of its company or its assets; |
• | prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of CoreWeave’s stockholders; provided that stockholder action by written consent of a majority of the voting power of all then-outstanding shares of its capital stock is permitted so long as the voting power of all then-outstanding shares of Class B common stock represents greater than a majority of the combined voting power of all then-outstanding shares of its capital stock; |
• | provide that CoreWeave’s board of directors is expressly authorized to make, alter, or repeal its amended and restated bylaws; and |
• | establish advance notice requirements for nominations for election to CoreWeave’s board of directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings. |
CoreWeave Common Stock | Core Scientific Common Stock | Implied Per Share Value of Merger Consideration | |||||||
June 25, 2025 | $159.50 | $12.30 | $19.70 | ||||||
July 3, 2025 | $165.20 | $18.00 | $20.40 | ||||||
[ ], 2025 | $[ ] | $[ ] | $[ ] | ||||||
1 | Based on our exclusive focus on AI cloud computing at the scale and with the capabilities of our platform, solutions, and services as compared to competing hyperscalers and our customer relationships with leading AI labs and AI enterprises, which position us to be among the first to experience and solve the challenges facing the AI cloud computing industry at scale. |
• | AI has advanced significantly. There is a proliferation of new use cases as AI models become more advanced and their capabilities extend beyond simple prediction and rules-based pattern recognition, to foundational model-based applications with human-like reasoning and judgment capabilities. AI is moving beyond generative AI, which is focused on content creation, to agentic AI that takes action to assist and advise across myriads of use cases. |
• | AI is significantly improving outcomes for businesses and individuals. AI is enabling a tectonic shift in productivity that is fundamentally changing the way we interact with technology on a daily basis and is driving material impacts such as faster drug discovery, personalized education, shorter software development cycles, better sales and customer support, and a multitude of other use cases. AI is also helping to narrow the skills gap that exists in specialized, yet highly in-demand occupations, including engineering, law, design, and medicine. |
• | AI is a strategic priority for organizations. AI has become a primary source of competitive differentiation. Management teams and boards are reshaping their technology budgets and rearchitecting their broader corporate strategies through the lens of AI as a strategic imperative. |
• | Foundational models are pervasive and effective. The explosion of commercially available foundational models, both proprietary and open-source, is democratizing access to AI and enabling more enterprises to develop AI products and services. Furthermore, continued investments in and the resulting effects of scaling have made these models more impactful and useful. Availability of performant and efficient cloud infrastructure is critical to run these models effectively. |
• | The amount of data has grown rapidly. The vast amount of enterprise data and accessible public data is being further supplemented by the emergence and rapid growth of AI-generated synthetic data, creating a massive volume of data used to build and train AI models. Enormous amounts of compute and storage capacity will be required to process this data so that it can be deployed for AI use cases. |
• | Infrastructure has evolved to enable AI workloads. New generations of infrastructure deliver significantly greater performance for AI workloads, with much greater speed and at dramatically lower cost, which in turn spurs more innovation as the infrastructure becomes more accessible. GPU performance, which powers AI model training and inference, has increased 7,000 times over the past two decades. |

• | Superior infrastructure performance and efficiency. The AI cloud should be able to extract the maximum possible output from the underlying GPUs and other infrastructure components. To achieve this, it needs to deliver a combination of performance and resiliency to ensure maximum AI training and inference uptime. |
• | Maximize performance. The AI cloud should run the latest and highest performance components and leverage an optimized technology stack that reduces latency and overhead to increase performance. Generalized clouds include virtualized compute, storage, and networking, and a host of managed services that are not required by AI workloads and typically consume additional resources, degrading performance. |
• | Minimize downtime and failure rates. The AI cloud should be able to identify and rapidly solve performance issues and prevent failures before they occur. AI workloads push infrastructure to its limits, causing nodes to fail and inducing storage, memory, and network latencies, which interrupt training runs. This creates delays and increases the cost of compute. GPU offerings from generalized clouds do not have capabilities required for high-performance AI workloads due to their CPU-centric heritage. CPU-based clouds lack the remediation capabilities, such as predictive maintenance and proactive health monitoring, |
• | Rapid access to the latest advancements in infrastructure. AI advancement is limited by the infrastructure that supports it. To continuously push the AI frontier, customers should be able to access the latest advancements in technology for each component of their AI infrastructure. Bleeding-edge AI training workloads today benefit from running on the latest GPUs, CPUs, and DPUs, from the most advanced storage, networking, and memory, and from high-density liquid-cooled data center racks to maximize performance and efficiency. Moreover, the latest advancements in infrastructure technology are not in and of themselves enough. Customers benefit from an integrated solution that enables seamless deployment, automation, orchestration and monitoring of their infrastructure and workloads. |
• | Immediate “out-of-the-box” functionality. The AI cloud should deliver an autonomous, self-service approach with seamless deployment and automation, enabling developers and researchers to focus on delivering cutting-edge AI innovations. If not set up in the right way, due to the newness and the sheer scale of AI infrastructure deployments, GPU acceptance, provisioning, burn-in and testing issues can take months, which can significantly delay time to solution for the latest AI models and the products built on top of them. Moreover, when infrastructure is ready, it typically takes significant involvement from engineering resources to consume the infrastructure and deploy workloads due to a lack of provisioning automation. The AI cloud should be built to minimize delays and resource intensity and work out-of-the-box at scale. |
• | Ability to run and dynamically balance all types of AI workloads. The AI cloud should incorporate dynamic workload scheduling and balancing between inference and training to optimize resource utilization and performance. At present, many AI developers use Slurm and Kubernetes as their orchestration and scheduling frameworks for training and inference compute, respectively, and are forced to run separate pools of capacity for each. This results in underutilization of their infrastructure, which results in a material reduction of efficiency and increase in cost. Customers should be able to host a wide variety of AI workloads such as training and inference on the same clusters concurrently and seamlessly. |
• | Flexibility and customization with a specialized technology stack. Generalized cloud environments lack the flexibility to meet the specialized needs of AI applications, often forcing customers into rigid, predefined solutions. The AI cloud should be built to enable maximum composability, offering customers the freedom to tailor infrastructure and operational setup around their unique set of design requirements. Customers need a trusted partner with a track record of delivering performant and efficient AI cloud services at massive scale. |
• | Lower performance-adjusted cost. The AI cloud should deliver superior value by prioritizing performance and efficiency to help ensure that customers get the maximum utilization out of their infrastructure investments. Generalized clouds that are not purpose-built for AI burden customers running AI workloads with lengthy setup times, higher failure rate, longer downtime, and manual engineering workflows. As a result, running AI workloads on them requires more time, effort, and compute, degrading cost relative to performance. |

• | Highly efficient infrastructure. Our CoreWeave Cloud Platform delivers more optimized MFU than the cloud infrastructure provided by generalized hyperscalers, thereby minimizing the efficiency gap between the observed GPU cluster performance and the theoretical maximum. Based on internal testing, our CoreWeave Cloud Platform offers up to approximately 20% improvement in system MFU over comparative benchmark MFU performance. This is achieved through the performance at scale of our CoreWeave Cloud Platform, including optimizations such as Tensorizer to accelerate modeling loading and checkpointing, our purpose-built infrastructure, and our rapid fault remediation and failure prevention capabilities. As a result, our customers either derive more performance out of their existing clusters or need less infrastructure to achieve the same level of performance. |
• | Performance at scale. Our infrastructure is optimized to run AI workloads, delivering cutting-edge performance to AI model training and inference use cases. Our capabilities, such as Bare Metal GPU nodes, operate with highly performant system technologies, a scale-out network with one of the industry’s leading effective network speeds, storage services with data read speeds of up to 2GB per second per GPU, and software optimizations to efficiently utilize infrastructure performance. Our compute nodes spin up rapidly, our cloud enables seamless autoscaling to accommodate complex training runs, and our rapid model loading capabilities, facilitated by our Tensorizer solution, significantly reduce inference latency. Our CoreWeave Cloud Platform has broken performance records, including setting an MLPerf record that was 29 times faster than competitors in 2023. And recently, we delivered another best-performing submission with the largest-ever MLPerf Training v5.0 submission on NVIDIA Blackwell, using 2,496 NVIDIA Blackwell GPUs running on CoreWeave’s AI-optimized cloud platform. |
• | Reliability and Resilience. Our Mission Control suite of capabilities help deliver and maintain vetted cloud infrastructure and provide observability into the health and performance of the entire solution. This helps ensure that our customers’ clusters continue to operate at ideal performance, quickly recover from any hardware events, and ultimately get better value by using our cloud solution. Moreover, our automated GPU node validation capabilities ensure when nodes are remediated that they are immediately made available for use and do not remain idle. This allows our customers to focus more of their time and resources on building new products faster instead of managing AI infrastructure. |

• | Faster access to latest AI infrastructure advancements. Our customers benefit from faster access to the latest AI infrastructure advancements, including our access to the latest GPU technologies at scale. Our CoreWeave Cloud Platform enables customers to run their AI workloads on highly performant compute, networking, and storage infrastructure, optimized through our dedicated infrastructure management and workload orchestration software. We have a track record of being among the first to market with cutting-edge infrastructure technology. For instance, we were among the first to deliver NVIDIA H100, H200, GH200 clusters and the first to deliver GB200 clusters into production at scale and launch instances based on RTX Pro 6000. We now have one of the widest Blackwell portfolios available, including B200, and we were the first cloud provider with an initial deployment of NVIDIA GB300 NVL72-based systems. We are able to deploy the newest chips in our infrastructure and provide the compute capacity to customers in as little as two weeks from receipt from our OEM partners such as Dell and Super Micro. This allows our customers to take advantage of the latest innovations in AI infrastructure and performance to innovate, build new products, and serve customers faster. |
• | Highly performant on day 1. Our full-featured managed software services make the consumption of infrastructure seamless. Automated provisioning and node validation remove the need for manual burn-in testing and ensure our highly-performant CoreWeave Cloud Platform is up and running for new customers and ready for consumption in a matter of hours from customer acceptance. Customers take receipt of the infrastructure and can immediately schedule and run training and inference jobs instead of investing significant time and resources in stress-testing compute nodes and verifying their health. CKS helps to ensure workloads of any type can be immediately scheduled on the infrastructure, while Mission Control automatically vets all the infrastructure to ensure on an ongoing basis that any faults are proactively detected and remediated. This shifts the burden of infrastructure management away from customers, significantly reducing costs and accelerating their time to solution. |
• | Efficient GPU fleet utilization. Our CoreWeave Cloud Platform is architected to support all types of AI workloads, including training (consisting of pre-training and fine tuning), synthetic data generation, and inference, covering the full spectrum of customer requirements. Customers can orchestrate all these types of inference and training workloads across the same cluster simultaneously, enabled by our industry-leading Slurm integration, SUNK. Running different types of jobs on the same cluster at the same time increases the utilization of a customer’s AI infrastructure by allowing customers to seamlessly transition between Slurm based training jobs and containerized inference workloads on the same GPU cluster, negating the need to have two discrete clusters with lower efficiency. CKS, in conjunction with SUNK, enables this intelligent management of workload scheduling to prioritize serving inference demand spikes and better utilize GPU clusters across training and inference. |
• | Flexible technology stack. We adapt to our customers’ needs, enabling our customers to obtain the platform most ideal for their AI applications to run on. Our team is committed to moving quickly and solving problems for our customers that have never been addressed before as they develop and serve the next generation of foundational models. This partnership extends beyond support. Our flexibility is a key asset for our customers as we do not ask them to compromise, but rather empower them to integrate with our platform in the way that best suits their needs. Our microservices-based architecture tailored to AI enables this flexibility. For instance, customers can choose to bring their own storage instance, opt to run on Bare Metal, can elect for committed or on-demand deployment, and can generally configure their use of our CoreWeave Cloud Platform to best fit their requirements. This enables customers to obtain the platform most ideal for their AI applications to run on, providing them with exactly what they require without needing them to make tradeoffs or compromises that leads to reduced efficiency and increased costs. |
• | Lower performance-adjusted cost. We deliver efficiency to our customers through fully optimized AI performance out-of-the-box, our rapid cluster remediation and failure prevention capabilities, and our differentiated ability to simultaneously and seamlessly run inference and training jobs on the same clusters. All this results in significantly improved infrastructure efficiency and higher MFU, which translates to lower costs relative to solutions provided by other cloud service providers for demanding AI workloads. |
• | We are purpose-built for AI. Our platform is fundamentally architected from the ground up to deliver cutting-edge performance for AI workloads. We have reimagined the traditional cloud architecture to deliver the infrastructure and technology stack required for AI, optimizing it to remove services such as the hypervisor layer and other unnecessary managed services that would otherwise cause performance leakage. It is built to efficiently run workloads on Bare Metal nodes, which makes our CoreWeave Cloud Platform more transparent given the wealth of GPU node-level metrics generated by our stack that most competing solutions are unable to retrieve. Our Managed Software Services, which include our orchestration solution, CKS, and our application services, are optimized for complex AI workloads. Our infrastructure is built on cutting-edge components, including the latest-generation GPUs, networking, and high-performance storage, all working cohesively to deliver unprecedented performance to our customers. Importantly, our data centers are also designed with our “no compromise” philosophy centered around AI, with our current builds incorporating liquid cooling where possible to maximize rack density and drive higher utilization of our data center footprint. These innovations are what enable us to help bridge the efficiency gap between the approximately 35% real-world infrastructure MFU and the 100% theoretical maximum. |
• | We live at the bleeding-edge of technology. Our diverse, multi-disciplinary team is founded on a culture of saying yes to delivering our customers’ needs. We are fearless in facing and overcoming complex engineering challenges, and we hire individuals who help contribute to and maintain a culture centered around this philosophy. We raise the standards of execution to meet the needs of our customers, which include some of the largest and most sophisticated organizations that themselves live on the bleeding-edge. We have demonstrated this in our ability to create some of the largest and most performant GPU clusters assembled to date, develop a rich suite of software and services that maximizes infrastructure utilization and efficiency, deliver against an accelerated data center build schedule, and consistently be among the first to market with cutting-edge infrastructure components. We were among the first to deliver NVIDIA H100, H200, GH200 clusters and the first to deliver GB200 clusters into production at scale and launch instances based on RTX Pro 6000. We now have one of the widest Blackwell portfolios available, including B200, and we were the first cloud provider with an initial deployment of NVIDIA GB300 NVL72-based systems. |
• | We operate at scale. We benefit from a network of 33 active purpose-built data centers supported by approximately 470 MW of active power as of June 30, 2025. There is a massive operational capability difference between operating clusters of thousands versus tens of thousands of GPUs. Our track record of operating at scale enables us to participate in this market in ways that others cannot. Our specialization in deploying AI infrastructure at massive scale enables us to serve some of the world’s leading providers of AI who require massive deployments in order to effectively train and serve the latest foundational models. Moreover, it enables us to benefit from clear economies of scale. It lends us critical brand recognition in the AI ecosystem that accelerates inbound demand for our solutions. It strengthens our supply chain relationships and enhances our access to the best engineering and product talent. And, importantly, it enables us to detect issues and derive insights from across our AI infrastructure sooner than our competitors. Over the long term, our platform delivers superior performance and value as a result. |
• | We have a proven track record of securing power. Power is a key enabler of the AI revolution and an asset that we have managed to secure at scale. As of June 30, 2025, we had approximately 470 MW of active power and approximately 2.2 GW of total contracted power. This provides us with a durable, multi-year runway in power capacity. We relentlessly and creatively explore additional opportunities to add power capacity, as demonstrated by our original agreements with Core Scientific for more than 500 MW of capacity as of December 31, 2024. |
• | We have demonstrated unique financing capabilities. We have designed our capital structure to enable the investments needed to maintain growth at the pace of AI innovation. We have pioneered GPU infrastructure-backed lending, and to date, we have raised over $28.6 billion in debt and equity across 22 financings. In May 2024, we raised $7.6 billion in committed GPU infrastructure-backed debt led by Blackstone and Magnetar, which represents one of the largest private debt financings in history and signals the confidence that debt investors have in funding our company to build and scale the next generation AI cloud. Since then, we have built on our momentum with a further $2.6 billion GPU infrastructure- |
• | We maintain robust ecosystem relationships. We benefit from strong, mutually beneficial relationships with our suppliers and customers that strengthen our solution and market position. Our relationship with NVIDIA strengthens our supply chain. We work with NVIDIA to deploy the latest GPU technologies at scale. In turn, we are a partner to NVIDIA in that our proprietary software and purpose-built infrastructure help to minimize the efficiency gap between the observed GPU cluster performance and the theoretical maximum GPU cluster performance, help to diversify their customer base, and help to get their technology in the hands of end customers faster. Our relationships with some of the world’s leading and most discerning AI labs and AI enterprises, including Microsoft, Meta, and OpenAI, further position us as a cornerstone of the evolving AI ecosystem and creates a flywheel that strengthens our engineering advantage through continuous learning and development. |

• | Extend our product leadership and innovation. We pioneered2 the AI Hyperscaler and are committed to innovating to extend our technology leadership. Our team operates at the bleeding-edge of technological advancement and continues to deliver new solutions and optimize our technology stack to deliver substantial performance and efficiency gains for AI workloads at scale. We have delivered and unlocked |
2 | Based on the capabilities of our platform, solutions, and services as compared to competing hyperscalers, our track record of being among the first to deliver bleeding-edge infrastructure and technology, and our collaboration with leading data center providers and AI labs and AI enterprises to accelerate innovative technology and infrastructure in the AI cloud computing industry. |
• | Continue capturing additional workloads from existing customers. Our CoreWeave Cloud Platform serves some of the most powerful AI labs and AI enterprises that are building AI products today. Through some of these cornerstone customers, it addresses a massive volume of AI workloads directly from them or through their APIs. As these leading providers of AI continue to achieve product market fit with the latest foundational models, their training and inference workload volume will scale exponentially. Our dedicated focus on both AI labs and AI enterprises will enable us to achieve natural growth across this customer segment as AI continues to become ubiquitous, and as these customers realize the performance and efficiency benefits of our CoreWeave Cloud Platform. We have built dedicated teams of AI-experts across our engineering, product, sales and customer experience organization that understand customers’ needs for rapidly evolving AI use cases. These teams work hand-in-hand with our customers to help them better understand our product capabilities and innovations to best position us to capture increasing spend as they expand. |
• | Extend into broader enterprise customers across new industries and verticals. Our current and potential customers include the world’s premier AI labs and AI enterprises, for whom AI is a core component of their product strategy and overall business model, and who depend on our CoreWeave Cloud Platform to deliver the next generation of AI models and applications. As AI continues to become ubiquitous in daily life and as other verticals and industries, including regulated industries like banks, high-frequency trading, and pharmaceutical companies, begin to develop and build their own dedicated AI solutions, we plan to expand to serve those verticals and capitalize on the opportunity to provide our CoreWeave Cloud Platform to host their workloads. Although it is early, we have already started to see strong interest from such industries. We also anticipate that new industries and use cases will arise to take advantage of developing AI capabilities as AI models become more accessible and cheaper, presenting additional growth opportunities for our platform. We believe that our acquisition of Weights & Biases will enable us to improve our CoreWeave Cloud Platform to address the needs of customers who are researching, building, and deploying AI models and applications. Following closing of the acquisition, we have integrated Weights & Biases’ capabilities as a new entry point for customers to access our CoreWeave Cloud platform and take advantage of the differentiated infrastructure and managed software services that we offer such as our Mission Control Integration and W&B Inference, powered by the CoreWeave Cloud Platform. |
• | Expand internationally. We are expanding our business to capitalize on growing demand for AI applications and solutions across the globe, driven by customers’ desire to build their AI applications locally and minimize latency. In 2024, we established a presence in London, United Kingdom, Barcelona, Spain, and Falun, Sweden, with more than 40 MW of active power in these locations as of December 31, 2024. In addition, we have contracted data center capacity in Canada, Sweden, Norway, and other countries in Europe with additional capacity in the pipeline. In addition, regulatory frameworks are expected to increasingly restrict data from flowing across borders, meaning that AI models may eventually need to be trained on regional data pools and served locally. Expanding our reach in key international markets enables us to serve that regional demand for AI compute. We are methodical around our international expansion and tailor it to where we see the most demand for AI compute. |
• | Increase our vertical integration. We plan to continue to verticalize “up the stack” by innovating and adding to our software offerings to drive customer engagement and value (such as the acquisition of Weights & Biases). At the same time, we may continue to verticalize “down the stack” by enhancing our data center capabilities to bolster our access to data center capacity, future-proof our solutions, and drive further operational efficiency (such as the acquisition of Core Scientific). We intend to achieve further vertical integration either organically or through targeted acquisitions. |
○ | Verticalize “up the stack.” The strategic position of our solution as the control plane which drives the performance, efficiency and visibility into the underlying infrastructure enables us to build additional functionality and services on top of it, including dedicated layers of abstraction and automation to simplify the way customers interact with our infrastructure, as well as solutions for fine-tuning AI models and production environments for AI applications. This enables our customers to access |
○ | Verticalize “down the stack.” As data centers continue to evolve and take center stage as the next-generation supercomputers driving the AI revolution, our ability to further manage and customize our data center footprint will de-risk our future growth and expense. Currently, the majority of our data center portfolio is leased. We may make investments into data centers and increase the proportion of our data center footprint where we have direct ownership stakes. This will enable us to have more control and accountability over the delivery timeline of new builds, and allow us to exert more control over our data center costs. |
• | Maximize the economic life of our infrastructure. We seek to maximize the value of our fleet of GPUs to the fullest extent possible, and do this by monetizing the infrastructure underlying expired contracts through either another contract for the remainder of its economic life or through an on-demand consumption pool. We expect a large number of GPUs to become available for the on-demand distributed compute pool as our customers renew contracts with future generations of chips. These current generation chips will be well-suited to handle inference workloads and lower intensity training workloads after contracts expire, which will lead to cost optimal solutions for our customers. As the AI revolution continues and more widespread enterprise adoption of AI workloads occurs, there will be a breadth of workload complexity levels which will need to be matched to infrastructure with varying levels of performance and cost. Some of those workloads will be less computationally intensive and can be served by older generations of infrastructure. |

• | Compute. Our compute is delivered through combinations of GPU and CPU nodes interconnected with state-of-the-art, high-performance networking technology such as NVIDIA InfiniBand and optimized through DPUs in a high throughput network topology that provides extensive scalability for AI workloads. GPU nodes are the primary engines for AI compute and are supported by the latest generation of CPUs, memory, PCI-Express data interconnects, NVMe SSDs, and DPUs. These components help to extract maximum performance out of GPUs and also offload non-core tasks. We continuously monitor the health and performance of GPU and CPU nodes to ensure improved resilience and rapid recovery. |
• | GPU Compute. We provide our customers with access to a vast portfolio of high-performance GPUs that are purpose-built for AI. This includes Blackwell chips, such as the NVIDIA GB200 that we were the first to market with at production scale, Hopper chips, and more. Our H100 architecture enabled us to break the MLPerf record in 2023, delivering training speeds 29 times faster than competitors at greater scale. And recently, we delivered another best-performing submission with the largest-ever MLPerf Training v5.0 submission on NVIDIA Blackwell, using 2,496 NVIDIA Blackwell GPUs running on CoreWeave’s AI-optimized cloud platform. We were among the first to deliver NVIDIA H100, H200, GH200 clusters and the first to deliver GB200 clusters into production at scale and launch instances based on RTX Pro 6000. We now have one of the widest Blackwell portfolios available, including B200, and we were the first cloud provider with an initial deployment of NVIDIA GB300 NVL72-based systems. |
• | CPU Compute. We offer versatile CPU instances to support AI workloads. Our infrastructure utilizes some of the industry’s highest performing and latest CPUs instead of prior generation technology that can degrade GPU performance and utility. Our CPUs complement our GPUs by performing tasks, including data pre-processing, control plane functions, and workload orchestration, which frees GPUs to focus on compute intensive tasks. |
• | DPUs. DPUs optimize compute for AI workloads by offloading networking, security, and storage management tasks from GPUs and CPUs. They are a critical enabling component for increasing overall efficiency and performance. |
• | Nimbus. Nimbus is our control and data-plane software running on our DPUs inside Bare Metal instances, performing the typical role of a hypervisor in enabling security, flexibility and performance. Nimbus-enabled DPUs remove the need for a virtualization layer and give customers the flexibility to run directly on our servers without a hypervisor, enabling greater compute performance. Nimbus also provides security through the isolation of customer models and data encryption, while enabling them to set up Virtual Private Cloud environments. |
• | Networking. Our networking architecture is highly specialized and uniquely designed to meet the complex needs of AI use cases. It includes our high-performance InfiniBand based cluster networking, our data center network fabric which connects our GPU and CPU nodes to our control plane via DPUs for efficient offloading of certain processing tasks, our VPC networking framework, as well as our Direct Connect offering which provides enterprise-grade networking and supports multi-cloud deployments. The ultra-fast connection and superior throughput enabled by our networking architecture ensures faster training and inference times for our customers. |
• | Cluster Networking is the result of our relationship with NVIDIA to design a networking architecture that is purpose-built for AI clusters. The NVIDIA InfiniBand network that we deploy is one of the largest in existence with up to 3,200Gbps of non-blocking GPU interconnect and provides industry-leading effective networking throughput to accelerate time to train and serve models. Our Blackwell deployments will further be supported by external NVLink Switches, a low latency, scalable, and energy-efficient protocol that allows GPUs to communicate with other GPUs and CPUs within the same and different systems more efficiently. These technologies enable us to offer our customers access to tens of thousands of GPUs connected in a single cluster, and the ability to create massive megaclusters. Our megacluster resilience is supported by Mission Control, which prevents and rapidly remediates any deficiencies that arise. |
• | VPC Networking creates isolated virtual networks to manage CoreWeave Cloud Platform resources, allows customers to securely connect compute, storage, and networking resources to their development and deployment platforms using the latest security best practices including encryption, isolation, and access control. |
• | CoreWeave Direct Connect plugs into our carrier grade networking backbone and enables embedded scale that supports our data centers. It is built to support multi-cloud needs, operates across the United States and Europe, and provides private, highly performant connections to transfer data with speed and security. It allows our customers to easily connect their CoreWeave clusters with resources available at other cloud providers or on-premises. Direct Connect boasts port speeds of up to 400Gbps, flexible options to connect through either dedicated ports or existing carriers, and budget-friendly costs with no data transfer or egress fees. |
• | Storage. Our systems incorporate enterprise-grade, software-defined scale-out storage capabilities. Our highly performant, secure, and reliable storage capabilities are designed for the most complex and demanding AI workloads. They load data at rapid speeds, enabling large distributed AI workloads to be scaled up in seconds. These storage capabilities also allow customers to benefit from auto-provisioning of GPUs and store large volumes of model checkpoints and intermediate results so that teams can stay on track after interruptions to their training or inference jobs. Our purpose-built storage architecture enables our customers to achieve significantly faster load times. Our storage services, which include object storage and distributed file storage, leverage industry-best security practices, including encryption at rest and in transit, role-based identity access management, and authentication. |
• | Object Storage. Given traditional object storage solutions are not designed for accelerated workloads, customers typically need to leverage a caching layer on top of object storage to run their GPU clusters at top performance. Our object storage solution is built from the ground-up specifically for AI. It eliminates the need for an intermediate cache based on a file storage system. It leverages our proprietary Local Object Transport Accelerator, which caches data locally onto GPU nodes to deliver the performance required to go straight from object storage to GPUs and is able to provide up to 66% price/performance than alternative solutions from traditional providers. |
• | Distributed File Storage. We offer distributed file storage solutions that centralize asset storage and support parallel computation setups. For customers who require these features and prefer to utilize a distributed file storage system in addition to object storage, our Distributed File Storage system provides the flexibility to do so. Our platform also enables customers who run on-premise to integrate their own distributed file storage system into our platform, providing a truly flexible technology stack that is designed to support our customers’ storage needs. |
• | Dedicated Storage Clusters. Our microservices based architecture allows us to support our customers’ choice of storage back-ends. We work with an ecosystem of storage cloud partners to provide flexibility and choice in order to get access to their preferred storage solutions that are well integrated with our CoreWeave Cloud Platform. |

• | CoreWeave Kubernetes Service. CKS is our AI-optimized, managed Kubernetes service that minimizes the burden of managing large GPU clusters. CKS is purpose-built for AI workloads and delivers fast performance, security, and flexibility in a fully managed Kubernetes solution. CKS has built-in guardrails and automated processes specialized for AI workloads that reduce the need for teams to spend countless hours managing complex Kubernetes clusters. CKS clusters leverage Bare Metal nodes without a hypervisor to maximize node performance, and our DPU-based architecture for complete isolation and acceleration with private-cluster VPCs. As such, CKS ensures that each node operates at peak performance within a secure, isolated environment. There are extensive customization options available to manage data, control access and policy, and handle authentication and other security controls, giving customers ultimate flexibility and authority over their specific data management practices. |
• | Virtual Private Cloud. Our VPC solution allows customers to utilize an isolated, private section of our CoreWeave Cloud Platform where they can run their resources in a controlled network environment. It delivers a flexible experience backed by enhanced security, with both direct control and a high degree of customization. It enables hyper specific networking policies on a workload-by-workload basis, including terminating VPNs, managing routing, and access control. Our robust node isolation capabilities create both data and VPC segregation that deliver maximum security for our customer workloads. |
• | Bare Metal. Our Bare Metal service is fast, reliable, and performant. The vast majority of AI workloads do not need virtualization. Instead, they need direct access to resources to run training, inference, and experimentation with maximum performance and low latency. We eliminate the need to have a hypervisor layer and enable our customers to run Kubernetes, or an orchestration platform of their choice, directly on Bare Metal instances. This allows us to combine the flexibility of cloud-like provisioning and the power and performance of dedicated hardware, unlocking higher performance, increasing reliability, freeing up compute resources, and allowing for in-depth insights on cluster health and performance through granular metrics. For customers who prefer a more managed experience, our Bare Metal service also enables customers to spin up Bare Metal nodes in CKS and offload certain basic functions such as storage and network drivers. |
• | Slurm on Kubernetes Integration (SUNK). Slurm is an open-source workload manager popular among AI model developers and other users of high-performance compute. It is an industry leader for the orchestration of massive parallel scheduling jobs such as training LLMs. Kubernetes, on the other hand, is designed for containerized workloads in cloud-native environments making it particularly well suited for model serving. Customers previously had to either choose between Slurm or Kubernetes on a per cluster basis for their resource management needs, even though the two applications serve different use cases and excel in different environments. Often, this led to maintaining two distinct platforms and pools of compute. We have eliminated the need to choose between Slurm or Kubernetes by creating SUNK, a proprietary offering released in early 2024 that integrates Slurm with CKS and allows for Slurm jobs to run inside Kubernetes. This allows developers to leverage the resource management of both Slurm and Kubernetes and results in a seamless end-user experience. Different AI workloads can be co-located on the same cluster, including training, inference, and experimentation, unlocking greater workload fungibility. SUNK enhances the efficiency of compute by sharing resources between Slurm and Kubernetes and streamlining deployment of our system. Introducing Slurm into our stack has solved a major infrastructure pain point for our customers while reducing their total cost of ownership. |
• | CoreWeave Tensorizer. CoreWeave Tensorizer is our training and inference optimization solution that spins up models rapidly from storage directly into GPU memory from a variety of different endpoints. It serializes models into a single binary file and incorporates a caching layer to quickly flow models to the closest node to the client, thereby dramatically cutting down resource expenditure caused by long loading |
• | Weights & Biases Models. Following the closing of our acquisition of Weights & Biases, our platform now includes integrations to the Models product-line, which extends the capabilities we currently offer with SUNK and Tensorizer to include real-time tracking and visualization of training runs, customer packaging, and workflow optimization, and the ability to further optimize hyperparameters, track model lineage, and fine-tune both open-source and proprietary models. |
• | Inference Optimization & Services. Our platform is optimized for inference, delivering unparalleled flexibility, efficiency and access to the compute required to serve these workloads effectively. Through our planned inference optimization services, customers will be able to right-size their workloads with access to a varied GPU fleet customized to their specific performance and cost requirements, and can provision what they need when they need it to match the complexity of their workloads. Following the closing of the acquisition, we have implemented integrations with the Weights & Biases’ Weave product into our inference optimization services, such as “W&B Inference, powered by CoreWeave,” supporting the real-time monitoring and debugging of LLMs and prompts, providing additional tools for rigorous evaluation of generative AI applications, and enabling monitoring and debugging agents and prompts. |
• | Fleet LifeCycle Controller (FLCC). Our Fleet LifeCycle Controller automates node provisioning, testing, and monitoring to validate nodes and systems for Day 1 operations and beyond. |
• | Node LifeCycle Controller (NLCC). Our Node LifeCycle Controller proactively assesses ongoing node health and performance to ensure problematic nodes are replaced with healthy ones before they cause failures. Both FLCC and NLCC are systems that are running on our back-end. |
• | Observability. Our Observability solution provides access to a rich collection of node and system-level metrics to complement the capabilities of Mission Control that help prevent or quickly identify system faults and restore system-level performance. Faults can occur for various reasons, such as bad user configuration (memory allocation issues), misbehaving software updates, server component malfunctions, or issues in the high speed node-to-node network. Customers can collect and receive alerts on metrics across their fleet, using dashboards that visualize either the entire cluster or individual jobs, and identify root-cause issues in a matter of minutes, as well as early warning signs that enable them to replace or repair nodes that are close to failure. Our Observability solution gives customers deep insight into their infrastructure down to the temperature of individual GPUs. |

• | Fleet Ops and Cloud Ops: Teams that support our FLCC and NLCC solutions and function as operations centers supporting overall system resilience across our customers’ infrastructure. Our Fleet Ops team monitors how fleets are operating, while our Cloud Ops team monitors customer-specific deployments. |
• | Support specialists: Dedicated Support Operations Engineers and Customer Success Engineers who are tasked with setting-up deployments and working with customers to scale workloads as quickly and efficiently as possible. These teams help our customers achieve their goals with our product through proactive support and resources and focus on understanding and assisting customers post-sale to foster long-term relationships. Our team of engineering experts is available 24/7 to assist customers and provide the support needed to ensure optimal cluster performance. Support specialists also include our Documentation team, which creates and maintains the technical documentation to support our customer success, sales, and marketing teams. |
• | Solutions architects: Experts who work with our engineering teams to ensure customer infrastructure runs at peak performance. Our solutions architects focus on helping customers understand and derive value from our platform, and cover both pre-sale and post-sale processes including proof-of-concept, implementation, switching to new architectures, and ongoing management/deployment. They ensure customers derive maximum value from their infrastructure and assist with any tuning work required to unlock the leading performance of our platform. |

• | Cutting-edge data center technologies maximize rack density. Our data centers are purposefully designed to maximize rack density and drive power per rack. They utilize advanced liquid cooling systems that enable the efficient use of space by removing the bulky chillers and airflow management equipment required in air cooling systems. The improved heat capacity of liquid cooling systems also allows us to stand up racks closer together, supporting higher power density while preventing performance degradation of our systems due to overheating. Liquid cooling systems, while highly efficient at supporting dense, power-intensive workloads, require a fundamental redesign of the data center in order to accommodate necessary piping, pumps, and heat exchangers. This often entails having a separate subfloor to contain routing and plumbing infrastructure while keeping the main floor more organized and compact to drive density. |

• | Broad Footprint. We have architected a distributed and interconnected portfolio of data centers that delivers a high density of compute close to major population centers, thereby minimizing latency for end users. Our portfolio covers cities spanning the United States and is rapidly expanding into new markets in Europe, delivering high-compute capacity to regions that are currently capacity constrained. |
• | Massive Scale. Delivering highly performant and flexible infrastructure means building high capacity data centers that can quickly scale from tens to hundreds of megawatts in response to burst workloads, i.e., sudden surges in demand. We leverage dark fiber connectivity to deliver rapid and efficient inter-data-center connectivity and enable customer workloads to burst across regions. By connecting multiple active purpose-built data centers with high speed interconnects, we deliver the flexible compute required for large scale supercomputers optimized for AI workloads, and can scale this compute to match our customers’ needs. |
• | Embedded Security. We reinforce our infrastructure with industry leading security standards and certifications, including SOC 2 and ISO 27001, to ensure that customers are met with the most robust data security practices. Our security measures also extend to our physical security, where we employ rigorous standards around background checks, access control, security awareness training, and a zero-trust framework. This multi-layered approach ensures a secure, resilient operating environment at every level of our data centers. |
• | Be Curious at Your Core. We foster a mindset of continuous learning, understanding that curiosity drives innovation and is essential in staying ahead of our competition. Curiosity is a driving force that allows us to explore ideas and innovations that push boundaries, challenge the status quo, and better serve our customers. |
• | Act Like an Owner. We take full responsibility for our work and our decisions to find the best solution to any challenge. We take initiative, hold ourselves accountable, and foster a culture where everyone feels empowered to contribute to our success. |
• | Empower Employees. We trust each other to make decisions, communicate transparently, and are clear on our goals. We support each other with the tools, resources, and feedback necessary to succeed. |
• | Deliver Best-in-Class Customer Experiences. We go above and beyond to understand our clients’ needs and aim to exceed expectations at every step. Our commitment to excellence ensures we build lasting partnerships and set the standard for exceptional service. |
• | Achieve More Together. Collaboration is at the heart of our success. Together, we unlock greater potential and solve challenges more effectively. We believe that by leveraging diverse perspectives, supporting each other, and working as one team, we can accomplish more than we could ever do alone. |
• | Diversity. Ensuring diversity—in background, skill set, and perspective—which is business critical to continuing to innovate and bring new products into the market to effectively serve our customer base and new AI use cases. |
• | Inclusion. Ensuring all employees have opportunities to learn, grow, develop, and perform the best work of their lives. |
• | Belonging. Ensuring that all our employees feel they are a meaningful part of CoreWeave and they matter. |
• | AI Natives: Customers whose core competency and singular focus is AI. These companies serve as important layers of abstraction for the market and enable end customers across industries to unlock the power of AI by accessing the power of foundational models. This vertical includes: |
• | AI Labs: Research organizations building their own foundational models through proprietary datasets, and creating products to deliver those models to the market. While these labs have tended to focus more on building general-purpose models, industry-specific AI labs, such as the AI cluster at the Chan Zuckerberg Initiative Foundation supporting research in the life sciences, are expected to become a growing part of this segment. These AI labs deliver their general purpose models or custom versions of those models via APIs to businesses of all shapes and sizes in order to power a growing range of applications. Our AI Lab customers include, among others, Cohere, Mistral AI, and OpenAI. |
• | AI Ops / ML Ops: Organizations providing software or platform solutions “up the stack” from cloud infrastructure to make AI adoption easier for businesses with inference or training needs. These companies provide a range of solutions, including access to pre-trained model hubs and datasets, APIs to streamline model deployment, and dedicated tooling that helps optimize training and fine-tuning techniques. Companies within this space will be critical enablers of AI and its broader adoption as they will support customers who either lack the willingness, expertise, or financial means to build proprietary models through their own research teams and dedicated infrastructure. AI Ops / ML Ops customers include, among others, Replicate. |
• | AI Enterprises: Large companies whose business and product are not AI, but are being driven by AI. These include Fortune 500 companies and other large enterprises with business models that are increasingly AI-enabled through their own development efforts and/or that leverage AI directly to drive internal efficiency gains. We have seen initial traction in adopting our platform from big tech, financial institutions, and life sciences companies to date with customers such as Meta, IBM, Microsoft, and Jane Street. |

• | Since 2022, Replicate has selected CoreWeave as its cloud provider to unlock access to high- performance compute for its inference needs, leveraging CoreWeave’s full-stack cloud platform delivered in a fully managed format. |
• | Radically simplified infrastructure management enabled Replicate to focus more on innovating across its platform and building client engagement and less on operating highly complex infrastructure. |
• | CoreWeave’s observability tools provided Replicate with valuable insights into billing and resource utilization. |
• | “CoreWeave is our key cloud provider and has been instrumental in enabling our demanding inference workloads to scale seamlessly. CoreWeave has delivered high performance, resilience, and reliability that directly enables us to allow our customers to access and fine tune some of the best AI models on the market with minimal friction.” - Ben Firshman, CEO at Replicate |

• | Since 2024, Jane Street has relied on CoreWeave to provide a full-stack compute solution purpose-built for the high performance and security requirements of Jane Street’s operations. |
• | Jane Street benefited from the broad and flexible array of CoreWeave’s offerings, including direct connections, dedicated storage, upgrade options, and more, when designing, executing, and scaling its own proprietary models. |
• | Through CoreWeave, Jane Street was able to obtain timely access to the latest cutting-edge infrastructure technologies, delivered in a fully managed fashion that enabled rapid deployment of workloads. |
• | CoreWeave provided Jane Street with scalability, enabling Jane Street to grow its training and inference workloads. |
• | Jane Street achieved higher overall compute performance thanks to CoreWeave’s high-performance compute specialization. |
• | “We decided on CoreWeave as our high-performance cloud provider after we saw how fast the CoreWeave team moved and got Hopper online first. We needed access to the latest cutting-edge hardware quickly, and we trusted CoreWeave to deliver it faster than any other provider. CoreWeave’s resilient, high-performance compute infrastructure is fundamental to allowing us to build quickly, as CoreWeave delivered a reliable cluster that could withstand our intense training requirements. CoreWeave’s deep technical capabilities and extensive scalability have been instrumental in pushing the boundaries of what’s possible in algorithmic trading.” - Craig Falls, Head of Quant Research, Jane Street |

• | Mistral selected CoreWeave in 2023 due to the strength of CoreWeave’s ML Perf benchmarks and CoreWeave’s track record of delivering InfiniBand-based networks for large GPU clusters that provided significant performance gains over clusters with ethernet-based networking. |
• | The CoreWeave Cloud Platform provided immediate access to NVIDIA H100 Tensor Core GPU-based infrastructure, which enabled Mistral to increase the speed of its training runs and release Mistral-7B only a few months after founding. |
• | CoreWeave’s Mission Control lifecycle automation was instrumental in monitoring and maintaining infrastructure health while running massive training workloads at maximum performance. This automation offloaded the burden of managing infrastructure from Mistral’s small team, allowing the team to focus on its mission of building high-quality models, executing their AI roadmap efficiently, and ultimately getting their models to market faster. |
• | CoreWeave’s deep technical partnership with Mistral as a customer involved a Kubernetes-based continuous delivery model in a shared GitOps repository, which ultimately removed operational responsibilities from Mistral’s hands. |
• | Over time, CoreWeave has become Mistral’s compute provider of choice due to its ability to deliver more performant deployments with the latest state-of-the-art NVIDIA architecture while lowering its cost per FLOP through its automation, monitoring, and infrastructure health management software. |
• | “CoreWeave’s Mission Control has been transformative for our infrastructure, unlocking higher cluster performance and dramatically accelerating our time to market. CoreWeave’s intelligent lifecycle management and optimization tools and robust support solutions, have been critical in our journey to becoming an industry-leading AI model developer.” - Arthur Mensch, Chief Executive Officer and Co-Founder at Mistral |
• | our proven track record of delivering performance and reliability at scale; |
• | our ability to service high-intensity AI workloads with greater efficiency; |
• | our enhanced health monitoring and remediation capabilities; |
• | our automation and ease of use that shifts infrastructure management from our customers to our platform; |
• | our speed to market with the latest generation of GPUs; |
• | the scale of GPU clusters; |
• | our security; |
• | our brand awareness and reputation within the AI community; |
• | our customer experience, support, and service, with a focus on AI and accelerated computing use cases; |
• | our customization that enables bespoke configurations for customers reliant on specific technology such as storage; |
• | the price, total cost of ownership, and transparency; and |
• | our features, functionalities, and quality of user interface. |
Year Ended December 31, | |||||||||
2024 | 2023 | 2022 | |||||||
(in thousands) | |||||||||
Revenue | $1,915,426 | $228,943 | $15,830 | ||||||
Operating expenses: | |||||||||
Cost of revenue(1) | 493,350 | 68,780 | 12,122 | ||||||
Technology and infrastructure(1) | 960,685 | 131,855 | 18,106 | ||||||
Sales and marketing(1) | 18,389 | 12,917 | 2,481 | ||||||
General and administrative(1) | 118,644 | 29,842 | 6,001 | ||||||
Total operating expenses | 1,591,068 | 243,394 | 38,710 | ||||||
Operating income (loss) | 324,358 | (14,451) | (22,880) | ||||||
Loss on fair value adjustments | (755,929) | (533,952) | (2,884) | ||||||
Interest expense, net | (360,824) | (28,404) | (9,444) | ||||||
Other income, net | 48,194 | 18,760 | 192 | ||||||
Loss before provision for (benefit from) income taxes | (744,201) | (558,047) | (35,016) | ||||||
Provision for (benefit from) income taxes | 119,247 | 35,701 | (4,150) | ||||||
Net loss from continuing operations | $(863,448) | $(593,748) | $(30,866) | ||||||
Net loss from discontinued operations, net of tax | $— | $— | $(189) | ||||||
Net loss | $(863,448) | $(593,748) | $(31,055) | ||||||
(1) | Includes stock-based compensation expense as follows: |
Year Ended December 31, | |||||||||
2024 | 2023 | 2022 | |||||||
(in thousands) | |||||||||
Cost of revenue | $1,307 | $694 | $133 | ||||||
Technology and infrastructure | 10,137 | 7,100 | 624 | ||||||
Sales and marketing | 3,408 | 1,740 | 74 | ||||||
General and administrative | 16,635 | 5,620 | 659 | ||||||
Total stock-based compensation expense | $31,487 | $15,154 | $1,490 | ||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
(in thousands) | ||||||||||||
Revenue | $1,212,788 | $395,371 | $2,194,420 | $584,055 | ||||||||
Operating expenses: | ||||||||||||
Cost of revenue(1) | 312,667 | 108,838 | 575,061 | 168,058 | ||||||||
Technology and infrastructure(1) | 669,913 | 182,886 | 1,231,315 | 275,767 | ||||||||
Sales and marketing(1) | 36,799 | 4,172 | 47,348 | 8,222 | ||||||||
General and administrative(1) | 174,200 | 21,754 | 348,957 | 37,440 | ||||||||
Total operating expenses | 1,193,579 | 317,650 | 2,202,681 | 489,487 | ||||||||
Operating income (loss) | 19,209 | 77,721 | (8,261) | 94,568 | ||||||||
Gain (loss) on fair value adjustments | — | (310,231) | 26,837 | (407,731) | ||||||||
Interest expense, net | (266,966) | (66,766) | (530,801) | (107,422) | ||||||||
Other income (expense), net | 5,023 | 16,406 | 886 | 23,866 | ||||||||
Loss before provision for (benefit from) income taxes | (242,734) | (282,870) | (511,339) | (396,719) | ||||||||
Provision for (benefit from) income taxes | 47,775 | 40,151 | 93,811 | 55,550 | ||||||||
Net loss | $(290,509) | $(323,021) | $(605,150) | $(452,269) | ||||||||
(1) | Includes stock-based compensation as follows: |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
(dollars in thousands) | ||||||||||||
Cost of revenue | $2,701 | $350 | $5,394 | $738 | ||||||||
Technology and infrastructure | 47,683 | 2,080 | 102,282 | 4,437 | ||||||||
Sales and marketing | 8,494 | 848 | 11,314 | 1,715 | ||||||||
General and administrative | 86,127 | 4,382 | 209,988 | 8,959 | ||||||||
Total | $145,005 | $7,660 | $328,978 | $15,849 | ||||||||
Year Ended December 31, | |||||||||
2024 | 2023 | 2022 | |||||||
Revenue | 100% | 100% | 100% | ||||||
Operating expenses: | |||||||||
Cost of revenue | 26 | 30 | 77 | ||||||
Technology and infrastructure | 50 | 58 | 114 | ||||||
Sales and marketing | 1 | 6 | 16 | ||||||
General and administrative | 6 | 13 | 38 | ||||||
Total operating expenses | 83 | 106 | 245 | ||||||
Operating income (loss) | 17 | (6) | (145) | ||||||
Gain (loss) on fair value adjustments | (39) | (233) | (18) | ||||||
Interest expense, net | (19) | (12) | (60) | ||||||
Other income, net | 3 | 8 | 1 | ||||||
Loss before provision for (benefit from) income taxes | (39) | (244) | (221) | ||||||
Provision for (benefit from) income taxes | 6 | 16 | (26) | ||||||
Year Ended December 31, | |||||||||
2024 | 2023 | 2022 | |||||||
Net loss from continuing operations | (45) | (259) | (195) | ||||||
Net loss from discontinued operations, net of tax | — | — | (1) | ||||||
Net loss | (45)% | (259)% | (196)% | ||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
Revenue | 100% | 100% | 100% | 100% | ||||||||
Operating expenses: | ||||||||||||
Cost of revenue | 26 | 28 | 26 | 29 | ||||||||
Technology and infrastructure | 55 | 46 | 56 | 47 | ||||||||
Sales and marketing | 3 | 1 | 2 | 1 | ||||||||
General and administrative | 14 | 6 | 16 | 6 | ||||||||
Total operating expenses | 98 | 80 | 100 | 84 | ||||||||
Operating income (loss) | 2 | 20 | — | 16 | ||||||||
Gain (loss) on fair value adjustments | — | (78) | 1 | (70) | ||||||||
Interest expense, net | (22) | (17) | (24) | (18) | ||||||||
Other income (expense), net | — | 4 | — | 4 | ||||||||
Loss before provision for (benefit from) income taxes | (20) | (72) | (23) | (68) | ||||||||
Provision for (benefit from) income taxes | 4 | 10 | 4 | 10 | ||||||||
Net loss | (24)% | (82)% | (28)% | (77)% | ||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2025 | 2024 | Change | % Change | 2025 | 2024 | Change | % Change | |||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Revenue | $1,212,788 | $395,371 | $817,417 | 207% | $2,194,420 | $584,055 | $1,610,365 | 276% | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2025 | 2024 | Change | % Change | 2025 | 2024 | Change | % Change | |||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Cost of revenue | $312,667 | $108,838 | $203,829 | 187% | $575,061 | $168,058 | $407,003 | 242% | ||||||||||||||||
Percentage of revenue | 26% | 28% | 26% | 29% | ||||||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2025 | 2024 | Change | % Change | 2025 | 2024 | Change | % Change | |||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Technology and infrastructure | $669,913 | $182,886 | $487,027 | 266% | $1,231,315 | $275,767 | $955,548 | 347% | ||||||||||||||||
Percentage of revenue | 55% | 46% | 56% | 47% | ||||||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2025 | 2024 | Change | % Change | 2025 | 2024 | Change | % Change | |||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Sales and marketing | $36,799 | $4,172 | $32,627 | 782% | $47,348 | $8,222 | $39,126 | 476% | ||||||||||||||||
Percentage of revenue | 3% | 1% | 2% | 1% | ||||||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2025 | 2024 | Change | % Change | 2025 | 2024 | Change | % Change | |||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
General and administrative | $174,200 | $21,754 | $152,446 | 701% | $348,957 | $37,440 | $311,517 | 832% | ||||||||||||||||
Percentage of revenue | 14% | 6% | 16% | 6% | ||||||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2025 | 2024 | Change | % Change | 2025 | 2024 | Change | % Change | |||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Gain (loss) on fair value adjustments | $— | $(310,231) | $310,231 | NM | $26,837 | $(407,731) | $434,568 | NM | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2025 | 2024 | Change | % Change | 2025 | 2024 | Change | % Change | |||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Interest expense, net | $(266,966) | $(66,766) | $(200,200) | 300% | $(530,801) | $(107,422) | $(423,379) | 394% | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2025 | 2024 | Change | % Change | 2025 | 2024 | Change | % Change | |||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Other income (expense), net | $5,023 | $16,406 | $(11,383) | (69)% | $886 | $23,866 | $(22,980) | (96)% | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2025 | 2024 | Change | % Change | 2025 | 2024 | Change | % Change | |||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Provision for (benefit from) income taxes | $47,775 | $40,151 | $7,624 | 19% | $93,811 | $55,550 | $38,261 | 69% | ||||||||||||||||
Effective tax rate | (20)% | (14)% | (18)% | (14)% | ||||||||||||||||||||
Year Ended December 31, | ||||||||||||
2024 | 2023 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Revenue | $1,915,426 | $228,943 | $1,686,483 | 737% | ||||||||
Year Ended December 31, | ||||||||||||
2024 | 2023 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Cost of revenue | $493,350 | $68,780 | $424,570 | 617% | ||||||||
Percentage of revenue | 26% | 30% | ||||||||||
Year Ended December 31, | ||||||||||||
2024 | 2023 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Technology and infrastructure | $960,685 | $131,855 | $828,830 | 629% | ||||||||
Percentage of revenue | 50% | 58% | ||||||||||
Year Ended December 31, | ||||||||||||
2024 | 2023 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Sales and marketing | $18,389 | $12,917 | $5,472 | 42% | ||||||||
Percentage of revenue | 1% | 6% | ||||||||||
Year Ended December 31, | ||||||||||||
2024 | 2023 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
General and administrative | $118,644 | $29,842 | $88,802 | 298% | ||||||||
Percentage of revenue | 6% | 13% | ||||||||||
Year Ended December 31, | ||||||||||||
2024 | 2023 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Loss on fair value adjustments | $(755,929) | $(533,952) | $(221,977) | 42% | ||||||||
Year Ended December 31, | ||||||||||||
2024 | 2023 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Interest expense, net | $(360,824) | $(28,404) | $(332,420) | 1,170% | ||||||||
Year Ended December 31, | ||||||||||||
2024 | 2023 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Other income, net | $48,194 | $18,760 | $29,434 | 157% | ||||||||
Year Ended December 31, | ||||||||||||
2024 | 2023 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Provision for income taxes | $119,247 | $35,701 | $83,546 | 234% | ||||||||
Effective tax rate | (16)% | (6)% | ||||||||||
Year Ended December 31, | ||||||||||||
2023 | 2022 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Revenue | $228,943 | $15,830 | $213,113 | 1,346% | ||||||||
Year Ended December 31, | ||||||||||||
2023 | 2022 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Cost of revenue | $68,780 | $12,122 | $56,658 | 467% | ||||||||
Percentage of revenue | 30% | 77% | ||||||||||
Year Ended December 31, | ||||||||||||
2023 | 2022 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Technology and infrastructure | $131,855 | $18,106 | $113,749 | 628% | ||||||||
Percentage of revenue | 58% | 114% | ||||||||||
Year Ended December 31, | ||||||||||||
2023 | 2022 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Sales and marketing | $12,917 | $2,481 | $10,436 | 421% | ||||||||
Percentage of revenue | 6% | 16% | ||||||||||
Year Ended December 31, | ||||||||||||
2023 | 2022 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
General and administrative | $29,842 | $6,001 | $23,841 | 397% | ||||||||
Percentage of revenue | 13% | 38% | ||||||||||
Year Ended December 31, | ||||||||||||
2023 | 2022 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Loss on fair value adjustments | $(533,952) | $(2,884) | $(531,068) | NM | ||||||||
Year Ended December 31, | ||||||||||||
2023 | 2022 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Interest expense, net | $(28,404) | $(9,444) | $(18,960) | 201% | ||||||||
Year Ended December 31, | ||||||||||||
2023 | 2022 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Other income, net | $18,760 | $192 | $18,568 | NM | ||||||||
Year Ended December 31, | ||||||||||||
2023 | 2022 | Change | % Change | |||||||||
(dollars in thousands) | ||||||||||||
Provision for (benefit from) income taxes | $35,701 | $(4,150) | $39,851 | (960)% | ||||||||
Effective tax rate | (6)% | 12% | ||||||||||
Six Months Ended June 30 | Year Ended December 31, | ||||||||
2025 | 2024 | 2023 | |||||||
(in thousands) | |||||||||
Cash and cash equivalents | $1,152,883 | $1,361,083 | $217,147 | ||||||
Short-term investments | — | — | 2,368 | ||||||
Availability under existing facilities(1) | 3,685,113 | 4,406,181 | 925,076 | ||||||
Total liquidity | $4,837,996 | $5,767,264 | $1,144,591 | ||||||
(1) | Refers to secured commitments under the revolving credit facility and delayed draw term loan agreements. |
Six Months Ended June 30, | Year Ended December 31, | ||||||||||||||
2025 | 2024 | 2024 | 2023 | 2022 | |||||||||||
(in thousands) | |||||||||||||||
Net cash provided by operating activities | $(190,083) | $1,921,214 | $2,749,168 | $1,832,650 | $910 | ||||||||||
Net cash used in investing activities | (3,875,213) | (4,021,175) | (8,658,058) | (3,147,710) | (79,183) | ||||||||||
Net cash provided by financing activities | 4,083,046 | 2,859,784 | 7,464,648 | 1,787,751 | 81,454 | ||||||||||
1. | Identification of the contract, or contracts, with the customer. |
2. | Identification of the performance obligations in the contract. |
3. | Determination of the transaction price. |
4. | Allocation of the transaction price to the performance obligations in the contract. |
5. | Recognition of the revenue when, or as, a performance obligation is satisfied. |
• | contemporaneous valuations of our common stock performed by independent third-party specialists; |
• | the prices, rights, preferences, and privileges of our redeemable convertible preferred stock relative to those of our common stock; |
• | the prices paid for common or convertible preferred stock sold to third-party investors by us and in secondary transactions for shares repurchased by us in arm’s-length transactions, including any tender offers; |
• | the lack of marketability inherent in our common stock and involving securities in a private company; |
• | our actual operating and financial performance and estimated trends and prospects for our future performance; |
• | our stage of development; |
• | the hiring of key personnel and the experience of our management; |
• | the likelihood of achieving a liquidity event, such as an initial public offering, direct listing, or sale of our company, given prevailing market conditions; |
• | the market performance of comparable publicly traded companies; and |
• | U.S. and global capital market conditions. |
• | engagement with external consultants with extensive Sarbanes-Oxley Act experience |
• | implementation of IT general controls to manage access and program changes within our IT environment and to support the evaluation, monitoring, and ongoing effectiveness of key application controls and key reports; |
• | implementation of processes and controls to better identify and manage segregation of duties risks; |
• | designing and implementing controls related to significant accounts and disclosures to achieve complete, accurate and timely financial accounting, reporting and disclosures, including controls over account reconciliations, segregation of duties and the preparation and review of journal entries; |
• | continued hiring of additional accounting, finance and operations resources with appropriate and sufficient technical expertise and to better allow for segregation of conflicting duties; and |
• | consulting with experts on technical accounting matters, internal controls, and in the preparation of our financial statements. |
Name | Age | Position(s) | ||||
Executive Officers: | ||||||
Michael Intrator | 56 | Chief Executive Officer, President, and Chairman of the Board of Directors | ||||
Brian Venturo | 40 | Chief Strategy Officer and Director | ||||
Brannin McBee | 40 | Chief Development Officer | ||||
Nitin Agrawal | 46 | Chief Financial Officer | ||||
Kristen McVeety | 54 | General Counsel and Corporate Secretary | ||||
Chen Goldberg | 45 | Senior Vice President of Engineering | ||||
Non-Employee Directors: | ||||||
Karen Boone(1)(2) | 51 | Director | ||||
Jack Cogen(1)(3) | 69 | Director | ||||
Glenn Hutchins(2)(3)(4) | 69 | Director | ||||
Margaret C. Whitman(1)(3) | 69 | Director | ||||
(1) | Member of the audit committee. |
(2) | Member of the compensation committee. |
(3) | Member of the nominating and corporate governance committee. |
(4) | Lead independent director. |
• | the Class I directors include Michael Intrator and Jack Cogen and their terms will expire at the 2026 annual meeting of stockholders; |
• | the Class II directors include Margaret C. Whitman and Glenn Hutchins and their terms will expire at the 2027 annual meeting of stockholders; and |
• | the Class III directors include Brian Venturo and Karen Boone and their terms will expire at the 2028 annual meeting of stockholders. |
• | selecting a firm to serve as our independent registered public accounting firm to audit our consolidated financial statements; |
• | ensuring the independence of the independent registered public accounting firm; |
• | discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and that firm, our interim and year-end operating results; |
• | establishing procedures for employees to anonymously submit concerns about questionable accounting or audit matters; |
• | considering the adequacy of our internal controls; |
• | reviewing related party transactions that are material or otherwise implicate disclosure requirements; and |
• | approving, or as permitted, pre-approving all audit and non-audit services to be performed by the independent registered public accounting firm. |
• | evaluating, recommending, approving and reviewing executive officer and director compensation arrangements, plans, policies and programs maintained by CoreWeave; |
• | administering CoreWeave’s cash- and equity-based compensation plans; and |
• | reviewing with management the CoreWeave’s organization and people activities. |
• | identifying, considering, and recommending candidates for membership on our board of directors; |
• | developing and recommending our corporate governance guidelines and policies; |
• | overseeing the evaluation of our board of directors and our committees; |
• | advising our board of directors on corporate governance matters; and |
• | advising on any related matters required by federal securities laws. |
• | Audit committee chair: $30,000. |
• | Compensation committee chair: $20,000. |
• | Nominating and governance committee chair: $15,000. |
• | any breach of the director’s or officer’s duty of loyalty to us or our stockholders; |
• | any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
• | unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL; |
• | any transaction from which the director or officer derived an improper personal benefit; and |
• | with respect to officers, any action by or in the right of the corporation. |
• | Michael Intrator, Chief Executive Officer and President; |
• | Brian Venturo, Chief Strategy Officer; and |
• | Brannin McBee, Chief Development Officer. |
Name and Principal Position | Fiscal Year | Salary ($) | Bonus ($)(1) | Stock Awards ($)(2) | All Other Compensation ($) | Total ($) | ||||||||||||
Michael Intrator, Chief Executive Officer | 2024 | 750,000 | 2,000,000 | — | 18,252(3) | 2,768,252 | ||||||||||||
Brian Venturo, Chief Strategy Officer | 2024 | 750,000 | 2,000,000 | — | 8,865(4) | 2,758,865 | ||||||||||||
Brannin McBee, Chief Development Officer | 2024 | 400,000 | 2,000,000 | — | 6,154(5) | 2,406,154 | ||||||||||||
(1) | The amounts presented represent discretionary bonuses paid for contributions to our performance. |
(2) | Each named executive officer was granted an RSU award that was subject to a time-based component and performance-based component (which constitutes the performance condition). As of the applicable grant date, we had not recognized stock-based compensation expense for these awards because achievement of the performance-based vesting component, as the performance condition, was not deemed probable. As a result, no value is included in the table for these awards. Assuming achievement of the performance-based vesting component, the aggregate grant-date fair values of the RSU awards for each of Mr. Intrator, Mr. Venturo, and Mr. McBee would have been $83,230,875, computed in accordance with ASC Topic 718, and representing the highest level of performance condition achievement for these awards. For information regarding the assumptions used in determining the fair value of these awards, please refer to Note 11 of the consolidated financial statements included elsewhere in this proxy statement/prospectus. |
(3) | Amounts reported in this column for Mr. Intrator represent the following: $12,692 for company contributions to our 401(k) plan and $5,560 for spousal travel expenses incurred by us. |
(4) | Amounts reported in this column for Mr. Venturo represent $8,865 for company contributions to our 401(k) plan. |
(5) | Amounts reported in this column for Mr. McBee represent $6,154 for company contributions to our 401(k) plan. |
Option Awards(1) | Stock Awards(1) | |||||||||||||||||||||||
Name | Vesting Commencement Date | Grant Date | Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Unexercisable | Option Exercise Price ($) | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested (#) | Market Value of Shares or Units of Stock That Have Not Vested ($) | ||||||||||||||||
Michael Intrator Chief Executive Officer | 2/26/2021 | 2/26/2021(2) | 500,000 | — | 0.38 | 2/25/2031 | ||||||||||||||||||
12/29/2022 | 12/29/2022(3) | 250,000 | 250,000 | 1.07 | 12/28/2027 | |||||||||||||||||||
6/28/2023 | 6/28/2023(4) | 1,120 | 1,880 | 2.80 | 6/27/2028 | |||||||||||||||||||
7/16/2023 | 7/16/2023(5) | 708,320 | 1,291,680 | 2.80 | 7/15/2028 | |||||||||||||||||||
12/31/2024 | 12/31/2024(6) | 1,750,000 | ||||||||||||||||||||||
Brian Venturo Chief Strategy Officer | 8/31/2020 | 8/31/2020(7) | 2,400,000 | — | 0.13 | 8/30/2030 | ||||||||||||||||||
12/29/2022 | 12/29/2022(8) | 250,000 | 250,000 | 1.07 | 12/28/2027 | |||||||||||||||||||
6/28/2023 | 6/28/2023(9) | 1,120 | 1,880 | 2.80 | 6/27/2028 | |||||||||||||||||||
7/16/2023 | 7/16/2023(10) | 708,320 | 1,291,680 | 2.80 | 7/15/2028 | |||||||||||||||||||
12/31/2024 | 12/31/2024(11) | 1,750,000 | ||||||||||||||||||||||
Brannin McBee Chief Development Officer | 12/29/2022 | 12/29/2022(12) | 100,000 | 100,000 | 1.07 | 12/28/2027 | ||||||||||||||||||
6/28/2023 | 6/28/2023(13) | 1,120 | 1,880 | 2.54 | 6/27/2033 | |||||||||||||||||||
7/16/2023 | 7/16/2023(12) | 354,160 | 645,840 | 2.54 | 7/15/2033 | |||||||||||||||||||
12/31/2024 | 12/31/2024(14) | 1,750,000 | ||||||||||||||||||||||
(1) | All outstanding equity awards were granted under the 2019 Plan. |
(2) | The fully vested option award vested as to 1/3rd of the total award on the first anniversary of the vesting commencement date and as to 1/36th of the total award on each monthly anniversary thereafter, subject to Mr. Intrator’s continued service with us. The shares of Class A common stock issuable upon the exercise of this option award are exchangeable for shares of Class B common stock pursuant to the Equity Exchange Rights. |
(3) | The option award vests as to 1/48th of the total award on each monthly anniversary of the vesting commencement date, subject to Mr. Intrator’s continued service with us. The shares of Class A common stock issuable upon the exercise of this option award are exchangeable for shares of Class B common stock pursuant to the Equity Exchange Rights. |
(4) | The option award vests as to 1/4th of the total award on the first anniversary of the vesting commencement date and as to 1/48th of the total award on each monthly anniversary thereafter, subject to Mr. Intrator’s continued service with us. The shares of Class A common stock issuable upon the exercise of this option award are exchangeable for shares of Class B common stock pursuant to the Equity Exchange Rights. Mr. Intrator was a holder of greater than 10% of our shares of common stock at the time of grant so, pursuant to Section 422 of the Code (as defined below), the exercise price of this incentive stock option award reflects 110% of the fair market value of our common stock at the time of grant. |
(5) | The option award vests as to 1/48th of the total award on each monthly anniversary of the vesting commencement date, subject to Mr. Intrator’s continued service with us. The shares of Class A common stock issuable upon the exercise of this option award are exchangeable for shares of Class B common stock pursuant to the Equity Exchange Rights. Mr. Intrator was a holder of greater than 10% of our shares of common stock at the time of grant so, pursuant to Section 422 of the Code, the exercise price of this incentive stock option award reflects 110% of the fair market value of our common stock at the time of grant. |
(6) | The RSUs vest based on the satisfaction of both a service-based vesting condition and a performance-based vesting condition. The service-based vesting condition and performance-based vesting condition were not satisfied as to any of the RSUs as of December 31, 2024. The RSUs vest as to 1/16th of the total award and may be settled for shares of Class A common stock on each quarterly anniversary of the vesting commencement date, once the performance-based vesting condition has been satisfied and subject to Mr. Intrator’s continued service with us. The performance-based vesting condition was satisfied in connection with our IPO. |
(7) | The fully vested option award vested as to 1/3rd of the total award on the first anniversary of the vesting commencement date and as to 1/36th of the total award on each monthly anniversary thereafter, subject to Mr. Venturo’s continued service with us. The shares of Class A common stock issuable upon the exercise of this option award are exchangeable for shares of Class B common stock pursuant to the Equity Exchange Rights. |
(8) | The option award vests as to 1/48th of the total award on each monthly anniversary of the vesting commencement date, subject to Mr. Venturo’s continued service with us. The shares of Class A common stock issuable upon the exercise of this option award are exchangeable for shares of Class B common stock pursuant to the Equity Exchange Rights. |
(9) | The option award vests as to 1/4th of the total award on the first anniversary of the vesting commencement date and as to 1/48th of the total award on each monthly anniversary thereafter, subject to Mr. Venturo’s continued service with us. The shares of Class A common stock issuable upon the exercise of this option award are exchangeable for shares of Class B common stock pursuant to the Equity Exchange Rights. Mr. Venturo was a holder of greater than 10% of our shares of common stock at the time of grant so, pursuant to Section 422 of the Code, the exercise price of this incentive stock option award reflects 110% of the fair market value of our common stock at the time of grant. |
(10) | The option award vests as to 1/48th of the total award on each monthly anniversary of the vesting commencement date, subject to Mr. Venturo’s continued service with us. The shares of Class A common stock issuable upon the exercise of this option award are exchangeable for shares of Class B common stock pursuant to the Equity Exchange Rights. The shares of Class A common stock issuable |
(11) | The RSUs vest based on the satisfaction of both a service-based vesting condition and a performance-based vesting condition. The service-based vesting condition and performance-based vesting condition were not satisfied as to any of the RSUs as of December 31, 2024. The RSUs vest as to 1/16th of the total award and may be settled for shares of Class A common stock on each quarterly anniversary of the vesting commencement date, once the performance-based vesting condition has been satisfied and subject to Mr. Venturo’s continued service with us. The performance-based vesting condition was satisfied in connection with our IPO. |
(12) | The option award vests as to 1/48th of the total award on each monthly anniversary of the vesting commencement date, subject to Mr. McBee’s continued service with us. The shares of Class A common stock issuable upon the exercise of this option award are exchangeable for shares of Class B common stock pursuant to the Equity Exchange Rights. |
(13) | The option award vests as to 1/4th of the total award on the first anniversary of the vesting commencement date and as to 1/48th of the total award on each monthly anniversary thereafter, subject to Mr. McBee’s continued service with us. The shares of Class A common stock issuable upon the exercise of this option award are exchangeable for shares of Class B common stock pursuant to the Equity Exchange Rights. |
(14) | The RSUs vest based on the satisfaction of both a service-based vesting condition and a performance-based vesting condition. The service-based vesting condition and performance-based vesting condition were not satisfied as to any of the RSUs as of December 31, 2024. The RSUs vest as to 1/16th of the total award and may be settled for shares of Class A common stock on each quarterly anniversary of the vesting commencement date, once the performance-based vesting condition has been satisfied and subject to Mr. McBee’s continued service with us. The performance-based vesting condition was satisfied in connection with our IPO. |
• | shares subject to options or SARs granted under our 2025 Plan that cease to be subject to the option or SAR for any reason other than exercise of the option or SAR; |
• | shares subject to awards granted under our 2025 Plan that are subsequently forfeited or repurchased by us at the original issue price; |
• | shares subject to awards granted under our 2025 Plan that otherwise terminate without such shares being issued; |
• | shares subject to awards granted under our 2025 Plan that are surrendered, cancelled, or exchanged for cash or a different award (or combination thereof); |
• | shares issuable upon the exercise of options granted under our 2019 Plan that, after the effective date of the 2025 Plan, are forfeited; |
• | shares issued pursuant to awards granted under our 2019 Plan that are forfeited or repurchased by us at the original price after the effective date of the 2025 Plan; and |
• | shares subject to awards under our 2019 Plan or our 2025 Plan that are used to pay the exercise price of an option or withheld to satisfy the tax withholding obligations related to any award. |
• | Proposal 1—the Merger Agreement Proposal: to adopt the Merger Agreement, a copy of which is attached as Annex A to this proxy statement/prospectus and the material provisions of which are summarized in the section titled “The Merger Agreement” beginning on page 218 of this proxy statement/prospectus, pursuant to which, among other things, Merger Sub will merge with and into Core Scientific and each outstanding share of Core Scientific common stock will be converted into the right to receive 0.1235 shares of CoreWeave common stock. |
• | Proposal 2—the Advisory Compensation Proposal: to approve, on a non-binding advisory basis, the compensation that may be paid or become payable to Core Scientific’s named executive officers that is based on or otherwise related to the Merger, the estimated value of which is disclosed in the table in the section titled “Interests of Core Scientific’s Directors and Executive Officers in the Merger—Quantification of Potential Payments and Benefits to Scientific’s Named Executive Officers” beginning on page 254 of this proxy statement/prospectus. |
• | Proposal 1: “FOR” the Merger Agreement Proposal; and |
• | Proposal 2: “FOR” the Advisory Compensation Proposal. |
• | Proposal 1—the Merger Agreement Proposal. The affirmative vote of holders of a majority of the issued and outstanding shares of Core Scientific common stock on the Core Scientific record date and entitled to vote thereon is required to adopt the Merger Agreement Proposal. The required vote on Proposal 1 is based on the number of outstanding shares—not the number of shares actually voted. The failure of any Core Scientific stockholder to submit a vote (i.e., by not submitting a proxy and not voting at the Special Meeting) and any abstention from voting by a Core Scientific stockholder will have the same effect as a vote “AGAINST” the Merger Agreement Proposal. Because the Merger Agreement Proposal is non-routine, brokers, banks and other nominees do not have discretionary authority to vote on the Merger Agreement Proposal, and will not be able to vote on the Merger Agreement Proposal absent instructions from the beneficial owner of any Core Scientific shares held of record by them. As a result, a broker non-vote will have the same effect as a vote “AGAINST” the Merger Agreement Proposal. |
• | Proposal 2—the Advisory Compensation Proposal. The affirmative vote of the holders of a majority of the votes cast on such matter, voting affirmatively or negatively (excluding abstentions and broker non-votes), where a quorum is present, is required to approve the Advisory Compensation Proposal. The required vote on the Advisory Compensation Proposal is based on the number of shares actually voted—not the number of outstanding shares of Core Scientific common stock entitled to be voted thereon. Abstentions from voting by a Core Scientific stockholder attending the Special Meeting or a failure to attend the Special Meeting virtually or by proxy will have no effect on the outcome of the vote on the Advisory Compensation Proposal. Brokers do not have discretion to vote on this proposal without your instruction. If you do not instruct your broker how to vote on this proposal, those shares will not be counted as present or represented by proxy at the Special Meeting and, as a result, will have no effect on the outcome of the vote on the Advisory Compensation Proposal. While the Core Scientific board intends to consider the vote resulting from the Advisory Compensation Proposal, the vote is advisory only and therefore not binding on Core Scientific, and, if the proposed Merger Agreement is adopted by Core Scientific stockholders and the Merger is consummated, the compensation that is the subject of the Advisory Compensation Proposal, including amounts Core Scientific is contractually obligated to pay, will be payable even if the Advisory Compensation Proposal is not approved. |
• | Internet: Core Scientific stockholders of record may submit their proxy over the internet at www.proxyvote.com. Internet voting is available 24 hours a day and will be accessible until 11:59 p.m., Eastern Time, on [ ]. Stockholders will be given an opportunity to confirm that their voting instructions have been properly recorded. Core Scientific stockholders who submit a proxy this way need not send in their proxy card by mail. |
• | Telephone: Core Scientific stockholders of record may submit their proxy by calling 1-800-690-6903. Telephone voting is available 24 hours a day and will be accessible until 11:59 p.m., Eastern Time, on [ ]. Easy-to-follow voice prompts will guide stockholders through the voting and allow them to confirm that their instructions have been properly recorded. Core Scientific stockholders who submit a proxy this way need not send in their proxy card by mail. |
• | Mail: Core Scientific stockholders of record may submit their proxy by properly completing, signing, dating and mailing their proxy card or voting instruction form in the self-addressed, stamped envelope (if mailed in the United States) included with this proxy statement/prospectus. Core Scientific stockholders who vote this way should mail the proxy card early enough so that it is received prior to the closing of the polls at the Special Meeting. |
• | Online During the Virtual Meeting: Core Scientific stockholders of record may attend the virtual Special Meeting by entering their unique 16-digit control number and vote online; attendance at the virtual Special Meeting alone will not, however, in and of itself constitute a vote or a revocation of a prior proxy. |
• | delivering written notice of revocation of the proxy to Core Scientific’s corporate secretary at Core Scientific’s principal executive offices at 838 Walker Road, Suite 21-2105, Dover, Delaware 19904, by no later than 11:59 p.m., Eastern Time on [ ]; |
• | delivering another proxy with a later date to Core Scientific’s corporate secretary at Core Scientific’s principal executive offices at 838 Walker Road, Suite 21-2105, Dover, Delaware 19904, by no later than 11:59 p.m., Eastern Time on [ ] (in which case only the later-dated proxy is counted and the earlier proxy is revoked); |
• | submitting another proxy again via the internet or by telephone at a later date, by no later than 11:59 p.m., Eastern Time on [ ] (in which case only the later-dated proxy is counted and the earlier proxy is revoked); or |
• | attending the Special Meeting virtually, using the stockholder’s unique 16-digit control number and voting their shares online during the meeting; attendance at the virtual Special Meeting will not, in and of itself, revoke a valid proxy that was previously delivered unless the stockholder gives written notice of revocation to the Core Scientific corporate secretary before the proxy is exercised or unless the stockholder votes their shares online during the Special Meeting. |
• | the stock-for-stock merger allows Core Scientific stockholders to participate in the value and opportunities of CoreWeave, including any potential appreciation of CoreWeave common stock and future growth, which the Core Scientific board viewed as an important opportunity for Core Scientific stockholders to enhance long-term returns; |
• | based on the exchange ratio, Core Scientific stockholders will own approximately 8.9% of the combined company on a fully diluted pro forma basis (based on the total number of outstanding shares of common stock of CoreWeave and Core Scientific as of July 7, 2025), allowing Core Scientific stockholders to participate in the benefits of future growth and expected synergies resulting from the Merger; |
• | based on the closing price of CoreWeave common stock of $165.20 on July 3, 2025, the last trading day prior to the announcement of the transaction, the Merger Consideration represented an implied value of $20.40 per share of Core Scientific common stock, which implied an approximately 65.9% premium to Core Scientific’s unaffected closing price of $12.30 on June 25, 2025, which was the last trading day prior to the publication of the first of several news stories in June 2025 speculating on the potential transaction; and |
• | based on the five-day VWAP of CoreWeave common stock of $161.03 for the five trading days prior to July 7, 2025, the Merger Consideration represented an implied value of $19.89 per share of Core Scientific common stock, which implies an approximately 61.71% premium to Core Scientific’s unaffected closing price of $12.30 on June 25, 2025, which was the last trading day prior to the publication of the first of several news stories in June 2025 speculating on the potential transaction. |
• | the potential to deliver an additional 1.5 GW of additional power to CoreWeave’s pipeline while combining Core Scientific’s leading data center development and operations team with CoreWeave’s engineering team, creating an integrated platform and providing the combined company with direct control over the design and architecture of next generation builds to better serve customers, combined expertise and experience to address complex infrastructure engineering challenges, more visibility and control to optimize delivery timelines and costs of cloud infrastructure and potential for future expansions and additional power procurement; |
• | cash savings realized by CoreWeave internalizing leasing obligations to Core Scientific, which is expected to lead to an improved credit profile for the combined company and, together with the combined company’s increased size and scale, is expected to create increased borrowing capacity, while reducing cost of capital and enhancing liquidity; |
• | greater financing flexibility for the combined company given the ability to pursue additional infrastructure financing strategies to finance committed capital expenditures, and greater ability to attract new and diverse sources of financing to replace traditional debt or equity financing; |
• | the ability to leverage the larger scale and capability of the combined company to accelerate deployment of artificial intelligence and HPC workloads; |
• | cost synergies in the form of corporate general and administrative cost savings and operational efficiency through streamlining business operations and eliminating lease overhead to create potential for incremental cash flow; and |
• | the combined workforce is expected to continue to increase efficiency and deliver stockholder value, and the Merger Agreement includes provisions intended to facilitate the retention of certain Core Scientific employees and enhance their ability to provide value for stockholders of the combined company. |
• | Capital Access: The risk that data center builds generally require substantial debt and equity capital, and that existing sources of such capital tend to provide more flexible financing terms to their existing data center partners given comfort surrounding proven execution. On the other hand, capital access tends to be more restricted for new developers with more stringent requirements of completion guarantees. |
• | Location: The risk that most potential customers are focused on inference-ready locations for data center capacity, including for AI training needs, which may make certain locations less desirable in an evolving market. |
• | Power: The need for guaranteed sources of power for data center locations to attract potential customers, and the risks that Core Scientific would not be able to secure sufficient capacity of power, or that such power would not be available until future years. |
• | New Customers: The risk that Core Scientific may have difficulty attracting additional customers for its colocation operations, including because many customers tend to be substantially exclusive in their choice |
• | Supply and Demand Risk: The risk that an evolving space with multiple new operators may lead to substantial data center overbuild, reducing both leasing potential and margins. Further improvements in technology may require lower data center power to drive higher computer processing potential, driving down demand in future years and potentially making obtaining new customers more challenging and uncertain. |
• | Strategic Pivot: The risk that Core Scientific may be unable to successfully complete its previously announced strategic transition from digital asset mining and provision of digital infrastructure and third-party hosting services for digital asset mining to provision of high-density colocation services to third parties for GPU-based HPC operations, such as artificial intelligence-related applications, including the risk of being unable to obtain additional customers, and risks related to continuing Core Scientific’s hosted bitcoin mining or self-mining operations. |
• | Expiration of CoreWeave Contracts: The risk that the Colocation Contracted Business would experience a significant drop in revenue once the existing contracts with CoreWeave expire at the end of their term in 2038 if CoreWeave fails to renew or exercise their right to extend such contracts. |
• | Fixed Exchange Ratio. The Core Scientific board considered the risk that because the Merger Consideration is based on a fixed exchange ratio rather than a fixed value, Core Scientific stockholders will bear the risk of a decrease in the trading price of CoreWeave common stock during the pendency of the Merger and the Merger Agreement does not provide Core Scientific with a collar or a value-based termination right, which means that the market value of the Merger Consideration (though not the pro forma ownership interest of Core Scientific stockholders in CoreWeave common stock) could decrease prior to the effective time if the trading price of CoreWeave common stock decreases. |
• | Different Strategic Alternatives. The Core Scientific board considered the risk that a different strategic alternative potentially could be more beneficial to Core Scientific stockholders than the Merger, although no alternative acquisition proposals had been identified or had materialized. |
• | Expiration of Lock-Up of CoreWeave Common Stock. The Core Scientific board considered that holders representing substantially all of the pre-IPO CoreWeave common stock (and securities convertible into CoreWeave common stock) are subject to lock-up agreements or market standoff provisions that prohibit the sale or other disposition of such securities until the earlier of either (i) after the close of trading on the second trading day after CoreWeave publicly announces earnings for the second quarter of 2025 or (ii) September 23, 2025. Accordingly, the Core Scientific board considered the possibility that Core Scientific stockholders will bear the risk of a decrease in the trading price of CoreWeave common stock following the expiration of the lock-up period. |
• | Termination Fee. The Core Scientific board considered the obligation to pay CoreWeave a termination fee of $270 million, depending on, among other factors, whether a third party making a superior proposal (as hereinafter defined) meets certain criteria specified in the Merger Agreement, as further described in “The Merger Agreement—Termination of the Merger Agreement” and “The Merger Agreement—No Solicitation.” |
• | Interim Operating Covenants. The Core Scientific board reviewed and considered the restrictions imposed on Core Scientific’s business and operations during the pendency of the Merger and, although it concluded that such restrictions are reasonable and not unduly burdensome, such restrictions may delay or prevent Core Scientific from undertaking business opportunities that may arise or other actions it could potentially otherwise take with respect to the operations of Core Scientific pending the consummation of the Merger, including actions which may be needed to obtain new customers for Core Scientific’s high-density colocation services business. |
• | Risks Associated with the Pendency of the Merger. The Core Scientific board reviewed and considered the risks and contingencies relating to the announcement and pendency of the Merger (including the likelihood of litigation or other opposition challenging the Merger and the other transactions contemplated by the Merger Agreement) and the risks and costs to Core Scientific if the Merger is not completed in a timely manner or if the Merger does not close at all, including potential employee attrition, the impact on Core Scientific’s relationships with customers, suppliers, service providers, consultants and employees or other important business counterparties and the effect termination of the Merger Agreement may have on the trading price of Core Scientific common stock and Core Scientific’s operating results. In addition, the Core Scientific board considered the possibility that the Merger may not be completed, or that completion may be delayed for reasons that are beyond the control of Core Scientific or CoreWeave, including the failure of Core Scientific stockholders to approve the Merger Agreement Proposal or the failure of Core Scientific or CoreWeave to satisfy other requirements that are conditions to closing the Merger. |
• | Risks to Core Scientific’s Stock Price. The Core Scientific board considered the risk that the failure to complete the Merger could negatively affect the price of Core Scientific common stock and/or the future business and financial results of Core Scientific. |
• | Possible Failure to Integrate. The Core Scientific board reviewed and considered the potential challenges and difficulties in integrating the operations of Core Scientific and CoreWeave and the risk that operational efficiencies between the two companies, or other anticipated benefits of the Merger, might not be realized or might take longer to realize than expected. |
• | Opportunity to Receive Acquisition Proposals and to Terminate the Merger in Order to Accept a Superior Proposal. The Core Scientific board considered the possibility that a third party may be willing to enter into a strategic combination with Core Scientific on terms more favorable than the Merger. In connection therewith, the Core Scientific board considered the terms of the Merger Agreement placing certain limitations on the ability of Core Scientific to initiate, seek or solicit, or knowingly encourage or facilitate any inquiries or the making of any proposal by a third party with respect to an acquisition proposal and to disclose any nonpublic information to, or engage in discussions or negotiations with, a third party interested in pursuing an alternative business combination transaction (unless such third party has made an unsolicited bona fide written acquisition proposal (as hereinafter defined) that constitutes or is reasonably likely to lead to a superior proposal (as hereinafter defined) and such third party enters into a confidentiality agreement with Core Scientific having provisions that are no less favorable to such party than those contained in the confidentiality agreement between Core Scientific and CoreWeave), as further described in “The Merger Agreement—No Solicitation.” |
• | Risks Associated with Regulatory Approval. The Core Scientific board considered that the Merger is conditioned on the absence of an injunction prohibiting the consummation of the Merger and the expiration or termination of the waiting period under the HSR Act. Core Scientific and CoreWeave have agreed to use their respective reasonable best efforts to take all actions necessary, proper or advisable to complete the Merger and the other transactions contemplated by the Merger Agreement as soon as reasonably practicable, including obtaining each regulatory approval necessary to complete the Merger or to avoid an action or proceeding by a governmental body seeking to prevent the consummation of the Merger under any antitrust law. In addition, CoreWeave has agreed to use reasonable best efforts to take all actions |
• | Merger Costs. The Core Scientific board considered the significant costs associated with the completion of the Merger, including Core Scientific management’s time and energy and potential opportunity cost that will be incurred by the combined company as a result of the Merger, as well as the transaction expenses arising from the Merger. |
• | Third-Party Consents. The Core Scientific board considered the risk that Core Scientific and CoreWeave may be obligated to complete the Merger without having obtained appropriate consents, approvals or waivers from the counterparties under certain of Core Scientific’s contracts that require consent or approval to consummate the Merger, and the risk that such consummation could trigger the termination of, or default under, such contracts or the exercise of rights by the counterparties under such contracts. |
• | Appraisal Rights. The Core Scientific board considered the fact that there are no appraisal rights for Core Scientific stockholders in connection with the Merger under Delaware law. |
• | Other Risks. The Core Scientific board considered risks of the type and nature described under the sections titled “Cautionary Statement Regarding Forward-Looking Statements” and “Risk Factors.” |
• | Transaction Synergies. The Merger is expected to accelerate CoreWeave’s strategy to deploy artificial intelligence and high-performance computing workloads at scale. The integration of Core Scientific’s high-performance data center infrastructure with CoreWeave’s platform is expected to enhance CoreWeave’s performance and expertise to help its customers harness the full potential of artificial intelligence. |
• | Operational Efficiency. Integrating the ownership of Core Scientific’s high-performance data center infrastructure enables CoreWeave to enhance operating efficiency while de-risking future expansion, solidifying its growth trajectory. The Merger is expected to generate cost savings through streamlining business operations and eliminating lease overhead to be paid for existing contractual sites. |
• | Financing Flexibility. The Merger is expected to open access to diverse financing sources for CoreWeave, allowing it to pursue infrastructure financing strategies to finance committed capital expenditures at a more attractive cost of capital. |
• | Power Ownership and Expanded Expertise. As a result of the Merger, CoreWeave is expected to gain greater access to a critical power footprint and optionality for future power capacity. CoreWeave will have direct input over design and architecture of next generation builds and more visibility to improve delivery timelines and costs of cloud infrastructure. Core Scientific augments CoreWeave’s expertise in power procurement, construction and site management for infrastructure assets. |
• | the conversion of the BTC Self Mining & Hosting Business in 2027 to Colocation Pipeline capacity; |
• | that executing on the Colocation Pipeline Business plan would require deployment of over $7 billion of capital expenditures over an eight-year period (over half of which would be spent in the first three years) to build out new colocation sites at the cost per MW assumed in the Core Scientific Standalone Projections; |
• | Core Scientific would successfully sign new colocation contracts with other potential customers on the timeline, at the duration/renewal rate, and at the revenue rates per MW assumed in the Core Scientific Standalone Projections; |
• | the conversion of Core Scientific into a real estate investment trust (“REIT”) in 2028, as a result of which no corporate taxes would be payable for the fiscal years ending December 31, 2028 through December 31, 2043 for the Colocation Contracted Business and December 31, 2028 through December 31, 2032 for the Colocation Pipeline Business; and |
• | with respect to the Colocation Contracted Business, CoreWeave would elect to utilize one five-year extension to the term of each of the colocation agreements between Core Scientific and CoreWeave. |
Year Ending December 31, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3Q 2025E(5) | 2026E | 2027E | 2028E | 2029E | 2030E | 2031E | 2032E | 2033E | 2034E | 2035E | 2036E | 2037E | 2038E | 2039E | 2040E | 2041E | 2042E | 2043E | |||||||||||||||||||||||||||||||||||||||
(in millions) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Cash Revenue(1) | $48 | $338 | $419 | $577 | $775 | $804 | $811 | $829 | $858 | $888 | $919 | $952 | $985 | $1,019 | $1,055 | $1,092 | $1,130 | $986 | $184 | ||||||||||||||||||||||||||||||||||||||
Adjusted Cash EBITDA(2) | $12 | $231 | $293 | $446 | $639 | $663 | $682 | $703 | $728 | $752 | $778 | $804 | $832 | $860 | $889 | $919 | $955 | $837 | $150 | ||||||||||||||||||||||||||||||||||||||
Capital Expenditures(3) | $(95) | $(9) | $(3) | $(8) | $(10) | $(10) | $(10) | $(10) | $(11) | $(11) | $(11) | $(12) | $(12) | $(13) | $(13) | $(14) | $(14) | $(13) | $(3) | ||||||||||||||||||||||||||||||||||||||
Unlevered Free Cash Flow(4) | $(90) | $179 | $234 | $430 | $622 | $645 | $663 | $685 | $708 | $732 | $757 | $782 | $809 | $836 | $865 | $894 | $929 | $818 | $147 | ||||||||||||||||||||||||||||||||||||||
(1) | Net Cash Revenue, a non-GAAP financial measure, refers to total revenue including the impact of annual escalators less any pass-through costs, with revenue recognized when received. |
(2) | Adjusted Cash EBITDA, a non-GAAP financial measure, refers to earnings before interest, taxes, depreciation and amortization adjusted for company defined non-recurring and non-cash items, stock-based compensation, and one-time expenses, with revenue recognized when received. |
(3) | Capital Expenditures, a non-GAAP financial measure, refers to required capital needed by Core Scientific to build and deliver the contracted colocation sites to CoreWeave; the management assumption for the development capital expenditure for the Colocation Contracted Business was approximately $100 million for the 70 MW expansion at Core Scientific’s Denton facility, implying approximately $1.5 million/MW of capital expenditure. |
(4) | Unlevered Free Cash Flow, a non-GAAP financial measure, refers to cash flow from operations before interest payments, adjusted to include capital expenditures, changes in net working capital, and stock-based compensation. For the period from April 2025 through December 2025, Core Scientific management identified certain one-time, non-recurring cash financial and legal expenses that were added back to Adjusted Cash EBITDA and not deducted from the Unlevered Free Cash Flow. These cash expenses, if deducted from the Unlevered Free Cash Flow, would further burden the free cash flow of Core Scientific. |
(5) | Reflects the nine-month period from April 2025 through December 2025. PJT Partners’ analysis utilized a June 30, 2025 valuation date and thus only used data from the last two quarters of 2025, resulting in Unlevered Free Cash Flows of ($62); these Unlevered Free Cash Flows are also burdened by one-time expenses related to cash legal and financial fees of ($1). |
Year Ending December 31, | |||||||||||||||||||||||||||
3Q 2025E(5) | 2026E | 2027E | 2028E | 2029E | 2030E | 2031E | 2032E(5) | ||||||||||||||||||||
(in millions) | |||||||||||||||||||||||||||
Net Cash Revenue(1) | $2 | $35 | $217 | $553 | $827 | $939 | $1,032 | $1,117 | |||||||||||||||||||
Adjusted Cash EBITDA(2) | $(53) | $(50) | $98 | $384 | $624 | $719 | $796 | $866 | |||||||||||||||||||
Capital Expenditures(3) | $(539) | $(1,365) | $(2,222) | $(1,579) | $(618) | $(515) | $(391) | $(104) | |||||||||||||||||||
Unlevered Free Cash Flow(4) | $(626) | $(1,455) | $(2,162) | $(1,239) | $(37) | $159 | $359 | $714 | |||||||||||||||||||
(1) | Net Cash Revenue, a non-GAAP financial measure, refers to total revenue including the impact of annual escalators less any pass-through costs, with revenue recognized when received. |
(2) | Adjusted Cash EBITDA, a non-GAAP financial measure, refers to earnings before interest, taxes, depreciation and amortization adjusted for company defined non-recurring and non-cash items, stock-based compensation, and one-time expenses, with revenue recognized when received. |
(3) | Capital Expenditures, a non-GAAP financial measure, refers to required capital needed by Core Scientific to build and deliver the Colocation Pipeline sites to new potential customers assuming signing of new colocation contracts in the future; the management assumption for the development capital expenditure for the Colocation Pipeline Business was approximately $7.1 billion for approximately 600 MWs, implying approximately $11.9 million/MW of capital expenditure given limited or low possibility for other potential customers to share the capital expenditure costs for these sites. |
(4) | Unlevered Free Cash Flow, a non-GAAP financial measure, refers to cash flow from operations before interest payments, adjusted to include capital expenditures, changes in net working capital, and stock-based compensation. For the period from April 2025 through December 2025, Core Scientific management identified certain one-time, non-recurring cash financial and legal expenses that were added back to Adjusted Cash EBITDA and not deducted from the Unlevered Free Cash Flow. These cash expenses, if deducted from the Unlevered Free Cash Flow, would further burden the free cash flow of Core Scientific. PJT Partners’ analysis utilized 2033E Adjusted Cash EBITDA of $899, which estimate was provided by Core Scientific management, in calculating terminal value. |
(5) | Reflects the nine-month period from April 2025 through December 2025. PJT Partners’ analysis utilized a June 30, 2025 valuation date and thus only used data from the last two quarters of 2025, resulting in Unlevered Free Cash Flows of ($561); these Unlevered Free Cash Flows are also burdened by one-time expenses related to cash legal and financial fees of ($3). |
Year Ending December 31, | ||||||||||||||||||||||||
3Q 2025E(3) | 2026E | 2027E | 2028E | 2029E | 2030E | 2031E | 2032E | |||||||||||||||||
(in millions) | ||||||||||||||||||||||||
Revenue | $220 | $177 | $112 | $— | $— | $— | $— | $— | ||||||||||||||||
Adjusted Cash EBITDA(1) | $73 | $68 | $46 | $— | $— | $— | $— | $— | ||||||||||||||||
Capital Expenditures | $— | $— | $— | $— | $— | $— | $— | $— | ||||||||||||||||
Unlevered Free Cash Flow(2) | $59 | $55 | $35 | $— | $— | $— | $— | $— | ||||||||||||||||
(1) | Adjusted Cash EBITDA, a non-GAAP financial measure, refers to earnings before interest, taxes, depreciation and amortization adjusted for company defined non-recurring and non-cash items, stock-based compensation, and one-time expenses. |
(2) | Unlevered Free Cash Flow, a non-GAAP financial measure, refers to cash flow from operations before interest payments, adjusted to include capital expenditures, changes in net working capital, and stock-based compensation. For the period from April 2025 through December 2025, Core Scientific management identified certain one-time, non-recurring cash financial and legal expenses that were added back to Adjusted Cash EBITDA and not deducted from the Unlevered Free Cash Flow. These cash expenses, if deducted from the Unlevered Free Cash Flow, would further burden the free cash flow of Core Scientific. |
(3) | Reflects the nine-month period from April 2025 through December 2025. PJT Partners’ analysis utilized a June 30, 2025 valuation date and thus only used data from the last two quarters of 2025, resulting in Unlevered Free Cash Flows of ($39); these Unlevered Free Cash Flows are also burdened by one-time expenses related to cash legal and financial fees of ($1). |
Year Ending December 31, | ||||||||||||||||||||||||
3Q 2025E(1) | 2026E | 2027E | 2028E | 2029E | 2030E | 2031E | 2032E | |||||||||||||||||
(in millions) | ||||||||||||||||||||||||
Net Operating Loss Utilization Cash Tax Savings | $— | $70 | $26 | $— | $— | $— | $— | $— | ||||||||||||||||
(1) | Reflects the nine-month period from April 2025 through December 2025. PJT Partners’ analysis utilized a June 30, 2025 valuation date and thus only used data from the last two quarters of 2025. |
Year Ending December 31, | ||||||||||||||||||
3Q 2025E(4) | 2026E | 2027E | 2028E | 2029E | 2030E | |||||||||||||
(in millions) | ||||||||||||||||||
Revenue | $4,040 | $12,307 | $17,614 | $20,354 | $22,813 | $24,310 | ||||||||||||
Adjusted EBIT(1) | $656 | $2,924 | $4,845 | $5,707 | $6,593 | $7,147 | ||||||||||||
Adjusted EBITDA(2) | $2,727 | $9,166 | $13,538 | $15,899 | $17,607 | $18,806 | ||||||||||||
Capital Expenditures | $(20,251) | $(17,186) | $(15,492) | $(15,356) | $(15,636) | $(15,141) | ||||||||||||
Unlevered Free Cash Flow(3) | $(14,728) | $(11,746) | $(7,532) | $305 | $52 | $1,659 | ||||||||||||
Net Operating Loss Utilization Cash Tax Savings | $— | $21 | $355 | $456 | $558 | $500 | ||||||||||||
(1) | Adjusted EBIT, a non-GAAP financial measure, refers to earnings before interest and taxes, adjusted for company defined non-recurring and non-cash items, stock-based compensation, and one-time expenses. |
(2) | Adjusted EBITDA, a non-GAAP financial measure, refers to earnings before interest, taxes, depreciation and amortization adjusted for company defined non-recurring and non-cash items, stock-based compensation, and one-time expenses. |
(3) | Unlevered Free Cash Flow, a non-GAAP financial measure, refers to cash flow from operations before interest payments, adjusted to include capital expenditures, changes in net working capital, and stock-based compensation. |
(4) | Reflects the nine-month period from April 2025 through December 2025. PJT Partners’ analysis utilized a June 30, 2025 valuation date and thus only used data from the last two quarters of 2025, resulting in Unlevered Free Cash Flows of ($9,489). |
• | reviewed certain publicly available business and financial information, including publicly available research analysts’ financial forecasts, relating to Core Scientific and CoreWeave; |
• | reviewed certain internal information relating to the business, earnings, cash flow, assets, liabilities and prospects of Core Scientific furnished to Moelis by Core Scientific, including financial forecasts provided to or discussed with us by the management of Core Scientific which are referred to in this proxy statement/prospectus as the “Core Scientific Standalone Projections” (see the section titled “The Merger—Certain Unaudited Prospective Financial Information—Core Scientific Standalone Projections”); |
• | reviewed (a) certain information relating to the business, earnings, cash flow, assets, liabilities and prospects of CoreWeave furnished to Moelis by or at the direction of the management of CoreWeave and (b) certain financial forecasts of CoreWeave that were provided to and discussed with Moelis by the management of Core Scientific, including a certain equity research analyst model that the management of CoreWeave provided to management of Core Scientific, which are referred to collectively in this proxy statement/prospectus as the “CoreWeave Standalone Projections” (see the section titled “The Merger—Certain Unaudited Prospective Financial Information—CoreWeave Standalone Projections”) and, together with the Core Scientific Standalone Projections, are referred to in this proxy statement/prospectus as the “Core Scientific Management Projections”; |
• | reviewed information regarding the capitalization of Core Scientific furnished to Moelis by Core Scientific and the capitalization of CoreWeave furnished to Moelis by the management of CoreWeave; |
• | reviewed information regarding the strategic and financial benefits (including potential synergies) to the combined company discussed with Core Scientific, |
• | conducted discussions with members of the senior managements and representatives of Core Scientific and participated in discussions with members of senior management of CoreWeave concerning the information described above, as well as the businesses and prospects of Core Scientific and CoreWeave generally; |
• | reviewed the reported prices and trading activity for Core Scientific common stock and CoreWeave common stock, including the market liquidity and average daily trading volumes of CoreWeave common stock relative to Core Scientific’s market capitalization; |
• | reviewed publicly available financial and stock market data of certain other companies in lines of business that Moelis deemed relevant; |
• | reviewed the financial terms of certain other transactions as Moelis deemed appropriate; |
• | reviewed a draft, dated July 7, 2025, of the Merger Agreement; |
• | participated in certain discussions and negotiations among representatives of Core Scientific and CoreWeave and their advisors; and |
• | conducted such other financial studies and analyses and took into account such other information as Moelis deemed appropriate. |
• | “EBITDA” was generally calculated as the relevant company’s earnings before interest, taxes, depreciation and amortization. |
• | “Adjusted EBITDA” was generally calculated as the relevant company’s EBITDA, adjusted for company defined non-recurring and non-cash items, stock based compensation, one-time expenses, and, for Core Scientific capital expenditure crediting under Core Scientific’s existing contracts with CoreWeave. |
• | “Total Enterprise Value” (or “TEV”) was generally calculated as the market value of the relevant company’s fully diluted common equity based on its closing stock price on a specified date, plus (a) debt, including financing leases less (b) cash, cash equivalents, short-term investments, and Bitcoin based on its price on a specified date plus (c) the book value of preferred stock and non-controlling interests less (d) equity method/investments in unconsolidated subsidiaries, where applicable (in each of the foregoing cases as of the relevant company’s most recently reported quarter end and adjusted for subsequent events). |
• | The implied per share consideration (based on the closing price of CoreWeave common stock of $165.20 on July 3, 2025, the last trading day prior to the announcement of the transaction and the exchange ratio) was $20.40. |
Implied Exchange Ratio(1) | Implied Pro Forma Core Scientific Ownership Percentage(1) | |||||
DCF Analysis | 0.043 - 0.154x | 3.1% - 11.6% | ||||
(1) | The high end of the range of the implied exchange ratios and the implied pro forma Core Scientific ownership percentages represent the high end of the implied per share value range or implied equity value range of Core Scientific versus the low end of the implied per share value range or implied equity value range of CoreWeave, respectively. The low end of the range of the implied exchange ratios and the implied pro forma Core Scientific ownership percentages represents the low end of the implied per share value range or implied equity value range of Core Scientific versus the high end of the implied per share value range or implied equity value range of CoreWeave, respectively. |
• | Equinix Inc. (“Equinix”) |
• | Digital Realty Trust, Inc. and Digital Realty Trust, L.P. (together, “Digital Realty”) |
• | Keppel DC REIT Management Pte. Ltd. (“Keppel DC REIT”) |
• | Digital Core REIT Management Pte. Ltd. (“Digital Core REIT”) |
Selected Companies | TEV/Adj. EBITDA – CY2026E | TEV/Adj. EBITDA – CY2027E | ||||
Equinix | 18.6x | 17.1x | ||||
Digital Realty | 20.2x | 17.9x | ||||
Keppel DC REIT | 20.7x | 19.6x | ||||
Digital Core REIT | 17.8x | 16.0x | ||||
Mean | 19.3x | 17.6x | ||||
Median | 19.4x | 17.5x | ||||
Core Scientific Consensus (as of July 3, 2025) | 19.8x | 12.5x | ||||
Core Scientific Consensus Unaffected (as of June 25, 2025) | 12.8x | 8.2x | ||||
• | Pureplay Cloud |
○ | Oracle Corporation (“Oracle”) |
○ | Nebius B.V. (“Nebius”) |
• | Diversified Cloud |
○ | Microsoft Corporation (“Microsoft”) |
○ | Amazon.com, Inc. (“Amazon”) |
○ | Google LLC (“Google”) |
○ | International Business Machines Corporation (“IBM”) |
CoreWeave Selected Companies | TEV/Adj. EBITDA – CY2026E | TEV/Adj. EBITDA – CY2027E | TEV/Adj. EBIT – CY2027E | |||||||||||
![]() | Oracle | 20.4x | 16.6x | 21.6x | ||||||||||
Nebius | 38.2x | 13.6x | [NM] | |||||||||||
![]() | Microsoft | 18.4x | 15.8x | 19.5x | ||||||||||
Amazon | 12.4x | 10.4x | 20.7x | |||||||||||
Google | 11.1x | 9.8x | 13.6x | |||||||||||
IBM | 16.2x | 15.1x | 21.2x | |||||||||||
Mean | 19.5x | 13.5x | 19.3x | |||||||||||
Median | 17.3x | 14.3x | 20.7x | |||||||||||
CoreWeave Consensus (as of July 3, 2025) | 12.0x | 8.2x | 23.9x | |||||||||||
CoreWeave Consensus (Unaffected as of June 25, 2025) | 11.6x | 8.0x | 23.1x | |||||||||||
Implied Exchange Ratio(1) | Implied Pro Forma Core Scientific Ownership Percentage | |||||
TEV/Adj. EBITDA – CY2026E | 0.053 − 0.116x | 4.0 − 8.5% | ||||
TEV/Adj. EBITDA – CY2027E | 0.064 – 0.139x | 4.8 – 10.7% | ||||
TEV/Adj. EBITDA/EBIT – CY2027E(2) | 0.100 – 0.179x | 7.3 – 13.3% | ||||
(1) | The high end of the range of the implied exchange ratios and the implied pro forma Core Scientific ownership percentages represent the high end of the implied per share value range or implied equity value range of Core Scientific versus the low end of the implied per share value range or implied equity value range of CoreWeave, respectively. The low end of the range of the implied exchange ratios and the implied pro forma Core Scientific ownership percentages represents the low end of the implied per share value range or implied equity value range of Core Scientific versus the high end of the implied per share value range or implied equity value range of CoreWeave, respectively. |
(2) | Moelis’ analysis utilized 2027E Adjusted EBITDA for Core Scientific and Adjusted EBIT for CoreWeave as valuation metrics; while not directly comparable, these represented the closest approximation given the Core Scientific selected publicly traded companies analysis does not utilize EBIT as a valuation metric. |
• | reviewed certain publicly available information concerning the business, financial condition and operations of Core Scientific and CoreWeave; |
• | reviewed certain internal information concerning the business, financial condition and operations of Core Scientific prepared and furnished to PJT Partners by the management of Core Scientific; |
• | reviewed certain information concerning the business, financial condition and operations of CoreWeave furnished to PJT Partners by or at the direction of the management of CoreWeave; |
• | reviewed certain internal financial analyses, estimates and forecasts relating to Core Scientific, including projections that were prepared by or at the direction of the management of Core Scientific and approved for PJT Partners’ use by the Core Scientific board, which are referred to in this proxy statement/prospectus as the “Core Scientific Standalone Projections” (see the section titled “The Merger—Certain Unaudited Prospective Financial Information—Core Scientific Standalone Projections”); |
• | reviewed certain financial analyses, estimates and forecasts relating to CoreWeave that were provided to and discussed with PJT Partners by the management of Core Scientific, including a certain equity research analyst’s model that the management of CoreWeave provided to PJT Partners and management of Core |
• | held discussions with members of senior management of Core Scientific and participated in discussions with members of senior management of CoreWeave, in each case, concerning, among other things, their evaluation of the Merger and the Core Scientific’s and CoreWeave’s respective businesses, operating and regulatory environments, financial conditions, prospects and strategic objectives, and potential strategic and financial benefits to the combined company; |
• | reviewed the historical market prices and trading activity for the Core Scientific common stock and the CoreWeave common stock; |
• | compared certain publicly available financial and stock market data for Core Scientific and CoreWeave with similar information for certain other companies that PJT Partners deemed to be relevant; |
• | reviewed a draft, dated July 7, 2025, of the Merger Agreement; and |
• | performed such other financial studies, analyses and investigations, and considered such other matters, as PJT Partners deemed necessary or appropriate for purposes of rendering its opinion. |
Core Scientific Standalone DCF Analysis | Implied equity values per share of Core Scientific common stock | ||
Core Scientific Standalone Projections | $13.17 – $18.47 | ||
CoreWeave Standalone DCF Analysis | Implied equity values per share of CoreWeave common stock | ||
CoreWeave Standalone Projections | $90.77 – $184.23 | ||
Implied Exchange Ratio | |||
DCF Analysis | 0.0715 - 0.2035x | ||
• | financial, operating and public trading data relating to selected publicly-traded data infrastructure companies which, in its professional judgement, PJT Partners deemed comparable to Core Scientific, and which PJT Partners reviewed and compared in order to assess how the public market values shares of similar publicly-traded companies and to provide a range of relative implied equity values per share of Core Scientific common stock on a standalone basis, in each case by reference to these comparable companies; |
• | historical trading prices of Core Scientific common stock during the 52-week period ending June 25, 2025, which indicated low and high closing prices of Core Scientific common stock during such period of $6.20 to $18.63, as compared to the implied offer price per share of Core Scientific common stock of $19.70 (based on the prices of Core Scientific common stock and CoreWeave common stock as of June 25, 2025, the last trading day prior to media reports that Core Scientific and CoreWeave were in merger discussions); and |
• | publicly available Wall Street research analysts’ share price targets in the next 12 months for Core Scientific common stock, which indicated a target share price range for Core Scientific common stock of $15.00 to $20.00, as compared to the implied offer price per share of Core Scientific common stock of $19.70 (based on the prices of Core Scientific common stock and CoreWeave common stock as of June 25, 2025, the last trading day prior to media reports that Core Scientific and CoreWeave were in merger discussions). |
• | the receipt of CoreWeave common stock as Merger Consideration provides Core Scientific stockholders with the opportunity to have an ownership stake in the combined company which is expected to provide a number of significant potential strategic opportunities and benefits to create additional value for Core Scientific stockholders, including through cost synergies in the form of corporate general and administrative cost savings and operational efficiency through streamlining business operations and eliminating lease overhead to create potential for incremental cash flow, leveraging the larger scale and capability of the combined company to accelerate deployment of artificial intelligence and HPC workloads, and obtaining greater financing flexibility given the ability of the combined company to pursue additional infrastructure financing strategies to finance committed capital expenditures, and greater ability to attract new and diverse sources of financing to replace traditional debt or equity financing; |
• | the proposed transaction eliminates the risks and uncertainties to Core Scientific of remaining an independent public company pursuing its standalone plan, which would involve significant near-term capital expenditures and execution risk to secure power, customers and financing for its Colocation Pipeline Business; and |
• | the Core Scientific board carefully considered strategic alternatives in consultation with its advisors, including considering whether to continue operating Core Scientific as an independent company or seek a business combination with another party. Core Scientific’s financial advisors had each expressed their respective views that there were not likely to be any potential alternative counterparties that would be interested and able to pursue a strategic transaction with Core Scientific, and the fact that no other potential acquirors contacted Core Scientific to express an interest in pursuing a potential acquisition of Core Scientific, including following the June 4, 2024 Bloomberg report regarding CoreWeave’s June 2024 Proposal and the June 26, 2025 Wall Street Journal report that Core Scientific and CoreWeave were in discussions regarding a potential transaction. After considering the alternatives and overseeing extensive negotiations between Core Scientific and CoreWeave and their respective advisors (resulting in multiple increased offers from CoreWeave, with the culmination of CoreWeave stating that the 0.1235 exchange ratio represented its best and final offer, which represented an increase of approximately 34% over the exchange ratio in CoreWeave’s June 6 Proposal), the Core Scientific board determined that the Merger is the best available option for Core Scientific and its stockholders. The Core Scientific Board also considered that, given the existence of a ‘fiduciary out’ and a reasonable termination fee, the Merger Agreement would not likely preclude or unduly discourage any third party with the financial capability and strategic interest of acquiring Core Scientific from pursuing a potential superior proposal. |
• | a holder of a Tranche 1 Warrant as of immediately prior to the effective time will be entitled, following the effective time, and subject to the terms and conditions of the Core Scientific Warrant Agreement, to receive a New Tranche 1 Warrant exercisable for a number of shares of CoreWeave common stock equal to (1) the Warrant Shares (as defined in the Core Scientific Warrant Agreement) underlying such Tranche 1 Warrant, multiplied by (2) the exchange ratio, with such New Tranche 1 Warrant having an exercise price per Warrant |
• | a holder of a Tranche 2 Warrant as of immediately prior to the effective time will be entitled, following the effective time, and subject to the terms and conditions of the Core Scientific Warrant Agreement, to receive a Converted Tranche 2 Warrant (as defined in the Core Scientific Warrant Agreement), which Converted Tranche 2 Warrant will be exercisable for a number of Warrant Shares with an exercise price of $7.50 per Warrant Share (subject to adjustment as set forth in the Core Scientific Warrant Agreement and otherwise on the same terms as the Tranche 2 Warrants), which will be converted into a New Tranche 2 Warrant exercisable for a number of shares of CoreWeave common stock equal to (a) the Warrant Shares underlying the Converted Tranche 2 Warrants, multiplied by (b) the exchange ratio, with such New Tranche 2 Warrant having an exercise price per Warrant Share equal to $7.50 per Warrant Share divided by the exchange ratio, and otherwise having terms substantially the same as the terms of the Tranche 1 Warrants. |
• | receipt of the Core Scientific Stockholder Approval; |
• | this registration statement on Form S-4 becoming effective under the Securities Act, no SEC stop order suspending the effectiveness of this registration statement having been issued by the SEC and remaining in effect and no proceedings for such purpose pending before the SEC; |
• | the expiration or termination of the waiting period (and any extension thereof, including any commitment to, or agreement with, any governmental body to delay the consummation of, or not to consummate before a certain date, the transactions contemplated by the Merger Agreement) applicable to the transactions contemplated by the Merger Agreement under the HSR Act; |
• | the absence of any order enacted, promulgated, issued or entered by any governmental body enjoining, restraining, preventing or prohibiting the consummation of the Merger and the absence of any law in effect or enacted or promulgated prohibiting or making illegal the consummation of the Merger; and |
• | the approval for listing on Nasdaq, subject to official notice of issuance, of the CoreWeave common stock issuable to the Core Scientific stockholders in the Merger. |
• | certain representations and warranties Core Scientific made in the Merger Agreement regarding certain aspects of corporate organization and corporate power, authority and enforceability, certain aspects of Core Scientific’s capitalization, certain aspects of Core Scientific’s subsidiaries, non-violation, broker’s fees, rights agreements and fairness opinions being true and correct in all material respects, on and as of the closing, with the same force and effect as if made on and as of the closing (except to the extent any such representation and warranty expressly relates to an earlier date (in which case as of such earlier date)); provided that all “Core Scientific Material Adverse Effect” (with such term as described in the section titled “—Definition of ‘Material Adverse Effect”’), “material” and “materiality” qualifications contained in such representations and warranties will be disregarded; |
• | certain representations and warranties Core Scientific made in the Merger Agreement regarding certain aspects of capitalization being true and correct in all respects (except for de minimis inaccuracies relative to the total fully diluted equity capitalization of Core Scientific), on and as of the closing, with the same force and effect as if made on and as of the closing (except to the extent any such representation and warranty expressly relates to an earlier date (in which case as of such earlier date)); provided that all “Core Scientific Material Adverse Effect,” “material” and “materiality” qualifications contained in such representations and warranties will be disregarded; |
• | certain representations and warranties Core Scientific made in the Merger Agreement regarding the absence of a Core Scientific Material Adverse Effect having occurred between March 31, 2025 and the date of the Merger Agreement being true and correct in all respects as of the closing; |
• | each of the other representations and warranties Core Scientific made in the Merger Agreement being true and correct as of the closing (without giving effect to any “material,” “materiality,” “Core Scientific Material Adverse Effect” or similar phrases (other than the word “material” in the definition of “material contract”)) as if made as of the closing (except to the extent any such representation and warranty expressly relates to an earlier date (in which case as of such earlier date)), except where the failure of any such representations and warranties to be true and correct has not had and would not reasonably be expected to have, individually or in the aggregate, a Core Scientific Material Adverse Effect; |
• | compliance by Core Scientific in all material respects with all of the covenants and agreements under the Merger Agreement required to be performed by Core Scientific at or prior to the closing; |
• | the absence of a Core Scientific Material Adverse Effect (defined below) since the date of the Merger Agreement; and |
• | the delivery by Core Scientific to CoreWeave of a certificate executed by a duly authorized officer of Core Scientific, dated as of the closing date, stating that the conditions in the six preceding bullet points have been satisfied. |
• | certain representations and warranties CoreWeave and Merger Sub made in the Merger Agreement regarding certain aspects of corporate organization and corporate power, authority and enforceability, certain aspects of CoreWeave’s capitalization, certain aspects of CoreWeave’s subsidiaries, non-violation, and broker’s fees being true and correct in all material respects, on and as of the closing, with the same force and effect as if made on and as of the closing (except to the extent any such representation and warranty expressly relates to an earlier date (in which case as of such earlier date)); provided that all “CoreWeave Material Adverse Effect” (with such term as described under the section titled “—Definition of ‘Material Adverse Effect”’), “material” and “materiality” qualifications contained in such representations and warranties will be disregarded; |
• | certain representations and warranties CoreWeave and Merger Sub made in the Merger Agreement regarding certain aspects of CoreWeave’s capitalization being true and correct in all respects (except for de minimis inaccuracies relative to the total fully diluted equity capitalization of CoreWeave), on and as of the closing, with the same force and effect as if made on and as of the closing (except to the extent any such representation and warranty expressly relates to an earlier date (in which case as of such earlier date)); provided that all “CoreWeave Material Adverse Effect” (with such term as described under the section titled “—Definition of ‘Material Adverse Effect”’), “material” and “materiality” qualifications contained in such representations and warranties will be disregarded; |
• | certain representations and warranties CoreWeave made in the Merger Agreement regarding the absence of a CoreWeave Material Adverse Effect having occurred between March 31, 2025 and the date of the Merger Agreement being true and correct in all respects as of the closing; |
• | each of the other representations and warranties CoreWeave made in the Merger Agreement being true and correct as of the closing (without giving effect to any “material,” “materiality,” “CoreWeave Material Adverse Effect” or similar phrases (other than the word “material” in the definition of “material contract”)) as if made as of the closing (except to the extent any such representation and warranty expressly relates to an earlier date (in which case as of such earlier date)), except where the failure of any such representations and warranties to be true and correct has not had and would not reasonably be expected to have, individually or in the aggregate, a CoreWeave Material Adverse Effect; |
• | compliance by each of CoreWeave and Merger Sub in all material respects with its respective covenants and agreements under the Merger Agreement required to be performed by it at or prior to the closing; |
• | the absence of a CoreWeave Material Adverse Effect (defined below) since the date of the Merger Agreement; and |
• | the delivery by CoreWeave to Core Scientific of a certificate executed by a duly authorized officer of CoreWeave, dated as of the closing date, stating that the conditions in the six preceding bullet points have been satisfied. |
• | corporate organization and corporate power; |
• | authority relative to execution and delivery of the Merger Agreement and the consummation of the transactions contemplated by the Merger Agreement and enforceability; |
• | capitalization; |
• | organization and standing of subsidiaries; |
• | absence of any conflict with or violation or breach of organizational documents or laws or additional payments as a result of consummation of the transactions contemplated by the Merger Agreement; |
• | required governmental and other regulatory filings and consents in connection with the transactions contemplated by the Merger Agreement; |
• | SEC documents, financial statements, and financial reporting procedures; |
• | undisclosed liabilities; |
• | absence of certain developments; |
• | compliance with laws; |
• | affiliate transactions; |
• | title to assets and real property; |
• | tax matters; |
• | material contracts and commitments; |
• | intellectual property; |
• | litigation; |
• | insurance; |
• | employee benefit plans; |
• | environmental matters; |
• | employment and labor matters; |
• | material relationships; |
• | government contracts; |
• | utility regulatory matters; |
• | fiber networks; |
• | broker’s fees; |
• | accuracy of disclosure; |
• | rights agreements; |
• | opinion of financial advisors; and |
• | non-reliance. |
• | corporate organization and corporate power; |
• | authority relative to execution and delivery of the Merger Agreement and the consummation of the transactions contemplated by the Merger Agreement and enforceability; |
• | capitalization; |
• | organization and standing of subsidiaries; |
• | absence of any conflict with or violation or breach of organizational documents or laws or additional payments as a result of consummation of the transactions contemplated by the Merger Agreement; |
• | required governmental and other regulatory filings and consents in connection with the transactions contemplated by the Merger Agreement; |
• | SEC documents, financial statements, and financial reporting procedures; |
• | undisclosed liabilities; |
• | absence of certain developments; |
• | compliance with laws; |
• | affiliate transactions; |
• | litigation; |
• | broker’s fees; |
• | accuracy of disclosure; |
• | ownership of Core Scientific’s equity interests; |
• | purpose of Merger Sub; |
• | qualification of the Merger as a “reorganization” for U.S. federal income tax purposes; and |
• | non-reliance. |
• | general business or economic conditions affecting the industry in which Core Scientific and its subsidiaries operate; |
• | acts of god, weather conditions or environmental events and natural disasters (including any earthquakes, floods, hurricanes, tropical storms, fires, or other natural disasters), health emergencies, pandemics or epidemics (or the escalation of any of the foregoing) and any governmental or industry responses thereto; |
• | political or geopolitical conditions (including tariffs and sanctions), the occurrence or the escalation or worsening of any military or terrorist actions or cyberterrorism (including cyberterrorism data breaches), civil or political unrest, acts of war, hostilities or sabotage; |
• | changes in economic, financial or market conditions, including changes in the artificial intelligence, financial, banking, currency, bitcoin, bitcoin mining, cryptocurrency, electricity, energy, power or securities markets and changes in cryptocurrency prices, commodity prices and regulatory, legislative or political conditions; |
• | changes in the prices of commodities, bitcoin or other digital assets after the date of the Merger Agreement; |
• | changes in GAAP after the date of the Merger Agreement; |
• | changes in laws or orders after the date of the Merger Agreement; |
• | changes in Core Scientific’s stock price or the trading volume of Core Scientific’s stock or any change in the credit rating of Core Scientific (provided that the underlying causes of any such change, to the extent not otherwise excluded from the definition of a Core Scientific Material Adverse Effect, may be taken into consideration when determining whether a Core Scientific Material Adverse Effect has occurred); |
• | the failure of Core Scientific to meet internal or analysts’ expectations, projections or results of operations (provided that the underlying causes of any such failure to meet expectations, projections or results of operations, to the extent not otherwise excluded from the definition of a Core Scientific Material Adverse Effect, may be taken into consideration when determining whether a Core Scientific Material Adverse Effect has occurred); |
• | any material adverse effect on the business, assets, results of operations or financial condition of CoreWeave or its subsidiaries and any impact thereof on Core Scientific or its subsidiaries; |
• | breaches or threatened breaches by CoreWeave or any of its subsidiaries of any commercial contract with Core Scientific or any of its subsidiaries; |
• | the execution or delivery of the Merger Agreement, the announcement of the Merger Agreement or the transactions contemplated by the Merger Agreement, the identity of the parties to the Merger Agreement or the taking of any action required by the Merger Agreement, including the impact of any of the foregoing on the relationships of Core Scientific or any of its subsidiaries with governmental bodies, customers, suppliers, power providers, utility companies, contractors, partners, officers, employees or other business relations (it being understood that this bullet will not apply to a breach of certain representations and warranties of Core Scientific relating to authority and enforceability, non-violation, consents, intellectual property and employee benefit plans or the accuracy of such representations and warranties for the purposes of determining whether certain conditions to closing have been satisfied); |
• | transaction litigation (provided that the underlying causes of any such litigation, to the extent not otherwise excluded from the definition of a Core Scientific Material Adverse Effect, may be taken into consideration when determining whether a Core Scientific Material Adverse Effect has occurred); and |
• | any action (1) expressly required by the Merger Agreement, (2) taken by Core Scientific or any of its subsidiaries with CoreWeave’s written consent, to the extent the consequences thereof are reasonably foreseeable, or taken at CoreWeave’s written request or (3) any failure by Core Scientific or any of its subsidiaries to take any action as a result of CoreWeave’s or any of CoreWeave’s subsidiaries’ failure or delay in providing consent, to the extent such failure or delay in providing consent would reasonably be expected to have a materially adverse effect on Core Scientific or its subsidiaries; |
• | general business or economic conditions affecting the industry in which CoreWeave and its subsidiaries operate; |
• | acts of god, weather conditions or environmental events and natural disasters (including any earthquakes, floods, hurricanes, tropical storms, fires, or other natural disasters), health emergencies, pandemics or epidemics (or the escalation of any of the foregoing) and any governmental or industry responses thereto; |
• | political or geopolitical conditions (including tariffs and sanctions), the occurrence or the escalation or worsening of any military or terrorist actions or cyberterrorism (including cyberterrorism data breaches), civil or political unrest, acts of war, hostilities or sabotage; |
• | changes in economic, financial or market conditions, including changes in the artificial intelligence, financial, banking, currency, bitcoin, bitcoin mining, cryptocurrency, electricity, energy, power or securities markets and changes in cryptocurrency prices, commodity prices and regulatory, legislative or political conditions; |
• | changes in the prices of commodities, bitcoin or other digital assets after the date of the Merger Agreement; |
• | changes in GAAP after the date of the Merger Agreement; |
• | changes in laws or orders after the date of the Merger Agreement; |
• | changes in CoreWeave’s stock price or the trading volume of CoreWeave’s stock or any change in the credit rating of CoreWeave (provided that the underlying causes of any such change, to the extent not otherwise excluded from the definition of a CoreWeave Material Adverse Effect, may be taken into consideration when determining whether a CoreWeave Material Adverse Effect has occurred); |
• | the failure of CoreWeave to meet internal or analysts’ expectations, projections or results of operations (provided that the underlying causes of any such failure to meet expectations, projections or results of operations, to the extent not otherwise excluded from the definition of a CoreWeave Material Adverse Effect, may be taken into consideration when determining whether a CoreWeave Material Adverse Effect has occurred); |
• | breaches or threatened breaches by Core Scientific or any of its subsidiaries of any commercial contract with CoreWeave or any of its subsidiaries; |
• | the execution or delivery of the Merger Agreement, the announcement of the Merger Agreement or the transactions contemplated by the Merger Agreement, the identity of the parties to the Merger Agreement or the taking of any action required by the Merger Agreement, including the impact of any of the foregoing on the relationships of CoreWeave or any of its subsidiaries with governmental bodies, customers, suppliers, power providers, utility companies, contractors, partners, officers, employees or other business relations (it being understood that this bullet will not apply to a breach of certain representations and warranties of CoreWeave relating to authority and enforceability, non-violation and consents or the accuracy of such representations and warranties for the purposes of determining whether certain conditions to closing have been satisfied)); |
• | transaction litigation (provided that the underlying causes of any such litigation, to the extent not otherwise excluded from the definition of a CoreWeave Material Adverse Effect, may be taken into consideration when determining whether a CoreWeave Material Adverse Effect has occurred); and |
• | any action expressly required by the Merger Agreement or any action taken by CoreWeave or any of the subsidiaries of CoreWeave at Core Scientific’s written request or with Core Scientific’s consent; |
• | enter into any new line of business outside the existing lines of business of Core Scientific and its subsidiaries as of the date of the Merger Agreement; |
• | (1) declare, set aside, establish a record date for or pay any dividends on or make other distributions (whether in cash, stock or property) in respect of any Core Scientific common stock or other equity securities of Core Scientific or its subsidiaries or (2) directly or indirectly redeem, repurchase, buyback or otherwise acquire any shares of Core Scientific common stock, Core Scientific subsidiary equity securities, any Core Scientific Convertible Notes, any Core Scientific warrants or any Core Scientific RSU Awards or Core Scientific PSU Awards with respect thereto, except, in each case, (A) for the declaration and payment of dividends or distributions by a direct or indirect wholly owned subsidiary of Core Scientific solely to its direct parent entity, (B) any forfeitures or repurchases of unvested Core Scientific RSU Awards, Core Scientific PSU Awards or other shares of securities of Core Scientific or its subsidiaries issued pursuant to or granted as awards under Core Scientific equity plans in accordance with the terms thereof as in effect as of the date of the Merger Agreement, (C) to satisfy any applicable tax withholding in respect of the vesting or settlement of any Core Scientific RSU Awards or Core Scientific PSU Awards, or (D) for the issuance of shares of Core Scientific common stock (and payment of cash in lieu of issuing any fractional share) to settle (x) any conversion of any of the Core Scientific Convertible Notes in accordance with the terms of the corresponding Core Scientific Notes Indenture or (y) any exercise of the Core Scientific warrants, in each case, as outstanding on the date of the Merger Agreement and in accordance with their respective terms on the date of the Merger Agreement, (E) payments of regular scheduled interest upon the Core Scientific Convertible Notes solely to the extent required pursuant to the terms of the corresponding Core Scientific 2029 and 2031 Notes Indentures or any exercise of the Core Scientific warrants, in each case, outstanding on the date of the Merger Agreement and in accordance with their respective terms as in effect on the date of the Merger Agreement, or (F) as required by the Core Scientific CVR Agreement; |
• | (x) issue, sell, pledge, dispose of or otherwise encumber, or authorize the issuance, sale, pledge, disposition or other encumbrance of, or make or exercise any option to purchase with respect to, (1) any shares of Core Scientific capital stock or any Core Scientific subsidiary equity securities, (2) any securities convertible |
• | except as required by the terms of a Core Scientific benefit plan as in effect as of the date of the Merger Agreement, (A) grant or increase (or promise to commit to grant or increase) the wages, salary, severance, equity or other compensation or benefits with respect to any of Core Scientific’s or any of its subsidiaries’ officers, directors, or employees, (B) establish, adopt, enter into, materially amend or terminate any Core Scientific benefit plan, other than the amendment of any Core Scientific benefit plan that is a broad-based welfare benefit plan in the ordinary course of business and in a manner that does not enhance the benefits under such Core Scientific benefit plan or increase the costs to Core Scientific or any of its subsidiaries, (C) accelerate the vesting, funding or time of payment of any compensation or other benefit, (D) enter into any transaction bonus, retention, change-of-control or similar agreement or arrangement with any employee of Core Scientific or any of its subsidiaries or pay or award (or commit to pay or award) any amounts in respect of the foregoing, (E) grant, or promise or commit to grant, any equity or equity-aligned awards or any long-term incentive awards, or (F) waive or release any noncompetition, non-solicitation, nondisclosure, noninterference, non-disparagement or other restrictive covenant obligation of any current or former employee or other individual service provider; |
• | (A) adopt, enter into or amend any collective bargaining agreement or other contract with any labor union, works council or other similar employee representative body applicable to Core Scientific or its subsidiaries, or (B) engage in any conduct that would result in an employment loss or layoff for a sufficient number of employees of Core Scientific or its subsidiaries which would constitute a “plant closing” or “mass layoff” under the Worker Adjustment and Retraining Notification Act; |
• | hire, engage, promote or terminate (other than for cause) any employee, except for (A) the hiring or engagement of any individual to whom an offer of employment has been extended on or prior to the date of the Merger Agreement as listed the confidential disclosure letter delivered by Core Scientific to CoreWeave and Merger Sub or (B) the hiring, engagement, promotion or termination of any employee below the title of Senior Manager and with a base salary less than $180,000 in the ordinary course of business consistent with past practice; |
• | (A) other than as expressly required by the Merger Agreement in furtherance of the transactions contemplated by the Merger Agreement, amend, or propose to amend any organizational document of Core Scientific (including by merger, consolidation or otherwise), (B) adopt a stockholders’ rights plan or similar plan or (C) other than the Merger Agreement, enter into any agreement with respect to the voting of Core Scientific capital stock or any Core Scientific subsidiary securities; |
• | effect a recapitalization, reclassification of shares, stock split, reverse stock split, combination, subdivision or similar transaction or authorize the issuance of any other securities in respect of, in lieu of, or in substitution for shares of Core Scientific capital stock; |
• | (A) adopt a plan of complete or partial liquidation or dissolution, of Core Scientific or any of its “significant subsidiaries,” as defined in Rule 1-02(w) of Regulation S-X or (B) enter into any merger, liquidation, dissolution, reorganization or restructuring of Core Scientific or any such “significant subsidiaries”; |
• | other than capital expenditures made pursuant to certain contracts related to properties being developed by Core Scientific and CoreWeave, incur, make or authorize any capital expenditures or any obligations or liabilities in respect thereof, other than capital expenditures that are in the ordinary course and do not exceed $5,000,000 individually or $10,000,000 in the aggregate or are contemplated by the confidential disclosure letter delivered by Core Scientific to CoreWeave and Merger Sub; |
• | acquire or agree to acquire, by merging or consolidating with, by purchasing an equity interest in or a portion of the assets of any business or any corporation, partnership, association or other business organization or division thereof, or otherwise acquire or agree to acquire any material assets of any other person, except for (A) purchases in the ordinary course of business or (B) transactions (1) solely among Core Scientific and one or more of its wholly owned subsidiaries, (2) solely among Core Scientific’s wholly owned subsidiaries or (3) pursuant to existing contractual obligations disclosed to CoreWeave prior to the date of the Merger Agreement, but excluding certain contractual obligations set forth in the confidential disclosure letter delivered by Core Scientific to CoreWeave and Merger Sub; |
• | (A) incur, assume, endorse, guarantee, or otherwise become liable for any indebtedness for borrowed money or any surety bonds or letters of credit obligations or issue or sell any debt securities or calls, options, warrants or other rights to acquire any debt securities (directly, contingently or otherwise) or enter into any “keep well” or other agreement to maintain any financial statement condition of another person (other than Core Scientific or any of its subsidiaries), (B) make any material loans or advances to any other person or (C) make any material capital contributions to, or investments in, any other person, except, in each case, for (1) among Core Scientific and its wholly owned subsidiaries or to or among any wholly owned subsidiaries of Core Scientific, (2) any surety bonds or letters of credit obligations incurred, assumed, endorsed, guaranteed or for which Core Scientific or any of its subsidiaries otherwise become liable in the ordinary course of business, (3) any advances or deposits for the future delivery of goods or services, including under co-location agreements, and (4) guarantees by Core Scientific or its subsidiaries of obligations of Core Scientific or any of its subsidiaries; |
• | sell, transfer, assign, mortgage, encumber, pledge, license, lease, sublease, abandon or otherwise withdraw or dispose of any properties or assets with a fair market value in excess of $3,000,000 in the aggregate except for, in each case, (A) certain liens permitted by the Merger Agreement, (B) sales of inventory and equipment, or of obsolete or worthless assets, in each case in the ordinary course of business and (C) any transaction (I) solely among Core Scientific and one or more of its wholly owned subsidiaries or (II) solely among Core Scientific’s wholly owned subsidiaries; |
• | (A) other than non-exclusive licenses granted in the ordinary course of business, sell, lease, assign, transfer, convey, dispose of, grant any license or sublicense in, to or under, create or incur any lien (other than certain liens permitted by the Merger Agreement) on, any material intellectual property owned by Core Scientific and its subsidiaries or (B) allow any material registered intellectual property to lapse or go abandoned, other than at the end of its maximum statutory term; |
• | pay, discharge, settle, compromise or satisfy, or offer or propose to pay, discharge, settle, compromise or satisfy, (A) any action or threatened action that results in the payment of monetary damages in excess of $3,000,000 in the aggregate, or that imposes any material restrictions or limitations upon the assets, operations or business of Core Scientific or any of its subsidiaries (or CoreWeave after closing) or equitable or injunctive remedies or the admission of wrongdoing by Core Scientific or any of its subsidiaries (or CoreWeave, after the closing) or (B) any action or threatened action (excluding any action or threatened action relating to taxes, such action and threatened actions being subject to the seventeenth bullet point of this section) that relates to the transactions contemplated by the Merger Agreement; |
• | change its fiscal year or change any of its financial accounting methods or practices or internal accounting controls or disclosure controls and procedures in any respect, except as required by GAAP, Regulation S-X of the Securities Act, or a governmental body or quasi-governmental authority (including the Financial Accounting Standards Board or any similar organization); |
• | other than in the ordinary course of business, (A) make, change or revoke any material tax election with respect to Core Scientific or any of its subsidiaries, (B) adopt or make any material change to any material method of tax accounting, (C) enter into any closing agreement relating to or affecting any material tax liability or refund of material taxes with respect to Core Scientific or any of its subsidiaries, (D) change any |
• | amend or modify in any material respect, terminate or fail to renew (including failing to exercise a renewal or extension option under) or grant any material waiver or consent under, any material contract (or any contract that, if existing on the date of the Merger Agreement, would be a material contract), or enter into any contract that, if existing on the date of the Merger Agreement, would be a material contract, or otherwise knowingly waive, release or assign any material rights, claims or benefits of Core Scientific or any of its subsidiaries with respect to any material contract (excluding certain contracts related to properties being developed by Core Scientific and CoreWeave, which are subject to the twenty-fourth bullet point of this section, and Core Scientific’s leases, which are subject to the twenty-fifth bullet point of this section), in each case other than (a) in the ordinary course and in a manner that is not reasonably expected to be adverse to Core Scientific or its subsidiaries or, after giving effect to the transactions contemplated by the Merger Agreement, CoreWeave and its subsidiaries, (b) the expiration or renewal of any material contract with a third party in accordance with its terms, or (c) as expressly contemplated by the Merger Agreement; |
• | take any action to exempt any person from any state takeover statute or similar statute or regulation that applies to Core Scientific with respect to an Acquisition Proposal, including the restrictions on “business combinations” set forth in Section 203 of the DGCL, except for CoreWeave, Merger Sub, or any of their respective subsidiaries or affiliates or to the extent permitted pursuant to the Merger Agreement; |
• | voluntarily abandon, withdraw, terminate, suspend, abrogate, amend or modify any permit issued to or held by Core Scientific or any of its subsidiaries in a manner that would materially impair the operation of the business of Core Scientific or any of its subsidiaries, taken as a whole; |
• | (A) fail to maintain any material property insurance currently in effect covering the real property owned by Core Scientific and its subsidiaries or (B) cancel, amend or modify any material license or permit held by Core Scientific with respect to the real property owned by Core Scientific and its subsidiaries, the real property leased by Core Scientific and its subsidiaries or any part thereof which would be binding after the effective time in a manner that would materially impair the operation or the use of such real property (as currently used in connection with Core Scientific’s business); |
• | initiate or consent to any material zoning reclassification of any real property owned or leased by Core Scientific and its subsidiaries or any material change to any approved site plan (in each case, that is material to such real property owned or leased by Core Scientific or plan, as applicable), special use permit or other land use entitlement affecting any material real property owned or leased by Core Scientific, in each case, in a manner that would materially inhibit Core Scientific’s ability to develop or use the real property owned or leased by Core Scientific and its subsidiaries for data center operations; |
• | fail to maintain in full force and effect existing material insurance policies (or substantially similar replacements thereto) (excluding property insurance covering real property owned by Core Scientific and its subsidiaries, which is the subject of the twenty-first bullet point of this section); provided that in the event of a termination, cancellation or lapse of any material insurance policy, Core Scientific will use reasonable best efforts to promptly obtain replacement policies on substantially consistent terms and providing substantially comparable insurance coverage with respect to the material assets, operations and activities of Core Scientific and its subsidiaries as currently in effect as of the date of the Merger Agreement; |
• | (A) enter into or materially amend, modify, waive any material rights under or grant any material consents under certain material contracts relating to certain of Core Scientific’s properties, other than in the ordinary course of business; provided that Core Scientific and its subsidiaries will not enter into any new co-location agreements with respect to any such properties or (B) enter into or materially amend, modify, waive any material rights under or grant any material consents under any non de minimis contract with respect to a property that is being developed by Core Scientific and CoreWeave; |
• | enter into or materially amend, renew or extend (or fail to exercise a renewal or extension option under), or materially modify a Core Scientific real property lease or terminate any Core Scientific real property lease (except any termination that will occur at the end of the maximum term of such real property lease), other than by extending such term through the payment of any extension fee in an amount up to $3,000,000; |
• | fail to take certain actions set forth in the confidential disclosure letter delivered by Core Scientific to CoreWeave and Merger Sub; or |
• | authorize, agree or commit to take any of the actions described in the bullet points above. |
• | declare, set aside, establish a record date for or pay any dividends on or make other distributions (whether in cash, stock or property) in respect of any CoreWeave capital stock, except (A) for the declaration and payment of dividends or distributions by a direct or indirect subsidiary of CoreWeave solely to its parent, (B) any forfeitures or repurchases of CoreWeave equity awards granted under the CoreWeave equity plans, or (C) to satisfy any applicable tax withholding in respect of the exercise, vesting or settlement of any CoreWeave equity award; |
• | issue, sell or authorize the issuance or sale of, or make any option to purchase with respect to, (1) any shares of CoreWeave capital stock or any equity securities of CoreWeave’s subsidiaries, (2) any securities convertible into or exchangeable or exercisable for any such shares or ownership interest, (3) any phantom equity or similar contractual rights or (4) any rights, warrants or options to acquire any such shares or securities exchangeable or convertible into such shares, except in each case: (A) the grant of CoreWeave equity awards or any other equity compensation award pursuant to any stockholder-approved equity plan, (B) for issuances of CoreWeave common stock upon the vesting, exercise or settlement of CoreWeave equity awards (and dividend equivalents thereon, if applicable) outstanding prior to the date of the Merger Agreement or issued after the date of the Merger Agreement in compliance with the Merger Agreement, (C) any exercise of the CoreWeave warrants and in accordance with their respective terms on the date of the Merger Agreement, (D) transactions solely between or among CoreWeave and its wholly owned subsidiaries, (E) or certain liens permitted by the terms of the Merger Agreement, (F) the issuance by CoreWeave of not more than 12.5% of the total number of shares of CoreWeave common stock issued and outstanding as of the date of the Merger Agreement determined on a fully-diluted basis, (G) the sale or issuance of CoreWeave common stock in connection with one or more mergers; acquisitions of securities, businesses, property or other assets, products or technologies; joint ventures; commercial relationships or other strategic corporate transactions or alliances, whether structured as a merger, stock purchase, business combination or otherwise and (H) the sale of CoreWeave common stock upon the exercise of the equity greenshoe option granted to Magnetar Financial LLC pursuant to a certain notes purchase agreement entered into by CoreWeave in 2021; |
• | other than as expressly permitted or required by the Merger Agreement in furtherance of the transactions contemplated by the Merger Agreement, amend, or propose to amend any of CoreWeave’s organizational documents (including by merger, consolidation or otherwise) in a manner that would be adverse to Core Scientific or Core Scientific’s stockholders; |
• | effect a recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction or authorize the issuance of any other securities in respect of, in lieu of, or in substitution for shares of its capital stock; |
• | adopt a plan of complete or partial liquidation or dissolution of CoreWeave or any of its “significant subsidiaries,” as defined in Rule 1-02(w) of Regulation S-X; |
• | authorize, agree or commit to take any of the actions described in the bullet points above. |
• | withhold, withdraw (or amend, qualify or modify in a manner adverse to CoreWeave or Merger Sub), or publicly propose to withdraw (or amend, qualify or modify in a manner adverse to CoreWeave or Merger Sub), the approval, recommendation or declaration of advisability by the Core Scientific board or any such committee of the Merger; |
• | recommend, adopt or approve, or propose publicly to recommend, adopt or approve any Acquisition Proposal or resolve to take such action; |
• | publicly make any recommendation in connection with a tender offer or exchange offer by a third party other than a recommendation against such offer or a temporary “stop, look and listen” communication by the Core Scientific board of the type contemplated by Rule 14d-9(f) under the Exchange Act; |
• | fail to include the Core Scientific board’s recommendation that Core Scientific stockholders approve the Merger and adopt the Merger Agreement (the “Core Scientific Board Recommendation”) in this proxy statement/prospectus; or |
• | fail to reaffirm or re-publish the Core Scientific Board Recommendation following the date any Acquisition Proposal or any material modification thereto is first publicly disclosed or announced within ten business days of being requested by CoreWeave to do so or, if earlier, not later than two business days prior to the Special Meeting (any action described in this bullet point and the three preceding bullet points being referred to as an “Adverse Recommendation Change”). Such ten business day period will be extended for an additional five business days following any material modification to any Acquisition Proposal occurring after the receipt of CoreWeave’s request. |
• | until four business days after Core Scientific provides written notice to CoreWeave advising CoreWeave that the Core Scientific board has received a Superior Proposal, specifying the terms and conditions of the proposal, identifying the person or group making the proposal and including copies of all documents pertaining to the proposal (with any change to the financial or other terms of a proposal that was previously the subject of a notice requiring a new notice, with the notice period in such case being two business days); |
• | if during such notice period, Core Scientific has negotiated, and has caused its representatives to negotiate in good faith with CoreWeave (to the extent CoreWeave wishes to negotiate) and CoreWeave proposes any alternative transaction in writing (including any modifications to the terms of the Merger Agreement), unless the Core Scientific board determines in good faith, after good faith negotiations between Core Scientific and CoreWeave (if such negotiations are requested by CoreWeave) during such notice period (after consultation with Core Scientific’s outside legal counsel and financial advisors and taking into account all financial, legal and regulatory terms and conditions of such alternative transaction proposal and expected timing of consummation and the relative risks of non-consummation of the alternative transaction proposal and the Superior Proposal) that the Acquisition Proposal giving rise to such notice period continues to be a Superior Proposal (assuming such revisions proposed by CoreWeave were to be given effect); and |
• | unless the Core Scientific board determines in good faith after consultation with its outside legal counsel and financial advisors that the failure to make an Adverse Recommendation Change would be inconsistent with its fiduciary obligations under applicable law. |
• | Core Scientific must first notify CoreWeave in writing at least four business days before taking such action of its intention to take such action, which notice must include a reasonably detailed description of such Intervening Event (with any material change to the facts and circumstances relating to the Intervening Event that was previously the subject of a notice requiring a new notice, with the notice period in such case being two business days); |
• | if requested by CoreWeave, Core Scientific must negotiate, and cause its representatives to negotiate, with CoreWeave and its representatives during such notice period regarding any proposal by CoreWeave to amend the terms of the Merger Agreement in response to such Intervening Event; and |
• | the Core Scientific board may not effect an Adverse Recommendation Change involving or relating to an Intervening Event unless, after such notice period, the Core Scientific board determines in good faith, after consultation with its outside legal counsel and taking into account any written proposal by CoreWeave to amend the terms of the Merger Agreement during such notice period, that the failure to take such action would continue to be inconsistent with its fiduciary duties under applicable law. |
• | initiate, seek or solicit, or knowingly encourage or facilitate (including by way of furnishing non-public information) or knowingly cooperate with or take any other action that would reasonably be expected to promote, directly or indirectly, any inquiries or the making or submission of any proposal by a third party that constitutes, or would reasonably be expected to lead to, an Acquisition Proposal; |
• | participate, engage in or continue discussions (except to notify a person that makes an inquiry or offer with respect to an Acquisition Proposal of the existence of the provisions of the Merger Agreement described by this paragraph or to clarify whether any such inquiry, offer or proposal constitutes an Acquisition Proposal) or negotiations with, or disclose any non-public information or data relating to, Core Scientific or any of its subsidiaries or afford access to the properties, books or records of Core Scientific, or any of its subsidiaries to, or otherwise knowingly assist, facilitate or encourage any effort by, any third party, in each case, that has made or could reasonably be expected to make, or in connection with, an Acquisition Proposal; |
• | enter into any agreement, including any letter of intent, term sheet, memorandum of understanding, agreement in principle, merger agreement, acquisition agreement or other similar agreement (other than certain confidentiality agreements permitted under the Merger Agreement), with respect to an Acquisition Proposal; or |
• | otherwise resolve or agree to do any of the items in the three bullet points above. |
• | obtaining all necessary actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals and, expirations or terminations of waiting periods from governmental bodies and making all necessary registrations and filings and taking all steps as may be reasonably necessary to obtain any such consent, decision, declaration, approval, clearance or waiver, or expiration or termination of a waiting period by or from, or to avoid an action or proceeding seeking to, pursuant to any antitrust law, enjoin, restrain, prevent, prohibit or make illegal consummation of the Merger or any other transaction contemplated by the Merger Agreement; |
• | obtaining all necessary consents, authorizations, approvals or waivers from third parties; |
• | defending any lawsuit or other legal proceeding, whether judicial or administrative, brought by any governmental body or third party challenging the Merger Agreement or seeking to enjoin, restrain, prevent, prohibit or make illegal consummation of the Merger or any other transaction contemplated by the Merger Agreement and contesting and seeking to have vacated, lifted, reversed or overturned any order that enjoins, restrains, prevents, prohibits or makes illegal consummation of the Merger or any other transaction contemplated by the Merger Agreement; and |
• | refraining from taking any action that would reasonably be expected to impede, interfere with, prevent or materially delay the consummation of the Merger, other than with respect to the matters set forth in the last paragraph of this section. |
• | committing to or effecting, by consent decree, hold separate order or otherwise, the sale, lease, license, divestiture or disposition of any assets, equity securities, rights, product lines, or businesses of Core Scientific, CoreWeave or any of their respective subsidiaries; |
• | terminating existing relationships, contractual rights or obligations of Core Scientific, CoreWeave or any of their respective subsidiaries; |
• | terminating any venture or other arrangement; |
• | creating any relationship, contractual right or obligation of Core Scientific, CoreWeave or any of their respective subsidiaries; |
• | effectuating any other change or restructuring of Core Scientific, CoreWeave or any of their respective subsidiaries; or |
• | otherwise taking or committing to take any actions with respect to the businesses, product lines or assets of Core Scientific, CoreWeave or any of their respective subsidiaries (and, in each case, enter into agreements or stipulate to the entry of an order or decree or file appropriate applications with any governmental body in connection with any of the foregoing); |
• | annual base salary or wages, as applicable, that are no less than the annual base salary or wages, as applicable, in effect for each such Core Scientific employee immediately prior to the effective time; |
• | target cash incentive opportunities that are no less than the target cash incentive opportunities in effect for such Core Scientific employee immediately prior to the effective time; |
• | annual target long-term incentive opportunities that are no less than the target long-term incentive opportunities in effect for similarly situated CoreWeave employees (excluding any off-cycle awards or any awards granted in connection with new hires or promotion); and |
• | employee benefits and other compensation (excluding any equity, equity-based or other long-term incentive compensation, deferred compensation, perquisites, change-in-control, transaction, stay, retention or similar bonuses or payments, severance or termination benefits) to such Core Scientific employee that are substantially comparable in the aggregate to those provided to such employee by Core Scientific and its subsidiaries immediately prior to the effective time or those provided to similarly situated employees of CoreWeave. |
• | confidentiality and reasonable access by CoreWeave and its representatives to personnel of and certain information about Core Scientific and its subsidiaries for purposes reasonably related to consummating the transactions contemplated by the Merger Agreement or preparing for post-Merger integration or restructuring and the development of mutually acceptable protocols to manage communications between the parties and their respective employees; |
• | consultation between Core Scientific and CoreWeave in connection with certain public announcements; |
• | requirement for CoreWeave and Core Scientific and their respective boards to, subject to the terms of the Merger Agreement, grant such approvals and take such actions to eliminate the effect of any takeover law on any of the transactions contemplated by the Merger Agreement; |
• | requirement for the CoreWeave board to approve the issuance of the Merger Consideration with respect to any employees of Core Scientific who, as a result of their relationship with CoreWeave, are subject or will become subject to the reporting requirements of Section 16 of the Exchange Act to the extent necessary for such issuance to be an exempt acquisition pursuant to SEC Rule 16b-3; |
• | requirement for the Core Scientific board to, to the extent necessary, approve the disposition of equity securities of Core Scientific by specified individuals to cause the disposition to be an exempt disposition under Rule 16b-3 of the Exchange Act; |
• | cooperation between Core Scientific and CoreWeave in the defense of certain litigation relating to the Merger and the transactions contemplated by the Merger Agreement; |
• | the use of Core Scientific’s and CoreWeave’s respective reasonable best efforts to cause the Merger to qualify as a “reorganization” within the meaning of Section 368(a) of the Code; |
• | cooperation between Core Scientific and CoreWeave in causing the delisting by the Surviving Corporation of Core Scientific common stock, the Tranche 1 Warrants and the Tranche 2 Warrants from Nasdaq and the deregistration of Core Scientific common stock, the Tranche 1 Warrants and the Tranche 2 Warrants under the Exchange Act; |
• | CoreWeave causing Merger Sub to not engage in any activities except as provided in or contemplated by the Merger Agreement; |
• | cooperation between Core Scientific and CoreWeave with respect to CoreWeave obtaining, at CoreWeave’s sole cost and expense, such title insurance (including any non-imputation and other endorsements) that CoreWeave reasonably determines to obtain in respect of the real property owned by Core Scientific and its subsidiaries; |
• | Core Scientific using reasonable best efforts to provide CoreWeave certain schedules of Core Scientific equity awards; |
• | requirement for Core Scientific to provide certain cooperation in connection with the arrangement of a debt financing undertaken by CoreWeave to finance the transactions contemplated by the Merger Agreement as may be customary and reasonably requested by CoreWeave; |
• | obtaining third party consents; |
• | further assurances; |
• | providing the other party with notice of certain events; and |
• | certain matters related to indebtedness of Core Scientific. |
• | at any time prior to the effective time, by the mutual written consent of CoreWeave and Core Scientific; |
• | by CoreWeave: |
• | at any time prior to the effective time, if any of Core Scientific’s covenants, representations or warranties contained in the Merger Agreement are or have become untrue, such that any of the closing conditions for CoreWeave relating to the accuracy of Core Scientific’s representations and warranties or compliance by Core Scientific with its covenants and agreements would not be satisfied, and such breach (A) is incapable of being cured by Core Scientific by or before the End Date or (B) is not cured within 30 days of receipt by Core Scientific of written notice from CoreWeave of such breach; provided, however, that CoreWeave will not have the right to terminate the Merger Agreement as described in this bullet point if any of CoreWeave or Merger Sub is then in breach of any representation, warranty, covenant or obligation under the Merger Agreement that would result in the failure to be satisfied of any of the closing conditions for Core Scientific relating to the accuracy of CoreWeave’s or Merger Sub’s representations and warranties or compliance by CoreWeave or Merger Sub with their covenants and agreements under the Merger Agreement; or |
• | at any time prior to obtaining the Core Scientific Stockholder Approval, if the Core Scientific board or any committee thereof makes an Adverse Recommendation Change; |
• | by Core Scientific: |
• | at any time prior to the effective time, if any of CoreWeave’s or Merger Sub’s covenants, representations or warranties contained in the Merger Agreement are or have become untrue, such that any of the closing conditions for Core Scientific relating to the accuracy of CoreWeave’s or Merger Sub’s representations and warranties or compliance by CoreWeave or Merger Sub with its covenants and agreements would not be satisfied, and such breach (A) is incapable of being cured by CoreWeave or Merger Sub, as the case may be, by or before the End Date, or (B) is not cured within 30 days of receipt by CoreWeave of written notice from Core Scientific of such breach; provided, however, that Core Scientific will not have the right to terminate the Merger Agreement as described in this bullet point if Core Scientific is then in breach of any representation, warranty, covenant or obligation under the Merger Agreement that would result in the failure to be satisfied of any of the closing conditions for CoreWeave relating to the accuracy of Core Scientific’s representations and warranties or compliance by Core Scientific with its covenants and agreements under the Merger Agreement; or |
• | at any time prior to obtaining the Core Scientific Stockholder Approval (and subject to Core Scientific’s obligation to pay CoreWeave the Termination Fee), upon written notice to CoreWeave, in order to enter into a definitive agreement with a third party providing for a Superior Proposal, if in connection with such Superior Proposal, Core Scientific has complied in all material respects with its requirements as described in the sections titled “—Obligations to Recommend the Adoption of the Merger Agreement” and “—No Solicitation”; |
• | by either CoreWeave or Core Scientific at any time prior to the effective time, if: |
• | (A) any order has become final and non-appealable, or (B) there is a law, in each case of (A) and (B) having the effect of permanently enjoining or restricting the consummation of the Merger or making the Merger illegal or otherwise prohibited; provided, however, that the right to terminate the Merger Agreement as described in this bullet point will not be available to any party whose material failure to comply with any provision of the Merger Agreement has been the primary cause of such order or law; |
• | the closing has not been consummated by the End Date; provided, that the right to terminate the Merger Agreement as described in this bullet point will not be available to any party whose material failure to comply with any provision of the Merger Agreement has been the primary cause of the failure of the Merger to occur on or before the End Date; or |
• | the Core Scientific Stockholder Approval has not been obtained at the Special Meeting, including any adjournment or postponement thereof; provided, that the right to terminate the Merger Agreement as |
• | CoreWeave, at any time prior to obtaining the Core Scientific Stockholder Approval, as a result of the Core Scientific board or any committee thereof making an Adverse Recommendation Change; |
• | CoreWeave due to Core Scientific’s intentional breach of any provision of the Merger Agreement and (A) after the date of the Merger Agreement and prior to such termination, any third party has publicly disclosed or otherwise communicated to the Core Scientific board an Acquisition Proposal and such Acquisition Proposal, if public, has not have been publicly withdrawn at least two business days prior to such termination, and (B) within 12 months of any termination described in this bullet point, (x) Core Scientific or any of its subsidiaries enters into a definitive agreement with respect to an Acquisition Proposal (substituting fifty percent (50%) for the twenty percent (20%) threshold set forth in the definition of “Acquisition Proposal” for all purposes under this bullet point) that is subsequently consummated or (y) Core Scientific or its subsidiaries consummates an Acquisition Proposal; |
• | Core Scientific, at any time prior to obtaining the Core Scientific Stockholder Approval, in order to enter into a definitive agreement with a third party providing for a Superior Proposal; or |
• | CoreWeave or Core Scientific as a result of (i) the Merger not having been consummated by the End Date without the Core Scientific Stockholder Approval having been obtained or (ii) the Core Scientific Stockholder Approval not having been obtained at the Special Meeting and (A) after the date of the Merger Agreement and prior to such termination, any third party has publicly disclosed an Acquisition Proposal and such Acquisition Proposal has not have been publicly withdrawn at least two business days prior to (x) the date of such termination (in the case of termination as a result of the Merger not having been consummated by the End Date) or (y) the Special Meeting (in the case of a termination as a result of the Core Scientific Stockholder Approval not having been obtained at the Special Meeting), and (B) within 12 months of any termination described in this bullet point, (x) Core Scientific or any of its subsidiaries enters into a definitive agreement with respect to an Acquisition Proposal (substituting fifty percent (50%) for the twenty percent (20%) threshold set forth in the definition of “Acquisition Proposal” for all purposes under this bullet point) that is subsequently consummated or (y) Core Scientific or its subsidiaries consummates an Acquisition Proposal. |
• | an individual citizen or resident of the United States; |
• | a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States or any of its political subdivisions; |
• | a trust if (i) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more United States persons (as defined in the Code) have the authority to control all substantial decisions of the trust or (ii) such trust has made a valid election under applicable U.S. Treasury regulations to be treated as a U.S. person; or |
• | an estate that is subject to U.S. federal income taxation on its income regardless of its source. |
• | banks, thrifts, mutual funds, insurance companies or other financial institutions; |
• | partnerships, S corporations, or other pass-through entities (or investors in partnerships, S corporations, or other pass-through entities); |
• | tax-exempt organizations or governmental organizations; |
• | dealers or brokers in stocks, securities, commodities, or currencies; |
• | traders in securities that elect to use a mark-to-market method of accounting; |
• | individual retirement or other deferred accounts; |
• | persons that hold shares of Core Scientific common stock as part of a straddle, hedge, appreciated financial position, constructive sale, conversion, integrated or other risk reduction transaction; |
• | regulated investment companies or real estate investment trusts; |
• | U.S. holders whose “functional currency” is not the U.S. dollar; |
• | U.S. expatriates; |
• | persons required to accelerate the recognition of any item of gross income as a result of such income being recognized on an “applicable financial statement”; |
• | holders who, directly, indirectly or constructively own (or at any time during the five-year period ending on the date of the Merger owned) 5% or more of Core Scientific common stock; |
• | holders who acquired their shares of Core Scientific common stock in exchange for claims arising out of the Core Scientific chapter 11 case; and |
• | stockholders who acquired their shares of Core Scientific common stock through the exercise of employee stock options, as a restricted stock award or otherwise as compensation. |
• | The relevant price per share of Core Scientific common stock is $13.34, which is the average closing price per share of Core Scientific common stock as reported on the Nasdaq over the first five business days following the first public announcement of the transaction on July 7, 2025. |
• | The effective time as referenced in this section occurred on August 14, 2025, which is the assumed date of the effective time solely for purposes of the disclosure in this section. |
• | The employment of each of Core Scientific's named executive officers was terminated by CoreWeave without “cause” or due to the executive’s resignation for “good reason” (as such terms are defined in the relevant plans and agreements), in either case immediately following the effective time. |
Name | Cash ($)(1) | Equity Awards ($)(2) | Benefits ($)(3) | Tax Reimbursement ($)(4) | Total ($) | ||||||||||
Adam Sullivan | 4,743,750 | 102,042,213 | 25,651 | 25,122,450 | 131,934,064 | ||||||||||
James Nygaard | 3,000,000 | 10,934,424 | 34,951 | 1,990,858 | 15,960,233 | ||||||||||
Todd M. DuChene | 2,625,000 | 32,924,217 | 64,768 | 8,145,422 | 43,759,407 | ||||||||||
(1) | Cash. These amounts include the salary- and bonus-related cash severance payable to each named executive officer in connection with his termination of employment at the effective time as provided for under the Letter Agreements. These severance payments are equal to two times the sum of (a) the named executive officer’s annual base salary at the rate in effect as of immediately prior to the Effective Time and (b) the named executive officer’s target annual cash incentive bonus as in effect immediately prior to the Effective Time. These severance payments are “double trigger” and are only payable upon the occurrence of both the effective time and the termination of employment of each named executive officer. The amounts in this column also include the 2025 annual bonus payments described above under the section titled “—2025 Annual Cash Bonuses of Executive Officers.” These bonus payments are “single trigger” and are payable upon the occurrence of the effective time. The estimated amount of each such payment is set forth in the table below: |
Name | 2x Salary ($) | 2x Bonus ($) | 2025 Bonus ($) | Total ($) | ||||||||
Adam Sullivan | 1,650,000 | 2,062,500 | 1,031,250 | 4,743,750 | ||||||||
James Nygaard | 1,200,000 | 1,200,000 | 600,000 | 3,000,000 | ||||||||
Todd M. DuChene | 1,050,000 | 1,050,000 | 525,000 | 2,625,000 | ||||||||
(2) | Equity Awards. These amounts reflect the potential value that each named executive officer could receive in connection with the accelerated vesting of unvested Core Scientific RSU Awards and Core Scientific PSU Awards. The Core Scientific RSU Awards and Core Scientific PSU Awards held by Core Scientific’s named executive officers that are outstanding as of immediately prior to the effective time will fully vest at the effective time (and such vesting is therefore pursuant to a “single-trigger” arrangement), with the Core Scientific PSU Awards deemed earned based on a performance level of 300%. For further details regarding the treatment of Core Scientific RSU Awards and Core Scientific PSU Awards in connection with the Merger, see “—Treatment of Core Scientific Equity Awards.” The estimated value of unvested Core Scientific RSU Awards and Core Scientific PSU Awards held by each named executive officer is set forth in the table below: |
Name | Core Scientific RSU Awards ($) | Core Scientific PSU Awards ($) | Total ($) | ||||||
Adam Sullivan | 42,355,384 | 59,686,829 | 102,042,213 | ||||||
James Nygaard | 10,934,424 | — | 10,934,424 | ||||||
Todd M. DuChene | 15,111,275 | 17,812,942 | 32,924,217 | ||||||
(3) | Benefits. These amounts reflect the cash payments for benefit continuation payable to each named executive officer in connection with his termination of employment at the effective time as provided for under the Letter Agreements, equal to 24 times the monthly cost of continuation coverage under Core Scientific’s group health plan pursuant to the Consolidated Omnibus Budget Reconciliation Act for the level of coverage in effect for the named executive officer and his dependents as of immediately prior to the Effective Time. These severance payments are “double trigger” and are only payable upon the occurrence of both the effective time and the termination of employment of the applicable named executive officer. |
(4) | Tax Reimbursements. These amounts reflect the estimated reimbursement payments for the named executive officers under the Excise Tax Reimbursement Agreements. These estimates were calculated taking into account the impact of an assumed valuation of each executive’s one-year post-termination non-compete covenant under his Excise Tax Reimbursement Agreement. For further details regarding the Excise Tax Reimbursement Agreements, see “—Excise Tax Reimbursement Agreements.” |
• | Application of the acquisition method of accounting under the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”) where the assets and liabilities of Core Scientific will be recorded by CoreWeave at their respective fair values as of the closing date of the Merger (“Closing Date”); |
• | Preliminary adjustments to conform the financial statement presentation of Core Scientific to that of CoreWeave; |
• | The Financing Transactions, as described and defined below; |
• | The settlement of pre-existing relationships; and |
• | Adjustments to reflect estimated acquisition-related costs of the Merger. |
• | The historical audited consolidated financial statements of CoreWeave and the related notes included herein as of and for the year ended December 31, 2024; |
• | The historical audited consolidated financial statements of Core Scientific and the related notes included in Core Scientific’s Annual Report on Form 10-K as of and for the year ended December 31, 2024; |
• | The historical unaudited condensed consolidated financial statements of CoreWeave and the related notes included herein as of and for the six months ended June 30, 2025; and |
• | The historical unaudited condensed consolidated financial statements of Core Scientific and the related notes included in Core Scientific’s Quarterly Report on Form 10-Q as of and for the six months ended June 30, 2025. |
CoreWeave Historical | Core Scientific Historical | Reclassification Adjustments | Notes | Financing Transaction Accounting Adjustments | Notes | Acquisition Transaction Accounting Adjustments | Notes | Settlement of Pre-existing Relationships Adjustments | Notes | Pro Forma Combined | |||||||||||||||||||||||
Assets | |||||||||||||||||||||||||||||||||
Current assets | |||||||||||||||||||||||||||||||||
Cash and cash equivalents | $1,152,883 | $581,345 | $— | $1,723,750 | 4(a) | $— | $— | $3,457,978 | |||||||||||||||||||||||||
Restricted cash and cash equivalents, current | 560,173 | — | — | — | — | — | 560,173 | ||||||||||||||||||||||||||
Accounts receivable, net | 1,933,698 | — | 1,910 | 2(a) | — | — | (1,378) | 6(a) | 1,934,230 | ||||||||||||||||||||||||
Digital assets | — | 172,772 | — | — | — | — | 172,772 | ||||||||||||||||||||||||||
Prepaid expenses and other current assets | 299,229 | — | 248,733 | 2(a) | — | — | (232,625) | 6(b)(i) | 315,337 | ||||||||||||||||||||||||
Customer funding receivable and other current assets | — | 250,643 | (250,643) | 2(a) | — | — | — | — | |||||||||||||||||||||||||
Total current assets | 3,945,983 | 1,004,760 | — | 1,723,750 | — | (234,003) | 6,440,490 | ||||||||||||||||||||||||||
Restricted cash and cash equivalents, non-current | 340,527 | — | — | — | — | — | 340,527 | ||||||||||||||||||||||||||
Property and equipment, net | 16,631,510 | 828,603 | — | — | 1,099,000 | 4(b) | — | 18,559,113 | |||||||||||||||||||||||||
Operating lease right-of-use assets | 3,380,201 | 108,584 | — | — | 34,083 | 4(c) | (96,640) | 6(i) | 3,426,228 | ||||||||||||||||||||||||
Intangible assets, net | 205,895 | — | 1,326 | 2(b) | — | 43,674 | 4(d) | — | 250,895 | ||||||||||||||||||||||||
Goodwill | 812,970 | — | — | — | 4,786,482 | 4(e) | 77,752 | 6(f) | 5,677,204 | ||||||||||||||||||||||||
Other non-current assets | 924,277 | 36,105 | (1,326) | 2(b) | — | — | (165,938) | 6(c)(j)(k) | 793,118 | ||||||||||||||||||||||||
Total assets | $26,241,363 | $1,978,052 | $— | $1,723,750 | $5,963,239 | $(418,829) | $35,487,575 | ||||||||||||||||||||||||||
CoreWeave Historical | Core Scientific Historical | Reclassification Adjustments | Notes | Financing Transaction Accounting Adjustments | Notes | Acquisition Transaction Accounting Adjustments | Notes | Settlement of Pre-existing Relationships Adjustments | Notes | Pro Forma Combined | |||||||||||||||||||||||
Liabilities, Redeemable Common Stock, and Stockholders’ Equity (Deficit) | |||||||||||||||||||||||||||||||||
Current liabilities | |||||||||||||||||||||||||||||||||
Accounts payable | $1,226,579 | $215,055 | $— | $— | $— | $(84,957) | 6(i)(k) | $1,356,677 | |||||||||||||||||||||||||
Accrued liabilities | 1,411,237 | — | 183,988 | 2(c)(d) | — | 45,559 | 4(f) | (147,094) | 6(k) | 1,493,690 | |||||||||||||||||||||||
Accrued expenses | — | 180,641 | (180,641) | 2(c) | — | — | — | — | |||||||||||||||||||||||||
Debt, current | 3,627,664 | — | 1,550 | 2(d) | — | — | — | 3,629,214 | |||||||||||||||||||||||||
Deferred revenue, current | 951,346 | 150,127 | — | — | — | (149,078) | 6(d) | 952,395 | |||||||||||||||||||||||||
Operating lease liabilities, current | 279,080 | — | 10,438 | 2(d) | — | — | (11,754) | 6(i) | 277,764 | ||||||||||||||||||||||||
Finance lease liabilities, current | 60,396 | — | 547 | 2(d) | — | — | — | 60,943 | |||||||||||||||||||||||||
Other current liabilities | 53 | 16,899 | (15,882) | 2(d) | — | — | — | 1,070 | |||||||||||||||||||||||||
Total current liabilities | 7,556,355 | 562,722 | — | — | 45,559 | (392,883) | 7,771,753 | ||||||||||||||||||||||||||
Debt, non-current | 7,423,837 | — | 1,057,696 | 2(e) | 1,723,750 | 4(a) | 27,304 | 4(g) | — | 10,232,587 | |||||||||||||||||||||||
Derivative and warrant liabilities | 698 | — | 1,316,690 | 2(f) | — | (92,555) | 4(h) | — | 1,224,833 | ||||||||||||||||||||||||
Deferred revenue, non-current | 3,896,173 | — | — | — | — | — | 3,896,173 | ||||||||||||||||||||||||||
Operating lease liabilities, non-current | 3,168,392 | — | 92,229 | 2(g) | — | — | (92,658) | 6(i) | 3,167,963 | ||||||||||||||||||||||||
Convertible and other notes payable, net of current portion | — | 1,057,696 | (1,057,696) | 2(e) | — | — | — | — | |||||||||||||||||||||||||
Finance lease liabilities, non-current | 3,112 | — | — | — | — | — | 3,112 | ||||||||||||||||||||||||||
Deferred tax liabilities, non-current | 245,659 | — | — | — | — | — | 245,659 | ||||||||||||||||||||||||||
Warrant liabilities | — | 1,316,690 | (1,316,690) | 2(f) | — | — | — | — | |||||||||||||||||||||||||
Other non-current liabilities | 126,331 | 105,620 | (92,229) | 2(g) | — | — | (11,040) | 6(e) | 128,682 | ||||||||||||||||||||||||
Total liabilities | 22,420,557 | 3,042,728 | — | 1,723,750 | (19,692) | (496,581) | 26,670,762 | ||||||||||||||||||||||||||
Commitments and contingencies | |||||||||||||||||||||||||||||||||
Redeemable common stock | |||||||||||||||||||||||||||||||||
Redeemable Class A common stock | 1,163,159 | — | — | — | — | — | 1,163,159 | ||||||||||||||||||||||||||
Stockholders’ equity (deficit) | |||||||||||||||||||||||||||||||||
Preferred stock | — | — | — | — | — | — | — | ||||||||||||||||||||||||||
Class A common stock | 2 | — | — | — | — | 4(i) | — | 2 | |||||||||||||||||||||||||
Common stock | — | 3 | — | — | (3) | 4(i) | — | — | |||||||||||||||||||||||||
Class B common stock | — | — | — | — | — | — | — | ||||||||||||||||||||||||||
Class C common stock | — | — | — | — | — | — | — | ||||||||||||||||||||||||||
Treasury stock, at cost | (33,524) | — | — | — | — | — | (33,524) | ||||||||||||||||||||||||||
Additional paid-in capital | 4,772,825 | 3,026,645 | — | — | 1,980,124 | 4(i) | — | 9,779,594 | |||||||||||||||||||||||||
Accumulated other comprehensive income (loss) | (271) | — | — | — | — | — | (271) | ||||||||||||||||||||||||||
Accumulated deficit | (2,081,385) | (4,091,324) | — | — | 4,002,810 | 4(i) | 77,752 | 6(f) | (2,092,147) | ||||||||||||||||||||||||
Total stockholders’ equity (deficit) | 2,657,647 | (1,064,676) | — | — | 5,982,931 | 77,752 | 7,653,654 | ||||||||||||||||||||||||||
Total liabilities, redeemable common stock, and stockholders’ equity (deficit) | $26,241,363 | $1,978,052 | $— | $1,723,750 | $5,963,239 | $(418,829) | $35,487,575 | ||||||||||||||||||||||||||
CoreWeave Historical | Core Scientific Historical | Reclassification Adjustments | Notes | Financing Transaction Accounting Adjustments | Notes | Acquisition Transaction Accounting Adjustments | Notes | Settlement of Pre-existing Relationships Adjustments | Notes | Pro Forma Combined | Notes | |||||||||||||||||||||||||
Revenue | $2,194,420 | $— | $158,153 | 2(h) | $— | $— | $(19,133) | 6(g) | $2,333,440 | |||||||||||||||||||||||||||
Digital asset self-mining revenue | — | 129,603 | (129,603) | 2(h) | — | — | — | — | ||||||||||||||||||||||||||||
Digital asset hosted mining revenue from customers | — | 9,417 | (9,417) | 2(h) | — | — | — | — | ||||||||||||||||||||||||||||
Colocation revenue | — | 19,133 | (19,133) | 2(h) | — | — | — | — | ||||||||||||||||||||||||||||
Operating expenses: | — | |||||||||||||||||||||||||||||||||||
Cost of revenue | 575,061 | — | 144,725 | 2(i) (j)(k) | — | 10,962 | 5(b) (c)(d) | (19,133) | 6(h) | 711,615 | ||||||||||||||||||||||||||
Cost of digital asset self-mining | — | 120,759 | (120,759) | 2(i) | — | — | — | — | ||||||||||||||||||||||||||||
Cost of digital asset hosted mining services | — | 6,620 | (6,620) | 2(i) | — | — | — | — | ||||||||||||||||||||||||||||
Cost of colocation services | — | 17,536 | (17,536) | 2(i) | — | — | — | — | ||||||||||||||||||||||||||||
Change in fair value of digital assets | — | (19,109) | — | — | — | — | (19,109) | |||||||||||||||||||||||||||||
Losses on exchange or disposal of property, plant and equipment | — | 4,172 | (4,172) | 2(j) | — | — | — | — | ||||||||||||||||||||||||||||
Technology and infrastructure | 1,231,315 | — | 13,089 | 2(j) (k)(l) | — | 248 | 5(b) | — | 1,244,652 | |||||||||||||||||||||||||||
Sales and marketing | 47,348 | — | 6,165 | 2(l) | — | 389 | 5(b) | — | 53,902 | |||||||||||||||||||||||||||
General and administrative | 348,957 | — | 82,163 | 2(k)(l) | — | 4,362 | 5(b) | — | 435,482 | |||||||||||||||||||||||||||
Selling, general and administrative | — | 97,055 | (97,055) | 2(l) | — | — | — | — | ||||||||||||||||||||||||||||
Total operating expenses | 2,202,681 | 227,033 | — | — | 15,961 | (19,133) | 2,426,542 | |||||||||||||||||||||||||||||
Operating income (loss) | (8,261) | (68,880) | — | — | (15,961) | — | (93,102) | |||||||||||||||||||||||||||||
Loss on debt extinguishment | — | (1,377) | 1,377 | 2(m) | — | — | — | — | ||||||||||||||||||||||||||||
Gain (loss) on fair value adjustments | 26,837 | — | (288,494) | 2(n) | — | — | — | (261,657) | ||||||||||||||||||||||||||||
Interest expense, net | (530,801) | 3,372 | (14,648) | 2(o) | (157,562) | 5(a) | 2,601 | 5(f) | — | (697,038) | ||||||||||||||||||||||||||
Change in fair value of warrants and contingent value rights | — | (288,494) | 288,494 | 2(n) | — | — | — | — | ||||||||||||||||||||||||||||
Other income (expense), net | 886 | (364) | 13,271 | 2(m)(o) | — | — | — | 13,793 | ||||||||||||||||||||||||||||
Loss before provision for (benefit from) income taxes | (511,339) | (355,743) | — | (157,562) | (13,360) | — | (1,038,004) | |||||||||||||||||||||||||||||
Provision for (benefit from) income taxes | 93,811 | 363 | — | (33,088) | 5(g) | (2,806) | 5(g) | — | 58,280 | |||||||||||||||||||||||||||
Net loss | $(605,150) | $(356,106) | $— | $(124,474) | $(10,554) | — | $(1,096,284) | |||||||||||||||||||||||||||||
Net loss attributable to common stockholders, basic | $(633,872) | $(67,002) | $(1,125,006) | 5(h) | ||||||||||||||||||||||||||||||||
Net loss attributable to common stockholders, diluted | $(660,717) | $(67,002) | $(1,151,851) | 5(h) | ||||||||||||||||||||||||||||||||
Net loss per share attributable to common stockholders, basic | $(1.73) | $(0.21) | $(2.77) | 5(h) | ||||||||||||||||||||||||||||||||
Net loss per share attributable to common stockholders, diluted | $(1.79) | $(0.21) | $(2.83) | 5(h) | ||||||||||||||||||||||||||||||||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic | 366,765 | 316,593 | 405,587 | 5(h) | ||||||||||||||||||||||||||||||||
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted | 368,607 | 316,593 | 407,429 | 5(h) | ||||||||||||||||||||||||||||||||
CoreWeave Historical | Core Scientific Historical | Reclassification Adjustments | Notes | Financing Transaction Accounting Adjustments | Notes | Acquisition Transaction Accounting Adjustments | Notes | Settlement of Pre-existing Relationships Adjustments | Notes | Pro Forma Combined | Notes | |||||||||||||||||||||||||
Revenue | $1,915,426 | $— | $510,672 | 2(p) | $— | $— | $(24,378) | 6(g) | $2,401,720 | |||||||||||||||||||||||||||
Digital asset self-mining revenue | — | 408,740 | (408,740) | 2(p) | — | — | — | — | ||||||||||||||||||||||||||||
Digital asset hosted mining revenue from customers | — | 77,554 | (77,554) | 2(p) | — | — | — | — | ||||||||||||||||||||||||||||
HPC hosting revenue | — | 24,378 | (24,378) | 2(p) | — | — | — | — | ||||||||||||||||||||||||||||
Operating expenses: | ||||||||||||||||||||||||||||||||||||
Cost of revenue | 493,350 | — | 387,631 | 2(q)(r) (s)(t) | — | 47,007 | 5(b) (c)(d) | (24,378) | 6(h) | 903,610 | ||||||||||||||||||||||||||
Cost of digital asset self-mining | — | 314,335 | (314,335) | 2(q) | — | — | — | — | ||||||||||||||||||||||||||||
Cost of digital asset hosted mining services | — | 53,558 | (53,558) | 2(q) | — | — | — | — | ||||||||||||||||||||||||||||
Cost of HPC hosting services | — | 21,709 | (21,709) | 2(q) | — | — | — | — | ||||||||||||||||||||||||||||
Change in fair value of digital assets | — | 1,052 | — | — | — | — | 1,052 | |||||||||||||||||||||||||||||
Change in fair value of energy derivatives | — | 2,757 | (2,757) | 2(r) | — | — | — | — | ||||||||||||||||||||||||||||
Losses on exchange or disposal of property, plant and equipment | — | 4,210 | (4,210) | 2(s) | — | — | — | — | ||||||||||||||||||||||||||||
Technology and infrastructure | 960,685 | — | 21,865 | 2(s) (t)(u) | — | 9,126 | 5(b) | — | 991,676 | |||||||||||||||||||||||||||
Sales and marketing | 18,389 | 9,969 | — | — | 18,985 | 5(b) | — | 47,343 | ||||||||||||||||||||||||||||
General and administrative | 118,644 | 110,448 | (1,097) | 2(t) | — | 160,255 | 5(b)(e) | — | 388,250 | |||||||||||||||||||||||||||
Research and development | — | 11,830 | (11,830) | 2(u) | — | — | — | — | ||||||||||||||||||||||||||||
Total operating expenses | 1,591,068 | 529,868 | — | — | 235,373 | (24,378) | 2,331,931 | |||||||||||||||||||||||||||||
Operating income (loss) | 324,358 | (19,196) | — | — | (235,373) | — | 69,789 | |||||||||||||||||||||||||||||
Loss on debt extinguishment | — | (487) | 487 | 2(v) | — | — | — | — | ||||||||||||||||||||||||||||
Gain (loss) on fair value adjustments | (755,929) | — | (1,369,157) | 2(w) | — | — | — | (2,125,086) | ||||||||||||||||||||||||||||
Interest expense, net | (360,824) | (37,070) | (7,026) | 2(x) | (351,537) | 5(a) | 1,171 | 5(f) | — | (755,286) | ||||||||||||||||||||||||||
Change in fair value of warrants and contingent value rights | — | (1,369,157) | 1,369,157 | 2(w) | — | — | — | — | ||||||||||||||||||||||||||||
Reorganization items, net | — | 111,439 | — | — | — | — | 111,439 | |||||||||||||||||||||||||||||
Other income (expense), net | 48,194 | 325 | 6,539 | 2(v)(x) | — | — | 34,797 | 6(h) | 89,855 | |||||||||||||||||||||||||||
Loss before provision for (benefit from) income taxes | (744,201) | (1,314,146) | — | (351,537) | (234,202) | 34,797 | (2,609,289) | |||||||||||||||||||||||||||||
Provision for (benefit from) income taxes | 119,247 | 859 | — | (73,823) | 5(g) | (49,182) | 5(g) | 7,307 | 5(g) | 4,408 | ||||||||||||||||||||||||||
Net loss | $(863,448) | $(1,315,005) | $— | $(277,714) | $(185,020) | $27,490 | $(2,613,697) | |||||||||||||||||||||||||||||
Net loss attributable to common stockholders, basic and diluted | $(937,765) | $(1,122,420) | $(2,688,014) | 5(h) | ||||||||||||||||||||||||||||||||
Net loss per share attributable to common stockholders, basic and diluted | $(4.30) | $(4.39) | $(10.47) | 5(h) | ||||||||||||||||||||||||||||||||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 217,854 | 255,832 | 256,676 | 5(h) | ||||||||||||||||||||||||||||||||
(a) | Represents a reclassification from customer funding receivable and other current assets to accounts receivable, net and prepaid expenses and other current assets. |
(b) | Represents a reclassification from other non-current assets to intangible assets, net. |
(c) | Represents a reclassification from accrued expenses to accrued liabilities. |
(d) | Represents a reclassification from other current liabilities to accrued liabilities, debt, current, operating lease liabilities, current, and finance lease liabilities, current. |
(e) | Represents a reclassification from convertible and other notes payable, net of current portion to debt, non-current. |
(f) | Represents a reclassification from warrant liabilities to derivative and warrant liabilities. |
(g) | Represents a reclassification from other non-current liabilities to operating lease liabilities, non-current. |
(h) | Represents a reclassification from digital asset self-mining revenue, digital asset hosted mining revenue from customers, and colocation revenue to revenue. |
(i) | Represents a reclassification from cost of digital asset self-mining, cost of digital asset hosted mining services, and cost of colocation services to cost of revenue. |
(j) | Represents a reclassification from losses on exchange or disposal of property, plant and equipment to cost of revenue and technology and infrastructure. |
(k) | Represents a reclassification of depreciation expense from cost of revenue and general and administrative to technology and infrastructure. |
(l) | Represents a reclassification from selling, general and administrative to technology and infrastructure, sales and marketing, and general and administrative. |
(m) | Represents a reclassification from loss on debt extinguishment to other income (expense), net. |
(n) | Represents a reclassification from change in fair value of warrants and contingent value rights to gain (loss) on fair value adjustments. |
(o) | Represents a reclassification of interest and investment income from interest expense, net to other income (expense), net. |
(p) | Represents a reclassification from digital asset self-mining revenue, digital asset hosted mining revenue from customers, and HPC hosting revenue to revenue. |
(q) | Represents a reclassification from cost of digital asset self-mining, cost of digital asset hosted mining services, and cost of HPC hosting services to cost of revenue. |
(r) | Represents an alignment of accounting policies that results in movement of the change in fair value related to energy derivatives from change in fair value of energy derivatives to cost of revenue. |
(s) | Represents a reclassification from losses on exchange or disposal of property, plant and equipment to cost of revenue and technology and infrastructure. |
(t) | Represents a reclassification of depreciation expense from cost of revenue and general and administrative to technology and infrastructure. |
(u) | Represents a reclassification from research and development to technology and infrastructure. |
(v) | Represents a reclassification from loss on debt extinguishment to other income (expense), net. |
(w) | Represents a reclassification from change in fair value of warrants and contingent value rights to gain (loss) on fair value adjustments. |
(x) | Represents a reclassification of interest income and investment income from interest expense, net to other income (expense), net. |
Core Scientific common stock outstanding as of June 30, 2025 | 303,146 | ||
Exchange ratio | 0.1235 | ||
Shares of CoreWeave Class A common stock to be issued to holders of Core Scientific common stock | 37,439 | ||
Price per share of CoreWeave Class A common stock(1) | $120.47 | ||
Preliminary estimated fair value of CoreWeave Class A common stock to be issued to holders of Core Scientific common stock | $4,510,218 | ||
Preliminary estimated fair value of CoreWeave Class A common stock to be issued to holders of Core Scientific In the Money Options(2) | 412 | ||
Preliminary estimated fair value of replacement equity awards attributable to pre-combination services(3) | 106,372 | ||
Preliminary estimated fair value of assumed debt in excess of par value(4) | 389,767 | ||
Settlement of pre-existing relationships(5) | (42,955) | ||
Total preliminary estimated merger consideration | $4,963,814 | ||
(1) | Represents the closing price per share of CoreWeave Class A common stock as of September 15, 2025. |
(2) | Represents the preliminary estimated fair value of approximately 3,418 shares of CoreWeave Class A common stock to be issued to holders of Core Scientific In the Money Options in connection with the Merger. |
(3) | Represents the estimated fair value of certain Core Scientific RSU Awards and Core Scientific PSU Awards granted to employees attributable to pre-combination services which are expected to be replaced by CoreWeave Rollover RSU Awards, CoreWeave Rollover PSU Awards and shares of CoreWeave Class A common stock in connection with the Merger. |
(4) | Represents the preliminary estimated fair value of convertible debt assumed by CoreWeave in excess of par value related to the Core Scientific 2029 Convertible Notes and the Core Scientific 2031 Convertible Notes in connection with the Merger, assuming that the conversion features embedded within are not bifurcated and recognized as a derivative liability consistent with Core Scientific’s historical unaudited condensed consolidated balance sheet as of June 30, 2025. |
(5) | Represents amounts related to the effective settlement of pre-existing relationships between CoreWeave and Core Scientific as of June 30, 2025. Refer to Note 6. Pro Forma Adjustments to Settle Pre-Existing Relationships for further details on the pre-existing relationships and the amounts that are being settled as of the effective time of the Merger. |
Stock Price | Total Preliminary Estimated Merger Consideration | |||||
30% increase | $156.61 | $6,349,005 | ||||
30% decrease | $84.33 | $3,575,308 | ||||
As of June 30, 2025 | |||
Assets | |||
Cash and cash equivalents | $581,345 | ||
Accounts receivable, net | 532 | ||
Digital assets | 172,772 | ||
Prepaid expenses and other current assets | 18,061 | ||
Property and equipment, net | 1,927,603 | ||
Intangible assets, net | 45,000 | ||
Operating lease right-of-use assets | 142,667 | ||
Other non-current assets | 28,959 | ||
Total assets, excluding goodwill | $2,916,939 | ||
Liabilities | |||
Accounts payable | $215,055 | ||
Accrued liabilities | 183,988 | ||
Debt, current | 1,550 | ||
Deferred revenue, current | 1,049 | ||
Operating lease liabilities, current | 10,438 | ||
Finance lease liabilities, current | 547 | ||
Other current liabilities | 1,017 | ||
Debt, non-current | 1,085,000 | ||
Derivative and warrant liabilities | 1,224,135 | ||
Operating lease liabilities, non-current | 92,229 | ||
Other non-current liabilities | 2,351 | ||
Total liabilities | $2,817,359 | ||
Net assets acquired (a) | $99,580 | ||
Preliminary estimated merger consideration (b) | $4,963,814 | ||
Estimated goodwill (b) – (a) | $4,864,234 | ||
(a) | Represents the issuance of the 2031 Senior Notes, which were initially issued in July 2025, for an aggregate principal amount of $1.8 billion, less $26 million of debt discounts and issuance costs. The net proceeds from the 2031 Senior Notes will be used for general corporate purposes. The unaudited pro forma condensed combined balance sheet does not include a pro forma adjustment related to the issuance of the 2030 Senior Notes, as the 2030 Senior Notes are already reflected within CoreWeave’s historical condensed consolidated balance sheet as of June 30, 2025. |
(b) | Represents an adjustment of $1.1 billion to increase the carrying amounts of Core Scientific’s property and equipment from their recorded net book values to their preliminary estimated fair values. This adjustment relates to land and power purchase agreements. The power purchase agreements are considered to be a component of the related data centers and the estimated useful lives are similar to that of the related data centers. As land is not a depreciable asset, and power purchase agreements relate to data centers under construction and not depreciated until the associated data centers are placed in service, no additional depreciation expense is recorded in the unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2025, and for the year ended December 31, 2024, related to this adjustment. The acquired property and equipment consist of the following with preliminary fair value estimates (in thousands): |
Estimated Useful Life | Preliminary Fair Value | |||||
Land and improvements | 20 years(1) | $44,481 | ||||
Building and improvements | 10 to 39 years | 206,963 | ||||
Mining and network equipment | 3 to 5 years | 62,322 | ||||
Electrical equipment | 15 years | 54,996 | ||||
Other property, plant and equipment | 5 to 7 years | 1,336 | ||||
Construction in progress(2) | 1,557,505 | |||||
Total fair value of Core Scientific’s property and equipment | 1,927,603 | |||||
Less: Core Scientific’s historical property and equipment, net | (828,603) | |||||
Pro forma adjustments to property and equipment, net | $1,099,000 | |||||
(1) | Estimated useful life of improvements. Land is not depreciated. |
(2) | Includes $1.1 billion of power purchase agreements. |
(c) | Represents an adjustment of $34 million, comprising a $40 million increase to recognize the favorable terms of the leases, partially offset by a $6 million decrease to remeasure acquired right-of-use assets and lease liabilities in accordance with ASC 842, with the right-of-use asset adjusted to equal the lease liability. |
(d) | Represents an adjustment of $44 million to record intangible assets acquired from Core Scientific at their estimated fair value of $45 million in connection with the Merger, offset by the elimination of $1 million in historical intangible asset book values. Intangible assets acquired from Core Scientific relate to developed technologies and have an estimated useful life of three years. |
(e) | Represents the recognition of the preliminary goodwill associated with the Merger, net of adjustment to preliminary goodwill for settlement of pre-existing relationships. Goodwill represents the total preliminary estimated merger consideration in excess of the fair value of the underlying net assets. |
(f) | Represents an adjustment of $46 million to record estimated acquisition-related costs expected to be incurred by CoreWeave as an increase to accrued liabilities and a corresponding increase to accumulated deficit. These costs are non-recurring and are not expected to have a continuing impact on the combined company’s operating results in future periods. |
(g) | Represents an adjustment of $27 million to debt, non-current to reflect the removal of historical unamortized debt issuance costs associated with the borrowings of the 2031 Convertible Senior Notes and the 2029 Convertible Senior Notes. |
(h) | Represents an adjustment of $93 million to record the estimated fair value of the New Tranche 1 Warrants and New Tranche 2 Warrants to be issued to Core Scientific warrant holders in connection with the Merger. |
(i) | The following table summarizes the transaction accounting adjustments impacting the equity balances of Core Scientific, as well as new equity issued as consideration for the Merger (in thousands): |
Adjustments to CoreWeave Equity(1) | Adjustments to Core Scientific Equity(2) | Acquisition- related Costs(3) | Total Transaction Accounting Adjustments | |||||||||
Class A common stock | $— | $— | $— | $— | ||||||||
Common stock | — | (3) | — | (3) | ||||||||
Additional paid-in capital | 5,006,769 | (3,026,645) | — | 1,980,124 | ||||||||
Accumulated deficit | (42,955) | 4,091,324 | (45,559) | 4,002,810 | ||||||||
Pro forma net adjustment to equity | $4,963,814 | $1,064,676 | $(45,559) | $5,982,931 | ||||||||
(1) | Adjustments to CoreWeave Equity: Represents the total preliminary estimated merger consideration of $5.0 billion, consisting of (i) issuance of approximately 37 million shares of CoreWeave Class A common stock with an estimated fair value of $4.5 billion, (ii) settlement of Core Scientific In the Money Options, (iii) conversion of Core Scientific RSU Awards and Core Scientific PSU Awards granted to employees attributable to pre-combination services that are being replaced by CoreWeave Rollover RSU Awards, CoreWeave Rollover PSU Awards and shares of CoreWeave class A common stock with an estimated fair value of $106 million, (iv) estimated fair value of $390 million in convertible debt assumed in excess of par value related to the Core Scientific 2029 Convertible Notes and the Core Scientific 2031 Convertible Notes, and (v) settlement of pre-existing relationships between CoreWeave and Core Scientific of $(43) million. Refer to Note 6. Pro Forma Adjustments to Settle Pre-Existing Relationships for further details. |
(2) | Adjustments to Core Scientific Equity: Represents the elimination of Core Scientific’s historical equity balances as of June 30, 2025. |
(3) | Acquisition-related Costs: Represents $46 million of estimated acquisition-related costs expected to be incurred by CoreWeave in connection with the Merger. |
(a) | Represents an adjustment to record $158 million and $352 million of interest expense for the six months ended June 30, 2025, and for the year ended December 31, 2024, respectively, associated with the borrowings of the 2031 Senior Notes and the 2030 Senior Notes. The incremental interest expense has been calculated as follows (in thousands): |
For the Six Months Ended June 30, 2025 | For the Year Ended December 31, 2024 | |||||
Interest expense on 2031 Senior Notes | $80,402 | $160,584 | ||||
Interest expense on 2030 Senior Notes | 95,700 | 190,953 | ||||
Subtotal | 176,102 | 351,537 | ||||
Less: Historical interest expense on 2030 Senior Notes | (18,540) | — | ||||
Pro forma adjustment to interest expense, net | $157,562 | $351,537 | ||||
(b) | Represents the adjustments of $5 million and $169 million to record incremental stock-based compensation expense for the six months ended June 30, 2025, and the year ended December 31, 2024, respectively, to reflect the post-combination portion of the Core Scientific equity awards which are expected to be replaced by CoreWeave equity awards. The value for the replacement awards is based on the CoreWeave Class A common stock price as of September 15, 2025. The breakdown of the adjustment is as follows (in thousands): |
For the Six Months Ended June 30, 2025 | For the Year Ended December 31, 2024 | |||||
Cost of revenue | $305 | $25,818 | ||||
Technology and infrastructure | 248 | 9,126 | ||||
Sales and marketing | 389 | 18,985 | ||||
General and administrative | 4,362 | 114,696 | ||||
Pro forma adjustment to stock-based compensation expense | $5,304 | $168,625 | ||||
(c) | Represents an adjustment of $4 million and $7 million to record amortization expense for favorable contractual lease terms when compared to the market for the six months ended June 30, 2025, and for the year ended December 31, 2024, respectively. |
(d) | Represents an adjustment of $7 million and $14 million to reflect amortization expense for the six months ended June 30, 2025, and for the year ended December 31, 2024, respectively, for the estimated fair value of acquired intangible assets on a straight-line basis over their estimated useful lives. |
(e) | Represents an adjustment of $46 million to record estimated acquisition-related costs expected to be incurred by CoreWeave in connection with the Merger for the year ended December 31, 2024. These costs are non-recurring and are not expected to have a continuing impact on the combined company’s operating results in future periods. |
(f) | Represents an adjustment of $3 million and $1 million to eliminate Core Scientific’s historical amortization of deferred financing costs for the six months ended June 30, 2025, and for the year ended December 31, 2024, respectively. |
(g) | Represents the estimated income tax impact of adjustments to the unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2025, and for the year ended December 31, 2024. A federal statutory rate of 21% and 21% for the six months ended June 30, 2025, and for the year ended |
(h) | The unaudited pro forma condensed combined basic and diluted earnings per share calculations are based on the weighted average basic and diluted shares of CoreWeave. The following table summarizes the computation of the unaudited pro forma basic and diluted loss per share (in thousands, except per share data): |
For the Six Months Ended June 30, 2025 | For the Year Ended December 31, 2024 | |||||
Numerator: | ||||||
Pro forma combined net loss | $(1,096,284) | $(2,613,697) | ||||
Dividends and accretion on Series C redeemable convertible preferred stock | (28,722) | (74,317) | ||||
Net loss attributable to CoreWeave common stockholders, basic | $(1,125,006) | $(2,688,014) | ||||
Change in fair value of common stock warrants | (26,845) | — | ||||
Net loss attributable to CoreWeave common stockholders, diluted | $(1,151,851) | $(2,688,014) | ||||
Denominator: | ||||||
Historical CoreWeave weighted-average shares used in computing net loss attributable to common stockholders, basic | 366,765 | 217,854 | ||||
Shares of CoreWeave common stock to be issued(1) | 38,822 | 38,822 | ||||
Pro forma weighted-average shares used in computing net loss attributable to common stockholders, basic | 405,587 | 256,676 | ||||
Effect of dilutive securities: | ||||||
Common stock warrants | 1,842 | — | ||||
Pro forma weighted-average shares used in computing net loss attributable to common stockholders, diluted | 407,429 | 256,676 | ||||
Pro forma net loss per share attributable to common stockholders, basic | $(2.77) | $(10.47) | ||||
Pro forma net loss per share attributable to common stockholders, diluted | $(2.83) | $(10.47) | ||||
(1) | As the Transactions are being reflected as if they had been consummated at the beginning of the periods presented, the calculation of weighted average basic and diluted shares outstanding assumes the shares issuable in connection with the Merger have been outstanding for the entire periods presented. |
(2) | For the six months ended June 30, 2025, and for the year ended December 31, 2024, the dilutive effects of the combined company’s convertible notes, certain warrants, stock options, RSAs, RSUs, and PSUs were excluded from the calculation of pro forma net loss per share attributable to common stockholders, diluted because including them would have been anti-dilutive. |
Core Scientific Historical, Reclassified | Adjustments to Eliminate Balances from Pre-Existing Relationships | Notes | Core Scientific, as Adjusted | |||||||||
Assets | ||||||||||||
Cash and cash equivalents | $581,345 | $— | $581,345 | |||||||||
Accounts receivable, net | 1,910 | (1,378) | 6(a) | 532 | ||||||||
Digital assets | 172,772 | — | 172,772 | |||||||||
Prepaid expenses and other current assets | 248,733 | (230,672) | 6(b) | 18,061 | ||||||||
Property and equipment, net | 828,603 | — | 828,603 | |||||||||
Operating lease right-of-use assets | 108,584 | — | 108,584 | |||||||||
Intangible assets, net | 1,326 | — | 1,326 | |||||||||
Other non-current assets | 34,779 | (5,820) | 6(c) | 28,959 | ||||||||
Total assets, excluding goodwill | $1,978,052 | $(237,870) | $1,740,182 | |||||||||
Liabilities | ||||||||||||
Accounts payable | $215,055 | $— | $215,055 | |||||||||
Accrued liabilities | 183,988 | — | 183,988 | |||||||||
Debt, current | 1,550 | — | 1,550 | |||||||||
Deferred revenue, current | 150,127 | (149,078) | 6(d) | 1,049 | ||||||||
Operating lease liabilities, current | 10,438 | — | 10,438 | |||||||||
Finance lease liabilities, current | 547 | — | 547 | |||||||||
Other current liabilities | 1,017 | — | 1,017 | |||||||||
Debt, non-current | 1,057,696 | — | 1,057,696 | |||||||||
Operating lease liabilities, non-current | 92,229 | — | 92,229 | |||||||||
Other non-current liabilities | 13,391 | (11,040) | 6(e) | 2,351 | ||||||||
Total liabilities | $1,726,038 | $(160,118) | $1,565,920 | |||||||||
Net assets acquired | $252,014 | $(77,752) | 6(f) | $174,262 | ||||||||
(a) | Represents elimination of accounts receivable from CoreWeave. |
(b) | Represents elimination of certain customer funding receivables from CoreWeave for construction related payables and accrued expenses incurred on CoreWeave’s behalf. |
(c) | Represents elimination of lease receivable related to the Austin Lease. |
(d) | Represents elimination of prepayments received from CoreWeave in connection with the CoreWeave Colocation Agreements. |
(e) | Represents elimination of refundable security deposits received from CoreWeave. |
(f) | Reflects net assets eliminated from pre-existing relationships with a corresponding impact to preliminary goodwill. |
For the Six Month Ended June 30, 2025 | Notes | For the Year Ended December 31, 2024 | Notes | |||||||||||||||
CoreWeave | Core Scientific | CoreWeave | Core Scientific | |||||||||||||||
Revenue | $— | $(19,133) | 6(g) | $— | $(24,378) | 6(g) | ||||||||||||
Cost of revenue | $(19,133) | $— | 6(h) | $(24,378) | $— | 6(h) | ||||||||||||
(g) | Represents elimination of revenues recognized by Core Scientific for the six months ended June 30, 2025, and for the year ended December 31, 2024, related to the Austin Lease. |
(h) | Represents elimination of lease expense, included in cost of revenue, recognized by CoreWeave for the six months ended June 30, 2025, and for the year ended December 31, 2024, related to the Austin Lease. |
Estimated Settlement | Notes | CoreWeave’s Previously Recognized Net Assets (Liabilities) | Net Gain (Loss) | |||||||||
Austin Lease | $28,977 | 6(i) | $(5,820) | $34,797 | ||||||||
CoreWeave Colocation Agreements | 149,078 | 6(j) | 149,078 | — | ||||||||
Other Agreements | (221,010) | 6(k) | (221,010) | — | ||||||||
Total | $(42,955) | $(77,752) | $34,797 | |||||||||
Austin Lease | Notes | CoreWeave Colocation Agreements | Notes | Other Agreements | Notes | Total | |||||||||||||||
Prepaid expenses and other current assets | $1,953 | 6(i) | $— | $— | $1,953 | ||||||||||||||||
Operating lease right-of-use assets | 96,640 | 6(i) | — | — | 96,640 | ||||||||||||||||
Other non-current assets | — | 149,078 | 6(j) | 11,040 | 6(k) | 160,118 | |||||||||||||||
Total assets | $98,593 | $149,078 | $11,040 | $258,711 | |||||||||||||||||
Accounts payable | 1 | 6(i) | — | 84,956 | 6(k) | 84,957 | |||||||||||||||
Accrued liabilities | — | — | 147,094 | 6(k) | 147,094 | ||||||||||||||||
Operating lease liabilities, current | 11,754 | 6(i) | — | — | 11,754 | ||||||||||||||||
Operating lease liabilities, non-current | 92,658 | 6(i) | — | — | 92,658 | ||||||||||||||||
Total liabilities | $104,413 | $— | $232,050 | $336,463 | |||||||||||||||||
Net assets (liabilities) | $(5,820) | $149,078 | $(221,010) | $(77,752) |
(i) | The Austin Lease has no stated settlement terms and the contract is not cancelable. The estimated amount relates to preliminary valuations for which the contract is favorable from the perspective of CoreWeave based on market terms. |
(j) | The CoreWeave Colocation Agreements have no stated settlement terms, and are not cancelable. The CoreWeave Colocation Agreements were assessed to be at-market based on preliminary valuation performed comparing the contract terms and market terms, and the estimated settlement amounts were determined to be materially consistent with previously recorded amounts. The preliminary valuation performed is based on available information and certain assumptions including market data as of the valuation date. Accordingly, the estimated settlement amount is subject to further adjustment as additional information becomes available and as additional analyses and final valuations are completed. |
(k) | The Other Agreements between CoreWeave and Core Scientific include certain customer funding agreements whereby Core Scientific incurred certain construction-related payables and accrued expenses on CoreWeave’s behalf and refundable security deposits related to the Austin Lease. The agreements were assessed to be at-market and the estimated settlement amounts were determined to be materially consistent with the previously recorded amounts. |
• | 369,948,755 shares of our Class A common stock, held by 633 stockholders of record; |
• | 118,102,040 shares of our Class B common stock, held by 22 stockholders of record; |
• | no shares of our Class C common stock; |
• | no shares of preferred stock; |
• | 31,596,164 shares of our Class A common stock issuable upon the exercise of stock options, with a weighted-average exercise price of $1.14 per share, of which 9,109,000 shares will be exchangeable for an equal number of shares of our Class B common stock at the election of our Co-Founders upon exercise; |
• | 25,685,664 shares of our Class A common stock issuable upon the vesting and settlement of RSUs outstanding; |
• | 12,144,668 shares of our Class A common stock issuable upon the exercise of warrants to purchase shares of our Class A common stock, of which 7,807,282 had an exercise price of $0.0005 per share and 4,337,386 had an exercise price equal to the Regular Warrants Exercise Price; and |
• | 1,460,477 shares of our Class A common stock issuable upon the vesting of unvested RSA. |
• | before the stockholder became interested, our board of directors approved either the business combination or the transaction, which resulted in the stockholder becoming an interested stockholder; |
• | upon consummation of the transaction, which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans in some instances, but not the outstanding voting stock owned by the interested stockholder; or |
• | at or after the time the stockholder became interested, the business combination was approved by our board and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock, which is not owned by the interested stockholder. |
• | any merger or consolidation involving the corporation and the interested stockholder; |
• | any sale, transfer, lease, pledge, or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; |
• | subject to exceptions, any transaction that results in the issuance of transfer by the corporation of any stock of the corporation to the interested stockholder; |
• | subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and |
• | the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other financial benefits provided by or through the corporation. |
• | Multi-Class Common Stock. As described above in the section titled “—Common Stock—Voting Rights,” our amended and restated certificate of incorporation provides for a multi-class common stock structure pursuant to which holders of our Class B common stock may have significant influence over the outcome of matters submitted to our stockholders for approval, even if they own significantly less than a majority of the shares of our outstanding common stock, including the election of directors and significant corporate transactions, such as a merger or other sale of our company or its assets. Our Co-Founders have the ability to exercise significant influence over those matters. |
• | Board of Directors Vacancies. Our amended and restated certificate of incorporation and our amended and restated bylaws authorize generally only our board of directors to fill vacant directorships resulting from any cause or created by the expansion of our board of directors. In addition, the number of directors constituting our board of directors may be set only by resolution adopted by a majority vote of our entire board of directors. These provisions prevent a stockholder from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees. |
• | Classified Board. Our amended and restated certificate of incorporation and amended and restated bylaws provide that our board of directors is classified into three classes of directors. The existence of a classified board of directors could delay a successful tender offeror from obtaining majority control of our board of directors, and the prospect of that delay might deter a potential offeror. For additional information, see the section titled “Management—Classified Board of Directors.” |
• | Directors Removed Only for Cause. Our amended and restated certificate of incorporation provides that stockholders may remove directors only for cause and only by the affirmative vote of the holders of at least two-thirds of the voting power of the then-outstanding capital stock. |
• | Supermajority Requirements for Amendments of Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws. Our amended and restated certificate of incorporation further provides that the affirmative vote of holders of at least two-thirds of the voting power of all of the then outstanding shares of capital stock is required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to the classified board, the size of our board of directors, removal of directors, special meetings, and actions by written consent. The affirmative vote of holders of at least two-thirds of the voting power of all of the then outstanding shares of capital stock are required to amend or repeal our amended and restated bylaws, although our amended and restated bylaws may be amended by a simple majority vote of our board of directors. Additionally, in the case of any proposed adoption, amendment, or repeal of any provisions of the amended and restated bylaws that is approved by our board of directors and submitted to the stockholders for adoption, if two-thirds of our board of directors elects to submit such adoption, amendment, or repeal of any provisions of our amended and restated bylaws to our stockholders for adoption, then only the affirmative vote of a majority of the voting power of all of the then outstanding shares of capital stock shall be required to adopt, amend, or repeal any provision of our amended and restated bylaws. |
• | Stockholder Action; Special Meetings of Stockholders. Our amended and restated certificate of incorporation provides that our stockholders may not take action by written consent but may only take action at annual or special meetings of our stockholders; provided that stockholder action by written consent of a majority of the voting power of all then-outstanding shares of our capital stock is permitted so long as the voting power of all then-outstanding shares of Class B common stock represents greater than a majority of the combined voting power of all then-outstanding shares of our capital stock. As a result, holders of our capital stock, other than holders of a majority of then-outstanding shares of Class B common stock as previously described, would not be able to amend our amended and restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with our amended and restated bylaws. Our amended and restated certificate of incorporation and our amended and restated bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairperson of our board of directors, our chief executive officer, or our lead independent director, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders to take any action, including the removal of directors. |
• | Advance Notice Requirements for Stockholder Proposals and Director Nominations. Our amended and restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our amended and restated bylaws also specify certain requirements regarding the form and content of a stockholder’s notice. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our company. |
• | No Cumulative Voting. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation’s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation and amended and restated bylaws do not provide for cumulative voting. |
• | Issuance of Undesignated Preferred Stock. Our board of directors has the authority, without further action by the stockholders, to issue up to 100,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock enables our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. |
• | Choice of Forum. In addition, our amended and restated bylaws provide that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; any action asserting a claim against us is governed by the internal affairs doctrine or asserting an “internal corporate claim,” as defined by the DGCL; or any to interpret, apply, enforce, or determine the validity of the amended and restated certificate of incorporation or amended and restated bylaws. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our amended and restated bylaws also contain a Federal Forum Provision. While there can be no assurance that federal or state courts will follow the holding of the Supreme Court of the State of Delaware which recently found that such provisions are facially valid under Delaware law or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. As Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, there is uncertainty as to whether a court would enforce such provision. Further, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. In addition, the Federal Forum Provision applies, to the fullest extent permitted by law, to suits brought to enforce any duty or liability created by the Exchange Act. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder must be brought in federal court. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder. Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit a stockholder’s ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find the Federal Forum Provision in our amended and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could harm our business. |
• | we have been or are to be a participant; |
• | the amount involved exceeded or will exceed $120,000; and |
• | any of our directors, executive officers, or holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals, had or will have a direct or indirect material interest. |
Stockholder Common Stock | Shares of Class A Total Purchase Price | |||||
Funds affiliated with Glenn Hutchins(1) | 212,780 | $ 9,999,097 | ||||
(1) | Consists of shares held by certain funds for which Glenn Hutchins, a member of our board of directors, serves as investment manager. |
Stockholder Common Stock(5) | Shares of Class A Total Purchase Price | |||||
Persons and entities affiliated with Michael Intrator(1) | 1,063,980 | $49,999,245 | ||||
Persons and entities affiliated with Brian Venturo(2) | 2,241,560 | $ 105,336,856 | ||||
Persons and entities affiliated with Brannin McBee(3) | 2,075,080 | $97,513,519 | ||||
Kristen McVeety | 135,660 | $5,257,701 | ||||
Persons and entities affiliated with Jack Cogen(4) | 1,110,080 | $52,165,606 | ||||
(1) | Consists of shares held by Michael Intrator, our Chief Executive Officer, President, and chairman of our board of directors, and certain related persons and affiliates. |
(2) | Consists of shares held by Brian Venturo, our Chief Strategy Officer and a member of our board of directors, and certain related persons and affiliates. |
(3) | Consists of shares held by Brannin McBee, our Chief Development Officer, and certain related persons and affiliates. |
(4) | Consists of shares held by Jack Cogen, a member of our board of directors, and certain related persons and affiliates. |
(5) | All shares of our Class B common stock and convertible preferred stock were converted into shares of our Class A common stock immediately prior to being sold in the 2024 Tender Offer. |
Stockholder | Shares of Class A Common Stock(6) | Total Purchase Price | ||||
Persons and entities affiliated with Michael Intrator(1) | 7,098,620 | $ 109,978,920 | ||||
Persons and entities affiliated with Brian Venturo(2) | 4,622,520 | $71,616,703 | ||||
Persons and entities affiliated with Brannin McBee(3) | 3,447,360 | $53,409,948 | ||||
Kristen McVeety(4) | 83,480 | $1,293,356 | ||||
Persons and entities affiliated with Jack Cogen(5) | 8,002,260 | $ 123,979,015 | ||||
(1) | Consists of shares held by Michael Intrator, our Chief Executive Officer and chairman of our board of directors, and certain related persons and affiliates. |
(2) | Consists of shares held by Brian Venturo, our Chief Strategy Officer and a member of our board of directors, and certain related persons and affiliates. |
(3) | Consists of shares held by Brannin McBee, our Chief Development Officer, and certain related persons and affiliates. |
(4) | Consists of 83,480 shares directly held of record and sold by Kristen McVeety, our General Counsel and Secretary. The total purchase price reported in the table above includes $45,664 Ms. McVeety paid to us in connection with her net exercise of employee stock options concurrent with her sale in the 2023 tender offer. |
(5) | Consists of held by Jack Cogen, a member of our board of directors, and certain related persons and affiliates. |
(6) | All shares of our convertible preferred stock were converted into shares of our common stock immediately prior to being sold in the 2023 Tender Offer. |
Stockholder | Shares of Series B-1 Convertible Preferred Stock | Total Purchase Price | ||||
Michael Intrator(1) | 1,458,680 | $ 584,959 | ||||
Jack Cogen and affiliated entities(2) | 1,458,720 | $ 584,961 | ||||
(1) | Consists of shares directly held of record by Michael Intrator. Mr. Intrator is our Chief Executive Officer, President, and Chairman of our board of directors. Mr. Intrator and certain of his affiliates beneficially own more than 5% of our outstanding capital stock. |
(2) | Consists of shares acquired by entities affiliated with Jack Cogen, a member of our board of directors. Additionally, Mr. Cogen and certain of his affiliates beneficially own more than 5% of our outstanding capital stock. |
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
Authorized Capital Stock | CoreWeave’s authorized capital stock consists of (i) 3,400,000,000 shares of Common Stock, $0.000005 par value per share (“Common Stock”), of which (a) 3,000,000,000 shares are designated as CoreWeave common stock, (b) 200,000,000 shares are designated as Class B common stock, $0.000005 par value per share, and (c) 200,000,000 shares are designated as Class C common stock, $0.000005 par value per share, and (ii) 100,000,000 shares of Preferred Stock, $0.000005 par value per share (“Preferred Stock”). Under the CoreWeave certificate of incorporation, the number of authorized shares of any class of stock may be increased or decreased by a vote of the holders of the stock of CoreWeave entitled to vote, voting as a single class. In addition, under the CoreWeave certificate of incorporation, the CoreWeave board is authorized, subject to any limitations prescribed by the DGCL, to (i) provide for the issuance of shares of Preferred Stock in one or more series and to establish from time to time the number of shares to be included in each such series, (ii) fix the designation, powers, preferences and relative, participating, optional or other special rights of the shares of each such series, (iii) increase or decrease the number of shares of any such series, (iv) designate, fix and determine any new series of Preferred Stock without approval of the holders of Common Stock or Preferred Stock and (v) determine the powers, preferences and rights, including voting powers, dividend rights, liquidation rights, redemption rights and conversion rights, senior to, junior to or pari passu with the rights of the Common Stock, any series of the Preferred Stock or any future class or series of CoreWeave’s capital stock. As of September 9, 2025, there were (i) 380,162,985 shares of CoreWeave Class A common stock, (ii) 114,939,540 shares of CoreWeave Class B common stock, (iii) no shares of CoreWeave Class C common stock and (iv) no shares of CoreWeave Preferred Stock outstanding. | Core Scientific’s authorized capital stock consists of (i) 10,000,000,000 shares of Core Scientific common stock and (ii) 2,000,000,000 shares of preferred stock, $0.00001 par value per share (“Core Scientific preferred stock”). Under the Core Scientific certificate of incorporation, the number of authorized shares of Core Scientific common stock and Core Scientific preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) from time to time by the affirmative vote of the holders of at least a majority of the voting power of Core Scientific’s then outstanding shares of stock entitled to vote thereon, voting together as a single class. In addition, under the Core Scientific certificate of incorporation, the Core Scientific board is authorized, to the fullest extent permitted by the DGCL, to provide for the issuance of shares of Core Scientific preferred stock in one or more series and to fix for each such series (i) the number of shares constituting such series and the designation of such series, (ii) the voting powers (if any), whether full or limited, of the shares of such series, (iii) the powers, preferences, and relative, participating, optional or other special rights of the shares of each such series, and (iv) the qualifications, limitations, and restrictions thereof, and to cause to be filed with the Secretary of State of the State of Delaware a certificate of designation with respect thereto. As of September 9, 2025, there were (i) 306,543,223 shares of Core Scientific common stock and (ii) no shares of Core Scientific preferred stock outstanding. | ||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
Voting Rights | Except as otherwise expressly provided by the CoreWeave certificate of incorporation or as required by law, the holders of shares of Common Stock will at all times vote together as a single class and not as separate series or classes on all matters submitted to a vote of the stockholders of CoreWeave but will not be entitled to vote on any amendments to the CoreWeave certificate of incorporation that relate solely to the terms of one or more outstanding class or series of Preferred Stock if the holders of such affected class or series are entitled to vote thereon. On all matters on which holders of Common Stock are entitled to vote, (x) each holder of CoreWeave common stock has the right to one (1) vote per share of CoreWeave common stock held of record by such holder, (y) each holder of Class B common stock has the right to ten (10) votes per share of Class B common stock held of record by such holder and (z) shares of Class C common stock have no voting rights, except as otherwise required by law. | Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of Core Scientific preferred stock, the holders of Core Scientific common stock possess all voting power for the election of directors of the Core Scientific board and all other matters requiring stockholder action. Each outstanding share of Core Scientific common stock entitles the holder thereof to one vote on each matter properly submitted to the stockholders of Core Scientific for their vote. | ||||
Cumulative Voting | Under Delaware law, stockholders of a Delaware corporation do not have the right to cumulate their votes in the election of directors unless that right is granted in the certificate of incorporation of the corporation. The CoreWeave certificate of incorporation prohibits cumulative voting. | Under Delaware law, stockholders of a Delaware corporation do not have the right to cumulate their votes in the election of directors unless that right is granted in the certificate of incorporation of the corporation. The Core Scientific certificate of incorporation does not grant such right. | ||||
Quorum | The CoreWeave bylaws provide that the presence in person or by proxy at a meeting of the holders of a majority of the voting power of shares of stock issued and outstanding and entitled to vote at the meeting is a quorum. | The Core Scientific bylaws provide that the presence in person, by remote communication, if applicable, or by proxy of the holders of a majority of the voting power of the outstanding shares of stock entitled to vote at the meeting is a quorum. | ||||
Stockholder Rights Plans | CoreWeave does not have a stockholder rights plan. While CoreWeave has no present intention to adopt a stockholder rights plan, the CoreWeave board, pursuant to its authority to issue preferred stock, could do so without stockholder approval at any future time. See the section titled “Description of CoreWeave Capital Stock, New Tranche 1 Warrants and New Tranche 2 Warrants” beginning on page 277 of this proxy statement/prospectus. | Core Scientific does not have a stockholder rights plan. While Core Scientific has no present intention to adopt a stockholder rights plan, the Core Scientific board, pursuant to its authority to issue preferred stock, could do so without stockholder approval at any future time. | ||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
Rights of Preferred Stock | The CoreWeave certificate of incorporation provides that the CoreWeave board is authorized to determine the designation, powers (including voting powers), preferences and relative, participating, optional or other special rights (and the qualifications, limitations or restrictions thereof) of each series or class of Preferred Stock. As of the date of this proxy statement/prospectus, no shares of Preferred Stock were outstanding. | The Core Scientific certificate of incorporation provides that the Core Scientific board is authorized to determine the number of shares, designation, powers (including voting powers), preferences, and relative, participating, optional or other special rights (and the qualifications, limitations or restrictions thereof) of each series of Core Scientific preferred stock. As of the date of this proxy statement/prospectus, no shares of Core Scientific preferred stock were outstanding. | ||||
Preemptive Rights | Under Delaware law, stockholders of corporations have no preemptive rights unless the certificate of incorporation provides otherwise. The CoreWeave certificate of incorporation does not provide that stockholders have preemptive rights. | Under Delaware law, stockholders of corporations have no preemptive rights unless the certificate of incorporation provides otherwise. The Core Scientific certificate of incorporation does not provide that stockholders have preemptive rights. | ||||
Number of Directors | The DGCL provides that the board of directors of a Delaware corporation must consist of one or more directors as fixed by the company’s certificate of incorporation or bylaws. The CoreWeave board currently has six members. The CoreWeave certificate of incorporation and the CoreWeave bylaws provide that, subject to the special rights of the holders of any class or series of Preferred Stock to elect additional directors under specified circumstances, the total number of directors constituting the CoreWeave board will be fixed from time to time exclusively by resolution of the CoreWeave board. | The DGCL provides that the board of directors of a Delaware corporation must consist of one or more directors as fixed by the company’s certificate of incorporation or bylaws. The Core Scientific board currently has seven members. The Core Scientific certificate of incorporation provides that, subject to the special rights of the holders of any series of Core Scientific preferred stock to elect additional directors under specified circumstances, the total number of directors constituting the Core Scientific board will be fixed exclusively by the Core Scientific board. | ||||
Election of Directors | The CoreWeave bylaws provide that directors will be elected by a plurality of the votes cast by the holders of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors. Each director holds office until the earlier of (i) the date when such director’s successor has been duly elected and qualified or (ii) such director’s earlier death, resignation, disqualification or removal. Election of directors need not be by written ballot. | The Core Scientific certificate of incorporation provides that directors will be elected by a plurality of the votes cast by the holders of shares present in person or represented by proxy at the meeting of stockholders and entitled to vote thereon. Each director holds office until the earlier of (i) the date when such director’s successor has been duly elected and qualified or (ii) such director’s earlier death, resignation or removal. | ||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
Filling Vacancies on the Board of Directors | Under the CoreWeave certificate of incorporation, any vacancy occurring on the CoreWeave board, however caused, and any newly created directorship resulting from any increase in the authorized number of directors, may be filled by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum, or by a sole remaining director, and may not be filled by the stockholders. Any director elected to fill a vacancy or newly created directorship will hold office for the remainder of the term of the class of director in which the vacancy or new directorship was created and will hold office until such director’s successor will have been duly elected and qualified, or until such director’s earlier death, resignation, disqualification or removal. | Under the Core Scientific certificate of incorporation, any vacancy on the Core Scientific board resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, may be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Core Scientific board or by the sole remaining director, and not by the stockholders (unless the Core Scientific board determined by resolution that any such vacancy or newly created directorship be filled by the stockholders and except as otherwise provided by law). Any director elected to fill a vacancy or newly created directorship will hold office for a term expiring at the first annual meeting of stockholders held after such director’s election and will hold office until such director’s successor will have been duly elected and qualified, or until such director’s earlier death, resignation or removal. | ||||
Removal of Directors | Under the CoreWeave certificate of incorporation, no director may be removed from the CoreWeave board except for cause and only by the affirmative vote of the holders of at least two-thirds (2/3) of the voting power of all of the then-outstanding shares of CoreWeave’s capital stock entitled to vote generally in the election of directors, voting together as a single class. No decrease in the number of directors constituting the CoreWeave board will shorten the term of any director. | Under the Core Scientific certificate of incorporation, until the 2026 annual meeting of Core Scientific stockholders, no director may be removed from the Core Scientific board except for cause and only by the affirmative vote of the holders of at least a majority of the shares of capital stock of Core Scientific entitled to vote on the election of such directors, voting together as a single class. From and after the 2026 annual meeting of Core Scientific stockholders, any director of the Core Scientific board may be removed, with or without cause, only by the affirmative vote of the holders of at least a majority of the shares of capital stock of Core Scientific entitled to vote on the election of such directors, voting together as a single class. | ||||
Special Meetings of Directors | The CoreWeave bylaws provide that special meetings of the CoreWeave board may be called at the direction of the chairperson of the CoreWeave board, the chief executive officer, the lead independent director or a majority of the members of the CoreWeave board then in office. Any such meeting may be held on such date and at such time and place as such person or persons calling the meeting fixes. | The Core Scientific bylaws provide that special meetings of the Core Scientific board may be called at the direction of the chairperson of the Core Scientific board, the chief executive officer or the Core Scientific board. Any such meeting may be held on such date and at such time and place as such person or persons calling the meeting fixes. | ||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
Director Nominations by Stockholders | Under the DGCL, unless directors are elected by written consent in lieu of an annual meeting, an annual stockholder meeting will be held for the election of directors on a date and time designated by or in the manner provided in the bylaws. The CoreWeave bylaws provide that nominations of persons for election to the CoreWeave board and the proposal of other business to be considered by the stockholders may be made at an annual meeting of stockholders only (A) pursuant to CoreWeave’s notice of meeting (or any supplement thereto), (B) by or at the direction of the CoreWeave board or any committee thereof, (C) by any stockholder of CoreWeave who (x) was a stockholder of record of CoreWeave both at the time the notice was provided and at the time of the annual meeting, (y) is entitled to vote at the meeting and (z) complies with the notice procedures and other requirements set forth in the CoreWeave bylaws, or (D) as may be provided in the certificate of designations for any series of Preferred Stock. | Under the DGCL, unless directors are elected by written consent in lieu of an annual meeting, an annual stockholder meeting will be held for the election of directors on a date and time designated by or in the manner provided in the bylaws. The Core Scientific bylaws provide that nominations of persons for election to the Core Scientific board and the proposal of other business to be considered by the stockholders may be made at an annual meeting of stockholders only (A) pursuant to Core Scientific’s notice of meeting (or any supplement thereto), (B) by or at the direction of the Core Scientific board or any committee thereof, (C) by any stockholder of Core Scientific who (x) was a stockholder of record of Core Scientific both at the time the stockholder provided the required notice under the Core Scientific bylaws and at the time of the annual meeting, (y) is entitled to vote at the meeting and (z) complies with the notice procedures and other requirements set forth in the Core Scientific bylaws. | ||||
Stockholder Proposals (Other than Director Nominations) | Under the DGCL, meetings of stockholders may be held at such place as may be designated by or in the manner provided in the certificate of incorporation or bylaws, or if not so designated, as determined by the board of directors. The CoreWeave bylaws provide that nominations of persons for election to the CoreWeave board and the proposal of other business to be considered by the stockholders may be made at an annual meeting of stockholders only (A) pursuant to CoreWeave’s notice of meeting (or any supplement thereto), (B) by or at the direction of the CoreWeave board or any committee thereof, (C) by any stockholder of CoreWeave who (x) was a stockholder of record of CoreWeave both at the time the notice was provided and at the time of the annual meeting, (y) is entitled to vote at the meeting and (z) complies with the notice procedures and other requirements set forth in the CoreWeave bylaws, or (D) as may be provided in the certificate of designations for any series of Preferred Stock. | Under the DGCL, meetings of stockholders may be held at such place as may be designated by or in the manner provided in the certificate of incorporation or bylaws, or if not so designated, as determined by the board of directors. The Core Scientific bylaws provide that nominations of persons for election to the Core Scientific board and the proposal of other business to be considered by the stockholders may be made at an annual meeting of stockholders only (A) pursuant to Core Scientific’s notice of meeting (or any supplement thereto), (B) by or at the direction of the Core Scientific board or any committee thereof, (C) by any stockholder of Core Scientific who (x) was a stockholder of record of Core Scientific both at the time the stockholder provided the required notice under the Core Scientific bylaws and at the time of the annual meeting, (y) is entitled to vote at the meeting and (z) complies with the notice procedures and other requirements set forth in the Core Scientific bylaws. | ||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
Stockholder Action by Written Consent | The DGCL provides that, unless otherwise provided in a corporation’s certificate of incorporation or bylaws, any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, are signed by the holders of issued and outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. The CoreWeave certificate of incorporation provides that stockholders may not act by written consent in lieu of a meeting. Notwithstanding the foregoing, so long as the voting power of all of the then-outstanding shares of Class B common stock represents greater than a majority of the combined voting power of all of the then-outstanding shares of CoreWeave’s capital stock, any action required or permitted to be taken at any meeting of the stockholders of CoreWeave may be taken without a meeting if holders of a majority of the voting power of all of the then-outstanding shares of capital stock of CoreWeave entitled to vote thereon, voting together as a single class, consent in writing or by electronic transmission. | The DGCL provides that, unless otherwise provided in a corporation’s certificate of incorporation or bylaws, any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, are signed by the holders of issued and outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. The Core Scientific certificate of incorporation provides that stockholders may not act by written consent in lieu of a meeting. | ||||
Certificate of Incorporation Amendments | Under the DGCL, an amendment to a corporation’s charter generally requires the approval of the corporation’s board of directors and the holders of a majority of the outstanding stock entitled to vote thereon unless the charter requires a higher vote. In addition, if the proposed amendment would increase or decrease the aggregate number of authorized shares of a class of stock, increase or decrease the par value of the shares of such class or change the powers, preferences or special rights of the shares so as to affect them adversely, the holders of a majority of the outstanding shares of such class will be entitled to vote as a class upon the proposed amendment. The CoreWeave certificate of incorporation provides that the affirmative vote of the holders of at least two-thirds (2/3) of the | Under the DGCL, an amendment to a corporation’s charter generally requires the approval of the corporation’s board of directors and the holders of a majority of the outstanding stock entitled to vote thereon unless the charter requires a higher vote. In addition, if the proposed amendment would increase or decrease the aggregate number of authorized shares of a class of stock, increase or decrease the par value of the shares of such class or change the powers, preferences or special rights of the shares so as to affect them adversely, the holders of a majority of the outstanding shares of such class will be entitled to vote as a class upon the proposed amendment. The Core Scientific certificate of incorporation provides that the affirmative vote of the holders of at least two-thirds of | ||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
voting power of all of the then-outstanding shares of CoreWeave’s capital stock entitled to vote, voting together as a single class, is required to amend or repeal, or adopt any provision (other than Section 1.1 of Article IV regarding authorized shares); provided, that, if two-thirds (2/3) of the CoreWeave board has approved such amendment, then only the affirmative vote of the holders of a majority of the voting power of all of the then-outstanding shares of CoreWeave’s capital stock entitled to vote, voting together as a single class (in addition to any other vote required by law), is required to approve such amendment. Prior to an automatic conversion of all shares of Class B common stock and Class C common stock into shares of CoreWeave common stock in accordance with the CoreWeave certificate of incorporation, and in addition to any other vote required pursuant to Article X of the CoreWeave certificate of incorporation, CoreWeave will not, without the prior affirmative vote of the holders of at least two-thirds (2/3) of the then-outstanding shares of Class B common stock, voting separately as a single class: (i) amend any provision of the CoreWeave certificate of incorporation relating to the voting, conversion or other rights, powers, preferences, privileges or restrictions of the Class B common stock; (ii) reclassify any outstanding shares of CoreWeave common stock or Class C common stock into shares having rights as to dividends or liquidation that are senior to the Class B common stock or the right to have more than one (1) vote for each share thereof; or (iii) authorize, or issue any shares of, any class or series of capital stock of CoreWeave (other than Class B common stock) having the right to more than one (1) vote for each share thereof. The affirmative vote of the holders of CoreWeave common stock representing at least seventy-five percent (75%) of the voting power of all of the then-outstanding shares of CoreWeave common stock, voting separately as a single class, and the affirmative vote of the holders of Class B common stock representing at least seventy- | the voting power of all of the then outstanding shares of capital stock of Core Scientific entitled to vote generally in the election of directors, voting together as a single class, is required to alter, amend or repeal Articles V (board of directors; bylaw amendments and stockholder actions), VI (director and officer indemnification), VII (choice of forum) and VIII (amendments of the certificate of incorporation) of the Core Scientific certificate of incorporation. | |||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
five percent (75%) of the voting power of all of the then-outstanding shares of Class B common stock, voting separately as a single class, will be required to amend any provision inconsistent with, Section 3 of Article IV regarding common stock or Section 2 of Article X regarding amendments of the CoreWeave certificate of incorporation. | ||||||
Bylaw Amendments | Under the DGCL, the power to make, alter or repeal bylaws is conferred upon the stockholders. A corporation may, however, in its certificate of incorporation also confer upon the board of directors the power to make, alter or repeal its bylaws. The CoreWeave certificate of incorporation grants the CoreWeave board the power to adopt, amend and repeal the CoreWeave bylaws by a vote of a majority of the board. CoreWeave’s stockholders may also adopt, alter, amend or repeal the CoreWeave bylaws upon the affirmative vote of the holders of at least two-thirds (2/3) of the voting power of all of the then-outstanding shares of CoreWeave’s capital stock entitled to vote thereon, voting together as a single class; provided, that, in the case of any adoption, amendment or repeal of any provision of the CoreWeave bylaws that the CoreWeave board elects to submit to the stockholders for adoption and which is approved by at least two-thirds (2/3) of CoreWeave’s whole board, then, only the affirmative vote of the holders of a majority of the voting power of all of the then-outstanding shares of CoreWeave’s capital stock entitled to vote, voting together as a single class (in addition to any requirements of law), is required to adopt, amend or repeal any such provision of the CoreWeave bylaws. | Under the DGCL, the power to make, alter or repeal bylaws is conferred upon the stockholders. A corporation may, however, in its certificate of incorporation also confer upon the board of directors the power to make, alter or repeal its bylaws. The Core Scientific certificate of incorporation grants the Core Scientific board to adopt, amend or repeal the Core Scientific bylaws. Core Scientific’s stockholders may also adopt, amend or repeal the Core Scientific bylaws upon the affirmative vote of the holders of at least two-thirds of the voting power of all of the then-outstanding shares of the capital stock of Core Scientific entitled to vote generally in the election or directors, voting together as a single class. | ||||
Special Meetings of Stockholders | Under the CoreWeave certificate of incorporation, special meetings of CoreWeave’s stockholders may be called only by the chairperson of CoreWeave’s board, CoreWeave’s chief executive officer, the lead independent director or CoreWeave’s board acting pursuant to a resolution adopted by a majority of the whole board and may not be called by the stockholders or any other person or persons. The special meeting may be held either at a place, within or without the State of | Under the Core Scientific bylaws, special meetings of Core Scientific’s stockholders may be called only by the chairperson of Core Scientific’s board, Core Scientific’s chief executive officer, the Core Scientific board pursuant to a resolution adopted by a majority of the total number of authorized directors, or Core Scientific stockholders of record who own, in the aggregate, at least 20% of the voting power of the outstanding shares of Core Scientific then entitled to vote on the matter or matters to be brought before | ||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
Delaware as the CoreWeave board in its sole discretion may fix, or solely by means of remote communication as the CoreWeave board in its sole discretion may determine. Business transacted at any special meeting of stockholders will be limited to matters relating to the purpose or purposes stated in the notice of the meeting. | the proposed special meeting. The Core Scientific board (or its designee) will determine the date, time and play, if any, of such special meeting. No business may be transacted at such special meeting otherwise than specified in the notice of meeting. | |||||
Notice of Meetings of Stockholders | The CoreWeave bylaws provide that notice of all meetings of stockholders must be given in accordance with applicable law stating the date, time and place, if any, of the meeting, the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record date for determining the stockholders entitled to notice of the meeting). In the case of a special meeting, such notice must also set forth the purpose or purposes for which the meeting is called. Notice of any meeting of stockholders must be given not less than ten (10), nor more than sixty (60), days before the date of the meeting to each stockholder of record entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting. | The Core Scientific bylaws provide that notice of all meetings of stockholders must be given in accordance with applicable law stating the date, time and place, if any, of the meeting, the record date for determining stockholders entitled to vote at the meeting, if such record date is different from the record date for determining stockholders entitled to notice of the meeting, and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at any such meeting, and in the case of special meetings, the purpose or purposes of the meeting. Notice of any meeting of stockholders must be given not less than ten (10), nor more than sixty (60), days before the date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of such meeting. | ||||
Limitation of Personal Liability of Directors | The CoreWeave certificate of incorporation provides that, to the fullest extent permitted by law, no director or officer of CoreWeave will be personally liable to CoreWeave or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, as applicable. If the DGCL is amended to authorize the further elimination or limitation of the liability of a director or officer, then the liability of a director or officer of CoreWeave will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. | The Core Scientific certificate of incorporation provides that, to the fullest extent permitted by law, no director or officer of Core Scientific will be personally liable to Core Scientific or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, as applicable. If the DGCL is amended to authorize the further elimination or limitation of the liability of a director or officer, then the liability of a director or officer of Core Scientific will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. | ||||
Indemnification of Directors and Officers | Delaware law provides that a corporation has the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding by reason of the fact the person is or was a director, officer, employee or agent of the | Delaware law provides that a corporation has the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding by reason of the fact the person is or was a director, officer, employee or agent of the | ||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
corporation, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. Delaware law permits expenses (including attorneys’ fees) incurred by an officer or director of the corporation in defending any civil, criminal, administrative or investigative action, suit or proceeding to be paid by the corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it is ultimately determined that such person is not entitled to be indemnified by the corporation as authorized under the DGCL. Under the DGCL, the indemnification and advancement of expenses provided by, or granted pursuant to § 145, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and will inure to the benefit of heirs, executors and administrators of such a person. Pursuant to the CoreWeave bylaws, CoreWeave’s current and former directors and officers will be indemnified and held harmless by CoreWeave to the fullest extent permitted by the DGCL against all expenses, costs, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes and penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such indemnitee, provided such indemnitee acted in good faith and in a manner that the indemnitee reasonably believed to be in or not opposed to the best interests of CoreWeave, and, with respect to any criminal proceeding, had no reasonable cause to believe the indemnitee’s conduct was unlawful. Such indemnification will continue as to an indemnitee who has ceased | corporation, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. Delaware law permits expenses (including attorneys’ fees) incurred by an officer or director of the corporation in defending any civil, criminal, administrative or investigative action, suit or proceeding to be paid by the corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it is ultimately determined that such person is not entitled to be indemnified by the corporation as authorized under the DGCL. Under the DGCL, the indemnification and advancement of expenses provided by, or granted pursuant to § 145, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and will inure to the benefit of heirs, executors and administrators of such a person. Pursuant to the Core Scientific bylaws, Core Scientific’s current and former directors and executive officers will be indemnified and held harmless to the fullest extent permitted by the DGCL against all expenses (including attorneys’ fees), judgments, fines (including ERISA excise taxes or penalties) and amounts paid in settlement actually and reasonably incurred by such indemnitee, provided such indemnitee acted in good faith and in a manner that the indemnitee reasonably believed to be in or not opposed to the best interests of Core Scientific, and, with respect to any criminal proceeding, had no reasonable cause to believe the indemnitee’s conduct was unlawful, provided further that Core Scientific may modify the extent of such indemnification by | |||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
to be a director or officer of CoreWeave for such proceedings brought by reason of the fact that such person is or was a director or officer of CoreWeave. CoreWeave will indemnify such indemnitee seeking indemnity in connection with a proceeding initiated by such indemnitee only if such proceeding was authorized by the CoreWeave board or such indemnification is authorized by an agreement approved by the CoreWeave board. The CoreWeave bylaws permit CoreWeave to grant rights to indemnification and to advancement of expenses to any person who is or was a director, officer, employee or agent of CoreWeave. | individual contracts with its directors and executive officers. Core Scientific is not obligated such indemnitee in connection with a proceeding initiated by such indemnitee unless (i) such indemnification is expressly required to be made by applicable law, (ii) such proceeding was authorized by the Core Scientific board, (iii) such indemnification is provided by Core Scientific, in its sole discretion, pursuant to the powers vested in Core Scientific under the DGCL or any other applicable law and (iv) such indemnification is required to be made under Section 46(d) of the Core Scientific bylaws. | |||||
Dividends | The CoreWeave certificate of incorporation provides that, subject to the preferential or other rights of any holders of Preferred Stock then outstanding, the holders of all series of Common Stock are treated equally, identically and ratably, on a per share basis, with respect to any dividends or distributions (other than authorized repurchases of outstanding Common Stock) as may be declared and paid from time to time by the CoreWeave board out of any assets of CoreWeave legally available, unless a disparate dividend is approved in advance by the affirmative vote of the holders of a majority of the then-outstanding shares of each series of Common Stock, voting as separate series; provided, however, that, notwithstanding the foregoing, in the event a dividend or distribution (other than authorized repurchases of outstanding Common Stock) is paid in the form of shares of a series of Common Stock (or securities convertible into or exchangeable or exercisable for such shares), the holders of a series of Common Stock, as such, will receive shares of such series of Common Stock (or rights to acquire such shares). | The Core Scientific bylaws provide that the Core Scientific board may declare dividends upon the capital stock of Core Scientific, subject to the provisions of the Core Scientific certificate of incorporation and applicable law. Dividends may be paid in cash, in property, or in shares of Core Scientific’s capital stock, subject to the provisions of the Core Scientific certificate of incorporation and applicable law. | ||||
Stockholders’ Rights of Dissent and Appraisal | Delaware law provides that any stockholder of a corporation who holds shares of stock on the making of a demand pursuant to § 262(d) of the DGCL with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, who has otherwise complied with § 262(d) of the | Delaware law provides that any stockholder of a corporation who holds shares of stock on the making of a demand pursuant to § 262(d) of the DGCL with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, who has otherwise complied with § 262(d) of the | ||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
DGCL and who has neither voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance nor consented thereto in writing pursuant to § 228 of the DGCL will be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder’s shares of stock. Appraisal rights will be available under Delaware law for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation in a merger, consolidation, conversion, transfer, domestication or continuance to be effected, subject to the limitations detailed in § 262 of the DGCL. The DGCL further provides that any corporation may provide in its certificate of incorporation that appraisal rights will be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected, or a transfer, domestication or continuance effected. Neither the CoreWeave certificate of incorporation nor the CoreWeave bylaws address appraisal rights. | DGCL and who has neither voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance nor consented thereto in writing pursuant to § 228 of the DGCL will be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder’s shares of stock. Appraisal rights will be available under Delaware law for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation in a merger, consolidation, conversion, transfer, domestication or continuance to be effected, subject to the limitations detailed in § 262 of the DGCL. The DGCL further provides that any corporation may provide in its certificate of incorporation that appraisal rights will be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected, or a transfer, domestication or continuance effected. Neither the Core Scientific certificate of incorporation nor the Core Scientific bylaws address appraisal rights. | |||||
Anti-Takeover Provisions | CoreWeave has not opted out of § 203 of the DGCL, which prohibits a defined set of transactions between a Delaware corporation, such as CoreWeave, and an “interested stockholder.” An interested stockholder is generally defined as a person who, together with any affiliates or associates of such person “owns” (as defined in § 203 of the DGCL, which includes direct and indirect beneficial ownership) 15% or more of the outstanding voting stock of a Delaware corporation. This provision may prohibit the corporation from engaging in a business combination with an interested stockholder for a period of three years after the time the interested stockholder becomes an interested stockholder. The term “business combination” is broadly defined to include a broad array of transactions, including certain mergers, consolidations, sales or other dispositions of assets having an aggregate | Core Scientific has not opted out of § 203 of the DGCL, which prohibits a defined set of transactions between a Delaware corporation, such as Core Scientific, and an “interested stockholder.” An interested stockholder is generally defined as a person who, together with any affiliates or associates of such person “owns” (as defined in § 203 of the DGCL, which includes direct and indirect beneficial ownership) 15% or more of the outstanding voting stock of a Delaware corporation. This provision may prohibit the corporation from engaging in a business combination with an interested stockholder for a period of three years after the time the interested stockholder becomes an interested stockholder. The term “business combination” is broadly defined to include a broad array of transactions, including certain mergers, consolidations, sales or other dispositions of assets having an | ||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
market value of 10% or more of the aggregate market value of the consolidated assets of the corporation or all of the outstanding stock of the corporation, and certain other transactions that would increase the interested stockholder’s proportionate share ownership in the corporation, result in the interested stockholder’s acquisition of stock of a direct or indirect majority-owned subsidiary of the corporation or the receipt of the interested stockholder of certain financial benefits. This prohibition is effective unless: (i) the business combination or the transaction that resulted in the stockholder becoming an interested stockholder is approved by the CoreWeave board prior to the time the interested stockholder becomes an interested stockholder; (ii) the interested stockholder acquired at least 85% of the voting stock of CoreWeave not owned by directors who are also officers or by qualified employee stock plans, in the transaction in which it becomes an interested stockholder; or (iii) the business combination is approved by a majority of the CoreWeave board and by the affirmative vote of 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. | aggregate market value of 10% or more of the aggregate market value of the consolidated assets of the corporation or all of the outstanding stock of the corporation, and certain other transactions that would increase the interested stockholder’s proportionate share ownership in the corporation, result in the interested stockholder’s acquisition of stock of a direct or indirect majority-owned subsidiary of the corporation or the receipt of the interested stockholder of certain financial benefits. This prohibition is effective unless: (i) the business combination or the transaction that resulted in the stockholder becoming an interested stockholder is approved by the Core Scientific board prior to the time the interested stockholder becomes an interested stockholder; (ii) the interested stockholder acquired at least 85% of the voting stock of Core Scientific not owned by directors who are also officers or by qualified employee stock plans, in the transaction in which it becomes an interested stockholder; or (iii) the business combination is approved by a majority of the Core Scientific board and by the affirmative vote of 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. | |||||
Stockholder Vote on Fundamental or Extraordinary Corporate Transactions | In addition to any vote required pursuant to applicable law or the CoreWeave certificate of incorporation, the affirmative vote of the holders of a majority of the then-outstanding shares of each series of Common Stock, voting as separate series, is required to approve any merger, consolidation, conversion, transfer, domestication or continuance (whether or not CoreWeave is the surviving entity, a “Fundamental Change”) unless the holders of each series of Common Stock, as such, will be entitled to receive equal, identical and ratable per share distributions or payments, if any, in connection with such Fundamental Change; provided, however, that, notwithstanding the foregoing, in the case of a distribution or payment in the form of securities in connection with a Fundamental Change, any or all such series of Common Stock may (but is not required to) receive different or disproportionate distributions or payments in the form of securities of CoreWeave or another entity if the only difference among | Neither the Core Scientific certificate of incorporation nor the Core Scientific bylaws contains voting requirements for approval of mergers, sales or other fundamental or extraordinary corporate transactions that differ from those related to ordinary course corporate actions. | ||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
the securities distributed or paid to each series of Common Stock will be the voting rights thereof, which will be substantially similar to the voting rights of the series of Common Stock in respect of which such securities are distributed or paid; and provided, further, that in the event that the holders of a series of Common Stock are granted rights to elect to receive one of two or more alternative forms of consideration, the holders of each series of Common Stock will be deemed to have received equal, identical and ratable per share distributions or payments in connection with such Fundamental Change if holders of each series of Common Stock are granted substantially similar election rights. Notwithstanding the foregoing, (x) consideration to be distributed or paid to a holder of Common Stock in connection with any such Fundamental Change pursuant to any employment, consulting, severance or similar services arrangement or (y) a negotiated agreement between a holder of Common Stock and any counterparty (or an “affiliate” thereof (as defined pursuant to Rule 405 promulgated under the Securities Act) to a Fundamental Change wherein such holder is contributing, selling, transferring or otherwise disposing of shares of CoreWeave’s capital stock to such counterparty (or an “affiliate” thereof)) as part of a “rollover” or similar transaction that is in connection with such Fundamental Change, in each case, will not be deemed to be consideration distributed or paid to the holder of shares of Common Stock for these purposes. | ||||||
Exclusive Forum | The CoreWeave bylaws provide that unless CoreWeave consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if such court does not have jurisdiction, the federal district court for the District of Delaware) is the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of CoreWeave, (ii) any action asserting a claim for a breach of a fiduciary duty owed by any director, officer, other employee or agent stockholder of CoreWeave to CoreWeave or CoreWeave’s stockholders, (iii) any action asserting a claim against CoreWeave or any current or | The Core Scientific certificate of incorporation provides that unless Core Scientific consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if, the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if, all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action brought under Delaware statutory or common law: | ||||
CoreWeave Stockholder Rights | Core Scientific Stockholder Rights | |||||
former director, officer, stockholder, employee or agent of CoreWeave arising pursuant to any provision of the DGCL, the CoreWeave certificate of incorporation or the CoreWeave bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, (iv) any action to interpret, apply, enforce or determine the validity of the CoreWeave certificate of incorporation or the CoreWeave bylaws, (v) any action asserting a claim against CoreWeave governed by the internal affairs doctrine, or (vi) any action asserting an “internal corporate claim” as that term is defined in § 115 of the DGCL. In addition, unless CoreWeave consents in writing to the selection of an alternative forum, the federal district courts of the United States of America are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. | (i) any derivative claim or action brought on Core Scientific’s behalf; (ii) any claim or cause of action asserting a breach of fiduciary duty by any of Core Scientific’s current or former director, officer or other employee; (iii) any claim or cause of action asserting a claim against Core Scientific arising out of, or pursuant to, the DGCL, the certificate of incorporation or the bylaws; (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the certificate of incorporation or the bylaws (including any right, obligation, or remedy thereunder); (v) any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; or (vi) any claim or cause of action asserting a claim against Core Scientific or any of its directors, officers or other employees, that is governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. In addition, the federal courts of the United States of America are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. | |||||
• | each of CoreWeave’s current named executive officers and directors at September 9, 2025, each of whom are expected to continue as an executive officer or director of CoreWeave immediately after the consummation of the Merger; |
• | all executive officers and directors of CoreWeave as a group at September 9, 2025 and all executive officers and directors of CoreWeave as a group immediately after the consummation of the Merger; |
• | each person known by CoreWeave to be the beneficial owner of more than 5% of the outstanding shares of CoreWeave Class A common stock or Class B common stock at September 9, 2025 and/or as of immediately after the consummation of the Merger. |
1. | 380,162,985 shares of CoreWeave Class A common stock and 114,939,540 shares of CoreWeave Class B common stock outstanding at September 9, 2025 prior to the consummation of the Merger; |
2. | 39,581,232 shares of CoreWeave Class A common stock issued to Core Scientific stockholders in connection with the consummation of the Merger (assuming the full issuance of 288,460 shares of Core Scientific common stock for disputed claims in connection with Core Scientific’s Plan of Reorganization but no issuance of Core Scientific common stock pursuant to outstanding CVRs for payments that are not yet payable, and will not become payable, until January 23, 2026 and January 23, 2027); |
3. | No exercise of the 97,432,201 Tranche 1 Warrants and 12,118,829 Tranche 2 Warrants outstanding as of September 9, 2025 in connection with the consummation of the Merger and no exercise of the 97,432,201 New Tranche 1 Warrants and 12,118,829 New Tranche 2 Warrants immediately after the consummation of the Merger; |
4. | No conversion of the Core Scientific 2029 Convertible Notes and Core Scientific 2031 Convertible Notes as of September 9, 2025 in connection with the consummation of the Merger and no conversion of such notes immediately after the consummation of the Merger; and |
5. | The directors and executive officers of Core Scientific and 5% or more beneficial owners of Core Scientific common stock as of September 9, 2025 continuing to beneficially own an equal number of Core Scientific common stock as of the date of the Merger, which will be exchanged for CoreWeave Class A common stock in an amount determined pursuant to the exchange ratio. |
Shares Beneficially Owned Before the Merger Class A | Shares Beneficially Owned Before the Merger Class B | % Total Voting Power before the Merger | Shares Beneficially Owned After the Merger Class A | Shares Beneficially Owned After the Merger Class B | %Total Voting Power after the Merger | |||||||||||||||||||||||||
Name of Beneficial Owner | Shares | % | Shares | % | % | Shares | % | Shares | % | % | ||||||||||||||||||||
Named Executive Officers and Directors: | ||||||||||||||||||||||||||||||
Michael Intrator(2) | 7,343,688 | 1.93% | 56,902,460 | 48.67% | 37.20% | 7,343,688 | 1.75% | 56,902,460 | 48.67% | 36.27% | ||||||||||||||||||||
Brannin McBee(3) | 304,884 | * | 26,392,480 | 22.82% | 17.19% | 304,884 | * | 26,392,480 | 22.82% | 16.76% | ||||||||||||||||||||
Brian Venturo(4) | 879,720 | * | 38,212,300 | 32.16% | 24.42% | 879,720 | * | 38,212,300 | 32.16% | 23.82% | ||||||||||||||||||||
Karen Boone(5) | 15,680 | * | — | — | * | 15,680 | * | — | — | * | ||||||||||||||||||||
Jack Cogen(6) | 17,129,596 | 4.51% | — | — | 1.12% | 17,129,596 | 4.08% | — | — | 1.09% | ||||||||||||||||||||
Glenn Hutchins(7) | 399,400 | * | — | — | * | 399,400 | * | — | — | * | ||||||||||||||||||||
Margaret C. Whitman(8) | 2,580 | * | — | — | * | 2,580 | * | — | — | * | ||||||||||||||||||||
All executive officers and directors as a group (10 persons)(9) | 27,786,896 | 7.28% | 121,507,240 | 100.00% | 77.83% | 27,786,896 | 6.59% | 121,507,240 | 100.00% | 75.95% | ||||||||||||||||||||
Other 5% or Greater Stockholders: | ||||||||||||||||||||||||||||||
Funds or accounts managed or advised by Magnetar Financial LLC(10) | 105,282,503 | 26.81% | — | — | 6.83% | 105,282,503 | 24.36% | — | — | 6.66% | ||||||||||||||||||||
Entities affiliated with FMR LLC(11) | 25,016,051 | 6.58% | — | — | 1.64% | 25,016,051 | 5.96% | — | — | 1.59% | ||||||||||||||||||||
NVIDIA Corporation(12) | 24,182,460 | 6.36% | — | — | 1.58% | 24,182,460 | 5.76% | — | — | 1.54% | ||||||||||||||||||||
Entities affiliated with Jane Street Group LLC(13) | 19,994,532 | 5.26% | — | — | 1.31% | 19,994,532 | 4.76% | — | — | 1.27% | ||||||||||||||||||||
* | Less than 1% |
(1) | This table is based on information supplied by officers and directors and principal stockholders of CoreWeave and Schedules 13D and 13G and Forms 3 and 4 filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, CoreWeave believes that each of the stockholders named in the table has sole voting and investment power with respect to the shares indicated as beneficially owned. |
(2) | Consists of (i) 7,153,330 shares of CoreWeave Class A common stock directly held by Michael Intrator; (ii) 21,867,489 shares of CoreWeave Class B common stock directly held by Mr. Intrator; (iii) 1,980,900 shares of CoreWeave Class B common stock issuable upon the exercise of stock options directly held by Mr. Intrator which are exercisable within 60 days of September 9, 2025; (iv) 140,358 shares of CoreWeave Class A common stock issuable upon the vesting and settlement of restricted stock units within 60 days of September 9, 2025; (v) 365,200 shares of CoreWeave Class B common stock directly held by Mr. Intrator’s spouse; (vi) 50,000 shares of CoreWeave Class A common stock directly held by Omnadora Capital LLC (“Omnadora”); (vii) 25,549,280 shares of CoreWeave Class B common stock directly held by Omnadora; (viii) 266,031 shares of CoreWeave Class B common stock directly held by the PMI 2024 F&F GRAT (“PMI”), (ix) 7,240 shares of CoreWeave Class B common stock directly held by the Silver Thimble Resulting Trust (“Silver Thimble”); (x) 4,576,000 shares of CoreWeave Class B common stock directly held by the Intrator Family GST-Exempt Trust (the “Intrator GST Trust”); and (xi) 2,290,320 shares of CoreWeave Class B common stock directly held by the Intrator Family Trust (together with the Intrator GST Trust, the “Intrator Family Trusts”). Mr. Intrator serves as the sole manager of Omnadora Management LLC, which is the manager of Omnadora, and therefore may be deemed to exercise voting and investment discretion over securities held by Omnadora. Mr. Intrator’s spouse is the trustee of PMI and co-trustee of the Intrator Family Trusts and may be deemed to exercise voting and investment discretion over securities held by them. Mr. Intrator serves as the sole manager of Copper Thimble LLC, which is the investment manager of Silver Thimble, and therefore may be deemed to exercise voting and investment discretion over securities held by Silver Thimble. |
(3) | Consists of (i) 121,965 shares of CoreWeave Class A common stock directly held by Brannin McBee; (ii) 10,642,260 shares of CoreWeave Class B common stock directly held by Mr. McBee; (iii) 705,900 shares of CoreWeave Class B common stock issuable upon the exercise of stock options directly held by Mr. McBee which are exercisable within 60 days of September 9, 2025; (iv) 121,119 shares of CoreWeave Class A common stock issuable upon the vesting and settlement of restricted stock units within 60 days of September 9, 2025; (v) 2,300,300 shares of CoreWeave Class B common stock directly held by Mr. McBee’s spouse; (vi) 5,166,020 shares of CoreWeave Class B common stock directly held by the Brannin J. McBee 2022 Irrevocable Trust (“McBee Trust”); (vii) 6,000,000 shares of CoreWeave Class B common stock directly held by the Canis Major 2025 GRAT (the “Canis Major GRAT”); (viii) 104,000 shares of CoreWeave Class B common stock directly held by the Canis Major 2025 Family Trust LLC (“Canis Major LLC”); (ix) 360,000 shares of CoreWeave |
(4) | Consists of (i) 240,331 shares of CoreWeave Class A common stock directly held by Brian Venturo; (ii) 14,593,347 shares of CoreWeave Class B common stock directly held by Mr. Venturo; (iii) 3,880,900 shares of CoreWeave Class B common stock issuable upon the exercise of stock options directly held by Mr. Venturo which are exercisable within 60 days of September 9, 2025; (iv) 126,771 shares of CoreWeave Class A common stock issuable upon the vesting and settlement of restricted stock units within 60 days of September 9, 2025; (v) 2,001,900 shares of CoreWeave Class B common stock directly held by Mr. Venturo’s spouse; (vi) 6,274,500 shares of CoreWeave Class B common stock directly held by West Clay Capital LLC (“West Clay”); (vii) 5,402,057 shares of CoreWeave Class B common stock directly held by the 2023 Venturo Family GRAT dated June 30, 2023 (“Venturo GRAT I”); (viii) 1,788,596 shares of CoreWeave Class B common stock directly held by the Venturo Family 2024 Friends and Family GRAT (“Venturo GRAT II”); (ix) 4,271,000 shares of CoreWeave Class B common stock directly held by the Venturo Family GST Exempt Trust dated June 30, 2023 (the “Venturo GST Trust”); (x) 22,500 shares of CoreWeave Class A common stock directly held by Mr. Venturo’s father-in-law, who is a member of his household; (xi) 245,059 shares of CoreWeave Class A common stock directly held by the YOLO ECV Trust; and (xii) 245,059 shares of CoreWeave Class A common stock directly held by the YOLO APV Trust. Mr. Venturo serves as managing member of West Clay and as trustee of Venturo GRAT I and Venturo GRAT II and may be deemed to exercise voting and investment discretion over securities held by each of them. Mr. Venturo’s spouse serves as trustee of the Venturo GST Trust and may be deemed to exercise voting and investment discretion over securities held by it. Mr. Venturo may be deemed have beneficial ownership with respect to the shares of CoreWeave Class A common stock directly held by the YOLO ECV Trust and the YOLO APV Trust, by virtue of his power to replace their independent trustee. |
(5) | Consists of (i) 3,440 shares of CoreWeave Class A common stock directly held by Karen Boone; (ii) 1,720 shares of CoreWeave Class A common stock issuable upon the vesting and settlement of restricted stock units within 60 days of September 9, 2025; and (iii) 10,520 shares of CoreWeave Class A common stock directly held by The Boone Family Trust, dated August 6, 2015 (the “Boone Trust”). Karen Boone and her spouse are co-trustees of the Boone Trust and as such may be deemed to exercise voting and investment discretion over securities held by it. |
(6) | Consists of (i) 261,140 shares of CoreWeave Class A common stock directly held by Jack Cogen; (ii) 136,560 shares of CoreWeave Class A common stock directly held by Mr. Cogen’s spouse; (iii) 1,200,000 shares of CoreWeave Class A common stock directly held by the Cogen Family Trust, dated December 17, 2012 (“Cogen 2012 Trust”); (iv) 19,200 shares of CoreWeave Class A common stock directly held by the Jack D. Cogen 2020 Family Trust (“Cogen 2020 Trust”); (v) 126,220 shares of CoreWeave Class A common stock directly held by the Cherry Tree 2024 GRAT; (vi) 10,329,676 shares of CoreWeave Class A common stock directly held by CW Holding 987 LLC; (vii) 654,200 shares of CoreWeave Class A common stock directly held by Birch Tree Trust LLC; (viii) 654,200 shares of CoreWeave Class A common stock directly held by Chestnut Tree Trust LLC; (ix) 654,200 shares of CoreWeave Class A common stock directly held by Maple Tree Trust LLC; (x) 654,200 shares of CoreWeave Class A common stock directly held by Willow Tree Trust LLC; (xi) 110,000 shares of CoreWeave Class A common stock directly held by Birch Br Trust LLC; (xii) 110,000 shares of CoreWeave Class A common stock directly held by Chestnut Br Trust LLC; (xiii) 110,000 shares of CoreWeave Class A common stock directly held by Maple Br Trust LLC; (xiv) 110,000 shares of CoreWeave Class A common stock directly held by Willow Br Trust LLC; and (xv) 2,000,000 shares of CoreWeave Class A common stock directly held by Pine Tree Trust LLC (together with Birch Tree Trust LLC, Chestnut Tree Trust LLC, Maple Tree Trust LLC, Willow Tree Trust LLC, Birch Br Trust LLC, Chestnut Br Trust LLC, Maple Br Trust LLC, and Willow Br Trust LLC, the “Tree LLCs”). Mr. Cogen’s spouse is co-trustee of the Cogen 2012 Trust and as such may be deemed to exercise shared voting and investment discretion over securities held by it. Mr. Cogen may be deemed have beneficial ownership with respect to the shares of our Class A common stock directly held by the Cogen 2020 Trust, by virtue of his power to replace its trustee. Mr. Cogen serves as trustee of the Cherry Tree 2024 GRAT and as manager of CW Holding 987 LLC and each of the Tree LLCs and may be deemed to exercise voting and investment discretion over securities held by each of them. |
(7) | Consists of (i) 3,920 shares of CoreWeave Class A common stock directly held by Glenn Hutchins; (ii) 10,640 shares of CoreWeave Class A common stock directly held by North Island Inferno Fund II LLC (“North Island Inferno”); and (iii) 384,840 shares of CoreWeave Class A common stock directly held by Tide Mill LLC (“Tide Mill”). Mr. Hutchins serves as investment manager for North Island Inferno and as such may be deemed to exercise shared voting and investment discretion over securities held by it. The managing member of Tide Mill is North Island Management, LLC (“NIM”). Mr. Hutchins serves as chairman of NIM and may be deemed to directly or indirectly exercise voting and investment discretion over the investments of Tide Mill. The business address of each of the aforementioned parties is: 330 Madison Avenue, 33rd Floor, New York, NY 10017. |
(8) | Consists of (i) 1,280 shares of CoreWeave Class A common stock directly held by Margaret C. Whitman; and (ii) 1,300 shares of CoreWeave Class A common stock issuable upon the vesting and settlement of restricted stock units within 60 days of September 9, 2025. |
(9) | The reported amounts represent the total of all securities beneficially owned by our directors and officers, consisting of (i) 26,096,801 shares of CoreWeave Class A common stock; (ii) 114,939,540 shares of CoreWeave Class B common stock; (iii) 1,176,487 shares of CoreWeave Class A common stock issuable upon the exercise of stock options which are exercisable within 60 days of September 9, 2025; (iv) 6,567,700 shares of CoreWeave Class B common stock issuable upon the exercise of stock options which are exercisable within 60 days of September 9, 2025; and (v) 513,608 shares of CoreWeave Class A common stock issuable upon the vesting and settlement of restricted stock units within 60 days of September 9, 2025. |
(10) | Based on a statement filed on Schedule 13G with the SEC on April 1, 2025 by Magnetar Financial LLC (“MFL”), Magnetar Capital Partners LP, Supernova Management LLC and David J. Snyderman (collectively, with MFL, “Magnetar”), as well as a Form 4 filed by Magnetar on September 9, 2025, and Forms 3, as amended (collectively, the “Section 16 Reports”), filed with respect to transaction date March 27, 2025, by Magnetar, CW Opportunity LLC (“CW Opportunity”), and Magnetar Structured Credit Fund LP (“Magnetar SCF” and, together with Magnetar and CW Opportunity, the “Magnetar Entities”). Pursuant to the aforementioned disclosures, the securities reported as beneficially owned by the Magnetar Entities consist of (i) 7,140,206 shares of CoreWeave Class A common stock directly held by CW Opportunity 2 LP; (ii) 28,839,164 shares of CoreWeave Class A common stock directly held by CW Opportunity; (iii) 2,445,023 shares of CoreWeave Class A common stock and 1,335,913 shares of CoreWeave Class A common stock issuable upon the exercise of warrants |
(11) | Based solely on Amendment No. 1 to its statement filed with the SEC on August 6, 2025 on Schedule 13G by FMR LLC and Abigail P. Johnson (together, “FMR”), for themselves and on behalf of the following subsidiaries or affiliates of FMR: (i) FIAM LLC, Fidelity Diversifying Solutions LLC, Fidelity Management & Research Company LLC, and Strategic Advisers LLC, each as a beneficial owner in its capacity as a registered investment adviser, and (ii) Fidelity Institutional Asset Management Trust Company and Fidelity Management Trust Company, each as a beneficial owner in its capacity as a bank. Pursuant to the aforementioned statement, FMR LLC reported sole dispositive power over 25,016,050.65 shares of CoreWeave Class A common stock, sole voting power over 24,219,215.45 shares of CoreWeave Class A common stock, and shared dispositive or voting power over no securities. Ms. Johnson reported sole dispositive power over 25,016,050.65 shares of CoreWeave Class A common stock, and shared voting power and sole dispositive or voting power over no securities. Additionally, pursuant to the statement, members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders’ voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders’ voting agreement, members of the Johnson family may be deemed, under the Investment Advisers Act of 1940, as amended, to form a controlling group with respect to FMR LLC. The business address of each of the aforementioned parties is 245 Summer Street, Boston, Massachusetts 02210. |
(12) | Based solely on a statement filed with the SEC on May 15, 2025 on Schedule 13G by NVIDIA Corporation (“NVIDIA”). Pursuant to the statement, NVIDIA reported sole dispositive and voting power with respect to 24,182,460 shares of CoreWeave Class A common stock and shared dispositive or voting power with respect to no securities. The business address of NVIDIA is 2788 San Tomas Expressway, Santa Clara, California 95051. |
(13) | Based solely on a statement filed with the SEC on August 20, 2025 on Schedule 13G by Jane Street Group, LLC (“JS Group”), Jane Street Capital, LLC (“JS Capital”), Jane Street Options, LLC (“JS Options”), Jane Street Global Trading, LLC (“JS Trading”) and Jane Street Singapore Pte. Ltd (“JS Singapore”). Pursuant to the statement: (i) JS Group reported shared dispositive and voting power over 19,994,532 shares of CoreWeave Class A common stock and sole dispositive or voting power over no securities, (ii) JS Capital reported shared dispositive and voting power over 1,875,086 shares of CoreWeave Class A common stock and sole dispositive or voting power over no securities, (iii) JS Options reported shared dispositive and voting power over 11,049,400 shares of CoreWeave Class A common stock and sole dispositive or voting power over no securities, (iv) JS Trading reported shared dispositive and voting power over 5,693,017 shares of CoreWeave Class A common stock and sole dispositive or voting power over no securities, and (v) JS Singapore reported shared dispositive and voting power over 1,377,029 shares of CoreWeave Class A common stock and sole dispositive or voting power over no securities. The business address of JS Group, JS Capital, JS Options, and JS Trading is: 250 Vesey Street, 6th Floor, New York, NY 10281, and the business address of JS Singapore is: c/o Tricor Evatthouse Corporate Services (A division of Tricor Singapore Pte Ltd), 80 Robinson Road #02-00, Singapore 068898. |
Beneficial Ownership of Core Scientific Common Stock | ||||||
Name of Beneficial Owner | Number of Shares | Percent of Class | ||||
Directors and Named Executive Officers: | ||||||
Adam Sullivan(2) | 1,292,635 | * | ||||
Todd M. DuChene(3) | 1,439,132 | * | ||||
Denise Sterling(4) | 713,222 | * | ||||
James P. Nygaard, Jr.(5) | 335,002 | * | ||||
Jeff Booth(6) | 47,793 | * | ||||
Jordan Levy(7) | 158,993 | * | ||||
Yadin Rozov(8) | 107,793 | * | ||||
Eric Weiss(9) | 73,793 | * | ||||
All current directors and executive officers as a group (7 individuals) | 3,455,141 | 1.1% | ||||
5% Stockholders | ||||||
The Vanguard Group(10) | 27,249,215 | 8.9% | ||||
BlackRock, Inc.(11) | 23,299,564 | 7.6% | ||||
Two Seas Capital LP(12) | 19,122,842 | 6.2% | ||||
G1 Execution Services, LLC(13) | 18,336,176 | 6.0% | ||||
Situational Awareness LP(14) | 17,682,918 | 5.8% | ||||
* | Less than 1% |
(1) | This table is based on information supplied by officers and directors and principal stockholders of Core Scientific and Schedules 13D and 13G and Forms 3 and 4 filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, Core Scientific believes that each of the stockholders named in the table has sole voting and investment power with respect to the shares indicated as beneficially owned. |
(2) | Represents 1,118,531 shares of Core Scientific common stock owned by Mr. Sullivan and 114,364 Tranche 1 Warrants which are exercisable into shares of Core Scientific common stock at $6.81 per share and 59,740 shares of Core Scientific common stock issuable within 60 days of September 11, 2025. |
(3) | Represents 881,090 shares of Core Scientific common stock owned by Mr. DuChene, 537,133 Tranche 1 Warrants which are exercisable into shares of Core Scientific common stock at $6.81 per share and 20,909 shares of Core Scientific common stock issuable within 60 days of September 11, 2025. |
(4) | Represents 461,446 shares of Core Scientific common stock owned by Ms. Sterling, 123,696 Tranche 1 Warrants which are exercisable into shares of Core Scientific common stock at $6.81 per share, 103,080 Tranche 2 Warrants which are exercisable into shares of Core Scientific common stock at $.01 per share and 25,000 shares of common stock issuable within 60 days of September 11, 2025. |
(5) | Represents 201,645 shares of Core Scientific common stock owned by Mr. Nygaard and 133,357 Tranche 1 Warrants which are exercisable into shares of Core Scientific common stock at $6.81 per share. |
(6) | Represents 47,793 shares of Core Scientific common stock owned by Mr. Booth. |
(7) | Represents 158,993 shares of Core Scientific common stock owned by Mr. Levy. |
(8) | Represents 107,793 shares of Core Scientific common stock owned by Mr. Rozov. |
(9) | Represents 73,793 shares of Core Scientific common stock owned by Mr. Weiss. |
(10) | Based on a Schedule 13G filed with the SEC by The Vanguard Group on July 29, 2025. Of the shares of Core Scientific common stock beneficially owned, The Vanguard Group reported that it has sole dispositive power with respect to 26,589,700 shares, shared dispositive power with respect to 659,515 shares, sole voting power with respect to 0 shares, and shared voting power with respect to 306,408 shares. The Vanguard Group listed its principal place of business as 100 Vanguard Blvd., Malvern, PA 19355. |
(11) | Based on a Schedule 13G filed with the SEC by BlackRock, Inc. on July 16, 2025. Of the shares of Core Scientific common stock beneficially owned, BlackRock, Inc. reported that it has sole dispositive power with respect to 23,299,564 shares, shared dispositive power with respect to 0 shares, sole voting power with respect to 22,773,781 shares, and shared voting power with respect to 0 shares. BlackRock, Inc. listed its principal place of business as 50 Hudson Yards, New York, New York 10001. |
(12) | Based on a Schedule 13D filed with the SEC by Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi (together, “Two Seas”) on August 8, 2025. Of the shares of Core Scientific common stock beneficially owned, Two Seas reported that it has sole dispositive power with respect to 19,122,842 shares, shared dispositive power with respect to 0 shares, sole voting power with respect to 19,122,842 shares, and shared voting power with respect to 0 shares. Two Seas listed its principal place of business as 32 Elm Place, 3rd Floor, Rye, New York 10580. |
(13) | Based on a Schedule 13G filed with the SEC by G1 Execution Services, LLC, SIG Brokerage, LP, Susquehanna Investment Group and Susquehanna Securities, LLC on August 14, 2025. Of the shares of Core Scientific common stock beneficially owned, (i) G1 Execution Services, LLC reported that it has sole dispositive power with respect to 997 shares, shared dispositive power with respect to 18,336,176 shares, sole voting power with respect to 997 shares, and shared voting power with respect to 18,336,176 shares; (ii) SIG Brokerage, LP reported that it has sole dispositive power with respect to 93,916 shares, shared dispositive power with respect to 18,336,176 shares, sole voting power with respect to 93,916 shares, and shared voting power with respect to 18,336,176 shares; (iii) Susquehanna Investment Group reported that it has sole dispositive power with respect to 1,492,600 shares, shared dispositive power with respect to 18,336,176 shares, sole voting power with respect to 1,492,600 shares, and shared voting power with respect to 18,336,176 shares; and (iv) Susquehanna Securities, LLC reported that it has sole dispositive power with respect to 16,748,663 shares, shared dispositive power with respect to 18,336,176 shares, sole voting power with respect to 16,748,663 shares, and shared voting power with respect to 18,336,176 shares. G1 Execution Services, LLC listed its principal place of business as 175 W. Jackson Blvd., Suite 1700, Chicago, IL 60604. SIG Brokerage, LP, Susquehanna Investment Group and Susquehanna Securities, LLC each listed their principal place of business as 401 E. City Avenue, Suite 220, Bala Cynwyd, PA 19004. |
(14) | Based on a Schedule 13D filed with the SEC by Situational Awareness LP, SAI AI GP LP, Situational Awareness LLC, Situational Awareness Partners LP, Leopold Aschenbrenner and Carl Shulman (together, “Situational Awareness”) on August 19, 2025. Of the shares of Core Scientific common stock beneficially owned, Situational Awareness reported that it has sole dispositive power with respect to 0 shares, shared dispositive power with respect to 17,682,918 shares, sole voting power with respect to 0 shares, and shared voting power with respect to 17,682,918 shares. Situational Awareness listed its principal place of business as 512 Second Street, Suite 400, San Francisco, CA 94107. |
• | Core Scientific’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed on February 27, 2025. |
• | Core Scientific’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, which were filed on May 7, 2025 and August 8, 2025, respectively; |
• | Core Scientific’s Current Reports on Form 8-K filed on March 4, 2025, March 13, 2025, May 2, 2025, May 13, 2025, May 16, 2025, May 27, 2025 and July 7, 2025 (other than the portions of those documents not deemed to be filed). |
• | Core Scientific’s Definitive Proxy Statement on Schedule 14A for Core Scientific’s 2025 annual stockholder meeting, filed on March 28, 2025. |
• | The description of Core Scientific’s registered securities filed as Exhibit 4.11 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, including any amendments or reports filed for the purpose of updating such information. |
Term Location | |||
Adverse Recommendation Change | 7.04(b) | ||
Agreement | Preamble | ||
Anti-Corruption Laws | 4.10(f) | ||
Book-Entry Share | 3.03 | ||
Cancelled Shares | 3.01(a)(i) | ||
CERCLA | 4.19(a)(iv) | ||
Certificate | 3.03 | ||
Certificate of Merger | 2.03 | ||
Claim Expenses | 7.07(b) | ||
Closing | 2.02 | ||
Closing Date | 2.02 | ||
Company | Preamble | ||
Company 10-K | 4.03(e) | ||
Company Board | Recitals | ||
Company Board Recommendation | Recitals | ||
Company Common Stock | Recitals | ||
Company Disclosure Letter | Article IV | ||
Company Knowledge Persons | Definition of Knowledge, 1.01 | ||
Company Material Contract | 4.14(a) | ||
Company Organizational Documents | 4.01 | ||
Company Product | Section 4.15(c) | ||
Company Real Property | 4.12(c) | ||
Company Real Property Lease | 4.12(c) | ||
Company Real Property Leases | 4.12(c) | ||
Company SEC Documents | 4.07(a) | ||
Company Securities | 4.03(c) | ||
Company Software | Section 4.15(g) | ||
Company Stockholder Approval | 4.02 | ||
Company Stockholders | Recitals | ||
Company Stockholders’ Meeting | 7.03(a) | ||
Term Location | |||
Company Subsidiary Securities | 4.04(b) | ||
Confidentiality Agreement | 7.01(e) | ||
D&O Claim | 7.07(b) | ||
Davis Polk | 7.13(a) | ||
Debt Financing Sources | 7.22(a) | ||
Development Property | 4.12(g) | ||
DGCL | 2.01 | ||
Effective Time | 2.03 | ||
Electronic Delivery | 10.05 | ||
Eligible Shares | 3.01(a)(ii) | ||
End Date | 9.01(d)(ii) | ||
Enforceability Exceptions | 4.02 | ||
ERISA | 4.18(a) | ||
Exchange Act | 4.06 | ||
Exchange Agent | 3.04(a) | ||
Exchange Fund | 3.04(a) | ||
FCPA | 4.10(g) | ||
Forum | 10.06(b) | ||
HSR Act | 4.06 | ||
Indemnified Party | 7.07(b) | ||
Intended Tax Treatment | 7.13(a) | ||
Intentional Breach | 9.02 | ||
Joint Venture Entities | 4.03(e) | ||
Leased Real Property | 4.12(c) | ||
Maximum Premium | 7.07(c) | ||
Measurement Date | 4.03(a) | ||
Merger | Recitals | ||
Merger Consideration | 3.01(a)(ii) | ||
Merger Sub | Preamble | ||
Merger Sub Consents | 5.02 | ||
Merger Sub I Board | Recitals | ||
NASDAQ | 4.02 | ||
New Plans | 7.06(b) | ||
Non-DTC Book-Entry Share | 3.04(c) | ||
OECD Convention | 4.10(g) | ||
Owned Real Property | 4.12(b) | ||
Parent | Preamble | ||
Parent Balance Sheet Date | 5.08 | ||
Parent Board | Recitals | ||
Parent Class A Common Stock | Recitals | ||
Parent Disclosure Letter | Article V | ||
Parent Knowledge Persons | Definition of Knowledge, 1.01 | ||
Parent SEC Documents | 5.07(a) | ||
Parent Securities | 5.03(b) | ||
Parent Stockholders | Recitals | ||
Parent Subsidiary Securities | 5.04 | ||
Parties | Preamble | ||
Party | Preamble | ||
Patents | Definition of Intellectual Property, 1.01 | ||
Pre-Closing Period | 6.01(a) | ||
Term Location | |||
Pre-Stabilized Property | 4.12(e) | ||
Privacy Requirements | 4.10(f) | ||
Prohibited Payment | 4.10(g) | ||
Property Material Contracts | 4.14(a) | ||
Proxy Statement | 7.02(a) | ||
Registered IP | 4.15(a) | ||
Registration Statement | 7.02(a) | ||
Sarbanes-Oxley | 4.10(c) | ||
SEC | 4.06 | ||
Securities Act | 4.06 | ||
Security Breach | 4.15(h) | ||
Significant Subsidiary | 5.04 | ||
Strategic Direction | 7.05(e) | ||
Surviving Corporation | 2.01 | ||
Surviving Provisions | 9.02 | ||
Termination Fee | 9.03(b) | ||
Trade Control Laws | 4.10(h) | ||
Trade Secrets | Definition of Intellectual Property, 1.01 | ||
UK Bribery Act | 4.10(g) | ||
Wachtell | 7.13(a) | ||
WARN | 4.20(c) | ||
Notices to Parent and Merger Sub: | ||||||
CoreWeave, Inc. | ||||||
290 W Mount Pleasant Ave, Suite 4100 | ||||||
Livingston, NJ 07039 | ||||||
Attention: | Kristen McVeety | |||||
Email: [ ] | ||||||
with copies (which shall not constitute notice) to: | ||||||
Davis Polk & Wardwell LLP | ||||||
450 Lexington Avenue | ||||||
New York, New York 10017 | ||||||
and | ||||||
Davis Polk & Wardwell LLP | ||||||
900 Middlefield Road, Suite 200 | ||||||
Redwood City, California 94063 | ||||||
Attention: | Michael Gilson | |||||
Michael Kaplan | ||||||
Tierney O’Rourke | ||||||
Email: [ ] | ||||||
and | ||||||
Kirkland & Ellis LLP | ||||||
609 Main Street | ||||||
Houston, Texas 77002 | ||||||
Attention: | Douglas E. Bacon, P.C. | |||||
David B. Feirstein, P.C. | ||||||
Melissa D. Kalka, P.C. | ||||||
Email: [ ] | ||||||
Notices to the Company: | ||||||
Core Scientific, Inc. | ||||||
83 Walker Road, Suite 21-2105 | ||||||
Dover, Delaware 19904 | ||||||
Attention: | Todd M. DuChene | |||||
Email: [ ] | ||||||
with a copy (which shall not constitute notice) to: | ||||||
Wachtell, Lipton, Rosen & Katz | ||||||
51 West 52nd Street | ||||||
New York, New York 10019 | ||||||
Attention: | David A. Katz | |||||
Karessa L. Cain | ||||||
Email: [ ] | ||||||
CORE SCIENTIFIC, INC. | ||||||
By: | /s/ Adam Sullivan | |||||
Name: | Adam Sullivan | |||||
Title: | Chief Executive Officer | |||||
COREWEAVE, INC. | ||||||
By: | /s/ Michael Intrator | |||||
Name: | Michael Intrator | |||||
Title: | Chief Executive Officer | |||||
MIAMI MERGER SUB I, INC. | ||||||
By: | /s/ Michael Intrator | |||||
Name: | Michael Intrator | |||||
Title: | President, Chief Executive Officer | |||||


Very truly yours, | |||
/s/ MOELIS & COMPANY LLC | |||
MOELIS & COMPANY LLC | |||
![]() | ![]() | ||
(i) | reviewed certain publicly available information concerning the business, financial condition and operations of the Company and Purchaser; |
(ii) | reviewed certain internal information concerning the business, financial condition and operations of the Company prepared and furnished to us by the management of the Company; |
(iii) | reviewed certain information concerning the business, financial condition and operations of Purchaser furnished to us by or at the direction of the management of Purchaser; |
(iv) | reviewed certain internal financial analyses, estimates and forecasts relating to the Company, including projections that were prepared by or at the direction of the management of the Company and approved for our use by the Board of Directors of the Company (the “Board of Directors” or “you”) (collectively, the “Company Projections”); |
(v) | reviewed certain financial analyses, estimates and forecasts relating to Purchaser that were provided to and discussed with us by the management of the Company, including a certain equity research analyst’s model which Purchaser commented on and discussed with us and management of the Company, and which were approved for our use by the Board of Directors (collectively, the “Purchaser Projections” and, together with the Company Projections, the “Projections”); |
(vi) | held discussions with members of senior management of the Company and participated in discussions with members of senior management of Purchaser, in each case, concerning, among other things, their evaluation of the Transaction and the Company’s and Purchaser’s respective businesses, operating and regulatory environments, financial conditions, prospects and strategic objectives, and potential strategic and financial benefits to the combined company; |

(vii) | reviewed the historical market prices and trading activity for the Shares and the common stock of Purchaser; |
(viii) | compared certain publicly available financial and stock market data for the Company and Purchaser with similar information for certain other companies that we deemed to be relevant; |
(ix) | reviewed a draft, dated July 7, 2025, of the Agreement; and |
(x) | performed such other financial studies, analyses and investigations, and considered such other matters, as we deemed necessary or appropriate for purposes of rendering this opinion. |
Very truly yours, | |||
/s/ PJT Partners LP | |||
PJT Partners LP | |||
June 30, 2025 | December 31, 2024 | |||||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | $1,152,883 | $1,361,083 | ||||
Restricted cash and cash equivalents, current | 560,173 | 37,394 | ||||
Accounts receivable, net | 1,933,698 | 416,526 | ||||
Prepaid expenses and other current assets | 299,229 | 101,246 | ||||
Total current assets | 3,945,983 | 1,916,249 | ||||
Restricted cash and cash equivalents, non-current | 340,527 | 637,356 | ||||
Restricted marketable securities, non-current | — | 29,308 | ||||
Property and equipment, net | 16,631,510 | 11,914,774 | ||||
Operating lease right-of-use assets | 3,380,201 | 2,589,547 | ||||
Intangible assets, net | 205,895 | 4,909 | ||||
Goodwill | 812,970 | 19,544 | ||||
Other non-current assets(a) | 924,277 | 720,912 | ||||
Total assets | $26,241,363 | $17,832,599 | ||||
Liabilities, Redeemable Convertible Preferred Stock, Redeemable Common Stock, and Stockholders’ Equity (Deficit) | ||||||
Current liabilities | ||||||
Accounts payable | $1,226,579 | $868,259 | ||||
Accrued liabilities | 1,411,237 | 355,821 | ||||
Debt, current(a) | 3,627,664 | 2,468,425 | ||||
Deferred revenue, current | 951,346 | 768,927 | ||||
Operating lease liabilities, current | 279,080 | 213,104 | ||||
Finance lease liabilities, current | 60,396 | 57,801 | ||||
Other current liabilities(a) | 53 | 230,244 | ||||
Total current liabilities | 7,556,355 | 4,962,581 | ||||
Debt, non-current(a) | 7,423,837 | 5,457,915 | ||||
Derivative and warrant liabilities | 698 | 200,089 | ||||
Deferred revenue, non-current | 3,896,173 | 3,294,977 | ||||
Operating lease liabilities, non-current | 3,168,392 | 2,388,912 | ||||
Finance lease liabilities, non-current | 3,112 | 34,120 | ||||
Deferred tax liabilities, non-current | 245,659 | 149,232 | ||||
Other non-current liabilities | 126,331 | 36,260 | ||||
Total liabilities | 22,420,557 | 16,524,086 | ||||
Commitments and contingencies (Note 9) | ||||||
Redeemable convertible preferred stock and redeemable common stock(a) | ||||||
Redeemable convertible preferred stock, $0.000005 par value per share, no and 206,169 shares authorized as of June 30, 2025 and December 31, 2024, respectively; no and 184,635 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | — | 1,722,111 | ||||
Redeemable Class A common stock, $0.000005 par value per share, 29,874 and no shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 1,163,159 | — | ||||
Stockholders’ equity (deficit) | ||||||
Preferred stock, $0.000005 par value per share, 100,000 and no shares authorized as of June 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding as of June 30, 2025 and December 31, 2024 | — | — | ||||
June 30, 2025 | December 31, 2024 | |||||
Class A common stock, $0.000005 par value per share, 3,000,000 and 540,680 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 346,663 and 121,277 shares issued as of June 30, 2025 and December 31, 2024, respectively; and 340,075 and 114,689 shares outstanding as of June 30, 2025 and December 31, 2024, respectively | 2 | 1 | ||||
Class B common stock, $0.000005 par value per share, 200,000 and 150,000 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 118,102 and 118,198 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 0 | 0 | ||||
Class C common stock, $0.000005 par value per share, 200,000 and no shares authorized as of June 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding as of June 30, 2025 and December 31, 2024 | — | — | ||||
Treasury stock, at cost, 6,588 shares as of June 30, 2025 and December 31, 2024 | (33,524) | (33,524) | ||||
Additional paid-in capital | 4,772,825 | 1,096,160 | ||||
Accumulated other comprehensive income (loss) | (271) | — | ||||
Accumulated deficit | (2,081,385) | (1,476,235) | ||||
Total stockholders’ equity (deficit) | 2,657,647 | (413,598) | ||||
Total liabilities, redeemable convertible preferred stock, redeemable common stock, and stockholders’ equity (deficit) | $26,241,363 | $17,832,599 | ||||
(a) | Refer to Note 14—Related-Party Transactions for further information on related party arrangements. |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
Revenue | $1,212,788 | $395,371 | $2,194,420 | $584,055 | ||||||||
Operating expenses: | ||||||||||||
Cost of revenue | 312,667 | 108,838 | 575,061 | 168,058 | ||||||||
Technology and infrastructure | 669,913 | 182,886 | 1,231,315 | 275,767 | ||||||||
Sales and marketing | 36,799 | 4,172 | 47,348 | 8,222 | ||||||||
General and administrative | 174,200 | 21,754 | 348,957 | 37,440 | ||||||||
Total operating expenses | 1,193,579 | 317,650 | 2,202,681 | 489,487 | ||||||||
Operating income (loss) | 19,209 | 77,721 | (8,261) | 94,568 | ||||||||
Gain (loss) on fair value adjustments | — | (310,231) | 26,837 | (407,731) | ||||||||
Interest expense, net(a) | (266,966) | (66,766) | (530,801) | (107,422) | ||||||||
Other income (expense), net | 5,023 | 16,406 | 886 | 23,866 | ||||||||
Loss before provision for (benefit from) income taxes | (242,734) | (282,870) | (511,339) | (396,719) | ||||||||
Provision for (benefit from) income taxes | 47,775 | 40,151 | 93,811 | 55,550 | ||||||||
Net loss | $(290,509) | $(323,021) | $(605,150) | $(452,269) | ||||||||
Net loss attributable to common stockholders, basic | $(290,509) | $(338,617) | $(633,872) | $(467,865) | ||||||||
Net loss attributable to common stockholders, diluted | $(290,509) | $(338,617) | $(660,717) | $(467,865) | ||||||||
Net loss per share attributable to common stockholders, basic | $(0.60) | $(1.62) | $(1.73) | $(2.23) | ||||||||
Net loss per share attributable to common stockholders, diluted | $(0.60) | $(1.62) | $(1.79) | $(2.23) | ||||||||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic | 486,591 | 209,626 | 366,765 | 209,560 | ||||||||
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted | 486,591 | 209,626 | 368,607 | 209,560 | ||||||||
(a) | Refer to Note 14—Related-Party Transactions for further information on related party arrangements. |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
Net loss | $(290,509) | $(323,021) | $(605,150) | $(452,269) | ||||||||
Other comprehensive income (loss): | ||||||||||||
Unrealized gain (loss) on available-for-sale marketable securities, net | — | 27 | — | 85 | ||||||||
Change in fair value of derivatives, net | (271) | — | (271) | — | ||||||||
Total comprehensive loss | $(290,780) | $(322,994) | $(605,421) | $(452,184) | ||||||||
Redeemable Convertible Preferred Stock | Redeemable Class A Common Stock | Common Stock | Treasury Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Total Stockholders’ Equity (Deficit) | ||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||
Balance, December 31, 2024 | 184,635 | $1,722,111 | — | $— | 232,887 | $1 | $(33,524) | $1,096,160 | $— | $(1,476,235) | $(413,598) | ||||||||||||||||||||||
Series C redeemable convertible preferred stock accretion to redemption value | — | 29 | — | — | — | — | — | (29) | — | — | (29) | ||||||||||||||||||||||
Cash dividend on Series C redeemable convertible preferred stock | — | — | — | — | — | — | — | (28,693) | — | — | (28,693) | ||||||||||||||||||||||
Reclassification of warrants from liability to equity classified | — | — | — | — | — | — | — | 172,808 | — | — | 172,808 | ||||||||||||||||||||||
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and offering costs | — | — | — | — | 36,590 | — | — | 1,391,515 | — | — | 1,391,515 | ||||||||||||||||||||||
Conversion of redeemable convertible preferred stock in connection with initial public offering | (184,635) | (1,722,140) | 29,874 | 1,163,159 | 155,112 | 1 | — | 558,981 | — | — | 558,982 | ||||||||||||||||||||||
Issuance of common stock for contract incentive | — | — | — | — | 8,750 | — | — | 350,000 | — | — | 350,000 | ||||||||||||||||||||||
Issuance of common stock upon settlement of restricted stock units | — | — | — | — | 911 | — | — | — | — | — | — | ||||||||||||||||||||||
Tax withholdings on settlement of restricted stock units | — | — | — | — | (392) | — | — | (15,685) | — | — | (15,685) | ||||||||||||||||||||||
Exercise of stock options | — | — | — | — | 1,675 | — | — | 2,794 | — | — | 2,794 | ||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | — | — | 202,670 | — | — | 202,670 | ||||||||||||||||||||||
Net loss | — | — | — | — | — | — | — | — | — | (314,641) | (314,641) | ||||||||||||||||||||||
Balance, March 31, 2025 | — | — | 29,874 | 1,163,159 | 435,533 | 2 | (33,524) | 3,730,521 | — | (1,790,876) | 1,906,123 | ||||||||||||||||||||||
Issuance of common stock upon underwriters' exercise of over-allotment option, net of underwriting discounts and commissions | — | — | — | — | 1,760 | — | — | 67,669 | — | — | 67,669 | ||||||||||||||||||||||
Issuance of common stock and restricted stock awards for business combination | — | — | — | — | 19,174 | — | — | 928,900 | — | — | 928,900 | ||||||||||||||||||||||
Issuance of replacement restricted stock units for business combination | — | — | — | — | — | — | — | 3,861 | — | — | 3,861 | ||||||||||||||||||||||
Tax withholdings on issuance of common stock and restricted stock awards for business combination | — | — | — | — | (472) | — | — | (24,332) | — | — | (24,332) | ||||||||||||||||||||||
Issuance of common stock upon settlement of restricted stock units | — | — | — | — | 1,811 | — | — | — | — | — | — | ||||||||||||||||||||||
Tax withholdings on settlement of restricted stock units | — | — | — | — | (904) | — | — | (92,541) | — | — | (92,541) | ||||||||||||||||||||||
Exercise of stock options | — | — | — | — | 1,275 | — | — | 1,744 | — | — | 1,744 | ||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | — | — | 157,003 | — | — | 157,003 | ||||||||||||||||||||||
Other comprehensive income (loss) | — | — | — | — | — | — | — | — | (271) | — | (271) | ||||||||||||||||||||||
Net loss | — | — | — | — | — | — | — | — | — | (290,509) | (290,509) | ||||||||||||||||||||||
Balance, June 30, 2025 | — | $— | 29,874 | $1,163,159 | 458,177 | $2 | $(33,524) | $4,772,825 | $(271) | $(2,081,385) | $2,657,647 | ||||||||||||||||||||||
Redeemable Convertible Preferred Stock | Redeemable Class A Common Stock | Common Stock | Treasury Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Total Stockholders’ Equity (Deficit) | ||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||
Balance, December 31, 2023 | 154,678 | $464,690 | — | $— | 203,520 | $1 | $(32,054) | $48,397 | $(148) | $(612,787) | $(596,591) | ||||||||||||||||||||||
Issuance of Series B redeemable convertible preferred stock | 4,483 | 25,000 | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||
Closing settlement of Series B tranche option | — | 69,598 | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||
Exercise of stock options | — | — | — | — | 215 | — | — | 45 | — | — | 45 | ||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | — | — | 10,181 | — | — | 10,181 | ||||||||||||||||||||||
Other comprehensive income (loss) | — | — | — | — | — | — | — | — | 58 | — | 58 | ||||||||||||||||||||||
Net loss | — | — | — | — | — | — | — | — | — | (129,248) | (129,248) | ||||||||||||||||||||||
Balance, March 31, 2024 | 159,161 | 559,288 | — | — | 203,735 | 1 | (32,054) | 58,623 | (90) | (742,035) | (715,555) | ||||||||||||||||||||||
Issuance of Series C redeemable convertible preferred stock, net of issuance costs of $3.0 million | 29,523 | 1,147,476 | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||
Series C redeemable convertible preferred stock accretion to redemption value | — | 14 | — | — | — | — | — | (14) | — | — | (14) | ||||||||||||||||||||||
Paid-in-kind dividend on Series C redeemable convertible preferred stock | — | 15,582 | — | — | — | — | — | (15,582) | — | — | (15,582) | ||||||||||||||||||||||
Exercise of stock options | — | — | — | — | 411 | — | — | 597 | — | — | 597 | ||||||||||||||||||||||
Repurchase of common stock for business combination | — | — | — | — | (2,105) | — | — | — | — | — | — | ||||||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | — | — | 9,608 | — | — | 9,608 | ||||||||||||||||||||||
Other comprehensive income (loss) | — | — | — | — | — | — | — | — | 27 | — | 27 | ||||||||||||||||||||||
Net loss | — | — | — | — | — | — | — | — | — | (323,021) | (323,021) | ||||||||||||||||||||||
Balance, June 30, 2024 | 188,684 | $1,722,360 | — | $— | 202,041 | $1 | $(32,054) | $53,232 | $(63) | $(1,065,056) | $(1,043,940) | ||||||||||||||||||||||
Six Months Ended June 30, | ||||||
2025 | 2024 | |||||
Cash flows from operating activities: | ||||||
Net loss | $(605,150) | $(452,269) | ||||
Adjustments to reconcile net loss to net cash provided by (used in) operating activities | ||||||
Depreciation and amortization | 1,002,978 | 243,970 | ||||
Non-cash lease expense | 144,113 | 42,015 | ||||
Amortization of debt discounts and issuance costs and accretion of redemption premiums | 66,727 | 15,605 | ||||
Loss (gain) on fair value adjustments | (26,837) | 407,731 | ||||
Stock-based compensation | 328,978 | 15,849 | ||||
Deferred income taxes | 90,884 | 43,207 | ||||
Other non-cash reconciling items | 40,132 | (3,848) | ||||
Changes in operating assets and liabilities, net of effect of business acquisition: | ||||||
Accounts receivable | (1,504,696) | (180,748) | ||||
Prepaid expenses and other current assets | (120,448) | 1,636 | ||||
Accounts payable and accrued expenses | (289,173) | 697,848 | ||||
Deferred revenue | 742,892 | 1,524,487 | ||||
Lease liabilities | (110,451) | (20,708) | ||||
Other non-current assets | 49,968 | (413,561) | ||||
Net cash provided by (used in) operating activities | $(190,083) | $1,921,214 | ||||
Cash flows from investing activities: | ||||||
Purchase of property and equipment, including capitalized internal-use software | $(3,860,351) | $(3,989,096) | ||||
Sale of available-for-sale marketable securities | — | 840 | ||||
Maturities of marketable securities | 29,308 | 47,822 | ||||
Purchase of restricted marketable securities | — | (29,308) | ||||
Purchase of strategic investments | — | (50,000) | ||||
Sale of warrants received as lease incentive | 100,645 | — | ||||
Business combination, net of cash acquired | (45,706) | — | ||||
Issuance of notes receivable | (73,000) | — | ||||
Other investing activities | (26,109) | (1,433) | ||||
Net cash provided by (used in) investing activities | $(3,875,213) | $(4,021,175) | ||||
Cash flows from financing activities: | ||||||
Proceeds from issuance of debt | $4,432,723 | $1,821,541 | ||||
Repayments of debt | (1,574,867) | (74,416) | ||||
Payment of debt issuance costs | (36,536) | (3,479) | ||||
Issuance of redeemable convertible preferred stock, net of issuance costs | — | 1,172,476 | ||||
Redeemable convertible preferred stock cash dividends paid | (28,693) | — | ||||
Proceeds from exercise of stock options | 4,538 | 642 | ||||
Proceeds from initial public offering, net of underwriting discounts and commissions | 1,422,619 | — | ||||
Issuance of common stock, net of underwriting discounts and commissions | 67,669 | — | ||||
Payment of tax withholdings on settlement of RSUs and RSAs | (132,558) | — | ||||
Deferred offering costs paid | (27,763) | — | ||||
Other financing activities | (44,086) | (56,980) | ||||
Net cash provided by (used in) financing activities | $4,083,046 | $2,859,784 | ||||
Net increase in cash, cash equivalents, and restricted cash | $17,750 | $759,823 | ||||
Cash, cash equivalents, and restricted cash—beginning of period | 2,035,833 | 480,075 | ||||
Cash, cash equivalents, and restricted cash—end of period | $2,053,583 | $1,239,898 | ||||
Six Months Ended June 30, | ||||||
2025 | 2024 | |||||
Supplemental disclosures of cash flow information: | ||||||
Cash paid for interest, net of capitalized amounts | $361,557 | $24,862 | ||||
Non-cash investing and financing activities: | ||||||
Capitalized interest not yet paid | $21,980 | $36,052 | ||||
Operating lease right-of-use assets acquired through lease liability | 968,630 | 887,179 | ||||
Accounts payable and accrued expenses related to property and equipment additions | 2,132,972 | 146,867 | ||||
Issuance of common stock for contract incentive | 350,000 | — | ||||
Conversion of redeemable convertible preferred stock in connection with initial public offering | 1,722,140 | — | ||||
Fair value of common stock issued as consideration for a business combination | 928,900 | — | ||||
Fair value of equity awards assumed in a business combination | 3,861 | — | ||||
Reclassification of warrant liabilities to equity | 172,808 | — | ||||
Settlement of Series B tranche liability | — | 69,598 | ||||
Reclassification of customer deposit to debt | 230,244 | — | ||||
Non-cash investments | 71,947 | 7,633 | ||||
Warrants received as lease incentive | 89,956 | — | ||||
Reconciliation of cash, cash equivalents, and restricted cash to condensed consolidated balance sheets: | ||||||
Cash and cash equivalents | $1,152,883 | $1,028,044 | ||||
Restricted cash and cash equivalents, current | 560,173 | 79,725 | ||||
Restricted cash and cash equivalents, non-current | 340,527 | 132,129 | ||||
Total cash, cash equivalents, and restricted cash | $2,053,583 | $1,239,898 | ||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
Customer A | 71% | 59% | 72% | 51% | ||||||||
Customer B | * | 20% | * | 24% | ||||||||
Customer C | * | * | * | * | ||||||||
Customer D | * | * | * | * | ||||||||
* | Customer did not represent 10% or more of revenue. |
Fair Value Hierarchy | June 30, 2025 | December 31, 2024 | |||||||
Financial assets: | |||||||||
Cash and cash equivalents | |||||||||
Money market funds | Level 1 | $55,508 | $2,411 | ||||||
Restricted cash and cash equivalents, current | |||||||||
Money market funds | Level 1 | 518,199 | 24,185 | ||||||
Restricted cash and cash equivalents, non-current | |||||||||
Money market funds | Level 1 | — | 56,250 | ||||||
Restricted marketable securities, non-current | |||||||||
Certificates of deposit | Level 2 | — | 29,308 | ||||||
Prepaid expenses and other current assets | |||||||||
Foreign exchange forward contracts not designated as accounting hedges | Level 2 | 2,279 | — | ||||||
Other non-current assets | |||||||||
Power purchase agreements | Level 3 | 3,444 | 2,562 | ||||||
Total financial assets | $579,430 | $114,716 | |||||||
Financial liabilities: | |||||||||
Derivative and warrant liabilities | |||||||||
Interest rate swaps designated as accounting hedges | Level 2 | $271 | $— | ||||||
Warrant liabilities | Level 3 | — | 199,645 | ||||||
Power purchase agreements | Level 3 | 427 | 444 | ||||||
Total financial liabilities | $698 | $200,089 | |||||||
June 30, 2025 | December 31, 2024 | |||||
Derivative instruments designated as accounting hedges | ||||||
Interest rate swaps | $50,000 | $— | ||||
Derivative instruments not designated as accounting hedges | ||||||
Foreign exchange forward contracts | $107,748 | $— | ||||
Three and Six Months Ended June 30, 2025 | |||
Interest rate swaps designated as accounting hedges | |||
Loss recognized in other comprehensive income (loss), net | $(271) | ||
Foreign exchange forward contracts not designated as accounting hedges | |||
Gain recognized in other income (expense), net | $2,279 | ||
March 21, 2025 | December 31, 2024 | |||||
Stock price | $41 | $48 | ||||
Volatility | 60% | 60% | ||||
Risk-free rate | 4% | 4% | ||||
Dividend yield | 0% | 0% | ||||
Power Purchase Agreements – Asset | Warrant Liabilities | Power Purchase Agreements – Liability | |||||||
Balance at December 31, 2024 | $2,562 | $199,645 | $444 | ||||||
Adjustment to fair value | 882 | (26,837) | (17) | ||||||
Reclassification | — | (172,808) | — | ||||||
Balance at June 30, 2025 | $3,444 | $— | $427 | ||||||
Cash paid by the Company | $96,498 | ||
Fair value of Class A common stock and restricted stock awards issued by the Company | 928,900 | ||
Fair value of replacement restricted stock units | 3,861 | ||
Total purchase price | $1,029,259 | ||
Cash and cash equivalents | $50,792 | ||
Accounts receivable, net | 13,418 | ||
Prepaid expenses and other current assets | 2,205 | ||
Property and equipment, net | 858 | ||
Operating lease right-of-use assets | 1,080 | ||
Intangible assets, net | 207,600 | ||
Goodwill | 793,426 | ||
Other non-current assets | 178 | ||
Total assets acquired | $1,069,557 | ||
Accounts payable | 885 | ||
Accrued liabilities | 7,036 | ||
Deferred revenue, current | 25,414 | ||
Operating lease liabilities, current | 283 | ||
Other current liabilities | 31 | ||
Deferred revenue, non-current | 309 | ||
Operating lease liabilities, non-current | 797 | ||
Deferred tax liabilities, non-current | 5,543 | ||
Total liabilities assumed | $40,298 | ||
Total purchase price | $1,029,259 | ||
Fair Value | Useful Lives (in years) | |||||
Customer relationships | $36,100 | 12 | ||||
Developed technology | 161,800 | 5 - 7 | ||||
Trade name | 9,700 | 5 | ||||
Total | $207,600 | |||||
June 30, 2025 | December 31, 2024 | |||||
Technology equipment | $13,170,295 | $9,146,575 | ||||
Software | 459,742 | 139,508 | ||||
Data center equipment and leasehold improvements | 830,875 | 384,372 | ||||
Furniture, fixtures, and other assets | 12,949 | 8,684 | ||||
Construction in progress | 4,111,256 | 3,200,866 | ||||
Total property and equipment | 18,585,117 | 12,880,005 | ||||
Less: accumulated depreciation and amortization | (1,953,607) | (965,231) | ||||
Total property and equipment, net | $16,631,510 | $11,914,774 | ||||
Amount | |||
Balance at January 1, 2025 | $19,544 | ||
Addition | 793,426 | ||
Balance at June 30, 2025 | $812,970 | ||
June 30, 2025 | December 31, 2024 | ||||||||||||||||||||
Weighted- Average Remaining Useful Lives (in years) | Acquired Intangibles, Gross | Accumulated Amortization | Acquired Intangibles, Net | Acquired Intangibles, Gross | Accumulated Amortization | Acquired Intangibles, Net | |||||||||||||||
Acquired technologies | 5 | $167,253 | $(9,271) | $157,982 | $5,453 | $(3,611) | $1,842 | ||||||||||||||
Other(1) | 10 | 49,697 | (1,784) | 47,913 | 3,897 | (830) | 3,067 | ||||||||||||||
Total | $216,950 | $(11,055) | $205,895 | $9,350 | $(4,441) | $4,909 | |||||||||||||||
(1) | Included in Other are customer relationships and trade names. |
Years Ending December 31, | Amount | ||
Remaining portion of 2025 | $18,940 | ||
2026 | 36,264 | ||
2027 | 36,250 | ||
2028 | 36,082 | ||
2029 | 36,069 | ||
Thereafter | 42,290 | ||
Total expected future amortization expense | $205,895 | ||
June 30, 2025 | December 31, 2024 | |||||
Prepaid expenses | $114,367 | $67,393 | ||||
Strategic agreement contra-revenue asset | 41,136 | — | ||||
Other current assets | 143,726 | 33,853 | ||||
Total prepaid expenses and other current assets | $299,229 | $101,246 | ||||
June 30, 2025 | December 31, 2024 | |||||
Strategic agreement contra-revenue asset | $308,864 | $— | ||||
Prepaid expenses | 207,771 | 145,424 | ||||
Strategic investments | 117,220 | 102,220 | ||||
Equity method investment | 56,947 | — | ||||
June 30, 2025 | December 31, 2024 | |||||
Notes receivable | $56,862 | $107,597 | ||||
Escrow funds | — | 336,055 | ||||
Other non-current assets | 176,613 | 29,616 | ||||
Other non-current assets | $924,277 | $720,912 | ||||
June 30, 2025 | December 31, 2024 | |||||
Accrued purchases | $905,707 | $105,733 | ||||
Accrued interest | 219,114 | 157,310 | ||||
Other accrued liabilities | 286,416 | 92,778 | ||||
Total accrued liabilities | $1,411,237 | $355,821 | ||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
Operating lease cost | $180,450 | $65,781 | $335,502 | $100,757 | ||||||||
Variable lease cost | 57,851 | 10,524 | 101,780 | 13,438 | ||||||||
Total lease cost | $238,301 | $76,305 | $437,282 | $114,195 | ||||||||
Six Months Ended June 30, | ||||||
2025 | 2024 | |||||
Cash paid for amounts included in the measurement of lease liabilities: | ||||||
Operating cash flows from operating leases | $301,288 | $79,428 | ||||
June 30, 2025 | December 31, 2024 | |||||
Weighted-average remaining lease term (in years): | ||||||
Operating leases | 9 | 9 | ||||
Weighted-average discount rate: | ||||||
Operating leases | 12% | 12% | ||||
Future Payments | |||
Years Ending December 31, | Operating Leases | ||
Remaining portion of 2025 | $336,597 | ||
2026 | 683,723 | ||
2027 | 700,911 | ||
2028 | 710,950 | ||
2029 | 647,554 | ||
Thereafter | 2,620,187 | ||
Total undiscounted lease payments | 5,699,922 | ||
Less: imputed interest | (2,252,450) | ||
Present value of lease liabilities | $3,447,472 | ||
Maturities | Effective Interest Rates | June 30, 2025 | December 31, 2024 | |||||||||
DDTL 1.0 Facility | March 2028 | 15% | $1,782,500 | $2,012,500 | ||||||||
DDTL 2.0 Facility | May 2029 | 11% | 4,953,967 | 3,843,819 | ||||||||
2030 Senior Notes | June 2030 | 10% | 2,000,000 | — | ||||||||
2024 Term Loan Facility | April 2025 | 12% | — | 1,000,000 | ||||||||
Revolving Credit Facility | June 2027 | 7% | 450,000 | — | ||||||||
OEM Financing Arrangements | March 2026 – May 2028 | 9-10% | 1,728,388 | 1,177,158 | ||||||||
Magnetar Loan | January 2029 | 12% | 256,630 | — | ||||||||
Total principal of debt | 11,171,485 | 8,033,477 | ||||||||||
Less: Unamortized discount and issuance costs | (119,984) | (107,137) | ||||||||||
Total debt, net of unamortized discount and issuance costs | 11,051,501 | 7,926,340 | ||||||||||
Less: Debt, current | (3,627,664) | (2,468,425) | ||||||||||
Total debt, non-current | $7,423,837 | $5,457,915 | ||||||||||
Years Ending December 31, | Amount | ||
Remaining portion of 2025 | $986,052 | ||
2026 | 4,218,457 | ||
2027 | 2,833,142 | ||
2028 | 1,010,054 | ||
2029 | 123,780 | ||
Thereafter | 2,000,000 | ||
Total | $11,171,485 | ||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
Contractual interest expense | $250,312 | $100,237 | $483,084 | $164,859 | ||||||||
Amortization of debt discounts and issuance costs and accretion of redemption premiums | 29,036 | 7,547 | 66,727 | 15,605 | ||||||||
Less: capitalized interest | (23,186) | (40,687) | (36,278) | (72,864) | ||||||||
Total | $256,162 | $67,097 | $513,533 | $107,600 | ||||||||
Years Ending December 31, | Financing obligation | Finance lease | ||||
Remaining portion of 2025 | $9,835 | $9,360 | ||||
2026 | 19,658 | 18,720 | ||||
2027 | 19,645 | 18,720 | ||||
2028 | 19,630 | 18,720 | ||||
2029 | 19,616 | 18,720 | ||||
Thereafter | 175,800 | 168,480 | ||||
Total future payments | 264,184 | 252,720 | ||||
Less: amount representing interest | (149,548) | (130,350) | ||||
Total | 114,636 | 122,370 | ||||
Less: current portion | (2,910) | (3,682) | ||||
Long-term portion | $111,726 | $118,688 | ||||
Shares Authorized | Shares Issued and Outstanding | Issuance Price Per Share | Carrying Value | Aggregate Liquidation Preference | |||||||||||
Series Seed | 60,000 | 45,567 | $0.05 | $2,039 | $2,039 | ||||||||||
Series A | 24,182 | 19,361 | 0.12 | 2,256 | 2,256 | ||||||||||
Series B | 79,979 | 79,979 | 5.58 | 550,595 | 446,002 | ||||||||||
Series B-1 | 12,485 | 10,205 | 0.40 | 4,091 | 4,091 | ||||||||||
Series C | 29,523 | 29,523 | 38.95 | 1,163,130 | 1,163,671 | ||||||||||
Total | 206,169 | 184,635 | $1,722,111 | $1,618,059 | |||||||||||
Stock Options Outstanding | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value | |||||||||
Balance at January 1, 2025 | 47,219 | $1.74 | 7 | $2,163,455 | ||||||||
Granted | — | — | ||||||||||
Exercised | (2,950) | 1.53 | ||||||||||
Forfeited, expired, or canceled | (164) | 6.62 | ||||||||||
Outstanding at June 30, 2025 | 44,105 | $1.74 | 7 | $7,114,827 | ||||||||
Vested and expected to vest at June 30, 2025 | 44,105 | $1.74 | 7 | $7,114,827 | ||||||||
Exercisable at June 30, 2025 | 31,596 | $1.14 | 6 | $5,116,131 | ||||||||
Shares | Weighted- Average Fair Value Per Share | |||||
Balance at January 1, 2025 | 15,455 | $38.80 | ||||
Granted | 13,188 | 62.39 | ||||
Vested | (2,599) | 33.36 | ||||
Forfeited, expired, or canceled | (367) | 36.57 | ||||
Unvested balance at June 30, 2025 | 25,677 | $51.50 | ||||
Vested and not yet settled | 9 | 45.96 | ||||
Outstanding at June 30, 2025 | 25,686 | $51.50 | ||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
Cost of revenue | $2,701 | $350 | $5,394 | $738 | ||||||||
Technology and infrastructure | 47,683 | 2,080 | 102,282 | 4,437 | ||||||||
Sales and marketing | 8,494 | 848 | 11,314 | 1,715 | ||||||||
General and administrative | 86,127 | 4,382 | 209,988 | 8,959 | ||||||||
Total stock-based compensation expense(1)(2) | $145,005 | $7,660 | $328,978 | $15,849 | ||||||||
(1) | Stock-based compensation expense was net of capitalized costs primarily related to the development of internal-use software of $12 million and $2 million during the three months ended June 30, 2025 and 2024, respectively, and $31 million and $4 million during the six months ended June 30, 2025 and 2024, respectively. |
(2) | The Company recognized no and $177 million of stock-based compensation expense, net of no and $17 million of capitalized costs primarily related to the development of internal-use software, during the three and six months ended June 30, 2025, respectively, associated with vested RSUs as a result of the satisfaction of the liquidity-event performance-based vesting condition which was satisfied in connection with the IPO. |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
Numerator: | ||||||||||||
Net loss | $(290,509) | $(323,021) | $(605,150) | $(452,269) | ||||||||
Dividends and accretion on Series C redeemable convertible preferred stock | — | (15,596) | (28,722) | (15,596) | ||||||||
Net loss attributable to common stockholders, basic | $(290,509) | $(338,617) | $(633,872) | $(467,865) | ||||||||
Change in fair value of common stock warrants | — | — | (26,845) | — | ||||||||
Net loss attributable to common stockholders, diluted | $(290,509) | $(338,617) | $(660,717) | $(467,865) | ||||||||
Denominator: | ||||||||||||
Weighted-average shares used in computing net loss attributable to common stockholders, basic | 486,591 | 209,626 | 366,765 | 209,560 | ||||||||
Effect of dilutive securities: | ||||||||||||
Common stock warrants | — | — | 1,842 | — | ||||||||
Weighted-average shares used in computing net loss attributable to common stockholders, diluted | 486,591 | 209,626 | 368,607 | 209,560 | ||||||||
Net loss per share attributable to common stockholders, basic | $(0.60) | $(1.62) | $(1.73) | $(2.23) | ||||||||
Net loss per share attributable to common stockholders, diluted | $(0.60) | $(1.62) | $(1.79) | $(2.23) | ||||||||
As of June 30, | ||||||
2025 | 2024 | |||||
Redeemable convertible preferred stock | — | 188,684 | ||||
Outstanding convertible notes | — | 24,544 | ||||
Outstanding stock options | 44,480 | 49,949 | ||||
Outstanding RSUs and RSAs | 27,146 | — | ||||
Outstanding warrants to purchase common stock | 4,337 | 4,337 | ||||
ESPP | 147 | — | ||||
Total | 76,110 | 267,514 | ||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||
United States | $1,147,655 | $370,107 | $2,077,079 | $547,071 | ||||||||
All other countries | 65,133 | 25,264 | 117,341 | 36,984 | ||||||||
Total revenue | $1,212,788 | $395,371 | $2,194,420 | $584,055 | ||||||||
December 31, 2023 | December 31, 2024 | |||||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | $217,147 | $1,361,083 | ||||
Restricted cash and cash equivalents, current | 42,940 | 37,394 | ||||
Accounts receivable, net | 165,379 | 416,526 | ||||
Prepaid expenses and other current assets | 76,526 | 101,246 | ||||
Total current assets | 501,992 | 1,916,249 | ||||
Restricted cash and cash equivalents, non-current | 219,988 | 637,356 | ||||
Restricted marketable securities, non-current | 171,734 | 29,308 | ||||
Property and equipment, net | 3,483,990 | 11,914,774 | ||||
Operating lease right-of-use assets | 461,966 | 2,589,547 | ||||
Intangible assets, net | 7,003 | 4,909 | ||||
Goodwill | 19,544 | 19,544 | ||||
Other non-current assets(a) | 110,758 | 720,912 | ||||
Total assets | $4,976,975 | $17,832,599 | ||||
Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Deficit | ||||||
Current liabilities | ||||||
Accounts payable | $455,563 | $868,259 | ||||
Accrued liabilities | 77,782 | 355,821 | ||||
Debt, current(a) | 171,865 | 2,468,425 | ||||
Deferred revenue, current | 249,831 | 768,927 | ||||
Operating lease liabilities, current | 39,789 | 213,104 | ||||
Finance lease liabilities, current | 3,534 | 57,801 | ||||
Other current liabilities(a) | 97 | 230,244 | ||||
Total current liabilities | 998,461 | 4,962,581 | ||||
Debt, non-current(a) | 1,351,389 | 5,457,915 | ||||
Derivative and warrant liabilities | 527,047 | 200,089 | ||||
Deferred revenue, non-current | 1,754,873 | 3,294,977 | ||||
Operating lease liabilities, non-current | 432,653 | 2,388,912 | ||||
Finance lease liabilities, non-current | 510 | 34,120 | ||||
Deferred tax liabilities, non-current | 36,447 | 149,232 | ||||
Other non-current liabilities | 7,496 | 36,260 | ||||
Total liabilities | 5,108,876 | 16,524,086 | ||||
Commitments and contingencies (Note 9) | ||||||
Redeemable convertible preferred stock(a) | ||||||
Redeemable convertible preferred stock, $0.000005 par value per share, 176,646 and 206,169 shares authorized as of December 31, 2023 and 2024, respectively; 154,678 and 184,635 shares issued and outstanding as of December 31, 2023 and 2024, respectively | 464,690 | 1,722,111 | ||||
Stockholders’ deficit | ||||||
Class A common stock, $0.000005 par value per share, 469,031 and 540,680 shares authorized as of December 31, 2023 and 2024, respectively; 208,003 and 121,277 shares issued as of December 31, 2023 and 2024, respectively; and 203,520 and 114,689 shares outstanding as of December 31, 2023 and 2024, respectively | 1 | 1 | ||||
Class B common stock, $0.000005 par value per share, no and 150,000 shares authorized as of December 31, 2023 and 2024, respectively; no and 118,198 shares issued and outstanding as of December 31, 2023 and 2024, respectively | — | 0 | ||||
Treasury stock, at cost, 4,483 and 6,588 shares as of December 31, 2023 and 2024, respectively | (32,054) | (33,524) | ||||
Additional paid-in capital | 48,397 | 1,096,160 | ||||
Accumulated other comprehensive loss | (148) | — | ||||
Accumulated deficit | (612,787) | (1,476,235) | ||||
Total stockholders’ deficit | (596,591) | (413,598) | ||||
Total liabilities, redeemable convertible preferred stock, and stockholders’ deficit | $4,976,975 | $17,832,599 | ||||
(a) | Refer to Note 14—Related-Party Transactions for further information on related party arrangements. |
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Revenue | $15,830 | $228,943 | $1,915,426 | ||||||
Operating expenses: | |||||||||
Cost of revenue | 12,122 | 68,780 | 493,350 | ||||||
Technology and infrastructure | 18,106 | 131,855 | 960,685 | ||||||
Sales and marketing | 2,481 | 12,917 | 18,389 | ||||||
General and administrative | 6,001 | 29,842 | 118,644 | ||||||
Total operating expenses | 38,710 | 243,394 | 1,591,068 | ||||||
Operating income (loss) | (22,880) | (14,451) | 324,358 | ||||||
Loss on fair value adjustments | (2,884) | (533,952) | (755,929) | ||||||
Interest expense, net(a) | (9,444) | (28,404) | (360,824) | ||||||
Other income, net | 192 | 18,760 | 48,194 | ||||||
Loss before provision for (benefit from) income taxes | (35,016) | (558,047) | (744,201) | ||||||
Provision for (benefit from) income taxes | (4,150) | 35,701 | 119,247 | ||||||
Net loss from continuing operations | $(30,866) | $(593,748) | $(863,448) | ||||||
Net loss from discontinued operations, net of tax | $(189) | $— | $— | ||||||
Net loss | $(31,055) | $(593,748) | $(863,448) | ||||||
Net loss attributable to common stockholders, basic and diluted | $(31,055) | $(593,748) | $(937,765) | ||||||
Net loss from continuing operations per share attributable to common stockholders, basic and diluted | $(0.17) | $(3.09) | $(4.30) | ||||||
Net loss from discontinued operations per share attributable to common stockholders, basic and diluted | $0.00 | $— | $— | ||||||
Net loss per share attributable to common stockholders, basic and diluted | $(0.17) | $(3.09) | $(4.30) | ||||||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 180,632 | 192,164 | 217,854 | ||||||
(a) | Refer to Note 14—Related-Party Transactions for further information on related party arrangements. |
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Net loss | $(31,055) | $(593,748) | $(863,448) | ||||||
Other comprehensive income (loss): | |||||||||
Unrealized (loss) gain on available-for-sale marketable securities, net | (156) | 8 | 148 | ||||||
Total comprehensive loss | $(31,211) | $(593,740) | $(863,300) | ||||||
Redeemable Convertible Preferred Stock | Common Stock | Treasury Stock | Additional paid-in capital | Accumulated other comprehensive loss | Accumulated Deficit | Total Stockholders’ Deficit | |||||||||||||||||||||
Shares | Amount | Shares | Amount | ||||||||||||||||||||||||
Balance at January 1, 2022 | 83,775 | $5,290 | 180,000 | $1 | $— | $1,001 | $— | $12,016 | $13,018 | ||||||||||||||||||
Issuance of common stock warrants in connection with debt financing | — | — | — | — | — | 6,027 | — | — | 6,027 | ||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | 1,560 | — | — | 1,560 | ||||||||||||||||||
Unrealized loss on available-for-sale marketable securities | — | — | — | — | — | — | (156) | — | (156) | ||||||||||||||||||
Net loss | — | — | — | — | — | — | — | (31,055) | (31,055) | ||||||||||||||||||
Balance, December 31, 2022 | 83,775 | $5,290 | 180,000 | $1 | $— | $8,588 | $(156) | $(19,039) | $(10,606) | ||||||||||||||||||
Conversion of convertible promissory notes to Series B-1 redeemable convertible preferred stock | 12,485 | 5,006 | — | — | — | — | — | — | — | ||||||||||||||||||
Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $0 million and Series B Tranche Liability of $10 million | 75,496 | 410,465 | — | — | — | — | — | — | — | ||||||||||||||||||
Partial settlement of Series B tranche option | — | 45,531 | — | — | — | — | — | — | — | ||||||||||||||||||
Conversion of redeemable convertible preferred stock to common stock for secondary offering | (17,078) | (1,842) | 17,078 | — | — | 1,842 | — | — | 1,842 | ||||||||||||||||||
Issuance of common stock for private placement | — | — | 4,483 | — | — | 14,837 | — | — | 14,837 | ||||||||||||||||||
Issuance of common stock for business combination | — | — | 2,105 | — | — | — | — | — | — | ||||||||||||||||||
Exercise of stock options | — | — | 4,337 | — | — | 1,669 | — | — | 1,669 | ||||||||||||||||||
Repurchase of common stock | — | — | (4,483) | — | (32,054) | — | — | — | (32,054) | ||||||||||||||||||
Issuance of common stock warrants in connection with debt financing | — | — | — | — | — | 3,959 | — | — | 3,959 | ||||||||||||||||||
Settlement of notes due from employees | — | 240 | — | — | — | 132 | — | — | 132 | ||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | 17,370 | — | — | 17,370 | ||||||||||||||||||
Other comprehensive income | — | — | — | — | — | — | 8 | — | 8 | ||||||||||||||||||
Net loss | — | — | — | — | — | — | — | (593,748) | (593,748) | ||||||||||||||||||
Balance, December 31, 2023 | 154,678 | $464,690 | 203,520 | $1 | $(32,054) | $48,397 | $(148) | $(612,787) | $(596,591) | ||||||||||||||||||
Redeemable Convertible Preferred Stock | Common Stock | Treasury Stock | Additional paid-in capital | Accumulated other comprehensive loss | Accumulated Deficit | Total Stockholders’ Deficit | |||||||||||||||||||||
Shares | Amount | Shares | Amount | ||||||||||||||||||||||||
Issuance of Series B redeemable convertible preferred stock | 4,483 | 25,000 | — | — | — | — | — | — | — | ||||||||||||||||||
Closing settlement of Series B tranche option | — | 69,598 | — | — | — | — | — | — | — | ||||||||||||||||||
Issuance of Series C redeemable convertible preferred stock, net of issuance costs of $3 million | 29,523 | 1,147,476 | — | — | — | — | — | — | — | ||||||||||||||||||
Series C redeemable convertible preferred stock accretion to redemption value | — | 73 | — | — | — | (73) | — | — | (73) | ||||||||||||||||||
Cash dividend on Series C redeemable convertible preferred stock | — | — | — | — | — | (58,662) | — | — | (58,662) | ||||||||||||||||||
Paid-in-kind dividend on Series C redeemable convertible preferred stock | — | 15,582 | — | — | — | (15,582) | — | — | (15,582) | ||||||||||||||||||
Conversion of convertible notes to common stock | — | — | 24,544 | — | — | 1,080,295 | — | — | 1,080,295 | ||||||||||||||||||
Exercise of stock options | — | — | 2,879 | — | — | 2,890 | — | — | 2,890 | ||||||||||||||||||
Repurchase of common stock for business combination | — | — | (2,105) | — | — | — | — | — | — | ||||||||||||||||||
Repurchases of common stock from an employee | — | — | — | — | (1,470) | — | — | — | (1,470) | ||||||||||||||||||
Conversion of redeemable convertible preferred stock to common stock for secondary offering | (4,049) | (308) | 4,049 | — | — | 308 | — | — | 308 | ||||||||||||||||||
Stock-based compensation expense | — | — | — | — | — | 38,587 | — | — | 38,587 | ||||||||||||||||||
Other comprehensive income | — | — | — | — | — | — | 148 | — | 148 | ||||||||||||||||||
Net loss | — | — | — | — | — | — | — | (863,448) | (863,448) | ||||||||||||||||||
Balance, December 31, 2024 | 184,635 | $1,722,111 | 232,887 | $1 | $(33,524) | $1,096,160 | $— | $(1,476,235) | $(413,598) | ||||||||||||||||||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Cash flows from operating activities: | |||||||||
Net loss | $(31,055) | $(593,748) | $(863,448) | ||||||
Net loss from discontinued operations, net of tax | (189) | — | — | ||||||
Net loss from continuing operations | (30,866) | (593,748) | (863,448) | ||||||
Adjustments to reconcile net loss to net cash provided by operating activities | |||||||||
Depreciation and amortization | 11,695 | 103,210 | 863,413 | ||||||
Non-cash lease expense | 16 | 20,404 | 122,748 | ||||||
Amortization of debt discounts and issuance costs | 3,803 | 16,533 | 33,376 | ||||||
Loss on fair value adjustments | 2,884 | 533,952 | 755,929 | ||||||
Stock-based compensation | 1,490 | 15,154 | 31,487 | ||||||
Debt extinguishment loss | — | — | 11,708 | ||||||
Deferred income taxes | (1,284) | 35,816 | 112,785 | ||||||
Other non-cash reconciling items | — | 632 | 3,286 | ||||||
Changes in operating assets and liabilities, net of effect of business acquisition: | |||||||||
Accounts receivable | (1,893) | (162,413) | (279,720) | ||||||
Prepaid expenses and other current assets | (1,047) | (71,964) | (29,200) | ||||||
Accounts payable and accrued expenses | 1,404 | 26,807 | 510,568 | ||||||
Deferred revenue | 9,354 | 1,986,304 | 2,049,068 | ||||||
Lease liabilities | — | (9,302) | (87,611) | ||||||
Other non-current assets | 87 | (67,317) | (485,332) | ||||||
Other liabilities | — | (1,418) | 111 | ||||||
Net cash (used in) provided by continuing operations | (4,357) | 1,832,650 | 2,749,168 | ||||||
Net cash provided by operating activities—discontinued operations | 5,267 | — | — | ||||||
Net cash provided by operating activities | $910 | $1,832,650 | $2,749,168 | ||||||
Cash flows from investing activities: | |||||||||
Purchase of property and equipment, including capitalized internal-use software | (72,404) | (2,943,130) | (8,702,078) | ||||||
Sale of available-for-sale marketable securities | 7,000 | 5,689 | 2,470 | ||||||
Maturities of marketable securities | — | — | 185,218 | ||||||
Purchase of restricted marketable securities | — | (171,734) | (34,053) | ||||||
Purchase of strategic investments | — | (33,000) | (50,000) | ||||||
Issuance of notes receivable | — | — | (59,615) | ||||||
Other investing activities | (14,852) | (5,535) | — | ||||||
Net cash used in investing activities by continuing operations | (80,256) | (3,147,710) | (8,658,058) | ||||||
Net cash provided by investing activities—discontinued operations | 1,073 | — | — | ||||||
Net cash used in investing activities | $(79,183) | $(3,147,710) | $(8,658,058) | ||||||
Cash flows from financing activities: | |||||||||
Proceeds from issuance of debt | 60,000 | 1,415,862 | 7,022,291 | ||||||
Proceeds from issuance of convertible debt | 30,000 | — | — | ||||||
Repayments of debt | (3,055) | (2,180) | (588,555) | ||||||
Payment of debt issuance costs | (1,651) | (12,053) | (3,786) | ||||||
Issuance of redeemable convertible preferred stock, net of issuance costs | — | 420,765 | 1,172,476 | ||||||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Redeemable convertible preferred stock cash dividends paid | — | — | (57,745) | ||||||
Proceeds from exercise of stock options | — | 1,669 | 2,890 | ||||||
Common stock repurchased | — | (32,054) | (1,470) | ||||||
Proceeds from issuance of common stock | — | 14,837 | — | ||||||
Other financing activities | (3,840) | (19,095) | (81,453) | ||||||
Net cash provided by financing activities | $81,454 | $1,787,751 | $7,464,648 | ||||||
Net increase in cash, cash equivalents, and restricted cash | $3,181 | $472,691 | $1,555,758 | ||||||
Cash, cash equivalents, and restricted cash—beginning of period | 4,203 | 7,384 | 480,075 | ||||||
Cash, cash equivalents, and restricted cash—end of period | $7,384 | $480,075 | $2,035,833 | ||||||
Supplemental disclosures of cash flow information: | |||||||||
Cash paid for interest, net of capitalized amounts | $5,124 | $105 | $183,657 | ||||||
Cash paid for income taxes | $255 | $214 | $14,332 | ||||||
Non-cash investing and financing activities: | |||||||||
Capitalized interest | $— | $41,376 | $31,714 | ||||||
Operating lease right-of-use assets acquired through lease liability | 1,210 | 481,145 | 2,222,257 | ||||||
Right-of-use assets for lease modification and renewals | — | — | 18,987 | ||||||
Finance lease right-of-use assets acquired through lease liability | 14,622 | — | 141,916 | ||||||
Derivative liabilities from issuance of convertible notes | 10,841 | — | — | ||||||
Accounts payable and accrued expenses related to property and equipment additions | — | 482,330 | 892,632 | ||||||
Issuance of common stock in connection with conversion of convertible notes | — | — | 1,080,295 | ||||||
Settlement of Series B tranche liability | — | 45,531 | 69,598 | ||||||
Non-cash investments | — | — | 10,133 | ||||||
Stock-based compensation capitalized as internal-use software | — | 2,216 | 7,100 | ||||||
Deferred offering costs not yet paid | — | — | 7,951 | ||||||
Reconciliation of cash, cash equivalents, and restricted cash to consolidated balance sheets: | |||||||||
Cash and cash equivalents | $7,384 | $217,147 | $1,361,083 | ||||||
Restricted cash and cash equivalents, current | — | 42,940 | 37,394 | ||||||
Restricted cash and cash equivalents, non-current | — | 219,988 | 637,356 | ||||||
Total cash, cash equivalents, and restricted cash | $7,384 | $480,075 | $2,035,833 | ||||||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Customer A | * | 35% | 62% | ||||||
Customer B | * | 21% | * | ||||||
Customer C | * | 17% | 15% | ||||||
Customer D | 16% | * | * | ||||||
Customer E | 13% | * | * | ||||||
Customer F | 12% | * | * | ||||||
Customer G | * | * | * | ||||||
* | Customer did not represent 10% or more of revenue |
Technology equipment | 6 years | ||
Software | 3-6 years | ||
Data center equipment | 8-12 years | ||
Furniture, fixtures, and other assets | 3-5 years | ||
Leasehold improvements | Shorter of remaining lease term or estimated useful life | ||
Acquired technologies | 3 years | ||
Customer relationships | 13 years | ||
Trade names | 5 years | ||
1. | Identification of the contract, or contracts, with the customer |
2. | Identification of the performance obligations in the contract |
3. | Determination of the transaction price |
4. | Allocation of the transaction price to the performance obligations in the contract |
5. | Recognition of the revenue when, or as, a performance obligation is satisfied |
Fair Value Hierarchy | December 31, 2023 | December 31, 2024 | |||||||
Financial assets: | |||||||||
Cash and cash equivalents | |||||||||
Money market funds | Level 1 | $87,258 | $2,411 | ||||||
Restricted cash and cash equivalents, current | |||||||||
Money market funds | Level 1 | 42,940 | 24,185 | ||||||
Prepaid expenses and other current assets | |||||||||
Available-for-sale marketable securities | Level 2 | 2,368 | — | ||||||
Restricted cash and cash equivalents, non-current | |||||||||
Money market funds | Level 1 | 206,846 | 56,250 | ||||||
Restricted marketable securities, non-current | |||||||||
Certificates of deposit | Level 2 | 171,734 | 29,308 | ||||||
Other non-current assets | |||||||||
Power purchase agreements | Level 3 | 1,459 | 2,562 | ||||||
Total financial assets | $512,605 | $114,716 | |||||||
Financial liabilities: | |||||||||
Derivative and warrant liabilities | |||||||||
Bifurcated embedded derivative liabilities | Level 3 | $386,469 | $— | ||||||
Warrant liabilities | Level 3 | 70,930 | 199,645 | ||||||
Series B tranche liability | Level 3 | 69,648 | — | ||||||
Power purchase agreements | Level 3 | — | 444 | ||||||
Total financial liabilities | $527,047 | $200,089 | |||||||
December 31, 2023 | ||||||||||||
Adjusted Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||
Financial assets: | ||||||||||||
Cash and cash equivalents | ||||||||||||
Money market funds | $87,258 | $— | $— | $87,258 | ||||||||
Restricted cash and cash equivalents, current | ||||||||||||
Money market funds | 42,940 | — | — | 42,940 | ||||||||
Prepaid expenses and other current assets | ||||||||||||
Available-for-sale marketable securities | 2,354 | 14 | — | 2,368 | ||||||||
Restricted cash and cash equivalents, non-current | ||||||||||||
Money market funds | 206,846 | — | — | 206,846 | ||||||||
Restricted marketable securities, non-current | ||||||||||||
Certificates of deposit | 171,734 | — | — | 171,734 | ||||||||
Total | $511,132 | $14 | $— | $511,146 | ||||||||
December 31, 2024 | ||||||||||||
Adjusted Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||
Financial assets: | ||||||||||||
Cash and cash equivalents | ||||||||||||
Money market funds | $2,411 | $— | $— | $2,411 | ||||||||
Restricted cash and cash equivalents, current | ||||||||||||
Money market funds | 24,185 | — | — | 24,185 | ||||||||
Restricted cash and cash equivalents, non-current | ||||||||||||
Money market funds | 56,250 | — | — | 56,250 | ||||||||
Restricted marketable securities, non-current | ||||||||||||
Certificates of deposit | 29,308 | — | — | 29,308 | ||||||||
Total | $112,154 | $— | $— | $112,154 | ||||||||
December 31, 2023 | December 31, 2024 | |||||
Stock price | $18 | $48 | ||||
Volatility | 55% | 60% | ||||
Risk-free rate | 4% | 4% | ||||
Dividend yield | 0% | 0% | ||||
December 31, 2023 | |||
Stock price | $18 | ||
Volatility | 40% | ||
Risk-free rate | 4% | ||
Lattice or Monte Carlo model projection period (years) | 2 | ||
September 17, 2024 | |||
Stock price | $44 | ||
Discount rate | 12% | ||
December 31, 2023 | |||
Series B stock price | $21 | ||
Volatility | 21% | ||
Risk-free rate | 5% | ||
Power Purchase Agreements – Asset | Warrant Liabilities | Bifurcated Embedded Derivative Liabilities | Power Purchase Agreements – Liability | Series B Tranche Liability | |||||||||||
Balance at January 1, 2023 | $— | $3,887 | $4,901 | $— | $— | ||||||||||
Additions | 1,040 | 1,716 | 20,829 | — | 10,300 | ||||||||||
Adjustment to fair value | 419 | 68,334 | 360,739 | — | 104,879 | ||||||||||
Settlements | — | (3,007) | — | — | (45,531) | ||||||||||
Balance at December 31, 2023 | 1,459 | 70,930 | 386,469 | — | 69,648 | ||||||||||
Additions | — | — | — | 770 | — | ||||||||||
Adjustment to fair value | 1,103 | 128,715 | 627,263 | (326) | (49) | ||||||||||
Settlements | — | — | (1,013,732) | — | (69,599) | ||||||||||
Balance at December 31, 2024 | $2,562 | $199,645 | $— | $444 | $— | ||||||||||
December 31, 2023 | |||
Due in one year or less | $— | ||
Due over one year | 2,368 | ||
Total available-for-sale marketable securities | $2,368 | ||
Amount | |||
Identifiable assets | $8,802 | ||
Total liabilities assumed | (1,023) | ||
Net assets acquired | 7,779 | ||
Goodwill recognized | 19,447 | ||
Total purchase price | $27,226 | ||
December 31, 2023 | December 31, 2024 | |||||
Technology equipment | $1,298,127 | $9,146,575 | ||||
Software | 14,937 | 139,508 | ||||
Data center equipment and leasehold improvements | 29,332 | 384,372 | ||||
Furniture, fixtures, and other assets | 1,717 | 8,684 | ||||
Construction in progress | 2,256,673 | 3,200,866 | ||||
Total property and equipment | 3,600,786 | 12,880,005 | ||||
Less: accumulated depreciation and amortization | (116,796) | (965,231) | ||||
Total property and equipment, net | $3,483,990 | $11,914,774 | ||||
December 31, 2023 | December 31, 2024 | |||||
Beginning balance | $— | $7,496 | ||||
Additions | 7,254 | 26,293 | ||||
Accretion expense | 242 | 2,364 | ||||
Ending balance | $7,496 | $36,153 | ||||
Amount | |||
Balance at January 1, 2023 | $97 | ||
Addition from the acquisition of Conductor | 19,447 | ||
Balance at December 31, 2023 and 2024 | $19,544 | ||
December 31, 2023 | December 31, 2024 | |||||||||||||||||
Acquired Intangibles, Gross | Accumulated Amortization | Acquired Intangibles, Net | Acquired Intangibles, Gross | Accumulated Amortization | Acquired Intangibles, Net | |||||||||||||
Acquired technologies | $5,453 | $(1,600) | $3,853 | $5,453 | $(3,611) | $1,842 | ||||||||||||
Other(1) | 3,897 | (747) | 3,150 | 3,897 | (830) | 3,067 | ||||||||||||
Total | $9,350 | $(2,347) | $7,003 | $9,350 | $(4,441) | $4,909 | ||||||||||||
(1) | Included in Other are customer relationships and trade names. |
Years Ending December 31, | Amount | ||
2025 | $2,058 | ||
2026 | 441 | ||
2027 | 427 | ||
2028 | 261 | ||
2029 | 246 | ||
Thereafter | 1,476 | ||
Total expected future amortization expense | $4,909 | ||
December 31, 2023 | December 31, 2024 | |||||
Prepaid expenses | $54,338 | $67,393 | ||||
Tax receivables | 17,647 | 9,145 | ||||
Available-for-sale marketable securities | 2,368 | — | ||||
Other current assets | 2,173 | 24,708 | ||||
Total prepaid expenses and other current assets | $76,526 | $101,246 | ||||
December 31, 2023 | December 31, 2024 | |||||
Escrow funds | $— | $336,055 | ||||
Prepaid expenses | 51,193 | 145,424 | ||||
Notes receivable | — | 107,597 | ||||
Strategic investments | 42,087 | 102,220 | ||||
Other non-current assets | 17,478 | 29,616 | ||||
Total other non-current assets | $110,758 | $720,912 | ||||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Operating lease cost: | |||||||||
Operating lease cost | $236 | $41,515 | $288,628 | ||||||
Finance lease cost: | |||||||||
Amortization of ROU assets | $1,904 | $3,050 | $18,565 | ||||||
Interest on lease liabilities | 903 | 868 | 8,709 | ||||||
Total finance lease cost | $2,807 | $3,918 | $27,274 | ||||||
Variable lease cost | $370 | $16,028 | $54,633 | ||||||
Total lease cost | $3,413 | $61,461 | $370,535 | ||||||
December 31, 2023 | December 31, 2024 | |||||
Operating leases: | ||||||
Operating lease ROU assets | $461,966 | $2,589,547 | ||||
Operating lease liabilities, current | $39,789 | $213,104 | ||||
Operating lease liabilities, non-current | 432,653 | 2,388,912 | ||||
Total operating lease liabilities | $472,442 | $2,602,016 | ||||
Finance leases: | ||||||
Property and equipment | $15,250 | $157,146 | ||||
Less: amortization | (4,954) | (23,544) | ||||
Property and equipment, net | $10,296 | $133,602 | ||||
December 31, 2023 | December 31, 2024 | |||||
Finance lease liabilities, current | $3,534 | $57,801 | ||||
Finance lease liabilities, non-current | 510 | 34,120 | ||||
Total finance lease liabilities | $4,044 | $91,921 | ||||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Cash paid for amounts included in the measurement of lease liabilities: | |||||||||
Operating cash flows from operating leases | $456 | $30,381 | $253,285 | ||||||
Operating cash flows from finance leases | 903 | 868 | 8,709 | ||||||
Financing cash flows from finance leases | 3,840 | 7,606 | 54,052 | ||||||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Weighted-average remaining lease term (in years): | |||||||||
Operating leases | 6 | 8 | 9 | ||||||
Finance leases | 2 | 1 | 2 | ||||||
Weighted-average discount rate: | |||||||||
Operating leases | 12% | 12% | 12% | ||||||
Finance leases | 11% | 11% | 11% | ||||||
Future Payments | ||||||
Years Ending December 31, | Operating Leases | Finance Leases | ||||
2025 | $507,855 | $64,267 | ||||
2026 | 525,805 | 35,000 | ||||
2027 | 538,988 | — | ||||
2028 | 544,028 | — | ||||
2029 | 475,670 | — | ||||
Thereafter | 1,775,509 | — | ||||
Total undiscounted lease payments | 4,367,855 | 99,267 | ||||
Less: imputed interest | (1,765,839) | (7,346) | ||||
Present value of lease liabilities | $2,602,016 | $91,921 | ||||
Maturities | Effective Interest Rates | December 31, 2023 | December 31, 2024 | |||||||||
2021 Convertible Senior Secured Notes | October 2025 | 17% | $55,125 | $— | ||||||||
2022 Senior Secured Notes | October 2025 – April 2026 | 10% | 125,000 | — | ||||||||
Delayed Draw Term Loan Facility 1.0 | March 2028 | 15% | 1,374,924 | 2,012,500 | ||||||||
Delayed Draw Term Loan Facility 2.0 | May 2029 | 11% | — | 3,843,819 | ||||||||
2024 Term Loan Facility | December 2025 | 12% | — | 1,000,000 | ||||||||
Original Equipment Manufacturer financing arrangements | February 2026 – October 2027 | 9% – 11% | — | 1,177,158 | ||||||||
Total principal of debt | 1,555,049 | 8,033,477 | ||||||||||
Less: Unamortized discount and issuance costs | (31,795) | (107,137) | ||||||||||
Total debt, net of unamortized discount and issuance costs | 1,523,254 | 7,926,340 | ||||||||||
Less: Debt, current | (171,865) | (2,468,425) | ||||||||||
Total debt, non-current | $1,351,389 | $5,457,915 | ||||||||||
Years Ending December 31, | Amount | ||
2025 | $2,483,202 | ||
2026 | 3,102,384 | ||
2027 | 1,771,071 | ||
2028 | 548,093 | ||
2029 | 128,727 | ||
Total | $8,033,477 | ||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Contractual interest expense | $4,914 | $30,189 | $474,844 | ||||||
Amortization of debt discounts and issuance costs and accretion of redemption premiums | 3,803 | 16,533 | 33,376 | ||||||
PIK interest | — | 21,621 | — | ||||||
Less: capitalized interest | (343) | (41,376) | (159,017) | ||||||
Total | $8,374 | $26,967 | $349,203 | ||||||
• | Redemption—From the third anniversary until a QPCE, the Company has the right, at its option, to redeem up to a principal amount of $15 million at a redemption price equal to principal amount plus accrued and unpaid interest plus a premium amount such that the holders of such principal amount of debt realize an IRR of 20.00% with respect to such redeemed amounts. |
• | Conversion—Holders of the 2021 Convertible Senior Secured Notes have the right, at their option, to convert all or any portion of their notes into a number of shares of common stock at any time based on the outstanding principal and accrued interest divided by the conversion price in effect. The conversion price in effect shall be calculated as follows: |
• | Initially, the conversion price is equal to $675 million (the “Maximum Conversion Valuation”) divided by the fully diluted shares of common stock outstanding, which was $2.20 per share. |
• | If a qualified financing occurs prior to a QPCE, the Maximum Conversion Valuation will be reduced, but not increased, to the enterprise value derived from the qualified financing on a fully diluted basis. |
• | Upon the occurrence of a QPCE, the conversion price will be reduced, but not increased, to 75% of either the price per share offered to the public in an IPO, 75% of the stock price after the closing of a direct listing, or 75% of the stock valuation derived from a SPAC transaction. |
• | No premium if redeemed prior to April 17, 2024, or on or after October 2, 2025 (with respect to the notes issued in the First Closing, Second Closing and Third Closing) or prior to October 20, 2024, or on or after April 7, 2026 (with respect to the notes issued in the Fourth Closing). |
• | 10.00% premium if redeemed on or after April 17, 2024, but before July 17, 2024 (with respect to the notes issued in the First Closing, Second Closing and Third Closing) or on or after October 20, 2024, but before January 20, 2025 (with respect to the notes issued in the Fourth Closing). |
• | 8.50% premium if redeemed on or after July 17, 2024, but before October 17, 2024 (with respect to the notes issued in the First Closing, Second Closing and Third Closing) on or after January 20, 2025, but before April 20, 2025 (with respect to the notes issued in the Fourth Closing). |
• | 7.00% premium if redeemed on or after October 17, 2024, but before January 17, 2025 (with respect to the notes issued in the First Closing, Second Closing and Third Closing) or on or after April 20, 2025, but before July 20, 2025 (with respect to the notes issued in the Fourth Closing). |
• | 5.50% premium if redeemed on or after January 17, 2025, but before April 17, 2025 (with respect to the notes issued in the First Closing, Second Closing and Third Closing) or on or after July 20, 2025, but before October 20, 2025 (with respect to the notes issued in the Fourth Closing). |
• | 4.00% premium if redeemed on or after April 17, 2025, but before July 17, 2025 (with respect to the notes issued in the First Closing, Second Closing and Third Closing) or on or after October 20, 2025, but before January 20, 2026 (with respect to the notes issued in the Fourth Closing). |
• | 2.50% premium if redeemed on or after April 17, 2025, but before October 2, 2025 (with respect to the notes issued in the First Closing, Second Closing and Third Closing) on or after to January 20, 2026, but before April 7, 2026 (with respect to the notes issued in the Fourth Closing). |
• | First Closing: Penny warrants for 1,873,735 shares and regular warrants for 1,040,956 shares. |
• | Second Closing: Penny warrants for 1,873,735 shares and regular warrants for 1,040,956 shares. |
• | Third Closing: Penny warrants for 2,498,356 shares and regular warrants for 1,388,000 shares. |
• | Fourth Closing: Penny warrants for 1,561,456 shares and regular warrants for 867,474 shares. |
a) | if, prior to an IPO or SPAC Transaction, the Company completes a qualified equity financing, the purchase price or deemed purchase price per share of common stock in the qualified equity financing; or |
b) | the purchase price determined based on a valuation of the Company of: |
(i) | $1,500,000,000, if the principal amount of the 2022 Senior Secured Notes is repaid in full within one hundred twenty (120) days after the original issue date; |
(ii) | $1,300,000,000, if the principal amount of the 2022 Senior Secured Notes is repaid in full within one hundred twenty-one (121) to two hundred forty (240) days after the original issue date; |
(iii) | $1,100,000,000, if the principal amount of the 2022 Senior Secured Notes is repaid in full within two hundred forty-one (241) to three hundred sixty (360) days after the original issue date; or |
(iv) | $1,000,000,000, if the principal amount of the 2022 Senior Secured Notes is repaid in full three hundred sixty-one (361) or more days after the original issue date. |
Years Ending December 31, | Contractual Principal Payments | ||
2025 | $19,672 | ||
2026 | 19,658 | ||
2027 | 19,645 | ||
2028 | 19,630 | ||
2029 | 19,616 | ||
Thereafter | 175,800 | ||
Total future payments | 274,021 | ||
Less: amount representing interest | (158,081) | ||
Total financing obligation | $115,940 | ||
Less: current portion | (2,087) | ||
Long-term portion | $113,853 | ||
Shares Authorized | Shares Issued and Outstanding | Issuance Price Per Share | Carrying Value | Aggregate Liquidation Preference | |||||||||||
Series Seed | 60,000 | 48,896 | $0.05 | $2,205 | $2,205 | ||||||||||
Series A | 24,182 | 19,879 | 0.12 | 2,316 | 2,316 | ||||||||||
Series B | 79,979 | 75,496 | 5.58 | 455,996 | 421,001 | ||||||||||
Series B-1 | 12,485 | 10,407 | 0.40 | 4,173 | 4,173 | ||||||||||
Total | 176,646 | 154,678 | $464,690 | $429,695 | |||||||||||
Shares Authorized | Shares Issued and Outstanding | Issuance Price Per Share | Carrying Value | Aggregate Liquidation Preference | |||||||||||
Series Seed | 60,000 | 45,567 | $0.05 | $2,039 | $2,039 | ||||||||||
Series A | 24,182 | 19,361 | 0.12 | 2,256 | 2,256 | ||||||||||
Series B | 79,979 | 79,979 | 5.58 | 550,595 | 446,002 | ||||||||||
Series B-1 | 12,484 | 10,205 | 0.40 | 4,091 | 4,091 | ||||||||||
Series C | 29,523 | 29,523 | 38.95 | 1,163,130 | 1,163,671 | ||||||||||
Total | 206,169 | 184,635 | $1,722,111 | $1,618,059 | |||||||||||
Stock Options Outstanding | Weighted-Average Exercise Price | Weighted-Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value | |||||||||
Balance at January 1, 2023 | 32,655 | $0.33 | 8 | $20,770 | ||||||||
Granted | 23,300 | 3.48 | ||||||||||
Exercised | (4,337) | 0.38 | ||||||||||
Forfeited, expired, or canceled | (379) | 1.70 | ||||||||||
Outstanding at December 31, 2023 | 51,239 | $1.75 | 8 | $795,013 | ||||||||
Granted | — | — | ||||||||||
Exercised | (2,872) | 1.01 | ||||||||||
Forfeited, expired, or canceled | (1,148) | 4.05 | ||||||||||
Outstanding at December 31, 2024 | 47,219 | $1.74 | 7 | $2,163,455 | ||||||||
Vested and expected to vest at December 31, 2023 | 51,239 | $1.75 | 8 | $795,013 | ||||||||
Vested and expected to vest at December 31, 2024 | 47,219 | $1.74 | 7 | $2,163,455 | ||||||||
Exercisable at December 31, 2023 | 24,356 | $0.37 | 6 | $411,567 | ||||||||
Exercisable at December 31, 2024 | 31,019 | $0.98 | 6 | $1,444,794 | ||||||||
Year Ended December 31, 2022 | Year Ended December 31, 2023 | |||||
Fair value of common stock | $0.55 - 0.99 | $1.86 - 17.27 | ||||
Expected volatility | 97% | 58% | ||||
Expected term (in years) | 6 | 6 | ||||
Risk-free interest rate | 4% | 4% | ||||
Expected dividend yield | 0% | 0% | ||||
Shares | Weighted- Average Fair Value Per Share | |||||
Balance at January 1, 2024 | — | $— | ||||
Granted | 15,733 | 38.56 | ||||
Vested | — | — | ||||
Forfeited, expired, or canceled | (278) | 25.18 | ||||
Unvested balance at December 31, 2024 | 15,455 | $38.80 | ||||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Cost of revenue | $133 | $694 | $1,307 | ||||||
Technology and infrastructure | 624 | 7,100 | 10,137 | ||||||
Sales and marketing | 74 | 1,740 | 3,408 | ||||||
General and administrative | 659 | 5,620 | 16,635 | ||||||
Total stock-based compensation expense | $1,490 | $15,154 | $31,487 | ||||||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Domestic | $(35,016) | $(558,047) | $(743,667) | ||||||
Foreign | — | — | (534) | ||||||
Net loss before the provision for (benefit from) income taxes | $(35,016) | $(558,047) | $(744,201) | ||||||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Current: | |||||||||
Federal | $(1,664) | $— | $— | ||||||
State | (226) | — | 6,306 | ||||||
Foreign | — | — | 155 | ||||||
Total current income tax expense (benefit) | (1,890) | — | 6,461 | ||||||
Deferred: | |||||||||
Federal | (1,697) | 35,765 | 109,010 | ||||||
State | (563) | (64) | 3,196 | ||||||
Foreign | — | — | 580 | ||||||
Total deferred income tax expense (benefit) | (2,260) | 35,701 | 112,786 | ||||||
Total provision for (benefit from) income taxes | $(4,150) | $35,701 | $119,247 | ||||||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
U.S. federal tax benefit at statutory rate | 21.0% | 21.0% | 21.0% | ||||||
State income taxes, net of federal benefit | 4.1 | 0.1 | 0.1 | ||||||
Stock-based compensation | (0.4) | 0.5 | 1.9 | ||||||
Foreign tax rate differential | — | — | (0.1) | ||||||
Convertible interest | (0.7) | (0.2) | (0.2) | ||||||
Change in valuation allowance, net | (9.5) | (7.7) | (17.5) | ||||||
Derivative liabilities | (3.0) | (20.2) | (21.4) | ||||||
General business credit - federal | 0.1 | 0.2 | 0.3 | ||||||
Other | 0.3 | (0.1) | (0.2) | ||||||
Effective tax rate | 11.9% | (6.4)% | (16.1)% | ||||||
December 31, 2023 | December 31, 2024 | |||||
Deferred tax assets: | ||||||
Net operating losses | $200,057 | $766,434 | ||||
Lease liabilities | 112,634 | 540,405 | ||||
Capitalized research and development expenditures | 13,637 | 24,498 | ||||
Deferred revenue | 1,054 | 309,264 | ||||
December 31, 2023 | December 31, 2024 | |||||
Accrued liabilities and reserves | — | 2,811 | ||||
Interest expense carryforward | — | 61,443 | ||||
Research and development credits, net of reserve | 1,252 | 3,244 | ||||
Stock-based compensation | 2,135 | 7,593 | ||||
Other | 650 | 2,907 | ||||
Total deferred tax assets | 331,419 | 1,718,599 | ||||
Valuation allowance | (47,717) | (180,529) | ||||
Deferred tax assets, net of valuation allowance | 283,702 | 1,538,070 | ||||
Deferred tax liabilities: | ||||||
Property and equipment | (207,054) | (1,147,258) | ||||
Intangible assets | (1,446) | (969) | ||||
Operating and financing ROU assets | (111,649) | (539,075) | ||||
Total deferred tax liabilities | (320,149) | (1,687,302) | ||||
Net deferred tax liabilities, net of valuation allowance | $(36,447) | $(149,232) | ||||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Numerator: | |||||||||
Net loss from continuing operations | $(30,866) | $(593,748) | $(863,448) | ||||||
Net loss from discontinued operations | (189) | — | — | ||||||
Net loss | (31,055) | (593,748) | (863,448) | ||||||
Dividends and accretion on Series C redeemable convertible preferred stock | — | — | (74,317) | ||||||
Net loss attributable to common stockholders, basic and diluted | $(31,055) | $(593,748) | $(937,765) | ||||||
Denominator: | |||||||||
Weighted-average shares used in computing net loss attributable to common stockholders, basic and diluted | 180,632 | 192,164 | 217,854 | ||||||
Net loss from continuing operations per share attributable to common stockholders, basic and diluted | $(0.17) | $(3.09) | $(4.30) | ||||||
Net loss from discontinued operations per share attributable to common stockholders, basic and diluted | 0.00 | — | — | ||||||
Net loss per share attributable to common stockholders, basic and diluted | $(0.17) | $(3.09) | $(4.30) | ||||||
Year Ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
Redeemable convertible preferred stock | 83,775 | 154,678 | 184,986 | ||||||
Outstanding convertible notes | 22,773 | 24,544 | — | ||||||
Outstanding stock options | 32,655 | 51,239 | 47,219 | ||||||
Outstanding warrants to purchase common stock | 2,082 | 4,337 | 4,337 | ||||||
Total | 141,285 | 234,798 | 236,542 | ||||||
Year ended December 31, | |||||||||
2022 | 2023 | 2024 | |||||||
United States | $10,367 | $200,469 | $1,797,268 | ||||||
All other countries* | 5,463 | 28,474 | 118,158 | ||||||
Total revenue | $15,830 | $228,943 | $1,915,426 | ||||||
* | The United Kingdom accounted for 18% of total revenue for the year ended December 31, 2022 and less than 10% of revenue for the years ended December 31, 2023 and 2024. |
Year ended December 31, 2022 | |||
Blockchain and management services revenue | $9,692 | ||
Operating expenses | |||
Cost of revenue | 3,138 | ||
Equipment disposal gain | (99) | ||
Operating income | 6,653 | ||
Fair value adjustments of trading securities | (2,088) | ||
Assets impairment loss | (4,510) | ||
Other (income) expense, net | (300) | ||
Loss from discontinued operations before income tax | (245) | ||
Income tax benefit | (56) | ||
Net loss from discontinued operations, net of tax | $(189) | ||
Year ended December 31, 2022 | |||
Operating activities | |||
Net loss | $(189) | ||
Adjustments to reconcile net (loss) income to net cash from operating activities | |||
Depreciation | 1,428 | ||
Noncash lease expense | 6 | ||
Assets impairment | 4,510 | ||
Equipment disposal gain | (99) | ||
Fair value adjustments of trading securities | 2,088 | ||
Realized loss on trading securities | 300 | ||
Increase in digital currency from mining and management services | (9,692) | ||
Changes in operating assets and liabilities: | |||
Prepaid and other current assets | 115 | ||
Proceeds from sale of digital currency | 9,692 | ||
Net cash provided by discontinued operating activities | $8,159 | ||
Investing activities | |||
Proceeds from sales of trading securities | 866 | ||
Proceeds from sale of property and equipment | 207 | ||
Cash flows provided by investing activities of discontinued operations | $1,073 | ||
ITEM 20. | INDEMNIFICATION OF DIRECTORS AND OFFICERS |
• | any breach of the directors’ or officers’ duty of loyalty to CoreWeave or its stockholders; |
• | acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; |
• | under Section 174 of the DGCL (regarding unlawful dividends and stock purchases); |
• | any transaction from which the director or officer derived an improper personal benefit; and |
• | with respect to officers, any action by or in the right of the corporation. |
• | As permitted by the DGCL, CoreWeave’s bylaws provide that: |
• | CoreWeave is required to indemnify its directors and executive officers to the fullest extent permitted by the DGCL, subject to very limited exceptions; |
• | CoreWeave may indemnify its other employees and agents as set forth in the DGCL; |
• | CoreWeave is required to advance expenses, as incurred, to its directors and executive officers in connection with a legal proceeding to the fullest extent permitted by the DGCL, subject to very limited exceptions; and |
• | the rights conferred in the amended and restated bylaws are not exclusive. |
ITEM 21. | EXHIBITS AND FINANCIAL STATEMENT SCHEDULES |
(a) | The following exhibits are filed herewith or incorporated herein by reference: |
Exhibit Number | Description | ||
Agreement and Plan of Merger, dated as of July 7, 2025, among CoreWeave, Inc., Miami Merger Sub I, Inc. and Core Scientific, Inc. (included as Annex A to the proxy statement/prospectus that forms a part of this Registration Statement). | |||
Amended and Restated Certificate of Incorporation of CoreWeave, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Form S-8 filed with the SEC on April 18, 2025) | |||
Amended and Restated Bylaws of CoreWeave, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Form S-8 filed with the SEC on April 18, 2025) | |||
Form of Class A Common Stock certificate of CoreWeave, Inc. (incorporated by reference to Exhibit 4.1 to the Company’s Form S-1/A filed with the SEC on March 20, 2025) | |||
Third Amended and Restated Investors’ Rights Agreement between CoreWeave, Inc. and certain holders of its capital stock, dated May 16, 2024 (incorporated by reference to Exhibit 4.2 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Form of Regular Warrant between CoreWeave, Inc. and funds or accounts managed or advised by Magnetar (incorporated by reference to Exhibit 4.3 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Form of Penny Warrant between CoreWeave, Inc. and funds or accounts managed or advised by Magnetar (incorporated by reference to Exhibit 4.4 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Put Option Agreement between CoreWeave, Inc. and certain holders of its capital stock, dated May 16, 2024 (incorporated by reference to Exhibit 4.5 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Amended and Restated Registration Rights Agreement between CoreWeave, Inc. and funds or accounts managed or advised by Magnetar, as amended (incorporated by reference to Exhibit 4.6 to the Company’s Form S-1/A filed with the SEC on March 20, 2025) | |||
Indenture, dated as of May 27, 2025, by and among CoreWeave, Inc., the guarantor party thereto and Wilmington Trust, National Association, as trustee (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the SEC on May 28, 2025) | |||
Form of 9.250% Senior Notes due 2030 of CoreWeave, Inc. (included as Exhibit A to Exhibit 4.7) | |||
Indenture, dated as of July 25, 2025, by and among CoreWeave, Inc., the guarantors party thereto and Wilmington Trust, National Association, as trustee (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the SEC on July 28, 2025) | |||
Form of 9.000% Senior Notes due 2031 of CoreWeave, Inc. (included as Exhibit A to Exhibit 4.9) | |||
Form of Warrant Agreement between CoreWeave, Inc. and Computershare Trust Company, N.A. and Computershare, Inc., as Warrant Agent | |||
Opinion of Davis Polk & Wardwell LLP | |||
Tax Opinion of Davis Polk & Wardwell LLP | |||
Tax Opinion of Wachtell, Lipton, Rosen & Katz |
Exhibit Number | Description | ||
Form of Indemnification Agreement between CoreWeave, Inc. and each of its directors and executive officers (incorporated by reference to Exhibit 10.1 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
CoreWeave, Inc. 2019 Stock Option Plan, as amended, and related form agreements (incorporated by reference to Exhibit 10.2 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
CoreWeave, Inc. 2025 Equity Incentive Plan and related form agreements (incorporated by reference to Exhibit 10.3 to the Company’s Form S-1/A filed with the SEC on March 20, 2025) | |||
CoreWeave, Inc. 2025 Employee Stock Purchase Plan and related form agreements (incorporated by reference to Exhibit 10.4 to the Company’s Form S-1/A filed with the SEC on March 20, 2025) | |||
CoreWeave, Inc. Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.5 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
CoreWeave, Inc. Senior Executive Change in Control and Severance Plan (incorporated by reference to Exhibit 10.6 to the Company’s Form S-1/A filed with the SEC on March 20, 2025) | |||
Office Lease, between CoreWeave, Inc. and Livingston Circle Associates, dated March 29, 2024 (incorporated by reference to Exhibit 10.7 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Credit Agreement between CoreWeave Compute Acquisition Co. II, LLC and the agents and lenders party thereto, dated July 30, 2023 (incorporated by reference to Exhibit 10.8 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
First Amendment to Credit Agreement between CoreWeave Compute Acquisition Co. II, LLC and the agents and lenders party thereto, dated May 16, 2024 (incorporated by reference to Exhibit 10.9 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Parent Guarantee and Pledge Agreement between CoreWeave, Inc. and U.S. Bank Trust Company, National Association, dated July 30, 2023 (incorporated by reference to Exhibit 10.10 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
First Amendment to Parent Guarantee and Pledge Agreement between CoreWeave, Inc., U.S. Bank Trust Company, National Association, and the lenders party thereto, dated November 8, 2023 (incorporated by reference to Exhibit 10.11 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Second Amendment to Parent Guarantee and Pledge Agreement between CoreWeave, Inc., U.S. Bank Trust Company, National Association, and the lenders party thereto, dated May 16, 2024 (incorporated by reference to Exhibit 10.12 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Credit Agreement between CoreWeave Compute Acquisition Co. IV, LLC and the agents and lenders party thereto, dated May 16, 2024 (incorporated by reference to Exhibit 10.13 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
First Amendment to Credit Agreement between CoreWeave, Inc., the guarantors party thereto, and the agents and lenders party thereto, dated August 29, 2024 (incorporated by reference to Exhibit 10.14 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Limited Waiver and Second Amendment to Credit Agreement between CoreWeave Compute Acquisition Co. IV, LLC, the Borrower party thereto, and the agents and lenders party thereto, dated December 31, 2024 (incorporated by reference to Exhibit 10.15 to the Company’s Form S-1 filed with the SEC on March 3, 2025) |
Exhibit Number | Description | ||
Parent Guarantee and Pledge Agreement between CoreWeave, Inc. and U.S. Bank Trust Company, National Association, dated May 16, 2024 (incorporated by reference to Exhibit 10.16 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Revolving Credit and Guaranty Agreement between CoreWeave, Inc., the guarantors party thereto, and the agents and lenders party thereto, dated June 21, 2024 (incorporated by reference to Exhibit 10.17 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Amendment No. 1 to Credit Agreement between CoreWeave, Inc., the guarantors party thereto, and the agents and lenders party thereto, dated October 7, 2024 (incorporated by reference to Exhibit 10.18 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Amendment No. 2 to Credit Agreement between CoreWeave, Inc., the guarantors party thereto, and the agents and lenders party thereto, dated December 2, 2024 (incorporated by reference to Exhibit 10.19 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Term Loan Credit and Guaranty Agreement between CoreWeave, Inc., the guarantors party thereto, and the agents and lenders party thereto, dated December 16, 2024 (incorporated by reference to Exhibit 10.20 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Form of Equity Exchange Right Agreement between CoreWeave, Inc. and each of Michael Intrator, Brian Venturo, and Brannin McBee (incorporated by reference to Exhibit 10.21 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Director Nomination Rights Agreement between CoreWeave, Inc. and funds or accounts managed or advised by Magnetar, dated May 20, 2024 (incorporated by reference to Exhibit 10.22 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Master Services Agreement between CoreWeave, Inc. and Microsoft Corporation, dated February 22, 2023 (incorporated by reference to Exhibit 10.23 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Master Services Agreement between CoreWeave, Inc. and OpenAI OpCo, LLC, dated March 7, 2025 (incorporated by reference to Exhibit 10.24 to the Company’s Form S-1/A filed with the SEC on March 12, 2025) | |||
Stock Issuance Agreement between CoreWeave, Inc. and OpenAI OpCo, LLC, dated March 7, 2025 (incorporated by reference to Exhibit 10.25 to the Company’s Form S-1/A filed with the SEC on March 12, 2025) | |||
Amendment No. 3 to the Revolving Credit and Guaranty Agreement, dated May 2, 2025, by and among CoreWeave, Inc., as the borrower, CoreWeave Cash Management LLC, as the guarantor, JPMorgan Chase Bank, N.A., as Administrative Agent and as a lender and the other lenders party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on May 6, 2025) | |||
Fourth Amendment to Credit Agreement between CoreWeave Compute Acquisition Co. IV, LLC and the lenders party thereto, dated June 6, 2025 (incorporated by reference to Exhibit 10.8 to the Company’s Form 10-Q filed with the SEC on August 12, 2025) | |||
Credit Agreement between CoreWeave Compute Acquisition Co. V, LLC, CoreWeave Compute Acquisition Co. VII, LLC, U.S. Bank National Association, as depository bank, MUFG Bank, Ltd., as administrative agent, U.S. Bank Trust Company, National Association as collateral agent, Morgan Stanley Asset Funding, Inc., MUFG Bank, Ltd. and Goldman Sachs Bank USA, as joint lead arrangers, and other lenders party thereto, dated July 28, 2025. (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on July 31, 2025) |
Exhibit Number | Description | ||
Parent Guarantee and Pledge Agreement between CoreWeave, Inc., CCAC VII Holdco LLC and U.S. Bank Trust Company, National Association, and the lenders party thereto, dated July 28, 2025. (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on July 31, 2025) | |||
Form of Assignment, Assumption and Amendment Agreement to the Contingent Value Rights Agreement between CoreWeave, Inc. and Computershare Inc. and its affiliate, Computershare Trust Company, N.A. as CVR agent | |||
List of Subsidiaries of CoreWeave, Inc. (incorporated by reference to Exhibit 21.1 to the Company’s Form S-1 filed with the SEC on March 3, 2025) | |||
Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm of CoreWeave, Inc. | |||
Consent of RSM US LLP, Independent Registered Public Accounting Firm of CoreWeave, Inc. | |||
Consent of Marcum LLP, Independent Registered Public Accounting Firm of Core Scientific, Inc. | |||
23.4** | |||
23.5** | Consent of Wachtell, Lipton, Rosen & Katz (included in Exhibit 8.2) | ||
Power of Attorney (included in the signature page to this Registration Statement) | |||
Form of Proxy Card of Core Scientific, Inc. | |||
Consent of Moelis & Company LLC | |||
Consent of PJT Partners LP | |||
101.INS* | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). | ||
101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | ||
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | ||
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | ||
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | ||
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | ||
104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | ||
Filing Fee Table |
# | Indicates management contract or compensatory plan. |
^ | The annexes, schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. CoreWeave agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof, to the SEC upon request. |
† | CoreWeave has omitted portions of the exhibit (indicated by “[*]”) as permitted under Item 601(b)(10) of Regulation S-K. |
* | Previously filed. |
** | Filed herewith. |
ITEM 22. | UNDERTAKINGS |
(a) | The undersigned registrant hereby undertakes: |
(1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
(i) | To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933. |
(ii) | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement. |
(iii) | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. |
(2) | That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
(3) | To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
(4) | That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. |
(5) | That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
(i) | Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
(ii) | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
(iii) | The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and |
(iv) | Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
(1) | The undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form. |
(2) | The registrant undertakes that every prospectus: (i) that is filed pursuant to paragraph (1) immediately preceding, or (ii) that purports to meet the requirements of Section 10(a)(3) of the Securities Act of 1933 and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
(c) | The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the proxy statement/prospectus pursuant to Item 4, 10(b), 11 or 13 of this form, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request. |
(d) | The undersigned registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective. |
(e) | Insofar as indemnification for liabilities under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is therefore unenforceable. In the event a claim of indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in a successful defense of any action, suit or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. |
COREWEAVE, INC. | |||||||||
By: | /s/ Michael Intrator | ||||||||
Name: | Michael Intrator | ||||||||
Title : | Chairman and Chief Executive Officer | ||||||||
Signature | Title | Date | |||||
/s/ Michael Intrator | Director, Chief Executive Officer and President (Principal Executive Officer) | September 17, 2025 | |||||
Michael Intrator | |||||||
* | Chief Financial Officer (Principal Financial Officer) | September 17, 2025 | |||||
Nitin Agrawal | |||||||
* | Chief Accounting Officer (Principal Accounting Officer) | September 17, 2025 | |||||
Jeffrey R. Baker | |||||||
* | Director and Chief Strategy Officer | September 17, 2025 | |||||
Brian Venturo | |||||||
* | Director | September 17, 2025 | |||||
Karen Boone | |||||||
* | Director | September 17, 2025 | |||||
Jack Cogen | |||||||
* | Director | September 17, 2025 | |||||
Glenn H. Hutchins | |||||||
* | Director | September 17, 2025 | |||||
Margaret C. Whitman | |||||||
*By: | /s/ Michael Intrator | Attorney-In-Fact | September 17, 2025 | ||||||
| Page | ||
|
Section 1.
|
Appointment of Warrant Agent
|
2
|
|
Section 2.
|
Issuances; Exercise Price
|
2
|
|
Section 3.
|
Form of Warrants
|
3
|
|
Section 4.
|
Execution of Global Warrant Certificates
|
3
|
|
Section 5.
|
Registration and Countersignature
|
4
|
|
Section 6.
|
Registration of Transfers and Exchanges
|
5
|
|
Section 7.
|
Duration and Exercise of Warrants
|
9
|
|
Section 8.
|
Cancellation of Warrants
|
13
|
|
Section 9.
|
Mutilated or Missing Global Warrant Certificates
|
13
|
|
Section 10.
|
Reservation of Warrant Shares
|
14
|
|
Section 11.
|
Listing
|
14
|
|
Section 12.
|
Adjustments and Other Rights of Warrants
|
14
|
|
Section 13.
|
No Fractional Shares
|
28
|
|
Section 14.
|
Redemption
|
28
|
|
Section 15.
|
Notices to Warrantholders
|
28
|
|
Section 16.
|
Merger, Consolidation or Change of Name of Warrant Agent
|
29
|
|
Section 17.
|
Warrant Agent
|
29
|
|
Section 18.
|
Change of Warrant Agent
|
35
|
|
Section 19.
|
Warrantholder Not Deemed a Stockholder
|
35
|
|
Section 20.
|
Notices to Company and Warrant Agent
|
35
|
|
Section 21.
|
Withholding and Reporting Requirements
|
36
|
|
Section 22.
|
Supplements and Amendments
|
37
|
|
Section 23.
|
Successors
|
37
|
|
Section 24.
|
Termination
|
38
|
|
Section 25.
|
Governing Law Venue and Jurisdiction; Trial By Jury
|
38
|
|
Section 26.
|
Benefits of this Agreement
|
38
|
|
Section 27.
|
Counterparts
|
39
|
|
Section 28.
|
Headings
|
39
|
|
Section 29.
|
Severability
|
39
|
|
Section 30.
|
Entire Agreement
|
39
|
|
Section 31.
|
Meaning of Terms Used in Agreement
|
39
|
|
Exhibit A
|
-
|
Form of Tranche 1 Global Warrant Certificate
|
|
Exhibit B
|
-
|
Form of Tranche 2 Global Warrant Certificate
|
|
Exhibit C-1
|
-
|
Form of Election to Exercise Book-Entry
|
|
Exhibit C-2
|
-
|
Form of Election to Exercise Direct Registration Warrants to be Completed by Direct Participant in the Depository Trust Company
|
|
Exhibit D
|
-
|
Form of Assignment
|
| X | = | the number of Warrant Shares issuable upon such exercise pursuant to this Section 7(e). |
| A | = | the Current Market Price of a Warrant Share on the Trading Day immediately preceding the date on which the Warrantholder delivers the Warrant Exercise Notice. |
| B | = | the Exercise Price for the Tranche 1 Warrants or Tranche 2 Warrants, as the case may be. |
| C | = | the number of Warrant Shares as to which the Tranche 1 Warrant or Tranche 2 Warrant, as the case may be, is then being exercised including the withheld Warrant Shares. |
| EP0 |
=
|
the Exercise Price in effect immediately prior to the Close of Business on the Record Date for such dividend or distribution, or immediately prior to the Open of Business on the effective date for such subdivision or combination, as
the case may be;
|
| EP1 | = |
the Exercise Price in effect immediately after the Close of Business on the Record Date for such dividend or distribution, or immediately after the Open of Business on the effective date for such subdivision or combination, as the case may be; |
| OS0 | = |
the number of shares of Common Stock outstanding immediately prior to the Close of Business on the Record Date for such dividend, distribution, subdivision or combination, or immediately prior to the Open of Business on the effective date for such subdivision or combination, as the case may be; and |
| OS1 | = |
the number of shares of Common Stock that would be outstanding immediately after, and solely as a result of, such dividend, distribution, subdivision or combination. |
| EP0 | = |
the Exercise Price in effect immediately prior to the Close of Business on the Record Date for such issuance; |
| EP1 | = |
the Exercise Price in effect immediately after the Close of Business on the Record Date for such issuance; |
| OS0 | = |
the number of shares of Common Stock outstanding immediately prior to the Close of Business on the Record Date for such issuance; |
| X | = |
the total number of shares of Common Stock issuable pursuant to such rights, warrants or convertible securities; and |
| Y | = |
the aggregate price payable to exercise such rights, warrants or convertible securities divided by the Current Market Price. |
| EP0 | = |
the Exercise Price in effect immediately prior to the Close of Business on the Record Date for such dividend or distribution; |
| EP1 | = |
the Exercise Price in effect immediately after the Close of Business on the Record Date for such dividend or distribution; |
| SP0 | = |
the Current Market Price; and |
| FMV | = |
the Market Price, on the Record Date for such dividend or distribution, of the shares of Capital Stock, evidences of indebtedness or property, rights or warrants so distributed or the amount of Cash expressed as an amount per share of outstanding Common Stock. |
| EP0 | = |
the Exercise Price in effect immediately prior to the Close of Business on the Record Date for such dividend or distribution; |
| EP1 | = |
the Exercise Price in effect immediately after the Close of Business on the Record Date for such dividend or distribution; |
| FMV0 | = |
the average of the Closing Sale Prices of the Capital Stock or similar equity interests distributed to holders of Common Stock applicable to one share of Common Stock over the 10 consecutive Trading Days commencing on, and including, the third Trading Day after the Ex-Date for such dividend or distribution; and |
| MP0 | = |
the average of the Closing Sale Prices of the Common Stock over the 10 consecutive Trading Days commencing on, and including, the third Trading Day after the Ex-Date for such dividend or distribution. |
| EP0 | = |
the Exercise Price in effect immediately prior to the Close of Business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires; |
| EP1 | = |
the Exercise Price in effect immediately after the Close of Business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires; |
| AC | = |
the aggregate value of all Cash and any other consideration (as determined by the Board of Directors in good faith) paid or payable for shares of Common Stock purchased in such tender or exchange offer; |
| OS0 | = |
the number of shares of Common Stock outstanding immediately prior to the date such tender or exchange offer expires (prior to giving effect to the purchase of all shares of Common Stock accepted for purchase or exchange in such tender or exchange offer); |
| OS1 | = |
the number of shares of Common Stock outstanding immediately after the date such tender or exchange offer expires (after giving effect to the purchase of all shares of Common Stock accepted for purchase or exchange in such tender or exchange offer); and |
| SP1 | = |
the average of the Closing Sale Prices of the Common Stock over the 10 consecutive Trading Day period commencing on, and including, the Trading Day next succeeding the date such tender or exchange offer expires. |
|
COREWEAVE, INC.
|
||
|
By:
|
||
|
Name:
|
||
|
Title:
|
||
|
COMPUTERSHARE INC. and
COMPUTERSHARE TRUST COMPANY, N.A. as Warrant Agent
On behalf of both entities
|
||
|
By:
|
||
|
Name:
|
||
|
Title:
|
||
|
No.
|
WARRANT TO PURCHASE
|
|
|
SHARES OF COMMON STOCK
|
||
|
COREWEAVE, INC.
|
||
|
By:
|
||
|
Name:
|
||
|
Title:
|
||
|
COMPUTERSHARE INC. and
COMPUTERSHARE TRUST COMPANY, N.A. as Warrant Agent
On behalf of both entities
|
||
|
By:
|
||
|
Name:
|
||
|
Title:
|
||
|
No.
|
WARRANT TO PURCHASE
|
|
|
SHARES OF COMMON STOCK
|
||
|
COREWEAVE, INC.
|
||
|
By:
|
||
|
Name:
|
||
|
Title:
|
||
|
COMPUTERSHARE INC. and
COMPUTERSHARE TRUST COMPANY, N.A. as Warrant Agent
On behalf of both entities
|
||
|
By:
|
||
|
Name:
|
||
|
Title:
|
||
| ☐ |
Cash exercise election
|
|
Name
|
|
|
Address:
|
|
|
Delivery Address (if different):
|
|
|
Name
|
|
|
Address:
|
|
|
Delivery Address (if different):
|
|
|
Social Security or Other Taxpayer Identification Number of Warrantholder:
|
|
|
Signature
|
|
| ☐ |
Cash exercise election
|
|
Dated
|
|
|
Signature
|
|
|
Social Security or Other Taxpayer Identification Number of Assignee
|
|
SIGNATURE GUARANTEED BY:
|
|
|
Davis Polk & Wardwell LLP
900 Middlefield Road
Redwood City, CA 94063
davispolk.com
|
| 1. |
The Company Common Stock, when issued and delivered as contemplated in the Registration Statement and in accordance with the terms and conditions of the Merger Agreement, will be validly issued, fully paid and non-assessable.
|
| 2. |
Assuming that the warrant agreement governing the New Tranche 1 Warrants and New Tranche 2 Warrants (the “Warrant Agreement”) and the New Tranche 1 Warrants and New Tranche 2 Warrants have been duly authorized by the warrant agent, when
the Warrant Agreement has been duly executed and delivered by the warrant agent and the Company, and such New Tranche 1 Warrants and New Tranche 2 Warrants have been duly executed and delivered in accordance with the Warrant Agreement and
applicable agreement against payment thereto, the New Tranche 1 Warrants and New Tranche 2 Warrants when issued as contemplated in the Registration Statement and in accordance with the terms and conditions of the Merger Agreement and the
Warrant Agreement, will constitute valid and binding obligations of the Company, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally, concepts of
reasonableness and equitable principles of general applicability; provided that we express no opinion as to the validity, legally binding effect or enforceability of any provision in the New Tranche 1 Warrants and New Tranche 2 Warrants that
require or relate to adjustments to the exercise price at a price or in an amount that a court would determine in the circumstances under applicable law to be commercially unreasonable or a penalty or forfeiture.
|
| 3. |
The Underlying Securities, when issued upon exercise by holders of the New Tranche 1 and New Tranche 2 Warrants and delivered against payment therefor in accordance with the terms and conditions of the Warrant Agreement, will be validly
issued, fully paid and non-assessable.
|
|
|
Davis Polk & Wardwell LLP
450 Lexington Avenue
New York, NY 10017
davispolk.com
|
|
Very truly yours,
|
|
|
/s/ Wachtell, Lipton, Rosen & Katz
|
| (i) |
if to the Company, to:
|
|
CoreWeave, Inc.
|
||
|
290 W Mt. Pleasant Ave., Suite 4100
|
||
|
Livingston, NJ 07039
|
||
|
Attention: Kristen McVeety
|
||
|
Email:
|
[ ] | |
|
with copies (which shall not constitute notice) to:
|
||
|
Davis Polk & Wardwell LLP
|
||
|
450 Lexington Avenue
|
||
|
New York, New York 10017
|
||
|
and
|
||
|
Davis Polk & Wardwell LLP
|
||
|
900 Middlefield Road, Suite 200
|
||
|
Redwood City, California 94063
|
||
|
Attention:
|
Michael Gilson
|
|
|
Michael Kaplan
|
||
|
Tierney O’Rourke
|
||
|
Email:
|
[ ]
|
|
| (ii) |
if to the Agent, to:
|
|
COREWEAVE, INC.
|
||
|
By:
|
||
|
Name:
|
||
|
Title:
|
||
|
CORE SCIENTIFIC, INC.
|
|||
|
By:
|
|||
|
Name:
|
|||
|
Title:
|
|||
|
COMPUTERSHARE INC. and
COMPUTERSHARE TRUST COMPANY, N.A.
as Agent
On behalf of both entities:
|
|||
|
By:
|
|||
|
Name:
|
|||
|
Title:
|
|||
Execution Version
CONTINGENT VALUE RIGHTS AGREEMENT
This CONTINGENT VALUE RIGHTS AGREEMENT (including the definitions set forth on Annex A and the provisions set forth on Annex B hereto, this “Agreement”), dated as of January 23, 2024, is by and between Core Scientific, Inc., a Delaware corporation (the “Company”) and Computershare Inc., a Delaware corporation (“Computershare”) and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, collectively, as CVR agent (the “Agent”).
RECITALS
WHEREAS, on December 21, 2022, the Company and each of its debtor affiliates, as debtors and debtors in possession (such affiliates, the “Debtor Affiliates”) commenced voluntary cases, captioned In re Core Scientific Inc., et al., Case No. 22 90341 (CML), under Chapter 11 of Title 11 of the United States Code, 11 U.S.C. §§ 101–1532, as amended (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”);
WHEREAS, on January 16, 2024, the Bankruptcy Court confirmed the Fourth Amended Joint Chapter 11 Plan of Core Scientific, Inc. and its Affiliated Debtors (With Technical Modifications) Docket No. 1722 (the “Plan”);
WHEREAS, pursuant to the terms and conditions of the Plan, on the Effective Date, the Company will issue and deliver to holders of April Convertible Notes Secured Claims and August Convertible Notes Secured Claims (each as defined in the Plan) contingent payment obligations, in the form of the CVRs (as defined herein) contemplated by this Agreement;
WHEREAS, the number of CVRs to be issued pursuant to this Agreement is 51,783,625 CVRs;
WHEREAS, the Company desires that the Agent act on behalf of the Company, and the Agent is willing to act in connection with the contingent payments obligations in respect of the CVRs; and
WHEREAS, contemporaneously with the Company’s entry into this Agreement, the Company has executed that certain calculation agent agreement (the “Calculation Agent Agreement”), dated as of January 23, 2024, by and between the Company and Delaware Trust Company (“Delaware Trust”) pursuant to which Delaware Trust has agreed to act as Calculation Agent, and references to such role in this Agreement shall be undertaken by Delaware Trust (the “Calculation Agent”).
NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:
ARTICLE I
CONTINGENT VALUE RIGHTS
| 1.1 |
Contractual Rights; Initial Holders of CVRs; Appointment of CVR Agent. |
| (a) |
The CVRs represent the contractual rights of the Holders to receive the Payment Amounts (as defined herein), if any, pursuant to and in accordance with the terms and conditions of this Agreement. |
| (b) |
Pursuant to the terms of the Plan, each holder of a Convertible Notes Secured Claim (as defined in the Plan) that receives a distribution of New Common Interests pursuant to the Convertible Noteholders Equity Distribution (as defined in the Plan) shall be an initial Holder. |
| (c) |
The Company hereby appoints the Agent to act as CVR agent in accordance with the express terms and conditions set forth in this Agreement (and no implied terms or conditions), and the Agent hereby accepts such appointment. |
1
| 1.2 |
Transferability. Subject to Section 1 of Annex B hereof, the CVRs shall be freely transferable and publicly tradeable by each Holder without the prior consent of the Company, the Agent or any other Person; provided, subject to Section 1.5(i), that the Company and the Agent may require (i) payment of a sum sufficient to cover any documentary, stamp, transfer or other similar Tax or charge that is imposed in connection with any such transfer or (ii) that the transferor establish to the reasonable satisfaction of the Company and the Agent that any such Taxes have been paid. The Agent shall have no obligation or duty to monitor, determine or inquire as to compliance with any restrictions on transfer or exchange imposed under this Agreement or under applicable law with respect to any transfer or exchange of any interest in any CVR other than to require delivery of such certificates and other documentation or evidence as are expressly required by, and to do so if and when expressly required by the terms of, this Agreement, and to examine the same to determine substantial compliance as to form with the express requirements hereof. |
| 1.3 |
Exemption from Securities Registration at Issuance. The issuance of the CVRs is exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the exemption provided by Section 1145 of the Bankruptcy Code. The CVRs shall not be considered a “debt security.” |
| 1.4 |
No Certificate; Registration; Change of Address; CUSIP Number. |
| (a) |
The CVRs shall be issued (1) to Holders in book-entry form on the CVR Register (as defined below), in customary form and substance (a “Book-Entry CVR”) or (2) in the form of one or more global certificates (the “Global CVRs”), substantially in the form appended hereto as Annex C. The CVRs shall not be evidenced by a physical certificate. |
| (b) |
Subject to the Company furnishing to the Agent the list of Holders, the Agent shall keep a register (the “CVR Register”) for the purpose of (i) identifying the Holders of the CVRs and (ii) documenting the CVRs, which CVR Register may be amended from time to time by the Agent to reflect any changes to Holders or the applicable number of CVRs as permitted hereunder. Until such list of Holders is furnished to the Agent, the Agent shall have no duties, responsibilities or obligations with respect to keeping the CVR Register, providing notices or making payments to such Holders. |
| (c) |
The Global CVRs issued shall be deposited with the Agent as custodian for the Depositary and registered in the name of Cede & Co., or such other entity designated by the Depositary as the Depositary’s nominee, in accordance with the Global CVR provisions set out in Annex B hereto. |
| (d) |
On the terms and subject to the conditions of this Agreement, in accordance with the terms of the Plan, the Company will issue the CVRs in the amounts and to the recipients specified in the Plan. Upon written order of the Company, the Agent shall (i) register in the CVR Register the Book-Entry CVRs and (ii) deliver or cause to be delivered to the Depositary one or more Global CVRs evidencing the CVRs. |
| (e) |
A Holder may make a written request to the Agent to change such Holder’s address of record in the CVR Register. Such written request must be duly executed by such Holder. Upon receipt of such written request, the Agent shall promptly record the change of address in the CVR Register. |
| (f) |
The CUSIP number of the CVRs is 21874A 122. Each of the Company and the Agent shall use such CUSIP number (or any equivalent number, to the extent CUSIP numbers are no longer generally in use) for all applicable bookkeeping purposes in connection with the CVRs. The Company and the Agent shall use such CUSIP number in notices in connection with the CVRs as a convenience to Holders; provided, however, that any such notice from the Company or the Agent may state that no representation is made as to the correctness of such number and any such notice shall not be affected by any defect in or omission of such number. The Company shall promptly notify, or shall cause the Agent to promptly notify, the Calculation Agent and the Holders in writing of any change in the CUSIP number of the CVRs. |
2
| (g) |
The initial Holder of the Global CVR shall be Cede & Co. as nominee for the Depositary. The Agent will have no responsibility whatsoever directly to the street name holders with respect to transfers of Global CVRs. With respect to any payments or issuances to be made under Section 1.5 below, the Agent will accomplish the payment to any former street name holders of Global CVRs by sending one lump sum payment or issuance to the Depositary. |
| 1.5 |
Testing Periods; Payment Amounts; Payment Procedures; Dispute Resolution; Record Date; Deduction or Withholding; Undelivered Payment Amounts; Liquidated Damages; Availability of Agreement to Holders. Contingent payments pursuant to the CVRs shall be made, to the extent payable, to the Holders after each of the First Testing Date, the Second Testing Date and the Third Testing Date, in each case as defined below and pursuant to the procedures set forth herein. The calculations called for herein shall be made by the Calculation Agent. All distributions made hereunder shall be made to Holders as of the close of business on the date of the applicable Testing Date (each such date, the record date for purposes of determining the Holders entitled to receive the corresponding Payment Amount) (1) with respect to cash payments, (i) in the case of Book-Entry CVRs held on the CVR Register, (a) with respect to any such Holder that has not provided the Agent wiring instructions in writing as of the close of business on the date of the applicable Testing Date, by check mailed to the address of such Holder reflected in the CVR Register as of 5:00 p.m. New York City time on the date of the applicable Testing Date, or (b) with respect to any such Holder that has provided the Agent wiring instructions in writing as of the close of business on the date of the applicable Testing Date, by wire transfer of immediately available funds to the account specified on such instruction, or (ii) in the case of Global CVRs, to beneficial holders in accordance with applicable rules and procedures of DTC or (2) with respect to distributions of New Common Interests, (i) in the case of Holders who hold their CVRs on the CVR Register, issue in the name of the Holder on the books and records of the Transfer Agent; or (ii) in the case of Global CVRs, issue to beneficial holders in accordance with applicable rules and procedures of DTC. |
| (a) |
The first testing period shall begin on the Effective Date and end on the first anniversary of the Effective Date (the first anniversary of the Effective Date, the “First Testing Date”). On or before 10:00 a.m. (New York City time) on a Business Day within thirty-five (35) calendar days following the First Testing Date, subject to the Dispute Resolution Procedures, the Company shall, if required pursuant to this Section 1.5(a), make a payment to the Agent, and the Agent shall transfer such funds promptly, and in no event later than five (5) Business Days following the receipt of each such payment, to Holders or DTC for the benefit of the corresponding beneficial owners of CVRs, as applicable, in each case in accordance with this Section 1.5 and pursuant to the terms set forth herein (the “Year 1 Contingent Payment Obligation”), in cash (in United States Dollars) in immediately available funds equal to the lesser of (i) $43,333,333.33 and (ii) the difference between (a) $260,000,000 and (b) the Fair Market Value of the Corresponding New Common Interests (the “First Anniversary Payment Amount”); provided, however, that to the extent that the Fair Market Value of the Corresponding New Common Interests is equal to or in excess of $260,000,000, the Company shall not owe any amounts to any Holder with respect to the First Testing Date, and for purposes of this Agreement, the Year 1 Contingent Payment Obligation shall be extinguished and be deemed to equal zero, and the Company shall provide an Officer’s Certificate to the Agent stating as such, substantially in the form of Exhibit D hereof. |
| (b) |
The second testing period shall begin on day after the first anniversary of the Effective Date and end on the second anniversary of the Effective Date (the second anniversary of the Effective Date, the “Second Testing Date”). Within thirty-five (35) calendar days following the Second Testing Date, subject to the Dispute Resolution Procedures, the Company shall, as applicable pursuant to this Section 1.5(b), (i) make a payment to the Agent, and the Agent shall transfer such funds promptly, and in no event later than five (5) Business Days following the receipt of each such payment, to Holders or DTC for the benefit of the corresponding beneficial owners of CVRs, as applicable, in each case in accordance with this Section 1.5 and pursuant to the terms set forth herein, or (ii) furnish to the Agent the Requisite New Common Interests Payment Documentation, in each case pursuant to the terms set forth herein (the “Year 2 Contingent Payment Obligation”), relating, as applicable, to a payment in cash (in United States Dollars) in immediately available funds or a number of New Common Interests (rounded up to the nearest whole New Common Interest), or a combination of the foregoing, in the Company’s sole discretion, equal to the lesser of (i) |
3
| $43,333,333.33 and (ii) the difference between (a) $260,000,000 minus the First Anniversary Payment Amount and (b) the Fair Market Value of the Corresponding New Common Interests (the “Second Anniversary Payment Amount”); provided, however, that to the extent that the Fair Market Value of the Corresponding New Common Interests is equal to or in excess of the difference of (x) $260,000,000 minus (y) the First Anniversary Payment Amount, the Company shall not owe any amounts to any Holder with respect to the Second Testing Date, and the Year 2 Contingent Payment Obligation shall be extinguished and be deemed to equal zero, and the Company shall provide an Officer’s Certificate to the Agent stating as such, substantially in the form of Exhibit D hereof. |
| (c) |
The third testing period shall begin on the day after the second anniversary of the Effective Date and end on the third anniversary of the Effective Date (the third anniversary of the Effective Date, the “Third Testing Date” and, together with the First Testing Date and the Second Testing Date, each, a “Testing Date”). Within thirty-five (35) calendar days following the Third Testing Date, subject to the Dispute Resolution Procedures, the Company shall, as applicable pursuant to this Section 1.5(c), (i) make a payment to the Agent, and the Agent shall transfer such funds promptly, and in any event no later than five (5) Business Days following the receipt of each such payment, to Holders or DTC for the benefit of the corresponding beneficial owners of CVRs, as applicable, in each case in accordance with this Section 1.5 and pursuant to the terms set forth herein, or (ii) furnish to the Agent the Requisite New Common Interests Payment Documentation, in each case pursuant to the terms set forth herein (the “Year 3 Contingent Payment Obligation” and together with the Year 1 Contingent Payment Obligation and the Year 2 Contingent Payment Obligation, the “Contingent Payment Obligations”), relating, as applicable, to a payment in cash (in United States Dollars) in immediately available funds or a number of New Common Interests (rounded up to the nearest whole New Common Interest), or a combination of the foregoing, in the Company’s sole discretion, equal to the lesser of (i) $43,333,333.33 and (ii) the difference between (a) $260,000,000 minus the sum of the First Anniversary Payment Amount and the Second Anniversary Payment Amount and (b) the Fair Market Value of the Corresponding New Common Interests (the “Third Anniversary Payment Amount” and, together with the First Anniversary Payment Amount and the Second Anniversary Payment Amount, the “Payment Amounts” and each a “Payment Amount”); provided, however, that to the extent that the Fair Market Value of the Corresponding New Common Interests is equal to or in excess of the difference of (x) $260,000,000 minus (y) the sum of the First Anniversary Payment Amount and the Second Anniversary Payment Amount, the Company shall not owe any amounts to any Holder with respect to the Third Testing Date, and the Year 3 Contingent Payment Obligation shall be extinguished and be deemed to equal zero, and the Company shall provide an Officer’s Certificate to the Agent stating as such, substantially in the form of Exhibit D hereof. |
| (d) |
The Calculation Agent, in consultation with the Company and in accordance with the Calculation Agent Agreement, shall determine each Payment Amount pursuant to the terms hereof and the terms of the Calculation Agent Agreement. Within three (3) Business Days after each Testing Date, the Calculation Agent, in consultation with the Company, shall deliver to the Company and the Agent a written notice stating (1) the date of such Testing Date and (2) the aggregate Payment Amount (if any) with respect to such Testing Date (including, in reasonable detail, the calculation thereof); provided, that, in the event of any dispute between the Calculation Agent and the Company with regard to the amount of such aggregate Payment Amount, the Company’s determination as to such aggregate Payment Amount shall be conclusive, subject to the terms and conditions of this Agreement. |
| (e) |
Within five (5) Business Days after each Testing Date, the Company shall cause the Agent to deliver to each Holder a written notice stating (1) the date of such Testing Date, (2) the aggregate Payment Amount (if any) with respect to such Testing Date (including, in reasonable detail, the calculation thereof), (3) the corresponding per-CVR Payment Amount (if any) (including, in reasonable detail, the calculation thereof), (4) with respect to the Second Anniversary Payment Amount and Third Anniversary Payment Amount (if any), the Company’s determination as to whether such Payment Amount will be made in cash (in United States Dollars) or New Common Interests (or both) and if |
4
| to be paid in whole or in part in New Common Interests, the number of New Common Interests that such Holder will receive, and (5) the corresponding Objection Deadline (as defined below) by which such Holder must object in connection with the contents of such written notice (such written notice, a “Payment Triggering Event Notice”, the form of which is attached hereto as Exhibit A). |
| (f) |
The Holders of not less than fifteen percent (15%) of the aggregate outstanding CVRs (collectively, the “Objecting Holders”) shall have ten (10) Business Days following the date on which a Payment Triggering Event Notice is sent pursuant to Section 1.5(e) hereof (the “Objection Deadline”) to object in writing to the aggregate Payment Amount (including the calculation thereof), the corresponding per-CVR Payment Amount (if any) and the number of New Common Interests to be paid in connection with such Payment Amount (if applicable) in such Payment Triggering Event Notice (such written objection, a “Payment Amount Objection Notice”, the form of which is attached hereto as Exhibit B) and deliver such Payment Amount Objection Notice to the Company, provided that, for the avoidance of doubt, such Payment Amount Objection Notice is only properly delivered to the Company if the aggregate number of CVRs represented by all Payment Objection Notices delivered is not less than fifteen percent (15%) of the outstanding CVRs. To the extent the Objecting Holders timely deliver a Payment Amount Objection Notice to the Company, the Calculation Agent (solely with respect to such Payment Amount), the Company, and such Objecting Holders shall have five (5) Business Days following the receipt of such Payment Amount Objection Notice (the “Resolution Date”) to amicably resolve in good faith any disagreement, dispute, difference or question in connection with such Payment Amount (including the calculation thereof), the corresponding per-CVR Payment Amount (if any) and the number of New Common Interests to be paid in connection with such Payment Amount (if applicable) (an “Amicable Resolution”). To the extent the Calculation Agent, in consultation with the Company, must amend the Payment Triggering Event Notice to make a correction, the Company shall promptly, and in any event no later than four (4) calendar days after the Resolution Date, deliver or cause the Agent to deliver to each Objecting Holder, such amended Payment Triggering Event Notice. The Company and each Objecting Holder shall have three (3) Business Days following the date on which such amended Payment Triggering Event Notice is sent by the Company or the Agent pursuant to this Section 1.5(f) (the “Second Objection Deadline”) to object in writing thereto by delivering a Payment Amount Objection Notice in relation thereto to the Company (which the Company shall promptly then provide to the Calculation Agent). In the event (i) no Payment Amount Objection Notice is delivered by the Objection Deadline, (ii) an Amicable Resolution is achieved by the Resolution Date, (iii) no Payment Amount Objection Notice is delivered by the Second Objection Deadline or (iv) a Payment Amount Objection Notice is delivered by the Second Objection Deadline, in each case, as applicable, the Company shall promptly pay to the Agent, and the Agent shall, promptly, and in no event later than five (5) Business Days after its receipt of such funds, pay to all Holders (including any Objecting Holders) any corresponding Payment Amount pursuant to Sections 1.5(a), 1.5(b), or 1.5(c), or in accordance with such Amicable Resolution, as applicable. In the event the procedures set forth in Section 1.5(g) are conducted, the Company shall promptly pay any corresponding Payment Amount to the Holders (including any Objecting Holders) in accordance with the immediately preceding sentence without delaying such payment until the conclusion of the procedures set forth in Section 1.5(g). For the avoidance of doubt, the Objecting Holders will (i) be paid the corresponding Payment Amount due to the Holders, concurrently with the other Holders, pursuant to this Section 1.5(f) in accordance with the immediately preceding sentence, and (ii) be paid any corresponding amount equal to the difference between the Disputed Payment Amount (as defined below) due to the Objecting Holders pursuant to Section 1.5(g) and the Payment Amount paid to the Objecting Holders pursuant to Section 1.5(f) upon the conclusion of the procedures set forth in Section 1.5(g). |
| (g) |
In the event of any continuing disagreement, dispute or difference among any of the Calculation Agent, the Company and the Objecting Holders in connection with the aggregate Payment Amount, the corresponding per-CVR Payment Amount or the number of New Common Interests to be paid in connection with such Payment Amount (if applicable) to the Objecting Holders (such disputed Payment Amount with respect to the Objecting Holders, the “Disputed Payment Amount”), after the procedures set forth in Section 1.5(f) have been conducted, which dispute cannot be amicably |
5
| resolved by the good faith efforts of the Calculation Agent (solely with respect to the Disputed Payment Amount), the Company and the Objecting Holders on or prior to the later of the (x) Resolution Date and (y) Second Objection Deadline, then such dispute shall be resolved by binding arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association. The arbitration panel shall be composed of three arbitrators, one of whom shall be chosen by the Company, one by the Majority of Objecting Holders, and the third by the two arbitrators so chosen; provided, however, that if the Calculation Agent is involved with a dispute regarding the Disputed Payment Amount, the third arbitrator on the arbitration panel shall be chosen by the Calculation Agent. If all or either of the Company, the Majority of Objecting Holders or the Calculation Agent, if applicable, fails to choose an arbitrator or arbitrators within fourteen (14) calendar days after receiving notice of commencement of arbitration, or if the two arbitrators fail to choose a third arbitrator within fourteen (14) calendar days after their respective appointments, the President of the American Arbitration Association shall, upon the request of all or any of the Company, the Majority of Objecting Holders or the Calculation Agent, if applicable, appoint or cause to be appointed the arbitrator or arbitrators required to complete the board or, if he or she shall decline or fail to do so, such arbitrator or arbitrators shall be appointed by the New York office of the American Arbitration Association. The decision of the arbitrators shall be by majority vote and, at the request of any of the Company, the Majority of Objecting Holders or the Calculation Agent, if applicable, the arbitrators shall issue a written opinion of findings of fact and conclusions of law, a copy of which shall be promptly provided to the Agent and the Calculation Agent by the Company. Costs shall be borne between the Company and the Objecting Holders, as determined by the arbitrators. Unless the Company, the Majority of Objecting Holders and the Calculation Agent, if applicable, shall otherwise agree to a place of arbitration, the place of arbitration shall be at New York, New York, U.S.A. The arbitration award shall be final and binding upon the Company, the Agent, the Calculation Agent and Objecting Holders and may be entered in any court having competent jurisdiction pursuant to this Agreement. Promptly, and no later than 10:00 a.m. (New York City time) on a Business Day within five (5) calendar days thereafter, upon a final arbitration award being awarded, (i) the Agent shall deliver to each Objecting Holder a notice of the arbitration award and (ii) the Company shall make a cash (in United States Dollars) payment to the Agent, or issue New Common Interests to the Objecting Holders as set forth in this Agreement, in each case to the extent applicable, and the Agent shall, promptly, and in no event later than five (5) Business Days following receipt of such funds, transfer such funds to the Objecting Holders, in each case in accordance with this Section 1.5 and pursuant to the terms set forth herein, of the corresponding amount equal to the difference between the Disputed Payment Amount and the Payment Amount paid to the Objecting Holders pursuant to Section 1.5(f) (consistent with such final arbitration award), if applicable. |
| (h) |
The Company shall set a record date for purposes of determining the Holders entitled to vote or consent to any action authorized or permitted under this Agreement. The record date in connection with any vote or consent to take any action by the Holders under this Agreement shall be the date that is ten (10) Business Days prior to the first solicitation of such vote or consent or such other date as the Company may select. No vote or consent to any action authorized or permitted under this Agreement, except with respect to Sections 1.5(f) and 1.5(g) hereof, shall be valid or effective if taken or made more than one hundred twenty (120) calendar days after the corresponding record date. If a record date is set, only the Holders as of such date shall be entitled to vote or consent to any action permitted under this Agreement, as applicable. The Company shall provide the Holders at least ten (10) Business Days’ notice of any record date set pursuant to this Section 1.5(h). |
| (i) |
All Payment Amounts shall be paid free and clear of and without any withholding or deduction, except to the extent required by applicable Law. To the extent required by applicable Laws, the Company, the Agent and any other applicable withholding agent shall be entitled to deduct or withhold, or cause to be deducted or withheld, from any amount payable hereunder, such Taxes as are required to be deducted or withheld as reasonably determined by such applicable withholding agent. To the extent that any amounts are so deducted or withheld, such deducted or withheld amounts shall be properly remitted to the appropriate taxing authority and will be treated for all purposes of this Agreement as having been paid or distributed to the Holder in respect of which such |
6
| deduction or withholding was made. No later than seventy-five (75) calendar days prior to the first Testing Date to occur after it becomes a Holder under this Agreement, or if less than seventy-five (75) calendar days remain to the next Testing Date, on the date that it becomes a Holder under this Agreement, a Holder shall deliver to the Company, the Agent and any applicable withholding agent an Internal Revenue Service Form W-8 or Internal Revenue Service Form W-9 or equivalent applicable form that is reasonably acceptable to the Company or the Agent, as applicable, to permit any payment of any Payment Amount to be made without deduction or withholding of any United States backup withholding Taxes. |
| (j) |
If any Payment Amount (or portion thereof, as applicable) is not able to be delivered to a Holder, or the corresponding Participants or beneficial owners of the CVRs (including as a result of uncashed checks, invalid DTC account address information or invalid information on the CVR Register) or otherwise remains unclaimed by a Holder on the date that is two (2) years after the date on which such Payment Amount became due and payable in accordance with this Agreement (or immediately prior to such earlier date on which such Payment Amount (or portion thereof, as applicable) would otherwise escheat to or become the property of any Governmental Authority), then: (i) such Payment Amount (or portion thereof, as applicable) will, to the extent permitted by applicable Law, become the property of the Company, free and clear of all claims or interest of any Person previously entitled thereto, and (ii) no consideration or compensation shall be payable therefor. Neither the Company nor the Agent will be liable to any Person in respect of such Payment Amount (or portion thereof, as applicable) delivered to a Governmental Authority pursuant to any applicable abandoned property, escheat or similar legal requirement under applicable Law, pursuant to this Section 1.5(j). In addition to and not in limitation of any other indemnity obligation herein, the Company agrees to indemnify and hold harmless the Agent with respect to any liability, penalty, cost or expense that the Agent may incur or be subject to in connection with transferring such property to the Company. |
| (k) |
Upon the occurrence of a Company Bankruptcy Event or the Company’s failure, for any reason, to timely pay in full any owed Payment Amount (subject to the Dispute Resolution Procedures) in accordance with the terms of this Agreement (each, a “Liquidated Damages Trigger Event”), the Company shall pay, as liquidated damages and not as a penalty, to the Agent, and the Agent shall transfer such funds either (i) to Holders directly for those Holders who hold Book-Entry CVRs, or (ii) to DTC in accordance with applicable rules and procedures of DTC for the benefit of the corresponding beneficial owners of the CVRs (for the avoidance of doubt, in the aggregate among clauses (i) and (ii)) (x) to the extent the Year 1 Contingent Payment Obligation was not previously paid in full or extinguished pursuant to the terms of this Agreement, $43,333,333.33 in cash (in United States Dollars), except that if the First Anniversary Payment Amount was conclusively calculated prior to the occurrence of the Liquidated Damages Trigger Event, the First Anniversary Payment Amount, in each case, less any amount actually paid in cash (in United States Dollars) by the Company with respect to any Year 1 Contingent Payment Obligation, plus (y) to the extent the Year 2 Contingent Payment Obligation was not previously paid in full or extinguished pursuant to the terms of this Agreement, $43,333,333.33 in cash (in United States Dollars), except that if the Second Anniversary Payment Amount was conclusively calculated prior to the occurrence of the Liquidated Damages Trigger Event, the Second Anniversary Payment Amount, in each case, less any amount actually paid in cash (in United States Dollars) or New Common Interests by the Company with respect to any Year 2 Contingent Payment Obligation plus (z) to the extent the Year 3 Contingent Payment Obligation was not previously paid in full or extinguished pursuant to the terms of this Agreement, $43,333,333.33 in cash (in United States Dollars), except that if the Third Anniversary Payment Amount was conclusively calculated prior to the occurrence of the Liquidated Damages Trigger Event, the Third Anniversary Payment Amount, in each case, less any amount actually paid in cash (in United States Dollars) or New Common Interests by the Company with respect to any Year 3 Contingent Payment Obligation. Upon the satisfaction in full of the obligations set forth in this Section 1.5(k) (the “Liquidated Damages Obligations”), the Contingent Payment Obligations shall be extinguished. The Company acknowledges the impossibility of ascertaining the amount of damages that would be suffered by the Holders by reason of the failure by the Company to perform its obligations hereunder and that the Liquidated Damages Obligations are reasonable estimates of the damages, which the Holders will suffer or incur as a result of the event |
7
| giving rise to the payment of the Liquidated Damages Obligations, and are not penalties. The Company irrevocably waives any right it may have to raise as a defense that any such liquidated damages are excessive, punitive or otherwise unenforceable. |
| (l) |
Upon written request, at its sole expense the Company shall make this Agreement available to the Holders until the expiration of this Agreement and the CVRs pursuant to Section 5.13. |
| 1.6 |
No Voting, Dividends or Interest; No Equity or Ownership Interest. Nothing contained in this Agreement shall be construed as conferring upon the Holder (solely in its capacity as the holder of CVRs) the right to vote or to receive distributions or to consent or to receive notice as a stockholder of the Company in respect of any meeting of stockholders of the Company for the election of directors of the Company or of any other matter, or any rights whatsoever as a stockholder of the Company. CVRs shall not represent any equity or ownership interest in the Company or any of its affiliates. |
| 1.7 |
Ability to Abandon CVRs. A Holder may at any time, at such Holder’s sole option, abandon any or all of such Holder’s remaining rights in a CVR by transferring such CVR to the Company or its Affiliates without consideration therefor. Nothing in this Agreement shall prohibit the Company or any of its Affiliates from offering to acquire or acquiring any CVRs for consideration from the Holders, in private transactions or otherwise, in its sole discretion. Any CVRs acquired by the Company or any of its Affiliates shall be automatically deemed extinguished and no longer outstanding, with prompt written notification by the Company to the Agent of such transfer and cancellation. |
| 1.8 |
Trust Indenture Act. The CVRs issued hereunder shall not constitute (i) a note, bond, debenture, evidence of indebtedness; (ii) a certificate of interest or participation in any such note, bond, debenture, or evidence of indebtedness; or (iii) a temporary certificate for, or guarantee of, any such note, bond, debenture, evidence of indebtedness, or certificate, in each of clauses (i), (ii) and (iii) hereof, as such terms are referenced in the TIA, and shall be exempt from the qualification provisions of the TIA. |
| 1.9 |
No Fractional Shares. The Company shall not be required to issue fractions of New Common Interests under this Agreement. If any fraction of a share of a New Common Interest would be issuable hereunder, such share shall be rounded to the next higher whole number. |
ARTICLE II
THE AGENT
| 2.1 |
Certain Duties and Responsibilities of the Agent. |
| (a) |
The Agent shall not have any liability for any actions taken, suffered or omitted to be taken in connection with this Agreement, except to the extent such liability arises as a result of its gross negligence, bad faith, willful misconduct or fraud (each as determined by a court of competent jurisdiction in a final and non-appealable judgment). Notwithstanding anything contained herein to the contrary, the Agent’s aggregate liability during any term of this Agreement with respect to, arising from, or arising in connection with this Agreement, or from all services provided or omitted to be provided under this Agreement, whether in contract, or in tort, or otherwise, is limited to, and shall not exceed, the amounts paid hereunder by the Company to the Agent as fees and charges, but not including reimbursable expenses, during the twelve (12) months immediately preceding the event for which recovery from Agent is being sought. |
| (b) |
The Agent shall be under no obligation to institute any action, suit or legal proceeding or to take any other action likely to involve expense or liability, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Company. All rights of action of any or all Holders under this Agreement may be enforced by the Agent, including, to the extent permitted by this Agreement, pursuant to a direction by the Majority Holders, and any action, suit or proceeding instituted by the Agent shall be brought in its name as the Agent and any recovery in connection |
8
| therewith shall be for the proportionate benefit of all the Holders, as their respective rights or interests may appear. The Holders, acting by the written consent of the Majority Holders, may direct in writing the Agent to act on behalf of the Holders in enforcing any of their rights hereunder. Notwithstanding anything to the contrary herein, the Agent shall be under no duty or obligation to institute any action, suit or proceeding, or to take any other action likely to result in the incurrence of expenses by the Agent; provided that, in the event that the Agent elects to institute any action, suit or proceeding, or to take any other action directed by the Holders, the Majority Holders (on behalf of all Holders) shall furnish the Agent with reasonable security and indemnity for any costs and expenses that may be incurred pursuant to an agreement in form and substance reasonably satisfactory to the Agent and shall reimburse the Agent for any such costs and expenses upon demand by the Agent. |
| 2.2 |
Certain Rights of the Agent. |
| (a) |
The Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied covenants or obligations shall be read into this Agreement against the Agent. |
| (b) |
The Agent shall be authorized and protected and shall incur no liability or responsibility to the Company or to any Holder for any action taken, suffered or omitted to be taken by it in reliance on any written notice, resolution, waiver, consent, order, certificate or other paper, document or instrument believed by it in the absence of bad faith to be genuine and to have been signed, sent or presented by the proper party or parties. The Agent shall not be deemed to have knowledge of any event of which it was supposed to receive notice thereof hereunder, and the Agent shall be fully protected and shall incur no liability for failing to take action in connection therewith unless and until it has received such notice in writing. |
| (c) |
The Agent may engage and consult with counsel, investment banking advisors, accountants or other professionals of its reasonable selection, and the advice or opinion of such outside counsel, investment banking advisors, accountants or other professionals shall be full and complete authorization and protection to the Agent, and the Agent shall be held harmless by the Company in respect of any action taken, suffered or omitted by it hereunder in the absence of bad faith and in reliance thereon. |
| (d) |
Any permissive rights of the Agent hereunder shall not be construed as a duty. |
| (e) |
The Agent shall not be required to give any note or surety in respect of the execution of such powers or otherwise in respect of such powers. |
| (f) |
The Company agrees to indemnify the Agent for, and to hold the Agent harmless from and against, any loss, liability, damage, claim, judgment, fine, cost, penalty, demands, suits or expense (“Loss”) (whether asserted by the Company, any Holder or any third party) suffered or incurred by the Agent arising out of or in connection with the Agent’s performance of its obligations under this Agreement, including, without limitation, the reasonable costs and expenses of defending the Agent against any claim, charge, demand, action, suit or loss arising out of or in connection with the execution, acceptance, administration, exercise and performance of its duties under this Agreement, including the costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder, except to the extent such Loss has been determined by a final non-appealable decision of a court of competent jurisdiction to have resulted from the Agent’s gross negligence, bad faith, willful misconduct or fraud. The Company’s obligations under this Section 2.2(f) to indemnify the Agent shall survive the expiration of the CVRs and the termination of this Agreement and the resignation, replacement or removal of the Agent. |
| (g) |
In addition to the indemnification provided under Section 2.2(f), but without duplication, the Company agrees to (i) pay the fees of the Agent in connection with the Agent’s performance of its obligations hereunder, as agreed upon in writing by the Agent and the Company on or prior to the |
9
| date of this Agreement (the “Fee Schedule”), and (ii) without limiting the foregoing (i), reimburse the Agent for all reasonable and documented out-of-pocket expenses, including all Taxes thereon (other than income, receipt, franchise or similar Taxes) and charges of any Governmental Authority, incurred by the Agent in the preparation, delivery, negotiation, amendment, administration and execution of this Agreement and the exercise and performance of its duties hereunder, including any stamp and transfer Taxes. The Company’s obligations under this Section 2.2(g) to compensate the Agent shall survive the expiration of the CVRs and the termination of this Agreement and the resignation, replacement or removal of the Agent. |
| (h) |
None of the provisions of this Agreement shall require the Agent to expend or risk its own funds or otherwise to incur any liability, financial or otherwise, in the performance of any of its duties hereunder, or in the exercise of any of its rights or powers if it shall have reasonable grounds for believing that repayment of such funds or indemnity satisfactory to it against such risk or liability is not assured to it. |
| (i) |
Anything in this Agreement to the contrary notwithstanding, in no event shall the Agent be liable for special, indirect, punitive, incidental or consequential loss or damage of any kind whatsoever (including but not limited to lost profits), even if the Agent has been advised of the likelihood of such loss or damage and regardless of the form of action. |
| (j) |
Whenever the Agent shall deem it desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder, the Agent may rely upon an Officer’s Certificate, which certificate shall be full authorization and protection to the Agent, and the Agent shall, in the absence of bad faith on its part, incur no liability and be held harmless by the Company for or in respect of any action taken, suffered or omitted to be taken by it under the provisions of this Agreement in reliance upon such certificate. |
| (k) |
The Agent shall have no liability and shall be held harmless by the Company in respect of the validity of this Agreement or the execution and delivery hereof (except the due execution and delivery hereof by the Agent and the enforceability of this Agreement against the Agent assuming the due execution and delivery hereof by the Company), nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement. |
| (l) |
The Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorneys, accountants, agents or other experts, and the Agent will not be liable for any act, default, neglect or misconduct of any such attorneys or agents or for any loss to the Company or the Holders resulting from any such act, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct in the selection and continued employment thereof (each as determined by a final non-appealable order, judgment, ruling or decree of a court of competent jurisdiction). |
| (m) |
The Agent shall not be liable for or by reason of, and shall be held harmless by the Company with respect to any of the statements of fact or recitals contained in this Agreement or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Company only. |
| (n) |
The Agent shall not incur any liability for not performing any act, duty, obligation or responsibility by reason of any occurrence beyond the control of the Agent (including without limitation any act or provision of any present or future law or regulation or governmental authority, any act of God, war, civil disorder or failure of any means of communication, terrorist acts, pandemics, epidemics, shortage of supply, breakdowns or malfunctions, interruptions or malfunction of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties). |
| (o) |
In no event shall the Agent be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, |
10
| including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, epidemic, pandemic, disease, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services, or other causes, in each case, reasonably beyond its control; it being understood that the Agent shall use reasonable efforts that are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances. |
| (p) |
In the event the Agent reasonably believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or other communication, paper or document received by the Agent hereunder, or is for any reasonably justifiable reason unsure as to what action to take hereunder, the Agent shall notify the Company in writing as soon as practicable, and upon delivery of such notice may, in its sole discretion, refrain from taking any action, and shall be fully protected and shall not be liable in any way to the Company or any Holder or other Person for refraining from taking such action, unless the Agent receives written instructions signed by the Company which eliminates such ambiguity or uncertainty to the reasonable satisfaction of the Agent. |
| (q) |
The Agent and the Company agree that all books, records, information and data pertaining to the business of the other party, including inter alia, personal, non-public Holder information, which are exchanged or received pursuant to the negotiation or the carrying out of this Agreement including the fees for services set forth in the Fee Schedule shall remain confidential, and shall not be voluntarily disclosed to any other person, except as may be required by law, including, without limitation, pursuant to subpoenas from state or federal government authorities (e.g., in divorce and criminal actions). |
| (r) |
The Agent shall act hereunder solely as agent for the Company and shall not assume any obligations or relationship of agency or trust with any of the owners or holders of the CVRs. For the avoidance of doubt, the Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holders with respect to any action or default by the Company, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Company. |
| (s) |
Subject to applicable Law, (i) the Agent and any shareholder, Affiliate, director, officer or employee of the Agent may buy, sell or deal in any securities of the Company or become peculiarly interested in any transaction in which such parties may be interested, or contract with or lend money to such parties or otherwise act as fully and freely as though it were not the Agent under this Agreement, and (ii) nothing herein will preclude the Agent from acting in any other capacity for the Company or for any other Person. |
| (t) |
Computershare shall hold all funds received under this Agreement as Agent in accordance with the terms of this Agreement in a bank account at a U.S. chartered commercial bank with consolidated assets of $100 billion or more selected by Computershare and as approved by the Company and listed in Annex D attached hereto. The Company shall have no responsibility or liability for any diminution of such funds that may result from any deposit made by Computershare in accordance with this paragraph, except for any loss of such funds as a result of a default by the bank where such funds are held. Computershare may from time to time receive interest and other earnings in connection with such deposits. The Agent shall not be obligated to pay such interest or earnings to the Company, any Holder or any other party. |
| 2.3 |
Compliance Certificates and Opinions. Upon any application or request by the Company to the Agent to take or refrain from taking any action under any provision of this Agreement, the Company shall furnish to the Agent an Officer’s Certificate stating that, in the opinion of the signer, all conditions precedent, if any, provided for in this Agreement (including any covenant compliance that constitutes a condition precedent, if any) relating to the proposed action have been complied with and, if requested by the Agent, an Opinion of Counsel stating that in the opinion of such counsel all such conditions precedent, if any, have been complied with, except that in the case of any such application or request as to which the furnishing of such documents is specifically required by any provision of this Agreement relating to such particular application or request, no additional certificate or opinion need be furnished. Notwithstanding the foregoing, and in accordance with |
11
| the Plan as confirmed by the Bankruptcy Court, in the event the Company elects to issue New Common Interests pursuant to the terms of this Agreement, no opinion shall be required from the Company in connection with such issuance of New Common Interests with respect to whether the New Common Interests are exempt from registration, are eligible for DTC book-entry delivery, settlement and depositary services, or validly issued, fully paid, and non-assessable. |
Each certificate or opinion with respect to compliance with a condition or covenant provided for in this Agreement shall include:
| (a) |
a statement that each individual signing such certificate or opinion has read such covenant or condition; |
| (b) |
a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based; |
| (c) |
a statement that, in the opinion of each such individual or such firm, such individual or firm has made such examination or investigation as is necessary to enable such individual or firm to express an informed opinion as to whether or not such covenant or condition has been complied with; and |
| (d) |
a statement as to whether, in the opinion of such individual, such condition or covenant has been complied with. |
| 2.4 |
Resignation and Removal; Appointment of Successor. |
| (a) |
The Agent may resign at any time by giving written notice thereof to the Company and the Holders specifying a date when such resignation shall take effect, which notice shall be sent at least thirty (30) calendar days prior to the date so specified. |
| (b) |
The Company and the Majority Holders shall each have the right to remove the Agent at any time by specifying a date when such removal shall take effect. Written notice of such removal shall be given by the Company or the Majority Holders to the Agent, as applicable, which notice shall be sent at least thirty (30) calendar days prior to the date so specified. |
| (c) |
If the Agent shall resign, become incapable of acting or is removed by the Company or the Majority Holders, the Company shall promptly appoint a qualified successor Agent, provided, that, the Majority Holders may notify the Company of their preference of qualified successor Agent hereunder and the Company shall reasonably take such preference into account in its selection. The successor Agent so appointed shall, forthwith upon its acceptance of such appointment in accordance with this Section 2.4(c) and Section 2.5, become the Agent for all purposes hereunder. Notwithstanding the foregoing, if the Company and the Majority Holders fail to make such appointment within a period of thirty (30) days after giving notice to the Agent of such removal or after they have been notified in writing of such resignation or incapacity by the resigning or incapacitated Agent, then any Holder may apply to any court of competent jurisdiction for the appointment of a successor Agent. |
| (d) |
The Company shall give notice of each resignation or removal of the Agent and each appointment of a successor Agent through the facilities of DTC in accordance with DTC’s procedures and/or by mailing written notice of such event by first-class mail, postage prepaid, to the Holders as their names and addresses appear in the CVR Register. Each notice shall include the name and address of the successor Agent. If the Company fails to send such notice within ten (10) Business Days after acceptance of appointment by a successor Agent, the successor Agent shall cause the notice to be mailed at the expense of the Company. Failure to give any notice provided for in this Section 2.4 shall not affect the legality or validity of the resignation or removal of the Agent or the appointment of the successor Agent, as the case may be. |
12
| (e) |
The Agent will cooperate with the Company and any successor Agent in connection with the transition of the duties and responsibilities of the Agent to the successor Agent, including transferring the CVR Register to the successor Agent; provided that, the predecessor Agent shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing. |
| (f) |
Any Person into which the Agent may be merged or converted or with which it may be consolidated, or any Person resulting from any merger, conversion or consolidation to which the Agent shall be a party, or any Person succeeding to the corporate trust business of the Agent shall be the successor of the Agent hereunder without the execution or filing of any paper with any party hereto or any further act on the part of any of the parties hereto except where an instrument of transfer or assignment is required by law to effect such succession, anything herein to the contrary notwithstanding. The Agent shall give notice to the Company promptly upon the occurrence of such transaction as described in this Section 2.4(f). |
| 2.5 |
Acceptance of Appointment by Successor. Every successor Agent appointed hereunder shall, at or prior to such appointment, execute, acknowledge and deliver to the Company and to the retiring Agent an instrument accepting such appointment and a counterpart of this Agreement, and thereupon such successor Agent, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the Agent; provided that upon the request of the Company or the successor Agent, such resigning or removed Agent shall execute and deliver an instrument transferring to such successor Agent all the rights, powers and trusts of such resigning or removed Agent. |
ARTICLE III
AMENDMENTS
| 3.1 |
Amendments Without Consent of Holders. |
| (a) |
The Company, at any time or from time to time, may unilaterally enter into one or more amendments hereto for any of the following purposes, without the consent of any of the Holders, so long as, in the cases of clauses (ii) through (iv) hereof, such amendments do not, individually or in the aggregate, adversely affect the interests of the Holders: |
| (i) |
to evidence the appointment of another Person as a successor Agent and the assumption by any successor Agent of the covenants and obligations of the Agent hereof in accordance with the provisions of this Agreement; |
| (ii) |
to add to any covenants of the Company such further covenants, restrictions, conditions or provisions as the Company shall determine to be for the protection of the Holders; |
| (iii) |
to cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with any other provision herein, or to make any other provisions with respect to matters or questions arising under this Agreement; |
| (iv) |
as may be necessary or appropriate to ensure that CVRs are not subject to registration under the Securities Act or the Exchange Act; |
| (v) |
to evidence the assignment of this Agreement by the Company as provided in Section 4.4; or |
| (vi) |
any other amendment hereto which would provide any additional rights or benefits to the Holders or that does not adversely affect the legal rights under this Agreement of any such Holder or the Agent. |
13
| (b) |
Promptly after the execution by the Company and the Agent of any amendment pursuant to the provisions of this Section 3.1, the Company shall send (or cause the Agent to send) a notice thereof through the facilities of DTC in accordance with DTC’s procedures and/or by first class mail to the Holders at their addresses as set forth on the CVR Register, setting forth in general terms the substance of such amendment. |
| 3.2 |
Amendments with Consent of Holders. |
| (a) |
In addition to any amendments to this Agreement that may be made by the Company without the consent of any Holder pursuant to Section 3.1, with the consent of the Majority Holders and the Agent, which consent shall not be unreasonably withheld, conditioned or delayed, whether evidenced in writing or taken at a meeting of the Holders, the Company and the Agent may enter into one or more amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement; provided that no amendment shall decrease the aggregate Payment Amount with respect to any Testing Date or amend Sections 1.5(a)-(c) or this Section 3.2(a) without the consent of each Holder. |
| (b) |
Promptly after the execution by the Company and the Agent of any amendment pursuant to the provisions of this Section 3.2 (but prior to the effectiveness of such amendment), the Company shall send (or cause the Agent to send) (at the Company’s sole expense) a notice thereof (i) in the case of Global CVRs, through the facilities of DTC in accordance with DTC’s procedures and (ii) in the case of Book-Entry CVRs held on the CVR Register, to each Holder on their address as set out in the CVR Register, in each case, setting forth in general terms the substance of such amendment. Any amendment to this Agreement made pursuant to this Section 3.2 shall become effective ten (10) Business Days following the mailing of such notice. |
| 3.3 |
Execution of Amendments. Each amendment to this Agreement shall be evidenced by a writing signed by the Agent and the Company. Upon the delivery of an Officer’s Certificate which states that the proposed supplement or amendment is in compliance with the terms of this Section 3 and provided that such supplement or amendment does not adversely affect the Agent’s rights, duties, liabilities, immunities or obligations hereunder, the Agent shall execute such supplement or amendment. Subject to compliance with this Section 3, the Agent may, but is not obligated to, enter into any such amendment that adversely affects the Agent’s own rights, protections, powers, trusts, privileges, covenants, indemnities or duties under this Agreement or otherwise. |
| 3.4 |
Effect of Amendments. Upon the execution of any amendment under this ARTICLE III, this Agreement shall be modified in accordance therewith, such amendment shall form a part of this Agreement for all purposes and every Holder shall be bound thereby. |
ARTICLE IV
MISCELLANEOUS
| 4.1 |
Notices to Agent and the Company. All notices and other communications under this Agreement shall be in writing (including by electronic transmission) and shall be deemed to have been duly delivered and received when delivered by hand, or when sent if delivered to a recognized courier or deposited in the mail, first class and postage prepaid and, in the case of notice or demand made by the Agent or by any Holder to or on the Company, immediately upon confirmation of transmission of electronic mail, where such notice is given by electronic mail, in each case to the intended recipient as set forth below: |
| (i) |
if to the Company, to: |
Core Scientific, Inc.
838 Walker Road Suite 21-2105
Dover, DE 19904
Attention: Legal
14
E-mail: legal@corescientific.com
with a copy (which shall not constitute notice) to:
Weil, Gotshal & Manges LLP
767 Fifth Avenue
New York, NY 10153
Attention: Merritt S. Johnson
Telephone: (212) 310-8280
E-mail: merritt.johnson@weil.com
| (ii) |
if to the Agent, to: |
Computershare Trust Company, N.A.,
Computershare Inc.
150 Royall Street
Canton, MA 02021
Attention: Client Services
| 4.2 |
Notice to Holders. All notices, requests and communications required to be given to the Holders shall be sufficiently given (unless otherwise herein expressly provided) if in writing and transmitted through the facilities of DTC in accordance with DTC’s procedures and/or mailed, first-class postage prepaid, to each Holder affected by such event, at his, her or its address set forth in the CVR Register, not later than the latest date, and not earlier than the earliest date, prescribed for the giving of such notice. In any case where notice to the Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the sufficiency of such notice with respect to other Holders. |
| 4.3 |
Entire Agreement. This Agreement and the Plan represent the entire understanding of the Company and the Holders with reference to the CVRs, and this Agreement supersedes any and all other oral or written agreements hereto made with respect to the CVRs. As between the Agent and the Company, this Agreement (including any schedules, annexes and exhibits hereto and the documents and instruments referred to herein) contain the entire understanding of the parties hereto with reference to the CVRs and matters contemplated hereby and supersedes all prior agreements, written or oral, among the parties with respect thereto. |
| 4.4 |
Successors and Assigns. The Company may assign, in its sole discretion and without the consent of any other party or Holder, any or all of its rights, interests and obligations hereunder to one or more its Affiliates (that are wholly owned direct or indirect subsidiaries of the Company) (each, an “Assignee”) and any such Assignee may thereafter assign, in its sole discretion and without the consent of any other party or Holder, any or all of its rights, interests and obligations set forth hereunder to one or more additional Assignees; provided, however, that in connection with any assignment to an Assignee, the Company shall agree to remain liable for the performance such Assignee of its obligations hereunder. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties to this Agreement and the Holders and their respective permitted successors and permitted assigns. The Agent may not assign this Agreement without the Company’s consent. This Agreement shall not restrict the Company’s or any successor’s ability to merge or consolidate or enter into or consummate any Change of Control; provided that in the event of a Change of Control, (i) the Company shall cause the surviving entity to assume the Company’s obligations, duties and covenants under this Agreement, (ii) the surviving entity shall be entitled to elect to make the Second Anniversary Payment Amount and/or Third Anniversary Payment Amount, as applicable, in common equity securities of the surviving entity (subject to adjustments in connection with any stock split, reverse stock split, recapitalization, reclassification, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, exchange, non-cash dividend or similar event in connection therewith or with the New Common Interests) (the “Surviving Entity Equity Securities”), in lieu of New Common Interests, only if such Surviving Entity Equity Securities are listed on a principal U.S. national securities exchange, and (iii) the provisions of this Agreement in connection with New Common Interests shall apply in the same manner and to the same extent to such Surviving Equity Securities. Any attempted assignment of this Agreement or any of such rights in violation of this Section 4.4 shall be void ab initio and of no effect. |
15
| 4.5 |
Benefits of Agreement. Nothing in this Agreement, express or implied, shall give to any Person (other than the parties to this Agreement, the Holders and their permitted successors and permitted assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the parties to this Agreement, the Holders and their permitted successors and permitted assigns. |
| 4.6 |
Governing Law. This Agreement shall be governed by and construed in accordance with the Laws of the State of New York, regardless of any provision of law or rule that might otherwise govern under applicable principles of conflicts of law thereof. |
| 4.7 |
Consent to Jurisdiction; Service of Process; Venue. Subject to Section 1.5(g), each of the parties to this Agreement and the Holders (a) irrevocably consents to the service of the summons and complaint and any other process (whether inside or outside the territorial jurisdiction of the Chosen Courts) in any Legal Proceeding relating to the transactions contemplated by this Agreement, for and on behalf of itself or any of its properties or assets, in accordance with Section 4.1 or in such other manner as may be permitted by applicable Law, but nothing in this Section 4.7 shall affect the right of any parties to this Agreement and the Holders to serve legal process in any other manner permitted by applicable Law; (b) irrevocably and unconditionally consents and submits itself and its properties and assets in any Legal Proceeding to the exclusive jurisdiction of the Chosen Courts in the event any dispute or controversy arises out of this Agreement or the transactions contemplated in this Agreement, or for recognition and enforcement of any judgment in respect thereof; (c) agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any Chosen Court; (d) agrees that any Legal Proceedings arising in connection with this Agreement or the transactions contemplated in this Agreement shall be brought, tried and determined only in the Chosen Courts; (e) waives any objection that it may now or hereafter have to the venue of any such Legal Proceeding in the Chosen Courts or that such Legal Proceeding was brought in an inconvenient court and agrees not to plead or claim the same; and (f) agrees that it will not bring any Legal Proceeding relating to this Agreement or the transactions contemplated hereby or thereby in any court other than the Chosen Courts. Each of parties to this Agreement and the Holders agrees that a final judgment in any Legal Proceeding in the Chosen Courts shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by applicable Law. |
| 4.8 |
WAIVER OF JURY TRIAL. EACH OF THE PARTIES TO THIS AGREEMENT AND THE HOLDERS ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE PURSUANT TO THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH PARTY TO THIS AGREEMENT AND HOLDER IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT THAT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL PROCEEDING (WHETHER FOR BREACH OF CONTRACT, TORTIOUS CONDUCT OR OTHERWISE) DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT. EACH PARTY TO THIS AGREEMENT AND HOLDER ACKNOWLEDGES AND AGREES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY TO THIS AGREEMENT OR ANY HOLDER HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER; (B) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER; (C) IT MAKES THIS WAIVER VOLUNTARILY; AND (D) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 4.8. |
| 4.9 |
Further Assurances. Subject to the provisions of this Agreement, the parties to this Agreement and the Holders will, from time to time, do all acts and things and execute and deliver all such further documents and instruments, as the other parties to this Agreement and the Holders may reasonably require to effectively carry out or better evidence or perfect the full intent and meaning of this Agreement. |
| 4.10 |
Severability. In the event that any provision of this Agreement, or the application thereof, becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably to effect the intent of the parties to this Agreement and the |
16
| Holders. The parties to this Agreement and the Holders further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such void or unenforceable provision; provided, however, that if such excluded provision shall materially and adversely affect the rights, immunities, liabilities, duties or obligations of the Agent, the Agent shall be entitled to resign immediately upon written notice to the Company. |
| 4.11 |
Headings. The headings and table of contents contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. |
| 4.12 |
Counterparts. This Agreement and any amendments to this Agreement may be executed in one or more textually identical counterparts, all of which will be considered one and the same agreement and will become effective when one or more counterparts have been signed by each of the parties to this Agreement and delivered to the other parties to this Agreement and the Holders, it being understood that all parties to this Agreement need not sign the same counterpart. Any such counterpart, to the extent delivered by fax or.pdf .tif, .gif, .jpg or similar attachment to electronic mail (any such delivery, an “Electronic Delivery”), will be treated in all manner and respects as an original executed counterpart and will be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. No party to this Agreement or Holder may raise the use of an Electronic Delivery to deliver a signature, or the fact that any signature or agreement or instrument was transmitted or communicated through the use of an Electronic Delivery, as a defense to the formation of a contract, and each party to this Agreement and Holder forever waives any such defense, except to the extent such defense relates to lack of authenticity. The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to this Agreement or any document to be signed in connection with this Agreement shall be deemed to include electronic signatures, including without limitation, digital signature provided by DocuSign, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature. The Company agrees to assume all risks arising out of the use of using digital signatures and electronic methods to submit communications to the Agent, including without limitation the risk of Agent acting on unauthorized instructions, and the risk of interception and misuse by third parties. |
| 4.13 |
Expiration. This Agreement and the CVRs shall expire and be of no force or effect, and the parties to this Agreement and the Holders shall have no liability hereunder (other than to the extent of any obligations which expressly survive or provide for performance following expiration), ten (10) calendar days after payment of any Payment Amount with respect to the Third Testing Date, or, if the Dispute Resolution Procedures are conducted, ten (10) calendar days following the conclusion of all procedures thereunder. Notwithstanding the foregoing, no such expiration shall affect any rights or obligations accrued prior to the effective date of such expiration. |
| 4.14 |
Legal Holidays. In the event that the day on which any Payment Amount is due shall not be a Business Day, then, notwithstanding any provision of this Agreement to the contrary, any payment required to be made in respect of the CVRs shall be made on the next succeeding Business Day with the same force and effect as if made on the last day on which such Payment Amount is due. |
| 4.15 |
Interpretation. When a reference is made in this Agreement to an Article, Annex or Section, such reference shall be to an Article, Annex or Section of this Agreement unless otherwise indicated. Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. All terms defined in this Agreement shall have the defined meanings when used in any certificate or other document made or delivered pursuant of this Agreement unless otherwise defined therein. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such term. Any agreement, instrument or statute defined or referred to herein or in any agreement or instrument that is referred to herein means such agreement, instrument or statute as from time to time amended, modified or supplemented, including (in the case of agreements or instruments) by waiver or consent and (in the case of statutes) by succession of comparable successor statutes and references to all attachments thereto and instruments incorporated therein. |
17
| References to a Person are also to its permitted successors and permitted assigns. References to clauses without a cross-reference to a Section or subsection are references to clauses within the same Section or, if more specific, subsection. References from or through any date means, unless otherwise specified, from and including or through and including, respectively. The symbol “$” refers to United States Dollars. |
| 4.16 |
No Fiduciary Obligations. Each of the Company and the Agent acknowledges and agrees that the other party, its Affiliates and their respective officers, directors and controlling Persons do not owe any fiduciary duties to the first party or any of its respective Affiliates, officers, directors or controlling Persons. The only obligations of the Company and the Agent to each other and their Affiliates and their respective officers, directors and controlling Persons arising out of this Agreement are the contractual obligations expressly set forth in this Agreement. |
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]
18
IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed by their respective duly authorized officers to be effective as of the date first above written.
| CORE SCIENTIFIC, INC. | ||
| By: |
/s/ Todd M. DuChene |
|
| Name: | Todd M. DuChene | |
| Title: | Chief Legal Officer, Chief Administrative Officer and Secretary | |
|
COMPUTERSHARE INC. and COMPUTERSHARE TRUST COMPANY, N.A. as Agent |
||
| On behalf of both entities: | ||
| By: |
/s/ Collin Ekeogu |
|
| Name: | Collin Ekeogu | |
| Title: | Manager, Corporate Actions | |
[Signature Page to Contingent Value Rights Agreement]
ANNEX A
CERTAIN DEFINED TERMS
“Affiliate” of any Person means any other Person that directly or indirectly, through one or more intermediates, controls, is controlled by, or is under common control with, such first Person.
“Bankruptcy Law” means Title 11 of the United States Code or any similar federal, state or foreign law for the relief of debtors, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, winding-up, restructuring, examinership or similar debtor relief laws.
“Business Day” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by law or other governmental action to be closed, or are in fact closed, in New York, New York.
“Change of Control” means (i) a sale or other disposition of all or substantially all of the assets of the Company on a consolidated basis (other than to any direct or indirect wholly owned subsidiary of the Company), (ii) a merger or consolidation involving the Company in which it is not the surviving entity, and (iii) any other transaction involving the Company in which it is the surviving entity but in which the stockholders of the Company immediately prior to such transaction own less than fifty percent (50%) of the surviving entity’s voting power immediately after the transaction, other than (x) the issuance of New Common Interests pursuant to (1) the exercise of the Company’s Warrants, (2) the conversion of the Convertible Notes into New Common Interests, or (3) the CVRs, and (y) any bona fide equity financing transaction solely related to the continued financing of the operations of the Company and its subsidiaries.
“Chosen Courts” means the courts of the State of New York and any federal courts located in such state (and appellate courts thereof).
“Company Bankruptcy Event” means an Insolvency Proceeding is commenced by the Company or any Guarantor; the Company or any Guarantor makes an offer of settlement, extension or composition to its unsecured creditors generally; a trustee is appointed to take possession of any substantial real or personal property of or to operate any of the business of the Company or any Guarantor; or an Insolvency Proceeding is commenced against the Company or any Guarantor, and the Company or such Guarantor consents to institution of the proceeding, the petition commencing the proceeding is not timely contested by the Company or such Guarantor, the petition is not dismissed within 60 days after filing, or an order for relief approving such Insolvency Proceeding is entered in the proceeding
“Convertible Notes” means the 10.00%/12.00% Cash/Cash-and-Payment in Stock Convertible Secured Notes due 2029, in the aggregate principal amount of $260,000,000, issued pursuant to the Convertible Notes Indenture. For the avoidance of doubt, no Additional Notes (as defined in the Convertible Notes Indenture) shall be included in the definition of Convertible Notes for purposes of this Agreement.
“Convertible Notes Indenture” means that certain convertible notes indenture, dated as of the Effective Date, among the Company as issuer, the guarantors from time to time party thereto and Wilmington Trust, National Association, as trustee and collateral agent, as may be amended or modified from time to time.
“Corresponding New Common Interests” means 51,783,625 New Common Interests (subject to adjustments in connection with any stock split, reverse stock split, recapitalization, reclassification, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, exchange, non-cash dividend or similar event in connection with the New Common Interests).
“CVR(s)” means the rights of a Holder to receive contingent payments in the form of cash and/or New Common Interests, as applicable, pursuant to this Agreement and the Plan.
“Depositary” means, with respect to the Global CVRs, DTC and any and all successors thereto appointed as Depositary hereunder and having become such pursuant to this Agreement.
“Dispute Resolution Procedures” means, collectively, the procedures set forth in Sections 1.5(f) and 1.5(g) hereof.
“DTC” means The Depository Trust Company or any successor entity thereto.
“Effective Date” means January 23, 2024.
“Fair Market Value” of the Corresponding New Common Interests means the following:
| i. |
As it relates to the First Testing Date, the product of (i) the VWAP of a single New Common Interest in the consecutive sixty (60) calendar day period immediately prior to the First Testing Date multiplied by (ii) the Corresponding New Common Interests as of the First Testing Date; |
| ii. |
As it relates to the Second Testing Date, the product of (i) the VWAP of a single New Common Interest in the consecutive sixty (60) calendar day period immediately prior to the Second Testing Date multiplied by (ii) the Corresponding New Common Interests as of the Second Testing Date; and |
| iii. |
As it relates to the Third Testing Date, the product of (i) the VWAP of a single New Common Interest in the consecutive sixty (60) calendar day period immediately prior to the Third Testing Date multiplied by (ii) the Corresponding New Common Interests as of the Third Testing Date. |
“Governmental Authority” means any government, any governmental or regulatory entity or body, department, commission, board, agency, instrumentality, legislature, taxing authority, political subdivision, bureau, official and any self-regulatory organization and any court, tribunal, judicial body, arbitrator or arbitration panel, in each case whether federal, state, county, provincial, and whether local, foreign or multinational.
“Guarantor” has the meaning ascribed thereto under the Convertible Notes Indenture.
“Holder” means a Person in whose name a CVR is registered in the CVR Register at the applicable time.
“Insolvency Proceeding” means any case or proceeding commenced by or against a Person under any state, federal or foreign law, rule or regulation for, or any agreement of such Person to any or a combination of the following: (a) the entry of an order for relief under the Bankruptcy Code, or any other insolvency, debtor relief or debt adjustment or reorganization law (including any moratorium or any other marshalling of the assets and liabilities of any Person and any similar laws, rules or regulations relating to or affecting the enforcement of creditors’ rights generally); (b) the appointment of a receiver, trustee, liquidator, administrator, conservator or other custodian for such Person or all or substantially all of its property; or (c) an assignment or trust mortgage for the benefit of creditors.
“Law” means any and all applicable federal, state, local, municipal, foreign, multinational or other law, statute, constitution, principle of common law, ordinance, code, rule, regulation, ruling, order or other legal requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by law under the authority of any Governmental Authority.
“Legal Proceeding” means any civil, criminal or administrative actions, demands, countersuits, proceedings suits, claims, charges, arbitrations, oppositions, investigations, reexaminations, lawsuits, litigations or other proceedings brought by or pending before any Governmental Authority.
“Majority Holders” means, as of any time of determination, Holders of not less than a majority of the outstanding CVRs.
“Majority of Objecting Holders” means, as of any time of determination, the Holders of the majority of the CVRs held by the Objecting Holders.
“New Common Interests” means common stock, par value $0.0001, of the Company to be issued (a) on the Effective Date or thereafter under the Plan or (b) as otherwise permitted pursuant to the Plan.
“Officer’s Certificate” means an officer’s certificate of the Company, signed by the Company’s Chief Executive Officer, Chief Financial Officer or other authorized officer, acceptable to the Agent.
“Opinion of Counsel” means written opinion from legal counsel acceptable to the Agent. The counsel may be external counsel or in-house counsel to the Company.
“Participant” means, with respect to DTC, a Person who has an account with DTC.
“Person” means any individual, corporation, partnership, limited liability company, trust, joint venture, governmental entity or other unincorporated entity, association or group.
“Relevant Stock Exchange” means the principal U.S. national securities exchange on which the New Common Interests (or such other security) are then listed; provided that, prior to the First Testing Date, the Company shall inform the Calculation Agent of the Relevant Stock Exchange on which the New Common Interests are then listed, and thereafter until the termination of this Agreement, the Company shall promptly inform the Calculation Agent of any change to the Relevant Stock Exchange.
“Requisite New Common Interests Payment Documentation” means the following: (i) a copy of an irrevocable instruction by the Company to the Transfer Agent (or other agent performing similar services for the Company) to issue to the applicable Holders the requisite number of New Common Interests in connection with the corresponding Payment Amount in the form appended hereto as Exhibit C; (ii) a copy of written confirmation from the Transfer Agent (or other agent performing similar services for the Company) that the issuance of the aforementioned New Common Interests to the applicable Holders has been completed; and (iii) an Officer’s Certificate addressed to the Agent, certifying that the aforementioned New Common Interests have been issued to the applicable Holders in connection with the corresponding Payment Amount (with respect to a Second Anniversary Payment Amount and Third Anniversary Payment Amount, also setting forth what portion, if any, of such Payment Amount was in cash).
“Tax” means all taxes, customs, tariffs, imposts, levies, duties, fees or other like assessments or charges of a similar nature, however denominated, imposed by a Governmental Authority, together with all interest, penalties and additions imposed with respect to such amounts.
“TIA” means the Trust Indenture Act of 1939, as amended.
“Trading Day” means a day on which: (1) trading in the New Common Interests (or other security for which a VWAP must be determined) generally occurs on the Relevant Stock Exchange or, if the New Common Interests (or such other security) is not then listed on a Relevant Stock Exchange, on the principal other market on which the New Common Interests (or such other security) is then traded; and (2) a VWAP for the New Common Interests (or other security for which a VWAP must be determined) is available on such securities exchange or market; provided that if the New common Interests (or other security for which a VWAP must be determined) is not so listed or traded, “Trading Day” means a Business Day. In the case of (1), if the New Common Interests (or other security for which a VWAP must be determined) are not then listed on a Relevant Stock Exchange, the Company shall promptly inform the Calculation Agent of any such change.
“Transfer Agent” means a transfer agent for the Company’s New Common Interests, as may be from time to time appointed by the Company.
“VWAP” means for any Trading Day, the per share volume-weighted average price as displayed under the heading “Bloomberg VWAP” on Bloomberg page “[CORZ]<equity>AQR” (or its equivalent successor if such page is not available) in respect of the period from the scheduled open of trading until the scheduled close of trading of the primary trading session on such Trading Day (or if such volume-weighted average price is unavailable, the market value of one New Common Interest on such Trading Day, determined, using a volume-weighted average method, by a nationally recognized independent investment banking firm retained for this purpose by the Company). The “VWAP” shall be determined without regard to after-hours trading or any other trading outside of the primary trading session trading hours. As of the date hereof, the ticker symbol of the Company is “CORZ”, and following the date hereof, the Company shall promptly inform the Calculation Agent of any change to the ticker symbol of the Company.
“Warrants” means the warrants issued pursuant to the warrant agreement, dated as of the Effective Date, among the Company, Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, as warrant agent.
ANNEX B
CERTAIN TERMS
| 1. |
Registration of Transfers and Exchanges. |
| a. |
Transfer and Exchange of Global CVRs or Beneficial Interests Therein. The transfer and exchange of Global CVRs or beneficial interests therein shall be effected through the Depositary, in accordance with this Agreement and the procedures of the Depositary therefor. |
| b. |
Exchange of a Beneficial Interest in a Global CVR for a Book-Entry CVR. |
| i. |
Any Holder of a beneficial interest in a Global CVR may, upon request, exchange such beneficial interest for a Book-Entry CVR. Upon receipt by the Agent from the Depositary or its nominee of written instructions or such other form of instructions as is customary for the Depositary on behalf of any Person having a beneficial interest in a Global CVR, the Agent shall cause, in accordance with the standing instructions and procedures existing between the Depositary and Agent, the number of CVRs represented by the Global CVR to be reduced by the number of CVRs to be represented by the Book-Entry CVRs to be issued in exchange for the beneficial interest of such Person in the Global CVR and, following such reduction, the Agent shall register in the name of the Holder a Book-Entry CVR and deliver to said Holder a statement, as issued by the Agent from time to time to the registered holder of Book-Entry CVRs reflecting such book-entry position (a “CVR Statement”). |
| ii. |
Book-Entry CVRs issued in exchange for a beneficial interest in a Global CVR pursuant to this Section 1 shall be registered in such names as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall instruct the Agent. The Agent shall deliver such CVR Statements to the Persons in whose names such Book-Entry CVRs are so registered. |
| c. |
Transfer and Exchange of Book-Entry CVRs. Book-Entry CVRs surrendered for exchange or for registration of transfer pursuant to this Section 1(c) or Section 1(i)(iv), shall be cancelled by the Agent. Such cancelled Book-Entry CVRs shall then be disposed of by or at the direction of the Company in accordance with applicable law. When Book-Entry CVRs are presented to or deposited with the Agent with a written request: |
| i. |
to register the transfer of the Book-Entry CVRs; or |
| ii. |
to exchange such Book-Entry CVRs for an equal number of Book-Entry CVRs of other authorized denominations; |
then in each case the Agent shall register the transfer or make the exchange as requested if its requirements for such transactions are met; provided, however, that the Agent has received a written instruction of transfer in a form satisfactory to the Agent, duly executed by the Holder thereof or by their attorney, duly authorized in writing.
| d. |
Restrictions on Exchange or Transfer of a Book-Entry CVR for a Beneficial Interest in a Global CVR. A Book-Entry CVR may not be exchanged for a beneficial interest in a Global CVR except upon satisfaction of the requirements set forth below. Upon receipt by the Agent of appropriate instruments of transfer with respect to a Book-Entry CVR, in a form satisfactory to the Agent, together with written instructions directing the Agent to make, or to direct the Depositary to make, an endorsement on the Global CVR to reflect an increase in the number of CVRs represented by the Global CVR equal to the number of CVRs represented by such Book-Entry CVR (such instruments of transfer and instructions to be duly executed by the holder thereof or the duly appointed legal |
| representative thereof or by his attorney, duly authorized in writing, such signatures to be guaranteed by an eligible guarantor institution participating in a signature guarantee program approved by a participant in the Securities Transfer Agent Medallion Program, the Stock Exchanges Medallion Program or the New York Stock Exchange, Inc. Medallion Signature Program (in each case, a “Signature Guarantee”), then the Agent shall cancel such Book-Entry CVR on the CVR Register and cause, or direct the Depositary to cause, in accordance with the standing instructions and procedures existing between the Depositary and the Agent, the number of CVRs represented by the Global CVR to be increased accordingly. If no Global CVRs are then outstanding, the Company shall issue and the Agent shall countersign by either manual, facsimile or other electronic signature a new Global CVR representing the appropriate number of CVRs. |
| e. |
Restrictions on Exchange or Transfer of Global CVRs. Notwithstanding any other provisions of this Agreement (other than the provisions set forth in Section 1(f)), unless and until it is exchanged in whole for a Book-Entry CVR, a Global CVR may not be transferred as a whole except by the Depositary to a nominee of the Depositary or by a nominee of the Depositary to the Depositary or another nominee of the Depositary or by the Depositary or any such nominee to a successor Depositary or a nominee of such successor Depositary. |
| f. |
Book-Entry CVRs. If at any time, the Depositary for the Global CVR notifies the Company that the Depositary is unwilling or unable to continue as Depositary for the Global CVR and a successor Depositary for the Global CVR is not appointed by the Company within ninety (90) days after delivery of such notice, then the Agent, upon written instructions signed by an Appropriate Officer of the Company and all other necessary information, shall register Book-Entry CVRs, in an aggregate number equal to the number of CVRs represented by the Global CVRs, in exchange for such Global CVRs, in such names and in such amounts as directed by the Depositary or, in the absence of instructions from the Depositary, the Company. |
| g. |
Restrictions on Transfers of CVRs. No CVRs shall be sold, exchanged or otherwise transferred in violation of the Securities Act or applicable state securities laws. Each Holder, by its acceptance of any CVR under this Agreement, acknowledges and agrees that the CVRs (including any New Common Interests issued at the Company’s discretion pursuant to this Agreement) were issued pursuant to an exemption from the registration requirement of Section 5 of the Securities Act provided by Section 1145 of the Bankruptcy Code, and to the extent that a Holder is an “underwriter” as defined in Section 1145(b)(1) of the Bankruptcy Code, such Holder may not be able to sell or transfer any New Common Interests in the absence of an effective registration statement under the Securities Act or an exemption from registration thereunder. |
| h. |
Cancellation of Global CVR Certificate. At such time as all beneficial interests in Global CVRs have either been exchanged for Book-Entry CVRs, redeemed, repurchased or cancelled, all Global CVRs shall be returned to, or retained and cancelled by, the Agent, upon written instructions from the Company satisfactory to the Agent. |
| i. |
Obligations with Respect to Transfers and Exchanges of CVRs. |
| i. |
To permit registrations of transfers and exchanges, the Company shall execute Global CVRs, if applicable, and the Agent is hereby authorized, in accordance with the provisions of this Section 1, to countersign by either manual, facsimile or other electronic signature such Global CVRs, if applicable, or register Book-Entry CVRs, if applicable, as required pursuant to the provisions of this Section 1. |
| ii. |
All Book-Entry CVRs and Global CVRs issued upon any registration of transfer or exchange of Book-Entry CVR or Global CVRs shall be the valid obligations of the Company, entitled to the same benefits under this Agreement as the Book-Entry CVRs or Global CVRs surrendered upon such registration of transfer or exchange. |
| iii. |
So long as the Depositary, or its nominee, is the registered owner of a Global CVR, the Depositary or such nominee, as the case may be, will be considered the sole owner or Holder of the CVRs represented by such Global CVRs for all purposes under this Agreement. Except as provided in Sections 1(b) and 1(f) upon the exchange of a beneficial interest in a Global CVRs for Book-Entry CVRs, owners of beneficial interests in a Global CVRs will not be entitled to have any CVRs registered in their names, and will under no circumstances be entitled to receive physical delivery of any such CVRs and will not be considered the owners or Holders thereof under the CVRs or this Agreement. Neither the Company nor the Agent, in its capacity as registrar for such CVRs, will have any responsibility or liability for any aspect of the records relating to beneficial interests in a Global CVRs or for maintaining, supervising or reviewing any records relating to such beneficial interests. Notwithstanding the foregoing, nothing herein shall prevent the Company, the Agent or any agent of the Company or the Agent from giving effect to any written certification, proxy or other authorization furnished by the Depositary or impair the operations of customary practices of the Depositary governing the exercise of the rights of a holder of a beneficial interest in a Global CVRs. |
| iv. |
Subject to Sections 1(b), 1(c) and 1(d) hereof, and this Section 1(i), the Agent shall, upon receipt of all information required to be delivered hereunder and any evidence of authority that may be reasonably required by the Agent, from time to time register the transfer of any outstanding CVRs in the CVR Register, upon surrender of Global CVRs, if applicable, representing such CVRs at the office of the Agent, duly endorsed, and accompanied by a completed form of assignment, duly signed by the Holder thereof or by the duly appointed legal representative thereof or by a duly authorized attorney and accompanied by a Signature Guarantee. Upon any such registration of transfer, a new Global CVR or a CVR Statement, as the case may be, shall be issued to the transferee. |
| 2. |
Execution of Global CVRs. |
| a. |
Global CVRs shall be signed on behalf of the Company by its Chief Executive Officer, its Chief Financial Officer, its President, its General Counsel, a Vice President, its Secretary, an Assistant Secretary or any other authorized person appointed by the board of directors (the “Board of Directors”) of the Company from time to time (each, an “Appropriate Officer”). Each such signature upon the Global CVRs may be in the form of a facsimile or electronic signature of any such Appropriate Officer and may be imprinted or otherwise reproduced on the Global CVRs and for that purpose the Company may adopt and use the facsimile or electronic signature of any Appropriate Officer. |
| b. |
If any Appropriate Officer who shall have signed any of the Global CVRs shall cease to be an Appropriate Officer before the Global CVRs so signed shall have been countersigned by the Agent or disposed of by the Company, such Global CVRs nevertheless may be countersigned and delivered or disposed of as though such Appropriate Officer had not ceased to be an Appropriate Officer of the Company, and any Global CVRs may be signed on behalf of the Company by any Person who, at the actual date of the execution of such Global CVRs, shall be an Appropriate Officer, although at the date of the execution of this Agreement such Person was not an Appropriate Officer. Global CVRs shall be dated the date of countersignature by the Agent and shall represent one or more whole CVRs. |
ANNEX C
FORM OF GLOBAL CVR
THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE CONTINGENT VALUE RIGHTS AGREEMENT (THE “CVR AGREEMENT”) HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE OF A DEPOSITARY OR A SUCCESSOR DEPOSITARY FOR THE BENEFIT OF THE BENEFICIAL OWNERS HEREOF. THIS SECURITY IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE CVR AGREEMENT, AND NO TRANSFER OF THIS SECURITY (OTHER THAN A TRANSFER OF THIS SECURITY AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY) MAY BE REGISTERED EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE CVR AGREEMENT.
UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DIRECT REGISTRATION FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”) TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.
CORE SCIENTIFIC, INC.
|
No. |
Certificate for | Contingent Value Rights | ||
|
CUSIP 21874A 122 |
[________] |
This certifies that __________, or registered assigns (the “Holder”), is the registered holder of the number of Contingent Value Rights (“CVRs”) set forth above. Each CVR entitles the Holder, subject to the provisions contained herein and in the CVR Agreement referred to on the reverse hereof, to payments from Core Scientific, Inc. a Delaware corporation (the “Company”), in an amount and in the form determined pursuant to the provisions set forth on the reverse hereof and as more fully described in the CVR Agreement referred to on the reverse hereof. Such payments shall be made by the Company in accordance with the terms of the CVR Agreement.
Payment of any amounts pursuant to this CVR certificate shall be made only to the Holder (as defined in the CVR Agreement) of this CVR certificate. Such payment shall be made at the office or agency maintained by the Company for such purpose; provided, however, that the Company may pay such amounts by wire transfer or check payable in such money or in New Common Interests, as defined in and in accordance with the terms of the CVR Agreement. Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company have been initially appointed as the Agent.
Reference is hereby made to the further provisions of this CVR certificate set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place.
Unless the certificate of authentication hereon has been duly executed by the Agent referred to on the reverse hereof by manual signature, this CVR certificate shall not be entitled to any benefit under the CVR Agreement, or be valid or obligatory for any purpose.
IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed.
Dated: [ ]
|
By: |
|
|
|
Name: |
||
|
Title: |
[Form of Reverse of CVR certificate]
1. This CVR certificate is issued under and in accordance with the Contingent Value Rights Agreement, dated as of January 23, 2024 (the “CVR Agreement”), between the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, as agent (the “Agent,” which term includes any successor Agent under the CVR Agreement), and is subject to the terms and provisions contained in the CVR Agreement, to all of which terms and provisions the Holder of this CVR certificate consents by acceptance hereof. The CVR Agreement is hereby incorporated herein by reference and made a part hereof. Reference is hereby made to the CVR Agreement for a full statement of the respective rights, limitations of rights, duties, obligations and immunities thereunder of the Company, the Agent and the Holders of the CVRs. All capitalized terms used in this CVR certificate without definition shall have the respective meanings ascribed to them in the CVR Agreement. Copies of the CVR Agreement can be obtained by contacting the Agent.
2. Contingent payments pursuant to CVRs shall be made, to the extent payable, to the Holders after each of the First Testing Date, the Second Testing Date and the Third Testing Date, in accordance with and pursuant to Section 1.5 of the CVR Agreement.
3. In the event of any conflict between this CVR certificate and the CVR Agreement, the CVR Agreement shall govern and prevail.
4. The First Anniversary Payment Amount, if any, subject to the Dispute Resolution Procedures, shall be payable by the Company in cash. Each of the Second Anniversary Payment Amount and Third Anniversary Payment Amount, if any, subject to the Dispute Resolution Procedures, shall be payable by the Company in cash and/or New Common Interests, or a combination of the foregoing, in the Company’s sole discretion, as set forth in the CVR Agreement. Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company have been initially appointed as Agent.
5. Holders may dispute the Payment Amount as set forth in Section 1.5 of the CVR Agreement.
6. The CVR Agreement permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of CVRs under the CVR Agreement by the Company with the consent of the Majority Holders.
7. No reference herein to the CVR Agreement and no provision of this CVR certificate or of the CVR Agreement shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay any Payment Amounts determined pursuant to the terms hereof and of the CVR Agreement at the times, place and amount, and in the manner, prescribed herein and in the CVR Agreement.
9. As provided in the CVR Agreement and subject to certain limitations therein set forth, the transfer of the CVRs represented by this CVR certificate is registrable on the CVR Register, upon surrender of this CVR certificate for registration of transfer at the office or agency of the Company maintained for such purpose duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Agent, duly executed by the Holder hereof or his or her attorney duly authorized in writing, and thereupon one or more new CVR certificates or Book-Entry CVRs, for the same amount of CVRs, will be issued to the designated transferee or transferees. The Company hereby initially designates the office of Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company at 150 Royall Street, Canton, MA 02021 as the office for registration of transfer of this CVR certificate.
10. As provided in the CVR Agreement and subject to certain limitations therein set forth, this CVR certificate is exchangeable for one or more CVR certificates or Book-Entry CVRs representing the same number of CVRs as represented by this CVR certificate as requested by the Holder surrendering the same.
11. No service charge will be made for any registration of transfer or exchange of CVRs, but the Company and the Agent may require payment of a sum sufficient to cover any documentary, stamp or similar issue or transfer taxes or other governmental charges imposed in connection with any registration of transfer or exchange.
12. Prior to the time of due presentment of this CVR certificate for registration of transfer, the Company, the Agent and any agent of the Company or the Agent may treat the Person in whose name this CVR certificate is registered as the owner hereof for all purposes, and neither the Company, the Agent nor any agent shall be affected by notice to the contrary.
13. Neither the Company nor the Agent has any duty or obligation to the holder of this CVR certificate, except as expressly set forth herein or in the CVR Agreement.
AGENT’S CERTIFICATE OF AUTHENTICATION
This is one of the Global CVRs referred to in the within-mentioned CVR Agreement.
Computershare Inc., a Delaware corporation and its
affiliate, Computershare Trust Company, N.A., a federally
chartered trust company, as the Agent
On behalf of both entities:
Dated: [ ]
|
By: |
|
|
|
Authorized Signatory |
EXHIBIT A
[COMPANY LETTERHEAD]
Payment Triggering Event Notice
[DATE]
This Payment Triggering Event Notice is being delivered to you pursuant to Section 1.5(e) of the Contingent Value Rights Agreement, dated as of [__], by and between Core Scientific, Inc. and Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, collectively, as CVR agent (the “Agreement”), in connection with the following Testing Date: [DATE].
Capitalized terms used herein but not otherwise defined shall have the meanings given to such terms in the Agreement.
Aggregate Payment Amount:___________________
Per-CVR Payment Amount: ____________________________
Calculation, in reasonable detail, of such aggregate Payment Amount and per-CVR Payment Amount: [__]
[(For Second Anniversary Payment and Third Anniversary Payment only):
Type of Payment Amount: Cash (United States Dollars) ☐
New Common Interests ☐]
The number of New Common Interests subject to Payment Amount: __________________]
Objection deadline in connection with the information herein: _____________________________________
EXHIBIT B
Payment Amount Objection Notice
[DATE]
[Core Scientific, Inc.
838 Walker Road Suite 21-2105
Dover, DE 19904
Attention: Legal
Email: legal@corescientific.com]
This Payment Amount Objection Notice is being delivered to you pursuant to Section 1.5(f) of the Contingent Value Rights Agreement, dated as of [__], by and between Core Scientific, Inc. and Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, collectively, as CVR agent.
The undersigned, as beneficial owner(s) of CVRs in the amount specified below, hereby objects to the following terms of the Payment Triggering Event Notice delivered on [DATE] in connection with [__] Testing Date:
|
☐ Aggregate Payment Amount (including the calculation thereof)
☐ Per-CVR Payment Amount
☐ Number of New Common Interests to be paid in connection with Payment Amount
☐ Other: [__]
Description of Objection: [__] |
||
| Number of CVRs beneficially owned: |
|
|
| Name: |
|
|
| Signature: |
|
|
| Signature must be guaranteed by a participant in the Securities Transfer Agent Medallion Program, the Stock Exchanges Medallion Program or the New York Stock Exchange, Inc. Medallion Signature Program | ||
| Title: |
|
|
| Street Address: |
|
|
| City, State and Zip Code: |
|
|
EXHIBIT C
[COMPANY LETTERHEAD]
Instruction Letter to Transfer Agent
[DATE]
[Computershare Trust Company, N.A.,
Computershare Inc. as Agent
150 Royall Street
Canton, MA 02021
Attention: Client Services]
Re: Authorization Letter for Issuance of Common Shares
Reference is made to (i) that certain CVR Agreement, dated as of January [24], 2024, by and between Core Scientific, Inc., a Delaware corporation (the “Company”), and Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, collectively, as CVR agent; and (ii) that certain Fourth Amended Joint Chapter 11 Plan of Core Scientific, Inc. and its Debtor Affiliates (as may be amended, modified or supplemented from time to time, the “Plan”), which was confirmed pursuant to an order of the United States Bankruptcy Court for the Southern District of Texas, Houston Division entered on January [16], 2024.
Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the CVR Agreement or the Plan, as applicable.
The Company hereby authorizes and instructs Computershare, as transfer agent and registrar to issue and allocate New Common Interests (CUSIP 21874A 106) as follows:
[IF ISSUING IN DTC]
Via SCL Add-to-Balance
| • |
To accept an SCL Add-to-Balance from Cede & Co. for [●] shares of New Common Interests (CUSIP 21874A 106). |
[IF ISSUING ON BOOKS AND RECORDS OF TRANSFER AGENT]
Via books and records of Transfer Agent
| • |
To issue [●] shares of New Common Interests (CUSIP 21874A 106) to those Holders who hold CVRs on the CVR Register, and to hold those shares for the same Holders on the books and records of the transfer agent. |
The foregoing issuance is in connection with the [Second Anniversary Payment Amount/Third Anniversary Payment Amount].
The “Effective Date” of the foregoing issuance shall be [●], 20[●].
The New Common Interests will be duly authorized, validly issued, fully paid and nonassessable.
|
CORE SCIENTIFIC, INC. |
||
|
By: |
|
|
|
Name: |
||
|
Title: |
||
EXHIBIT D
[COMPANY LETTERHEAD]
OFFICER’S CERTIFICATE
[DATE]
[Computershare Trust Company, N.A.,
Computershare Inc. as Agent
150 Royall Street
Canton, MA 02021
Attention: Client Services]
This Notice is being delivered to you pursuant to Section 1.5[(a), (b) or (c)] of the Contingent Value Rights Agreement, dated as of January [_], 2024, by and between Core Scientific, Inc. (the “Company”) and Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, collectively, as CVR agent (the “Agreement”), in connection with the following Testing Date: [DATE].
Capitalized terms used herein but not otherwise defined shall have the meanings given to such terms in the Agreement.
The undersigned hereby certifies, solely in [his/her] capacity as [TITLE] of the Company and not in [his/her] individual capacity, and on behalf of the Company, as of the date hereof, that:
[First Testing Date:
The Fair Market Value of the Corresponding New Common Interests is equal to or in excess of $260,000,000, and the Company does not owe any Holder, with respect to the First Testing Date, the Year 1 Contingent Payment Obligation and such Year 1 Contingent Payment Obligation is extinguished and deemed to be equal to zero.]
[Second Testing Date:
The Fair Market Value of the Corresponding New Common Interests is equal to or in excess of the difference of (x) $260,000,000 minus (y) the First Anniversary Payment Amount, and therefore the Company shall not owe any amounts to any Holder with respect to the Second Testing Date, and the Year 2 Contingent Payment Obligation shall be extinguished and deemed to be equal to zero.]
[Third Testing Date:
The Fair Market Value of the Corresponding New Common Interests is equal to or in excess of the difference of (x) $260,000,000 minus (y) the sum of the First Anniversary Payment Amount and the Second Anniversary Payment Amount, and therefore the Company shall not owe any amounts to any Holder with respect to the Third Testing Date, and the Year 3 Contingent Payment Obligation shall be extinguished and be deemed to be equal to zero.]
|
CORE SCIENTIFIC, INC. |
||
|
By: |
|
|
|
Name: |
||
|
Title: |
||
ANNEX D
APPROVED BANKS
| Banks |
| JP Morgan |
| Bank of America |
| Citibank |
| Wells Fargo |
| BMO |
| Truist |
| Bank of New York Mellon |
|
Very truly yours,
|
|
| /s/ Moelis & Company LLC |
|
|
MOELIS & COMPANY LLC
|
|
|
![]() |
|
Very truly yours,
|
|
| /s/ PJT Partners LP |
|
|
PJT Partners LP
|